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C1QTNF5 is a 25kDa short chain collagen of unknown function which is mutated in 
late-onset retinal macular degeneration (L-ORMD).  L-ORMD is an autosomal 
dominant disease characterised by sub-retinal pigment epithelial deposits leading to 
photoreceptor death and visual loss and shows several similarities to age-related 
macular degeneration (AMD). A Tyr402His polymorphism in complement factor H 
(CFH), a regulatory protein in the innate immune system, has been associated with 
increased risk of AMD.  C1QTNF5 and CFH are both expressed and secreted by the 
retinal pigment epithelium (RPE) which supports photoreceptors and is responsible 
for phagocytosis of shed rod photoreceptor outer segments (ROS).  The properties of 
the normal C1QTNF5 and disease-associated Ser163Arg mutation were examined in 
detail, including protein characterisation, cellular processing and function. 
Recombinant wild type and mutant C1QTNF5 were produced and their 
multimerisation and solubility functions compared. Both proteins were found to be 
soluble and to form similar multimeric species which were resistant to reducing 
conditions, as seen in other short chain collagens. Due to the similarities between L-
ORMD and AMD, a proposed interaction between C1QTNF5 and CFH was 
investigated. CFH is composed of 20 short consensus repeats (SCR) and interactions 
were confirmed between C1QTNF5 and both CFH and SCR modules 7-8 and 19-20. 
CFH showed a greater affinity for mutant C1QTNF5 compared with wild type on the 
basis of surface plasmon resonance assays. Stably transfected RPE-derived cell lines 
were created which expressed either wild type or mutant C1QTNF5.  Both proteins 
were found to be secreted and showed similar cellular processing with no evidence of 
aggregation or retention of the mutant protein within the endoplasmic reticulum. In 
order to investigate C1QTNF5 function, phagocytosis of ROS by the stably 
transfected cell lines was carried out.  Cells expressing wild type C1QTNF5 showed 
greater ROS phagocytosis compared with mutant C1QTNF5-expressing or 
untransfected cells.  Addition of anti-C1QTNF5 antibody increased ROS 
phagocytosis further. In summary, it is proposed that wild type and mutant 
C1QTNF5 are secreted by the RPE where they interact with CFH. C1QTNF5 is also 
 xvi
shown to have a role in ROS phagocytosis, with mutation in C1QTNF5 affecting 
phagocytosis efficiency, which may contribute to sub-RPE deposit formation. The 
results suggest that CFH may also be involved in this process, suggesting a common 
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1.1 The retina and retinal pigment epithelium 
The retinal pigment epithelium (RPE) is a monolayer of pigmented cells forming the 
outer most layer of the retina.  The RPE provides a supporting role for the retina, 
which contains the photoreceptor and nerve cells necessary for light processing, and 
acts as a barrier between the retina and the choroidal blood supply.  Figure 1.1 shows 
a cross section of the vertebrate eye, with the RPE and retina covering almost the 
entire of the inside of the eye, up to the ora serrata.  The only gap is where the optic 
nerve penetrates into the eye, creating the ‘blind spot’.  The macula is located 
directly posteriorly to the lens, in the central area of the retina.  It is yellow in colour 
and represents an area of high photoreceptor density, with its central region, the 
fovea, having the highest photoreceptor density necessary for sharp image processing 
(Hildebrand & Goslow, 2001). 
 
1.1.1 The structure of the retina 
The retina processes light entering the eye, converting this into nerve impulses sent 
down the optic nerve and to the brain for processing, and is comprised of distinct 
layers, as can be seen from Figure 1.2.  The most posterior layer is Bruch’s 
membrane, joining the outermost layer of the retina to the innermost layer of the 
choroid.  The RPE plasma membrane is continuous with Bruch’s membrane at its 
basal side, and apically it forms microvilli which interdigitate with the photoreceptor 
outer segments.  The RPE cells are pigmented, ensuring that no random reflection of 
light occurs within the eye.  The photoreceptors consist of rods and cones and 
contain pigments, enabling light absorption to be converted into nerve impulses.  
Cones contain several different pigments, each susceptible to distinct wavelengths of 
light allowing for colour vision.  The pigment present in rods is rhodopsin, with rods 
playing a role in night vision.  Photoreceptor outer segments consist of folded stacks 
of hundreds of pigment-containing lamellae and have narrow connections to their 
inner segments and the main cell body containing the nucleus and mitochondria.  The 
macula contains a higher density of cones than the more peripheral retina, with the 
fovea consisting of only cones.  The anterior retina layers are also thinnest at the  
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fovea, ensuring maximum light reaches the photoreceptors.  Photoreceptors synapse 
with bipolar cells, which in turn form synapses with the ganglion cells.  Plexiform 
nerve cells form a mesh at each end of the bipolar cells.  It is the ganglion cells 
which transmit the nerve impulses originating in the photoreceptors to the brain via 
their axons forming the optic fibre layer, which continues through the optic nerve to 





Figure 1.1: A cross section of the vertebrate eye.  
(source: http://www.vision3k.com/images/struc_eye.gif) 
 
The retina covers almost the entire inside of the eye, extending to 
the ora serrata.  The RPE is located beneath the retina.  The blind 
spot is created where the optic nerve pierces the retina.  The 
macular is located directly posterior to the lens and contains the 






Figure 1.2: A cross section of the vertebrate retina. 
(source: http://thalamus.wustl.edu/course/eye3.gif) 
 
Light entering the eye through the lens then travels through several 
cell layers before it reaches the photoreceptors.  Here it then 
activates rhodopsin and signal transduction from the 
photoreceptor, through the bipolar cells and ganglion cells.  The 
impulse then travels down the ganglion cell axons which comprise 




1.1.2 Bruch’s membrane 
Bruch’s membrane is a pentalaminar structure.  It is located beneath the retina, 
extending to the ora serrata and is pierced posteriorly by the optic nerve.  The five 
layers it consists of are the basement membrane of the choriocapillaris (BMC), the 
outer collagenous layer (OCL), the elastin layer (EL), the inner collagenous layer 
(ICL) and the basement membrane of the RPE (BMR) (Marmor & Wolfensberger, 
1998).  Under electron microscopy, the BMC consists of two layers; a pale layer and 
a darker, electron dense layer.  The dense layer is granular and contains collagens IV 
and VI, laminin and heparan sulphate, with collagen VI involved in basement 
membrane anchorage of the capillary epithelium (Marshall et al., 1993).  The OCL 
consists of collagens I, III and V, fibronectin, chondroitin sulphate, dermatan 
sulphate and proteoglycans.  The collagen fibres are predominantly in the plane of 
the membrane, although some extend up through the EL into the ICL.  The EL 
consists of an array of elastin fibres running parallel to Bruch’s membrane, with 
dense areas forming nodes and less dense areas forming pores.  The ICL is the same 
in composition as the OCL, although it is approximately twice the thickness.  Finally, 
the BMR forms an uninterrupted layer similar in structure and chemical composition 
to the BMC but excluding collagen VI (Marmor & Wolfensberger, 1998) 
 
Unlike the endothelial cells of the retinal blood vessels, the endothelial cells of the 
choriocapillaris are fenestrated, with the choroidal fenestrations permeable to 
proteins up to 70kDa (Pino et al., 1981).  The vessels of the choriocapillaris are 
approximately three times the width of the retinal blood vessels and have a two 
hundred-fold greater rate of blood flow (Alm et al., 1973).  This is to aid metabolite 
exchange by maintaining a high concentration gradient across the vessel walls.  
Metabolites and proteins can then pass through Bruch’s membrane to the RPE.  In 
addition to this inward flux there is also an outward flux of water and waste material 
from the RPE, with Bruch’s membrane presenting a negligible barrier.  However, as 
the eye ages the permeability of Bruch’s membrane decreases with detrimental 
effects on the RPE and retina (Marmor & Wolfensberger, 1998). 
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1.1.3 The embryonic development of the RPE 
Following invagination of the optic cup, the resulting two layers of neuroepithelium 
will flatten together and will become the RPE and retina.  They are separated by a 
thin lumen filled with the inter photoreceptor matrix (IPM), providing the signalling 
control required for the different differentiation pathways of the two layers.  
Development of the two layers occurs in concert, with the RPE necessary for correct 
retinal development, secreting signalling factors required for photoreceptor 
differentiation (reviewed by Strauss, 2005). 
 
Differentiation of the RPE is promoted by retinoic acid, secreted from the embryonic 
retinal anlage.  The neuroectodermal cells differentiate into pigmented epithelium 
and then start to express retinoic acid themselves, as well as RPE65 (retinal pigment 
epithelium-specific protein 65kDa), which is involved in the recycling of 
components of the visual cycle.  The RPE progenitor cells differentiate further to 
show apical to basolateral polarity, forming basal infoldings and apical microvilli.  
The basement membrane, in conjunction with the plasma membrane of the ajoining 
endothelium forms Bruch’s membrane, with the RPE cells themselves secreting the 
required extracellular matrix components.  Tight junctions form between the RPE 
cells and help to organise the cytoskeleton, further defining the apical to basolateral 
polarity.  The formation of tight junctions signifies the formation of the blood-retina 
barrier, and coinsides with the onset of epithelial transport by the RPE (Strauss, 
2005). 
 
In the adult eye, the RPE apically forms microvilli which interdigitate with the 
photoreceptors.  In the embryonic eye, this apical surface maturation is promoted by 
ezrin, causing the development of microvilli (Bonilha et al., 1999), with ezrin 
knockout mice having substantially reduced apical microvilli and basal infoldings, as 
well as retarded photoreceptor development (Bonilha et al., 2006).  Under normal 
developmental conditions, as the RPE extends its apical microvilli, so the primordial 
photoreceptors extend their outer sements.  When the process is complete the 
photoreceptor outer segments interdigitate with both long microvilli, which 
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maximise surface area for epithelial transport, and short microvilli, which are 
involved in phagocytosis of shed outer segments (Strauss, 2005). 
 
1.1.4 Transport mechanisms and growth factor secretion in the RPE 
The RPE plays a central role in supporting the retina and maintaining a constant 
microenvironment.  Part of this role involves ensuring the correct volume and 
composition of fluid in the subretinal space.  This is achieved through the transport 
of metabolites, fluid and ions.  The RPE is comprised of polarised epithelium, and so 
has different transport mechanisms at the apical and basolateral membranes.  Water 
transport occurs from the apical side to the basolateral side.  Apically, there are 
membrane Na+-K+-ATPases and Na+/K+exchangers, and basolaterally there are 
membrane Cl- channels and Cl-/HCO3
- exchangers, with the transport of water 
through aquaporins from the subretinal space into the RPE mainly driven by the 
transport of K+ and Cl-.  In addition to fluid transport, the RPE is responsible for the 
removal of lactic acid, a major metabolic end product, from the subretinal space.  
This occurs via apical lac--H+ transporters, with lactic acid expelled basally from the 
RPE via different basolateral lac--H+ transporters.  The pH balance within the RPE 
cells is maintained by Na+/H+ and Na+/HCO3
- exchangers in the apical membrane 
and Cl-/HCO3
- exchangers in the basolateral membrane (reviewed by Marmor & 
Wolfensberger, 1998, Strauss, 2005).   
 
The RPE also secretes a number of growth factors, each with different roles in 
maintaining the structure and efficient function of the retina.  Apically it secretes the 
neurotrophic factor pigment epithelium-derived factor (PEDF), and basally it 
secretes the vascular endothelial growth factor (VEGF).  PEDF is an inhibitor of 
retinal angiogenesis, inhibits the migration of endothelial cells and has been shown to 
reduce photoreceptor apoptosis induced by hydrogen peroxide.  VEGF promotes the 
growth of vascular endothelial cells and increases vascular permeability (reviewed 
by Tong et al., 2006).  VEGF and PEDF also have roles in retinal degeneration, 
discussed in Section 1.2.2.3.   
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Also secreted by the RPE are a number of proteins included in the family of matrix 
metalloproteases and their inhibitors.  Matrix metalloproteinases (MMP) and their 
inhibitors are involved in maintenance of the extracellular matrix (ECM) and Bruch’s 
membrane, with MMPs carrying out zinc-dependant ECM turnover.  MMPs and their 
inhibitors secreted by the RPE include collagenases, gelatinases and tissue inhibitors 
of metalloproteases (TIMP) (Alexander et al., 1990).  Mutations in one such TIMP, 
TIMP3, have been associated with a form of retinal degeneration called Sorsby 
Fundus Dystrophy.  This is an early-onset maculophathy with associated choroidal 
neovascularisation (CNV) and thickening of Bruch’s membrane, similar to AMD 
(see Section 1.2), which is thought to be caused by both loss of function of TIMP3 
and aggregation of the mutant protein (Arris et al., 2003, Lin et al., 2006). 
 
1.1.5 The visual cycle 
In addition to fluid and metabolite transport, the RPE is also responsible for the 
recycling of components involved in the visual cycle.  This process is summarised in 
Figure 1.3.  Signal transduction in the visual, or retinoid, cycle starts by rhodopsin 
light absorption in the photoreceptors.  Rhodopsin consists of a seven transmembrane 
domain G-coupled receptor, opsin and the chromophore, 11-cis-retinal (Hargrave, 
2001).  Following light absorption, 11-cis-retinal undergoes a conformational change 
to become all-trans-retinal, changing rhodopsin to meta-rhodopsin and activating 
signal transduction (Okada et al., 2001).  Activated rhodopsin is then phosphorylated 
by rhodopsin receptor kinase and subsequent binding of arrestin.  The now 
inactivated rhodopsin releases all-trans-retinal and binds 11-cis-retinal (Baylor, 
1996, Baylor et al., 1998). 
 
All-trans-retinal can be regenerated back into 11-cis-retinal by the enzyme cis-trans 
isomerise.  Photoreceptors lack this enzyme, so it is necessary for the all-trans-retinal 
to be transported to the RPE for this regeneration to occur.  An adenosine 
triphosphate (ATP)-binding cassette protein, ABCA4, transports the accumulated all-
trans-retinal from the interdiscal space into the photoreceptor cytosol.  Here it is 
reduced to all-trans-retinol by all-trans-retinol dehydrogenase, and translocated to 
the RPE by the carrier protein, interstitial retinal binding protein (IRBP).  Once 
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within the RPE, all-trans-retinol binds the cellular retinol binding protein, CRBP.  
Reisomerisation then occurs due to the binding of a protein complex consisting of 
lecithin retinol acyltransferase (LRAT), which transfers an acyl group to the all-
trans-retinol forming all-trans-retinyl, RPE65, an isomerohydrolase, which converts 
the all-trans-retinyl ester to 11-cis-retinol, the retinol dehydrogenase RDH5, which 
converts the 11-cis-retinol to 11-cis-retinal, and cellular retinaldehyde binding 
protein (CRALBP), which accelerates the RDH5 enzymatic reaction.  A 
supplementary pathway by which all-trans-retinal is converted back into 11-cis-
retinal involves the RPE-retinal G protein receptor opsin, which uses light energy to 
drive the isomerisation reaction.  It is suggested that this additional pathway helps to 
adapt the retinal turnover to changes in ambient light (reviewed by Strauss, 2005). 
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Figure 1.3: Retinoid processing in the visual cycle. 
(source: biophysics.bumc.bu.edu/faculty/cornwall/) 
 
Light entering the photorecetors activates rhodopsin, which 
contains the chormophore 11-cis-retinal.  This undergoes a 
conformational change to become all-trans-retinal, activating signal 
transduction.  All-trans-retinal is required to be transported to the 
RPE for recycling back into 11-cis-retinal.  For this to occur, the all-
trans-retinal is converted into all-trans-retinol, and transported by 
the carrier protein, IRBP, to the RPE.  Here the all-trans-retinol is 
converted to all-trans-retinyl, before undergoing a further 
conversion into 11-cis-retinol.  This can now be converted back 
into 11-cis-retinal and transported back to the photoreceptor to be 





1.1.6 RPE phagocytosis of rod outer segments 
Within the photoreceptors, there is continuous replacement of disc membranes and 
intermittent shedding of rod outer segments (ROS).  Shed ROS are phagocytosed by 
the RPE, forming phagosomes to be digested by RPE lysosomes (Young and Bok, 
1969).  This process follows a circadian rhythm with phagocytosis promoted by the 
onset of light (LaVail, 1976).  RPE phagocytosis of ROS shows high selectivity, with 
cultured RPE shown to have preference for ROS over red blood cells, algae, bacteria 
and yeast, suggesting the involvement of specific receptors and ligands (Mayerson 
and Hall, 1986).  In the macula, there is a higher ratio of photoreceptors to RPE cells 
requiring the RPE cells here to be adapted to cope with a higher turnover of ROS 
(Strauss, 2005). 
 
1.1.6.1 Receptors and ligands involved in ROS phagocytosis  
The presence of RPE/ROS-specific ligands and receptors involved in the RPE-ROS 
phagocytic cycle was confirmed by Gregory and Hall (1992) who raised an 
antiserum to an RPE plasma membrane-enriched fraction and showed this antiserum 
inhibited ROS binding to RPE.  It was initially suggested that a mannose receptor on 
the RPE plasma membrane could be involved in ROS uptake, possibly by 
recognising a mannose residue on rhodopsin.  However, this has not been confirmed, 
with conflicting studies either supporting (Boyle D et al., 1991, Lutz D et al., 1995) 
or dismissing (Hall et al,. 1990) this theory, and no conclusive evidence has as yet 
been presented.  Figure 1.4 summarises the receptors and ligands currently known to 
be involved in ROS phagocytosis by the RPE. 
 
Finnemann et al. (1997) have shown that the v5 integrin is involved in RPE 
phagocytosis of ROS.  They showed it is first detected in mice at P7, with adult 
levels reached at P11 (just prior to the start of phagocytosis at P12) and that blocking 
cultured cells with anti- v5 antibodies reduces their phagocytosis levels by 85%.  It 
was also shown that the v5 receptor is necessary for ROS binding only, not 
internalisation, indicating another process is involved in internalisation of the v5-
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ROS complex.  Nandrot et al. (2004) showed that in 5 knockout mice retinal 
photoresponses declined with age and autofluorescence increased.  When cultured,  
5-/- RPE showed no phagocytosis of ROS, and although in vivo basal levels of 
phagocytosis were maintained, the burst of phagocytic activity associated with the 
circadian shedding of ROS did not occur.  It was subsequently shown by Nandrot et 
al. (2007) that the ligand for v5 was the secreted glycoprotein milk fat globule E8 
(MFG-E8), which has been shown to co-localise to the subretinal space.  MFG-/- 
mice were found to lack the diurnal synchronisation of ROS phagocytosis, as was 
also observed in the 5-/- mice.  MFG-E8 binds the v5 integrin via its RGD motif, 
and also binds exposed phoshatidyl serine found on apoptotic cell surfaces.  It was 
found to increase ROS binding to wild-type RPE primary cultures but did not affect 
levels in v5-/- cells.  In addition to its phagocytic role, v5 also plays a role in 
apical retinal adhesion (Nandrot et al., 2006).  5-/- mice showed weakened retinal 
adhesion independent of circadian rhythm, indicating that v5 contributes to 
permanent retinal adhesion and stabilisation of the RPE/ROS interdigitation as well 
as binding ROS during phagocytosis. 
 
ROS binding to the v5 integrin has been shown to activate a signalling cascade 
involving focal adhesion kinase (FAK).  This in turn phosphorylates C-mer proto-
oncogene tyrosine kinase (MerTK), which activates the signalling cascade necessary 
for internalisation of the ROS (Finnemann et al., 2003, Finnemann et al., 2006).  
MerTK is a transmembrane protein with two fibronectin type-III domains, two 
immunoglobulin-like domains and one tyrosine kinase domain.  It is mutated in the 
Royal College of Surgeons rat (D’Cruz et al., 2000), which undergoes photoreceptor 
degeneration due to lack of ROS phagocytosis and accumulation of shed 
photoreceptors in the sub retinal space (Dowling et al., 1962, Bok et al., 1971), and 







Figure 1.4: Receptors and ligands involved in ROS phagocytosis by the 
RPE. 
 
CD36 recognises anionic phospholipids on the rod outer segment 
(ROS) surface, promoting phagocytosis.  In a separate pathway, 
the αvβ5 integrin is responsible for ROS binding, with MFG-E8 
acting as a ligand for both the integrin and the ROS.  CD81 plays 
an indirect role involving integrin processing.  ROS phagocytosis 
via this pathway activated FAK/MerTK signalling pathways 
















The tetraspanin, CD81, has also been shown to interact with the v5 integrin, 
although not in complex with FAK or MerTK (Chang et al., 2007).  Tetraspanins are 
four-transmembrane-domain proteins which act to regulate the function of integrins.  
They do this by regulating integrin trafficking and recycling, compartmentalization 
within the plasma membrane, facilitating lateral protein and lipid associations and 
recruiting intracellular signaling molecules to integrin tail domains (reviewed by 
Berditchevski et al., 2001, Hemler et al., 2005, Levy et al., 2005).  Co-
immunoprecipitation experiments comfirmed the interaction, and over-expression of 
CD81 in cultured RPE cells increased ROS binding when compared with the wild-
type.  CD81 over expression did not increase ROS binding in v5 integrin deficient 
cells, indicating that CD81 is not able to act independently of v5.  It was also 
shown that over-expression of CD81 increased apical surface levels of v5 integrin 
(Chang et al., 2007).   
 
Another receptor identified as having involvement in ROS phagoyctosis by the RPE 
is CD36 (Ryeom et al., 1996b).  CD36 is a heavily glycosylated plasma membrane 
protein which has been shown to have roles in the uptake of apoptotic cells and 
modified lipids (Silverstein et al., 2000).  Apoptotic cells have exposed anionic 
phospholypids such as phosphatidylserine (PS) and phosphatidylinositol (PI) in their 
plasma membrane, with these phospholipids shown to be present on the surface of 
shed ROS too (Anderson et al., 1970).  It was shown by Ryeom et al. (1996a) that 
such phospholipids were likely receptors for CD36, as PS and PI vesicles were 
internalised by cultured RPE and such internalisation was blocked with anti-CD36 
antibodies.  Again using anti-CD36 antibodies, Finnemann et al. (2001) showed that 
CD36 regulated the rate of ROS internalisation but does not act during binding, and 
that such internalisation is independent of the v5 integrin.  The antibodies cross-
linked CD36, up-regulating internalisation, probably due to CD36 dimerisation.  This 
supported a signalling role for the protein.  ROS are rich in unsaturated 
phospholipids such as docosahexaenoic acid (DHA) which is highly sensitive to 
oxidation.  Conformation that oxidised phospholipids were ligands for CD36-
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mediated phagocytosis of ROS came from analysis showing that light-induced 
oxidation of ROS phospholipids generated ligands for CD36-mediated phagocytosis 
by cultured RPE (Sun et al., 2006). 
 
 
1.2 Age-related macular degeneration 
Age-related macular degeneration (AMD) is a late-onset disease of the central retina.  
Taking many decades to develop, the disease causes degeneration of the central 
retina resulting in loss of central vision.  In some cases AMD can result in sudden 
loss of vision (Tezel et al., 2004).  It is the more severe form of the disease age-
related maculopathy (ARM) and is the leading cause of blindness in developed 
countries where its incidence is increasing (Evans et al., 1996).  A study of the UK 
population over 75 years of age estimated that 3.7% were visually impaired as a 
result of AMD.  For those over 90 years of age this rose to 14.4% (Evans et al., 
2004). 
 
1.2.1 General disease symptoms 
There are two forms of severe AMD, with geographic atrophy (GA, sometimes 
known as "dry AMD") and choroidal neovascularisation (CNV, or "wet AMD") 
respectively.  GA is characterised by progressive atrophy of the RPE, subsequent 
loss of photoreceptors and a slow reduction in central vision.  CNV includes 
abnormal blood vessel growth from the chriocapillaris, which can leak or 
haemorrhage into the retina and result in sudden loss of central vision.  In both forms 
of the disease, sub-RPE deposits are observed, adjacent to and within Bruch’s 
membrane.  It is normal for some sub-RPE deposits to be present in the ageing eye, 
but in the case of AMD, extensive deposits can lead to disruption of RPE function, 
subsequent photoreceptor dysfunction and retinal atrophy (Tezel, 2004).  Figure 1.5 
shows normal and diseased retinas.  In the early stages of the disease large, yellow 
drusen can be seen in the macula, although the patient has normal visual acuity.  In 
the later stages, retinal atrophy is also observed and the patient will have resulting 
deficiencies in central vision (Fine et al., 2000). 
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1.2.2 Deposits and changes in Bruch’s membrane 
Bruch’s membrane thickens with age and sub-RPE deposits can be observed (Bird et 
al., 2003).  Thickening of Bruch’s membrane is associated with increased lipid 
content and so decreased hydraulic conductivity and macromolecular permeability 
(Sheraidah et al., 1993, Starita et al., 1995, Moore et al., 2001).  One requirement of 
Bruch’s membrane is to allow metabolic exchange between the RPE and the 
choroidal blood vessels, so if this is reduced then normal photoreceptor function is 
compromised (Bird et al., 2003).   
 
The sub-RPE deposits associated with AMD consists of three classes: basal laminar 
deposits (BlamD, diffuse deposits external to Bruch’s membrane), basal linear 
deposits (BlinD, diffuse deposits internal to Bruch’s membrane) and drusen (focal 
deposits).  BlamD consist of fibrous long-spacing collagen and basement membrane 
materials, and are suggested to result from excess basement membrane secreted by a 
stressed RPE (van der Schaft et al., 1992, van der Schaft et al., 1993, Marshall et al., 
1992, Sarks et al., 2007).  BlinD consist of membranous material and are indicators 
of AMD disease progression.  BlinD always appear after BlamD, and once RPE 
atrophy has occurred deposits become less membranous and BlamD increases 







Figure 1.5: Diseased retina in AMD patients. 
(source: Fine et al., 2000) 
 
Normal and AMD diseased retinas: 
A – A healthy retina.  The inner circle defines the fovea, the outer 
circle the macula.  The arrow indicates the optic nerve. 
B – The early stages of AMD.  Arrows indicate large drusen, 
arrowheads indicate clumps of pigment.  The patient still has 
normal vision. 
C – The later stage of AMD.  The arrows indicate central atrophy.  
The surrounding retina is normal.  The patient will experience 
some loss of central vision. 
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Drusen are located between the RPE plasma membrane and the inner collagenous 
layer of Bruch membrane.  Drusen morphology can vary and various classification 
systems have been proposed, but it is generally accepted that drusen will fall into one 
of two categories: soft or hard.  Soft drusen have a diameter greater than 63µm with 
“visible thickness” whereas hard drusen are discrete and range in diameter from 1-
63µm.  It should be noted that BlinD are sometimes referred to as diffuse drusen 
(Hageman et al., 1999).   
 
Patients with large drusen have increased risk of developing CNV.  Once CNV has 
developed, subsequent leakage of fluid or blood can result in distortion of vision, a 
blind spot or, in extreme cases, sudden loss of vision (Fine et al., 2000). 
 
1.2.2.1 The composition of drusen 
Hageman et al., (2001) summarise various studies into the classification and 
composition of drusen.  Firstly, it is noted that although the role of drusen in AMD 
pathogenesis is not clear, their correlation with AMD is, so that the presence of 
drusen is considered a major risk factor for developing the disease.  The composition 
of soft and hard drusen is actually very similar, so although they differ 
morphologically they can be considered to be otherwise the same.  Drusen 
components identified include lipids, carbohydrates and protein.  Lipid components 
include esterified and unesterified cholesterol, or lipoprotein such as apolipoprotein 
E (ApoE).  The latter is probably produced locally within the retina whereas the other 
lipids would suggest vascular and hepatic origins respectively, pointing towards a 
heterogenous origin for drusen.  Drusen-associated carbohydrates include sialic 
acids, glucoconjugates with terminal glucose/mannose, N-acetylglucosamine and O-
glycosidically linked carbohydrates.  Many protein components have been identified, 
including ubiquitin, integrins, beta-amyloid and fibronectin, as have proteins with an 
immunological function including immunoglobulin, C5b-9, C1q and MHC class II 
antigens.  Crabb et al. (2002) carried out drusen proteome analysis by mass 
spectrometry and identified many proteins including TIMP-3, various crystallins and 
complement C9.  Oxidative protein modifications were also observed, suggesting a 
role for oxidative injury in AMD.  Complement factor H is also present in drusen 
 20 
(Bok et al., 2005), where immunohistology has revealed a drusen-wide localisation.  
The complement membrane attack complex (MAC) was shown to be associated with 
the drusen core.  Cellular components have also been found associated with drusen.  
RPE basal blebs extend into drusen and RPE-derived basal laminae and organelles 
are also observed.  Dentritic cell processes can be seen extending into the druse core 
(Hageman et al.,  2001).  
 
It has been shown that zinc has a high concentration in macular and peripheral sub-
RPE deposits, and is particular high within drusen themselves.  Zinc is known to play 
a role in the accumulation of deposits and aggregates in neurodegenerative diseases 
such as Alzheimer’s disease and Parkinson’s disease, so it has been suggested that 
the high concentrations of zinc observed here may too play a role in deposit 
formation (Lengyel et al., 2007). 
 
1.2.2.2 Lipofuscin deposits 
Lipofuscin deposits are fluorescent deposits associated with the ageing retina.  
Lipofuscin is thought to derive from lysosomal residual bodies arising from 
photoreceptor phagocytosis and digestion, and contain the end-products of 
oxidatively damaged lipids.  Indeed, lipofuscin has been shown to contain the 
pyridinium bis-retinoid, A2-E, which has been shown to inhibit lysosomal 
degradation of proteins in cultured RPE cells, supporting lipofuscin being the 
product of incomplete ROS digestion (Reinboth et al., 1997).  Lipids can be 
oxidatively damaged by light entering the eye, with the RPE pigment melanin 
helping to reduce this damage.  It therefore makes sense that there is a correlation 
between decreasing melanin levels and increasing lipofuscin levels (Weiter et al., 
1986).  Indeed, accumulations of lipofuscin are associated with the ageing retina 
(Feeny-Burns et al., 1984), and such deposits increase from the periphery to the 
posterior pole, with a drop in levels at the fovea, corresponding to levels of ROS 
phagocytosis (Weiter et al., 1986). 
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1.2.2.3 Choroidal neovascularisation in AMD 
It is thought that choroidal neovascularisation in AMD can arise due to unbalanced 
VEGF and PEDF expression.  VEGF and PEDF are growth factors secreted by the 
RPE which promote and inhibit angiogenesis.  VEGF levels are increased in the 
choroidal vascular membranes of patients with CNV, and animal models have shown 
VEGF can actually induce CNV.  Also, laser induction of CNV increases local 
VEGF levels, and adenoviral transfection of the VEGF gene in rats causes the 
development of CNV.  The specific role of PEDF in AMD is not clear.  At low doses 
it inhibits the effects of VEGF and so CNV formation, and in animal models, 
adenoviral expression of PEDF can reduce laser-induced CNV.  However, at high 
doses PEDF can induce endothelial proliferation (reviewed by Tong et al., 2006). 
 
1.2.3 Oxidative damage in the RPE and AMD 
The RPE is exposed to high levels of oxidative stress.  Some of this exposure is due 
to the phagocytosis of oxidised lipids contained in shed ROS, as discussed 
previously, whilst other exposures include short-wavelength radiation such as blue 
light (Algvere et al., 2006), lipofuscin, high levels of oxygen from the choroidal 
blood supply and toxins such as cigarette smoke (Beatty et al., 2000).  The retina has 
developed defence mechanisms to protect against such oxidative damage.  These 
include the antioxidant enzymes superoxide dismutase, catalase and glutathione 
peroxidise (Tate et al., 1995, Frank et al., 1999, Beatty et al., 2000).  It is thought 
that oxidative damage contributes to disease mechanisms in AMD. 
 
1.2.4 Immune complexes and inflammation in the pathogenesis of 
AMD 
The observation that proteins involved in immune responses, such as 
immunoglobulins, complement component C5 and the MAC, are associated with 
drusen led to the speculation that immune responses may contribute towards the 
pathogenesis of AMD.  Due to the high levels of IgG detected by immunohistology 
in donated eyes of affected individuals, it was suggested that drusen formation occurs 
as a result of an immune response directed against RPE-derived antigens (Johnson et 
al., 1999).  Hageman et al. (2001) reviewed the current literature on drusen, covering 
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classification, structure and content, and put forward a hypothesis whereby drusen 
biogenesis is mediated by dendritic cells, recruited to the site of dysfunctional or sub-
lethal RPE cells.  Such cells, stressed and maybe undergoing necrosis due to 
influences such as injury, lipofuscin accumulation or oxidative damage, would 
release soluble cytokines to recruit dendritic cells from the choroidal blood vessels.  
Dendritic cell processes have been reported associated with small drusen, and in 
some regions protruding through Bruch’s membrane.  Once recruited and activated, 
dendritic cells could sustain or amplify the local inflammation and, in the case of 
AMD, chronic inflammation would persist with knock-on autoimmune responses.  
Therefore, it was proposed that drusen biogenesis occurs via two stages.  The first 
stage involves a nucleation step, where RPE debris and dendritic cell-derived 
material accumulate, and the second stage involves deposition of drusen-associated 
constituents and a state of chronic inflammation leading to surrounding RPE cell 
dysfunction and subsequent retinal degeneration.  
 
Anderson et al. (2002) carried out histological analysis of >400 donor AMD eyes 
using light, confocal and electron microscopy.  They found lipofuscin-rich sub-RPE 
deposits containing recognisable organelles and melanin granules, suggesting an 
RPE origin for the debris.  Analysis of drusen revealed the presence of inflammatory 
products including apolipoprotein E (ApoE), acute phase proteins such as C-reactive 
protein (CRP) and vitronectin, complement components including C5, C5b-9, C3b 
and C3d (see Section 1.4.1) and the complement regulators membrane co-factor 
(CD46) and complement receptor 1 (CR1) (see Section 1.4.2).  Anderson et al. add 
to the hypothesis put forward by Hageman et al. to propose that primary RPE 
pathology (either genetic or environmental) compromises the RPE and causes the 
accumulation of debris between the basal lamina of the RPE and Bruch’s membrane.  
Accumulation of debris acts as a “seeding” event resulting in a pro-inflammatory 
signal, involving up-regulation of local pro-inflammatory mediators, activation of the 
complement cascade and so deposition of associated proteins.  Cellular blebs are 
proposed to act as nucleation sites for the formation of drusen, resulting in additional 
RPE cell degeneration of those cells in close proximity.  It should be noted these are 
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hypotheses only, and although they appear to best describe the data at hand there is 
as yet no conclusive evidence for the biogenesis of drusen. 
 
1.2.5 The role of phagocytes in AMD 
Phagocytes present in the adult retina include dendritic cells, microglia and 
macrophages.  Microglia can be found in the OPL, ONL and GCL, and originate 
from haemopoietic cells which enter via the blood vessels of the ciliary body and iris 
or the retinal vasculature, before differentiating into parenchymal microglia in the 
adult retina.  In the healthy adult retina they provide roles in host defence against 
invading pathogens, immunoregulation and tissue repair.  In the diseased eye they 
are involved in phagocytosis of sub-RPE debris (Chen et al., 2002).  Macrophages 
also play a role in sub-retinal debris clearance.  Ineffective clearance of debris by 
resident retinal phagocytes such as microglia and dendritic cells leads to the 
recruitment of macrophages from the choroidal blood suppy (Forrester, 2003).  
Electron microscopy of donated eyes has shown macrophages to be associated with 
deposits in patients with AMD (Killingsworth et al., 1990).  Recruited macrophages 
are activated and therefore pro-angiogenic.  It is therefore likely that their 
recruitment via chemoattractants such as immunoglobulins and complement 
components to the site of sub-retinal debris contributes towards disease progression 
(Forrester, 2003).  Further evidence for the role of macrophages in AMD comes from 
the observation that systemic macrophages are recruited to sites where CNV is laser-
induced in mice (Caicedo et al., 2005). 
 
1.2.5.1 Macrophage recruitment in AMD 
Supporting evidence of a role for macrophages in the clearance of sub-RPE debris 
and the pathogenesis of AMD comes from analyses looking at mice deficient in the 
monocyte chemoattractant protein-1 (MCP-1 or CCL-2) or its cognate chemokine 
receptor (CCR-2).  Mice deficient in either of these proteins developed lipofuscin 
deposits, drusen, photoreceptor atrophy and CNV, and had deposition of complement 
components and IgG in the RPE and choroid, as is seen in patients with AMD 
(Ambati et al., 2003).  It was therefore proposed that macrophage recruitment 
dysfunction may be involved in AMD pathogenesis.  However, a comprehensive 
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genetic analysis was carried out in two independent case-control studies which found 
no evidence for an association between either CCL-2 or CCR-2 genetic variants and 
AMD.  Levels of CCL-2 and CCR-2 mRNA were also examined in healthy and 
diseased RPE, with no differences in expression levels observed (Desprit et al., 
2008).  Therefore, no evidence could be found to support a role for CCL-2 or CCR-2 
polymorphisms in humans and risk of developing AMD. 
 
 
1.3 Risk factors for AMD 
Several risk factors have been identified for AMD.  These can be environmental, and 
include cigarette smoking, light exposure and dietary polyunsaturated fatty acid 
content (Hawkins et al., 1999, Mares-Perlman et al., 1995, Smith et al., 2001, 
Vojnikovic et al., 2007).  These environmental risk factors are all thought to 
contribute towards AMD disease progression by causing oxidative damage (Beatty et 
al., 2000).  Age is also a major risk factor for developing AMD.  In one study, whilst 
there was an AMD prevalence of 0.2% in individuals aged 55-64 years, this 
increased to 13% in those over 85 (Smith et al., 2001).  In addition to environmental 
factors, it has been shown that there is a strong genetic influence in AMD.  Analysis 
was carried out looking at AMD prevalence in monozygotic and dizygotic twins, 
with a concordance of 0.37 in the former compared with 0.19 in the latter.  The 
heritability of AMD was estimated at 45% (Hammond et al., 2002). 
 
1.3.1 Genes showing association with AMD 
Several genes have been associated with retinal degenerations, either mutated in 
diseases similar to AMD but showing Mendelian inheritance, or having 
polymorphisms which confer increased risk of developing AMD.   For instance, 
sequence variation in fibulin5, a member of the fibulin gene family has been 
associated with increased risk of AMD (Stone et al., 2004).  Fibulin proteins interact 
with other extracellular matrix proteins such as collagens, elastins, fibronectins and 
elastins, and fibulin3 was found to be mutated in a Malattia leventinese, a disease 
characterised by confluent sub-RPE drusen (Stone et al., 1999).  This would suggest 
extracellular matrix dysfunction can contribute towards AMD disease progression.  It 
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has also been suggested that polymorphisms in the photoreceptor cell-specific ATP-
binding cassette transporter gene (ABCA4) are associated with increased risk of 
AMD (Allikmets et al., 1997, Allikmets et al., 2000), although this has not been 
confirmed by others (Schmidt et al., 2003).  Other genes which have been implicated 
include fibulin6, VEGF, APOE and TLR4 (Toll-like receptor 4) (Scholl et al., 2007). 
 
1.3.2 Identifying loci 1q25-q31 and 10q26 associated with risk of AMD 
Whilst some models of AMD do show Mendelian inheritance, the vast majority of 
AMD risk appears to be complex, with disease susceptibility determined by a 
combination of environmental and genetic factors.  Linkage analysis was carried out 
looking at a large family consisting of 20 affected and 10 unaffected individuals, 
with polymorphism in the ARMD1 locus (1q25-q31) identified as being associated 
with increased risk (Klein, 1998).  Further studies were carried out using linkage 
analysis and genomewide association studies which supported this result.  Other 
regions were also identified, including a locus in chromosomal region 10q26 
(Majewski et al., 2003, Seddon et al., 2003, Iyengar et al., 2003, Schick et al., 2003, 
Weeks et al., 2004, Abecasis et al., 2004).  Fisher et al. (2005) carried out a genome-
scan-meta-analysis (GSMA) of the combined data from these studies and highlighted 
the 10q26 locus as showing the greatest AMD susceptibility risk (p=0.00025), 
although 1q25-q31 was also highlighted.  The 10q26 locus contains the genes for the 
high temperature requirement serine protease (HTRA1) and LOC387715 or ARMS2 
(age-related maculopathy susceptibility 2), and 1q26-q31 contains the regulators of 
complement activation (RCA) gene cluster. 
 
1.3.2.1 ARMS2/HTRA1 and risk of AMD 
The single nucleotide polymorphism (SNP) identified in 10q26 lies in an intergenic 
region between the genes for HTRA1 and ARMS2.  There is currently a debate 
surrounding which polymorphism in the two genes is responsible for the increased 
risk of AMD, which is compounded by the two proteins being in strong linkage 
disequilibrium (Allikmets et al., 2008).  It has been reported that a polymorphism in 
the promoter region of HTRA1 is responsible, with two studies in Chinese and 
Caucasian populations confirming this.  HTRA1 is a protease chaperone activated in 
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response to cellular stress, and immunostaining has shown it to be localised within 
drusen of AMD individuals (DeWan et al., 2006, Yan et al., 2006).  However, other 
studies have reported that the 10q26 locus risk is attributable to an allele arising from 
a deletion-insertion in ARMS2, removing the polyadenylation signal and resulting in 
unstable mRNA and a putative null allele (Kanda et al., 2007, Fritsche et al., 2008).  
The debate has yet to be resolved. 
 
1.3.2.2 The RCA gene cluster 
The “Regulators of Complement Activity” (RCA) gene cluster consists of a tandem 
array of >60 genes, 15 of which are complement-related.  Within this region is a 355-
kb segment encoding complement factor H (CFH) and the CFH-related proteins, 
CFHR3, CFHR1, CFHR4, CFHR2 and CFHR5.  Complement factor H is a 
regulatory protein in the alternative activation pathway of the complement system 
involved in innate immunity, and consists of 20 short consensus repeats (SCR).  
CFHR1-5 are thought to have arisen by partial gene duplication events of CFH, and 
contain homologues of CFH SCRs 6-9 and 19-20 (Zipfel et al., 1994).   
 
1.3.2.3 A complement factor H Y402H polymorphism and risk of AMD 
Following on from the identification of 1q26-q31 being associated with increased 
risk of AMD, further investigations were carried out into this region to narrow down 
the specific loci responsible.  Single nucleotide polymorphisms were analysed within 
this region, comparing case and control populations, with a Y402H polymorphism in 
CFH found to show significant association (p=4.95x10-10 and p<10-7).  Odds ratios of 
2.7/2.45 and 5.57 were given for heterozygosity and homozygosity of the high risk 
(402H) allele (Edwards et al., 2005, Haines et al., 2005).  The Y402H polymorphism 
was again confirmed by a genomewide association study, with a SNP identified that 
was in linkage disequilibrium with Y402H.  The homozygous risk was reported as a 
7.4-fold increase (Klein et al., 2005). 
 
1.3.2.4 Risk associated with other CFH SNPs and haplotypes 
Further investigation of CFH revealed additional SNPs associated with increased risk 
of AMD.  Maller et al. (2006) identified an intronic non-coding SNP showing strong 
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association, and Hageman et al. (2005) showed risk association of I62V, a missense 
variant present in a predicted exon splice enhancer.  Li et al. (2006) identified 20 
variants within CFH which showed strong association with disease susceptibility 
greater than that reported for Y402H, with the SNPs showing the strongest 
association occurring in non-coding regions suggesting regulation of CFH expression 
may be important for disease progression.  They found 4 major CFH haplotypes, 2 
protective and 2 risk, and numerous rare haplotypes.  From this it was concluded 
there are multiple disease-predisposing variants, and multiple CFH haplotypes 
modulate AMD risk.  Hageman et al. (2005) also identified CFH haplotypes 
associated with risk of AMD.  They identified an at-risk haplotype present in 50% of 
cases and 26% of controls, with homozygotes for the haplotype comprising 24% of 
cases and only 8% of controls.  Protective haplotypes were also identified (OR = 
0.44 – 0.55). 
 
1.3.2.5 CFH-like proteins and AMD risk 
An AMD protective haplotype was identified which contains an 83kb deletion of 
CFHR1 and CFHR3 (Hughes et al., 2006).  Looking at 173 cases and 170 controls, 
the deletion was found to be present in 20% of control chromosomes and 8% of 
cases.  The deletion occurs 6.4kb downstream of CFH and CFHL1 between two 
29kb duplicated segments of DNA.  This result was confirmed by Hageman et al. 
(2006), with Spencer et al. (2007) also confirming the protective effect of this 
delCFHR1/CFHR3 haplotype. 
 
1.3.2.6 Variants in Factor B and C2 are associated with risk of AMD 
Factor B and C2 are proteins involved in the same complement pathway as CFH.  
The genes BF and C2 are located in the Major Histcompatibility Complex III 
(MHCIII) region at chromosomal region 6p21.  Haplotypes were identified in two 
studies associated with reduced risk of AMD.  Gold et al. (2006) identified 
haplotypes of L9H in BF and E318D in C2 (haplotype A), and R32Q in BF with a 
variant in intron 10 of C2 (haplotype B) as conferring significantly reduced risks 
with odds rations of 0.45 and 0.36 respectively.  Maller et al. (2006) confirmed the 
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association of these alleles with AMD, with P<10-5 for haplotype A and P<10-11 for 
haplotype B. 
 
1.3.2.7 Variant in C3 is also associated with risk of AMD 
C3 and C5 are major components of the complement cascade of which CFH plays a 
part.  Yates et al. (2007) looked at 13 SNPs in C3 and C5 using English and Scottish 
cohorts to see if there was any association with AMD.  An R102G polymorphism 
was found to be significantly associated in both groups (English P= 5.9x10-5, 
Scottish P=5.0x10-5).  The C3 polymorphism L314P was also identified as showing 
association with risk of AMD.  R102G and L314P are in strong linkage 
disequilibrium, however it was shown by Spencer et al. (2008) that the R102G 
polymorphism acting alone best explains the effect on disease risk. 
 
 
1.4 The Complement System 
The complement system is part of the innate immune system.  It comprises >30 
plasma and cell surface proteins, and provides host protection against invading 
pathogens and altered host cells.  Complement activation can result in cell lysis, 
activation of inflammatory processes and phagocytosis (Walport et al., 2001, Gros et 
al. 2008).   
 
1.4.1 Complement activation 
Complement activation occurs via the classical, alternative or mannose-binding 
lectin (MBL) pathways, initiating enzymatic cascades which result in the formation 
of inflammatory mediators and the membrane attack complex (MAC).  This is a 
lipophilic protein complex which forms in the plasma membrane of targeted cells 
causing their lysis.  Figure 1.6 summarises the pathways involved in complement 
activation.  Following complement activation, C3 is cleaved to form C3b.  C3b binds 
to the C3 convertases C4bC2a and C3bBb, formed by the classical, MBL or 
alternative pathways, to form the C5 convertases.  These cleave C5 to C5a and C5b.  
C5b can then interact with C6, C7 and C8 at the target plasma membrane.  This 
complex then combines with several molecules of C9 which form the MAC, a ring  
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Figure 1.6: The complement pathway. 
(source: Walport, 2001) 
 
The three pathways involved in complement activation: 
During classical activation, the C1q complex binds to antibodies 
bound to a target surface.  C1q then cleaves C4 to C4a and C4b.  
C4b then cleaves C2, enabling the formation of the C4bC2a C3 
convertase.  During mannose-binding lectin (MBL) activation, MBL, 
in comlex with MASP1 and MASP2 (mannose-binding lectin-
associates proteases 1 and 2), binds to mannose residues on 
bacterial cell surfaces.  This then initiates formation of the C4bC2a 
C3 convertase in the same manner as C1q.  During alternative 
pathway activation, low levels of C3 cleavage occur in the plasma.  
The resulting C3b can bind to cell surfaces, bind factor B and form 
the C3bB complex.  Factor D then cleaves Factor B, resulting in 
the C3bBb C3 convertase.  Both forms of the C3 convertase 
cleave C3 into C3b, which can then bnd to C4b and form the C5 
convertase, and initiate formation of the membrane attack complex 
(MAC). 
 30 
structure traversing the plasma membrane and causing cell lysis (Walport et al. 2001, 
Gros et al. 2008). 
 
The classical activation pathway involves antibodies bound to target surfaces, which 
the C1 complex, comprising C1q, two molecules of C1r and two molecules of C1s, 
attaches to.  This allows C1s to cleave C4 into C4a and C4b.  C4b attaches to  
the target membrane and cleaves C2 into C2a and C2b.  C4b combines with C2a to 
form the C3 convertase of the classical pathway, C4bC2a.  This then cleaves C3 to 
form C3b (Walport et al., 2001). 
 
During MBL activation mannose-binding lectin (MBL) in complex with mannose-
binding lectin-associated proteases 1 and 2 (MASP1 and MASP2) binds to mannose 
groups on the surface of bacterial cells.  MASP2 cleaves C4 and, following the same 
mechanism as for the classical activation pathway, the C4bC2a convertase is formed.  
MASP1 is thought to cleave C3 directly to form C3b (Walport et al., 2001). 
 
At low levels, C3 spontaneously cleaves to form C3b in plasma.  This can then bind 
to target surfaces where it combines with Factor B.  Factor D then cleaves bound 
Factor B to form the C3 convertase of the alternative pathway, C3bBb.  Properdin 
then binds to stabilise the structure (Walport et al., 2001). 
 
As well as forming the C3 convertases, cleavage of C3 is also required for 
opsonization of target surfaces for phagocytosis, for instance by macrophages.  
Following initial cleavage of C3, C3b is further degraded to iC3b, C3c and C3dg.  
These proteins bind to target surfaces and act as ligands for phagocyte complement 
receptors (see Section 1.4.2) (van Lookeren Campagne et al., 2007). 
 
1.4.2 Regulation of complement activation 
Regulation of complement activation is required to prevent attack of host tissues.  
C3b is unable to discriminate against host or invading surfaces so mechanisms have 
evolved either to prevent C3b attachment to host surfaces or to deactivate it when it 
does.  Complement regulators are either soluble or surface bound.  Such surface-
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bound receptors are the complement receptors, membrane co-factor (CD46) and 
decay accelerating factor (CD55).  The main soluble regulator is CFH, which acts as 
a co-factor with Factor I (FI). 
 
The coating of particles with C3b opsinizes them for recognition and phagocytosis 
by phagocytes expressing the complement receptors.  These include CR1 (CD35), 
CR2 (CD21), CR3 (CD11b/CD18), CR4 (CD11c/CD18) (Pangburn et al., 1980, 
Holers et al., 1992) and the macrophage complement receptor CRIg.  The CRIg 
receptor consists of membrane-attached IgV domains (Helmy et al., 2006).  It not 
only acts as a receptor of C3b-opsonized particles, but also inhibits the C3bBb 
convertase by attachment and steric hindrance of substrate binding (Wiesmann et al., 
2006). 
 
CD46 is a type I transmembrane glycoprotein consisting of four short consensus 
repeats, followed by a serine, threonine and proline-rich region, a 12 amino acid 
region of unknown function, a transmembrane domain and a cytoplasmic anchor. 
CD46 is a cofactor for Factor I cleavage of C3b and C4b.  C3b is cleaved to form 
C3bi and soluble C3f, whereas C4b is cleaved to form C4d and soluble C4c (Riley-
Vargas et al., 2004).    
 
CD55 consists of four SCRs attached to the plasma membrane via a 
glycosylphosphatidylinositol (GPI)-anchor.  It prevents the assembly or promotes the 
disassembly of C3bBb (Kim et al., 2005). 
 
 
1.5 Complement Factor H 
Complement factor H (CFH) is a 155 kDa plasma glycoprotein consisting of 1213 
amino acids.  It is secreted mainly by the liver and into the circulation, and comprises 
20 SCRs, each of approximately 60 amino acids, and an 18 amino acid leader 
sequence (Whaley et al., 1976, Ripoche et al., 1988).   
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1.5.1 CFH co-factor activity with Factor I 
CFH was first shown to be a co-factor for Factor I-mediated degradation of C3b by 
Whaley et al (1976).  This was later confirmed by Pangburn et al (1977).  Factor H 
binds to C3b and prevents it from interacting with Factor B and acts as a co-factor in 
the cleavage of C3b to iC3b by Factor I, with which it also shows an interaction 
possibly to stabilise the complex (Pangburn et al., 1978, Nagaki et al., 1978, Conrad 
et al., 1978, Pangburn et al., 1977, Soames et al., 1997).  The domains within CFH 
capable of C3b binding have been identified to be within the N-terminal SCRs 1-4 
(Kuhn et al., 1995), the C-terminal SCR20, and a potential third site contained within 
the central SCRs of the molecule (Oppermann et al., 2006, Jokiranta et al., 2000, 
Sharma et al., 2003).  Further analysis of these sites revealed that each has a distinct 
C3b binding site.  SCR1-4 will only bind to uncleaved C3b, SCR12-14 will interact 
with C3b, C3c and C3d, and SCR20 will only interact with the C3d component of 
C3b (Jokiranta et al., 2000).  Binding to cell-surface-bound C3b has been shown to 
occur via SRCs 19-20 (Ferreira et al., 2006).   
 
1.5.2 DAF activity of CFH 
As well as showing co-factor activity for FI-mediated degradation of C3b, CFH 
shows decay accelerating activity, causing the dissociation of the C3 convertases 
bound to non-activator surfaces (Whaley et al., 1976).  This activity was confirmed 
by Kuhn et al. (1996) using alternative pathway convertases bound to the surface of 
sheep red blood cells.  Recombinant fragments of CFH showed this activity mapped 
to SCR1-4, and that this activity was shared with the alternatively-spliced form of 
CFH, FHL-1 (see Section 1.5.6).   
 
1.5.3 CFH binding polyanions and host cells 
Following on from the initial observation that certain micro-organism-derived 
polysaccharides could bind C3b and that this complex was then resistant to 
CFH/Factor I inactivation (Fearon et al., 1977), and from a further study showing 
host polyanions could enhance CFH affinity for C3b and so inhibit complement 
activation (Meri et al., 1990), it was found that CFH recognises and binds to certain 
polyanions on host surfaces, providing host protection from complement activation.  
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Various polyanions have been identified as showing interactions with CFH, with the 
polyanion interaction sites within CFH mapped to SCR7 and SCR20 (Blackmore et 
al., 1996, Blackmore et al., 1998).  Subsequently it has been shown that the initial 
binding of CFH to host endothelial cells occurs via the C-terminal SCR20 polyanion 
binding site (Jokiranta et al., 2005, Ferreira et al., 2006). 
 
1.5.4 CFH interacts with CRP 
C-reactive protein (CRP) is a 120kDa acute phase protein which causes amplification 
of the complement classical activation pathway (Volanakis et al., 1974).  It is a 
member of the pentraxin family of proteins, containing cyclic pentameric proteins.  
Synthesised in the liver, normal circulating plasma concentrations are less than 
1g/ml.  However, following stimulation of expression, for instance by interleukins 1 
(IL-1) and 6 (IL-6), plasma levels can increase up to 500g/ml (Baumann et al., 
1994).  It has been shown that CRP binds the surface of apoptotic cells, recruiting 
CFH and preventing assembly of the MAC.  CRP then activates the classical 
pathway and so C3 opsinisation, facilitating removal of the apoptotic cell by 
phagocytes such as macrophages.  CRP was also shown to up-regulate macrophage 
expression of the transforming growth factor  (TGF-), thus reducing inflammation 
(Gershov et al., 2000).  CRP binding sites within CFH have been mapped to SCR7 
and SCR8-11 (Jarva et al., 1999, Giannakis et al., 2003).  There is some debate over 
the physiological relevance of the published data regarding CRP interactions with 
CFH and its subsequent influence on the phagocytosis of apoptotic cells, with other 
published studies challenging these findings.  Hart et al. (2005) found no evidence 
that CRP facilitated uptake of apoptotic cells by macrophages, and Biro et al. (2007) 
suggest that in its native pentameric state CRP does not bind CFH.  Previous studies 
have used CRP coated directly onto surfaces, however Biro et al. showed that unless 
CRP is attached to its ligand, phosphatidyl choline, it looses its pentameric structure.  
Native CRP is unable to activate the classical pathway unless bound to 
phosphacholine, whereas denatured CRP can.  Also, when bound to phosphocholine, 
native CRP shows no interaction with CFH, suggesting that this interaction does not 
occur in vivo. 
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1.5.5 CFH secondary structure and regulation of activity 
It has been suggested that CFH in plasma exists as a coiled, omega structure, 
reducing the exposure of several SCR residues, and that upon binding to 
glycosaminoglycans (GAG) or host cells the protein undergoes a conformational 
change.  This then exposes residues and helps regulate when and where CFH activity 
can occur (Oppermann et al., 2006).  This model predicts that SCR20 is responsible 
for initial CFH ligand binding.  Observations that 1) binding of CFH to endothelial 
cells occurs via the carboxy-terminal of the protein (Jokiranta et al., 2005), 2) CFH 
interactions with cell-bound C3b can be inhibited by isolated recombinant SCR19-20 
(Ferreira et al., 2006), 3) the RGD domain in SCR4 is inaccessible in CFH but 
exposed in it’s alternatively spliced form Factor H-like protein 1 (FHL-1) (which 
lacks SCRs 8-20) (Hellwage et al., 1997), and 4) antibodies have been identified 
which interact with conformational epitopes of CFH but not the linear protein 
(Oppermann et al., 2006) all support this model.  Prosser et al. (2007) propose a 
model where CFH binds surface polyanions via SCR20 facilitating the subsequent 
binding of SCR6-8 (see Section 1.6.4, and Figure 1.8). 
 
1.5.6 CFH-like proteins FHL-1 and CFHR-1-5 
CFH, its alternatively spliced form FHL-1 and the CFH-like proteins, CFHR1-5, are 
all plasma glycoproteins predominantly produced and secreted by the liver.  FHL-1 
comprises CFH SCRs 1-7 plus 4 additional C-terminal amino acids.  CFHR1-5 
comprise SCRs which share homology with CFH SCRs 6-9 and 18-20 (Jozi et al., 
2008).   
 
1.5.6.1 CFHR1-5 functions 
The CFH-related proteins show similar ligand binding properties and functions to 
CFH (Jozsi & Zipfel, 2008).  CFHR1 is thought to compete for surface ligand 
binding with CFH, and so the protective effect of a CFHR1 and CFHR3 deletion 
with regards to developing AMD may be due to increased CFH protection in the 
retina.  CFHR3 and CFHR4 have been shown to bind the C3d region of C3b.  Whilst 
neither protein shows DAF activity or independent co-factor activity with Factor I, 
when a small amount of CFH or FHL-1 is present then they enhance Factor I 
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mediated C3b inactivation (Hellwage et al., 1999).  CFHR5 has been shown to bind 
C3b, heparin and CRP, and displays co-factor activity with Factor I for the 
degradation of C3bBb, although to a lesser degree than CFH (McRae et al., 2005).  
The proteins CFHR1-5 are therefore predicted to have roles in regulation of 
complement, either independently or possibly in cooperation or competition with 
CFH (Jozsi & Zipfel, 2008). 
 
1.5.6.2 FHL-1 function 
FHL-1, like CFH, displays decay accelerating factor (DAF) and factor I co-factor 
activity.  SCR1-4 have been shown to be necessary for co-factor activity with Factor 
I, as is observed with CFH, and, again as observed with CFH, DAF activity has also 
been mapped to this region, although FHL-1 shows reduced DAF activity when 
compared with CFH, and contains an exposed RGD motif on SCR4 which is not 
exposed on CFH.  This enables cell adhesion via integrin receptors, and FHL-1 is 
thought to play a role in the spreading and adhesion of anchorage-dependant cells 
(reviewed by Zipfel et al., 1999). 
 
 
1.6 CFH and disease mechanisms in AMD 
Following on from the studies implicating CFH polymorphism with increased risk of 
developing AMD, many studies have been carried out to investigate a function for 
CFH in AMD.  Studies have focused on roles for CFH in the healthy retina as well as 
how the Y402H polymorphism affects the protein function.   
 
1.6.1 CFH expression and CFH localisation in the eye 
A study by Mandal et al. (2006a) was carried out investigating CFH expression and 
localisation within the mouse eye.  CFH was detectable in the eye at P1, with no 
difference in expression levels at P30.  However, at P180 expression was 
significantly higher, and at P300 higher still.  Analysis of different eye tissues 
revealed CFH expression was mainly in the posterior tissues of the RPE, choroid and 
sclera, with low levels observed in the iris-ciliary body and lens.  Minimal expression 
was observed in the retina, and none was in the cornea.  Immunohistology of mouse 
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ocular tissues showed CFH localising to the RPE, ciliary epithelium, outer plexiform 
layer, inner plexiform layer, ganglion cell layers and in the limiting membranes, 
although it is acknowledged that labelling in the inner plexiform layer could be 
migratory ganglion cells.  Another study (Chen et al., 2006) showed, by 
immunohistology of mouse eye cryosections, that CFH was present in the choroidal 
vessels, Bruch’s membrane and RPE cells.  A diffuse punctate distribution was also 
observed in the interphotoreceptor matrix, although no staining was observed at any 
other localisation within the eye. 
 
1.6.2 CFH expression by the RPE 
CFH/FHL-1 is produced and secreted by mouse and human RPE cells (Chen et al., 
2006).  Because a major function of the RPE is phagocytosis of rod outer segments, 
and lipofuscin accumulation has been suggested to be caused by phagocytosis of 
oxidised ROS (ox-ROS), the effects on CFH production by RPE due to exposure to 
ROS and oxidised ROS were investigated.  Although short-term (2 hour) exposure to 
ROS and ox-ROS had no effects on CFH synthesis, after 24 hours exposure to ox-
ROS CFH synthesis decreased.  Normal ROS had no effect on levels of synthesis, 
although 24 hour exposure to both ROS and ox-ROS did lower intracellular CFH 
levels suggesting that CFH secretion is stimulated.  It is postulated that ox-ROS may 
damage the cells and impair their ability to produce CFH, and that this could be a 
gradual process exacerbated by an ageing RPE, resulting in less CFH secretion.  CFH 
secretion was also shown to be reduced in RPE cells by exposure to tumour necrosis 
factor  (TNF-) and IL-6, both inflammatory cytokines.  As low-level inflammation 
is associated with AMD, it is suggested there are potential implications for this result 
in AMD pathogenesis too (Chen et al., 2006). 
 
Oxidative stress has also been shown to affect CFH expression by the RPE (Wu et 
al., 2007).  Whilst interferon- (INF-) increases CFH expression, as shown by 
Western blot of cell lysates, oxidative stress due to exposure to H2O2, paraquat or 
FeSO4 reduced this effect.  The mechamism was shown to involve the activator 
signal transducers and activators of transcription 1 (STAT1) and repressor forkhead 
box 03 (FOXO3), with INF- inducing FOXO3 translocation to the nucleus and 
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binding to STAT1, and oxidative stress acetylating FOXO3 resulting in its 
preferential binding to the CFH promoter, reducing CFH expression. 
 
1.6.3 CFH knockout mouse and retinal phenotype 
A comparison was carried out between normal and age-matched CFH knockout 
(CFH-/-) mice.  Phenotypic observations included a reduction in visual acuity, 
increased photoreceptor dysfunction and increased sub-retinal autofluorescence when 
compared with the wild-type mouse.  In wild-type mice, C3 deposits are observed in 
Bruch’s membrane but not the RPE or retina, whereas in CFH-/- mice C3 deposits 
were also observed fragmented in Bruch’s membrane, extending into the RPE, and 
also in the neuroretina.  Ultrastructural phenotypes included reduced sub-RPE 
electron dense material and reduced Bruch’s membrane thickness.  It should be noted 
that this is the opposite of that observed in AMD patients.  It was suggested that in 
the CFH-/- mice increased C3 deposition leads to increased deposit clearance.  In 
addition, the RPE-ROS boundary is disrupted, with reduced apical microvilli and 
ROS misalignment.  The apical/basal polarity of RPE organelles also appears to be 
disrupted.  
 
1.6.4 Effects of the Y402H polymorphism on CFH function 
The Y402H polymorphism occurs in SCR7 of CFH.  This is a region which is 
involved in binding to GAGs and CRP.  Studies have been carried out to see if these 
functions are affected by this polymorphism and to gain insight into possible disease 
mechanisms.  Clark et al. (2006) investigated interactions of recombinant SCR6-8 
(402Y and 402H alleles) with different heparins.  It was found that the two alleles 
showed different binding properties dependant upon which heparin was present.  
Interactions were investigated by plate binding assay and heparin affinity columns, 
using various differently desulphated heparins.  It was hypothesised that age-related 
changes in GAG composition affect CFH binding and so have implications for AMD 
disease mechanisms.  Further investigation of the interaction with heparin was 
carried out by Herbert et al. (2007).  It was shown that SCR7 adopts an elongated 
structure with respect to neighbouring SCR6 and SCR8, exposing the Y402H 
residue, and that the structures were the same for the two variants.  The histidine 
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allele of SCR7 was found to have a higher affinity for heparin affinity columns and 
also gel mobility shift assays (GMSA) found it showed greater retardation of 
different size-fractionated heparins when compared to the tyrosine allele.  No 
differences were observed when SCR6-8 was used.  Fernando et al. (2007) however, 
provided data suggesting that SCR6-8 actually forms a bent-back structure, where 
SCR6 and SCR8 approach each other, with the heparin binding residues exposed on 
the outside curvature of the molecule, and that binding of heparin was likely to alter 
this structure slightly.  Prosser et al. (2007) determined the crystal structure of SCR6-
8 (histidine allele) in complex with sucrose octasulphate (SOS).  They showed that 
the Y402H residue is directly involved in GAG binding, in combination with other 
residues within SCR6-8.  They propose a model where these GAG binding residues 
are contained within a groove formed from modules 6-8, capable of interacting with 
a single GAG molecule.  Full length CFH is predicted to interact with this GAG 
molecule via modules 6-8 and 20, where it is localised to the surface and able to hold 
C3b in a pincer.  Having a tyrosine at residue 402 would alter the GAG specificity of 
the binding site. 
 
Laine et al. (2007) have reported differences between the two alleles in their ability 
to bind CRP.  CRP binding sites in CFH have been mapped to SCR7 and SCR8-11.  
They investigated the ability of either recombinant modules 5-7 (both alleles) or full 
length CFH (purified from plasma of either AMD patients homozygous for the 
histidine allele, or unaffected controls homozygous for the tyrosine allele).  They 
found that in both cases the histidine allele showed reduced binding affinity to CRP.  
This difference was greater for the recombinant modules SCR5-7, as would be 
expected due to the additional CRP binding site in full length CFH SCR8-11.  They 
suggest that a reduced binding affinity for CRP could reduce the ability of the CFH-
CRP complex to promote non-inflammatory debris clearance, leading to 
accumulation of debris and inflammation.  Other studies looking at the effects of the 
Y402H polymorphism of CFH ligand binding confirmed the reduced binding affinity 
of the histidine allele for CRP (Sjoberg et al., 2007, Skerka et al., 2007).  Skerka et 
al. also showed that the histidine allele of FHL-1 has reduced CRP binding ability, as 
well as to heparin.  Elevated levels of deposited CRP have been observed in the 
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choroidal stroma of individuals homozygous for the histidine allele (Johnson et al., 
2007).  No differences were observed for CFH or albumin, suggesting that the 
deposition is CRP-specific rather than a result of leaky choroidal capillaries.  It is 
proposed that this observation is due to a state of chronic inflammation due to altered 
complement inhibition as a result of the Y402H polymorphism. 
 
1.6.5 CFH mutations and kidney disease 
Mutations in CFH have also been associated with the kidney diseases 
membranoproliferative glomerulanephritis type II (MPGNII) and atypical haemolytic 
uraemic syndrome (aHUS).  MPGNII presents with complement-containing dense 
deposits in the basement membrane of the glomerular capillary wall, whereas aHUS 
presents with hemolytic anemia, glomerular endothelial cell damage, alternative 
pathway activation and progression to end-stage renal disease (Zipfel et al., 2006).  
Also associated with MPGNII are Bruch’s membrane deposits similar in structure 
and composition to the drusen observed in AMD (Mullins et al., 2001, Montes et al., 
2008).  Patients with MPGNII have low plasma CFH levels, as well as low C3 levels 
thought to be the result of CFH-deficient alternative complement pathway activation.  
C3 deposition is observed along the glomerular capillary walls and C3c was shown 
by immunohistology to be a primary component of the glomerular dense deposits, 
supporting this dysregulation of complement activation (Abrera-Abeleda et al., 2005, 
Montes et al., 2008).  MPGNII disease mechanisms are therefore thought to be the 
result of low plasma CFH causing systemic alternative pathway activation and dense 
deposit deposition on both Bruch’s memebrane and the kidney glomerular basement 
membrane.  This is supported by the observation that both pigs and mice deficient for 
CFH develop symptoms similar to MPGN II (Hogasen et al., 1995, Pickering et al., 
2002).   
 
Disease-causing mutations in aHUS tend to occur in the C-terminal SCR19-20.  This 
is the region involved in initial cell-surface polyanion binding, and it is thought that 
the disease-causing mutations compromise this ability.  This then results in surface 
complement activation and the subsequent aHUS-associated tissue damage 
(Jokiranta et al., 2005, Herbert et al., 2006).  Further structural analysis of the CFH 
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C-terminal polyanion binding site revealed that aHUS-associated mutations directly 
affected this binding site (Herbert et al., 2006).  In addition to mutations within CFH, 
aHUS can arise due to non-homologous recombination within the RCA gene cluster 
resulting in a CFH/CFHR1 hybrid gene, consisting of the first 21 exons of CFH and 
the last 2 exons of CFHR1 (Venables et al., 2006).  Further aHUS-associated non-
homologous recombinations within the RCA gene cluster have resulted in deletions 
of CFHR3 and CFHR1, whilst leaving CFH intact, suggesting that CFHR3 and/or 
CFHR1 have roles in regulating complement activation on cell and tissue surfaces 
(Zipfel et al., 2007) (see Section 1.5.6).   
 
 
1.7 Late-onset retinal macular degeneration 
Late-onset retinal macular degeneration (L-ORMD) is a rare, autosomal dominant 
disease characterised by extensive sub-RPE deposits, leading to progressive loss of 
central and then peripheral vision (Duval et al., 1986, Brosnahan et al., 1994, Kuntz 
et al., 1996, Milam et al., 2000, Jacobson et al., 2001).  The disease is similar to 
AMD with punctate yellow-white lesions observed in the retina of affected 
individuals.  First reported disease symptoms are visual disturbances and difficulty in 
dark adaptation from about the fifth decade.  A study looking at 3 affected families 
testing 17 individuals at 50:50 risk of developing L-ORMD found such dark 
adaptation abnormalities to be an early phenotypic marker for disease progression 
(Jacobson et al., 2001).  Investigations revealed rod adaptation kinetics to be 
affected, resulting in a reduction in rod electroretinography (ERG) b-wave kinetics 
(Kuntz et al., 1996, Milam et al., 2000). These dark adaptation abnormalities were 
more pronounced in the macula than in the peripheral retina (Figure 1.7) (Hayward et 
al., 2003).  Affected individuals have also been reported to have long anterior lens 
zonules (Ayyagari et al., 2005). 
 
1.7.1 Diseased retinal structure 
Post-mortem examination was carried out on donated eye from elderly affected 
individuals, revealing posterior retinal disruption affecting the photoreceptors, RPE 
and Bruch’s membrane, although the retina anterior to this did not appear to be 
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greatly affected.  There was thinning of the retina, photoreceptor loss, retinal atrophy 
and a hyper-pigmented macula.  New blood vessels were formed extending from the 
choriocapillaris through Bruch’s membrane, and disciform scarring was also 
observed indicating old CNV (Kuntz et al., 1996, Milam et al., 2000).  Studies on 
eyes donated from two affected brothers showed retinal atrophy except in the 
peripheral retina and only the occasional photoreceptor in the macula.  Rod outer 
segments were shortened with disorganised disc membranes, with this 
disorganisation being greater in the central retina (Duval et al., 1986).  A donated eye 
from an affected individual aged 80 years showed extensive deposits between the 
RPE and Bruch’s membrane, with associated degeneration of the neural retina 
including loss of cells and normal retinal structure (Figure 1.7) (Hayward et al., 
2003). 
 
1.7.2 Sub-RPE deposits in L-ORMD 
Extensive deposits were observed between Bruch’s membrane and the RPE, ending 
anteriorly at the ora serrata and posteriorly at the edge of Bruch’s membrane at the 
optic nerve head.  In places the deposits were greater than 50m thick and extended 
from the basal lamina of the RPE to the inner collagenous layer of Bruch’s 
membrane (Kuntz et al., 1996).  These deposits were found to have many 
components including collagen, lipids, amyloid P, lysozyme, elastin, apolipoprotein 
B-100, calcium, esterified and unesterified cholesterol and rhodopsin, with Muller 
cell processes also observed in some regions (Kuntz et al., 1996, Milam et al., 2000).  
Duval et al. (1986) carried out light microscopy analysis of deposits showing 
occasional mononuclear cells and lipofuscin autofluorescence.  Electron microscopy 
revealed fibrous growth, with deposits anteriorly showing amorphous material with 
electron dense material inclusions and posteriorly showing more granular material 
and possible macrophages.  Further microscopy studies were carried out by Milam et 
al. (2000).  Light microscopic analysis of sections of a donated eye revealed spheres 
of deposits, elevating overlying RPE cells (Figure 1.8), with thick laminated deposits 
formed by coalescence of these spherical deposits (Figure 1.8).  Electron microscopy 
confirmed the apical displacement of RPE cells by spherical deposits, which 






Figure 1.7: Sub-RPE deposits observed in L-ORMD patients. 
(Hayward et al., 2003) 
 
Patients with L-ORMD have extensive sub-RPE deposits. 
The normal retina (A) has a thin Bruch’s membrane (BrM) and 
healthy neural retina. 
The L-ORMD retina (B) has a thick layer of extracellular deposits, 
with heavily pigmented RPE cells (arrow).  The neural retina is also 





 Figure 1.8: Microscopic analysis of L-ORMD deposits  
(source: Milam et al., 2000) 
 
A - Pathology of a donor L-ORMD eye, showing atrophic retina and 
optic nerve (arrow head), thinned retina and hyperpigmented 
macula (*). Pigment deposits are observed in the far peripheral 
retina (arrow). 
B – Bruch’s membrane (B) is thickened and there is a decreased 
number of photoreceptors (p) (n – inner nuclear layer). 
C – Far peripheral retina showing spherical deposits (*) elevating 
overlying RPE cells (arrowhead) (p – photoreceptor nuclei). 
D – Midperipheral retina, showing thick laminated deposits (*) 
between the RPE (arrowhead) and the elastin layer of Bruch’s 
membrane (arrow), c indicates new capillaries.  No photoreceptros 
are present. 
E – Sub-RPE deposits are formed by coalescence of sherical 
deposits seen in C (arrowheads – RPE cells).   
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collagen.  Basal processes from the RPE extended into the deposits and observed 
omega-shaped profiles suggested exocytosis of packets of fibrillar material into the 
deposits.  The deposits were described as resembling the BlamD but not the BlinD 
seen in AMD. 
 
1.7.3 Identification of a disease-causing mutation in C1QTNF5 
With initial patient diagnosis that of an autosomal dominant retinitis pigmentosa 
screening was carried out for mutations in rhodopsin, peripherin and TIMP3, 
however no mutations were found (Kuntz et al., 1996).  Genetic analysis was 
subsequently carried out looking at 14 affected families to identify a disease-causing 
mutation.  The mutation was found to be a serine to arginine (Ser163Arg) mutation 
in C1q and tumour necrosis factor related protein 5 (C1QTNF5), with 7/14 affected 
families and 0/100 control families showing the mutation (Hayward et al., 2003).  
C1QTNF5 is located in chromosomal region 11q23, and is contained entirely within 
the 3’ untranslated region of the MFRP gene.  MFRP encodes a protein of unknown 
function which shares homology with the Frizzled family of receptors (see Section 
1.7.9).  It was shown by PCR amplification of retinal DNA that both genes are co-
expressed as a bicistronic transcript.  C1QTNF5 consists of 3 exons, with the disease-
causing C to G transversion occurring in the third exon.  The mutation occurs in a 
highly conserved residue, showing conservation from mammals to birds and fish 
(Hayward et al., 2003). 
 
1.7.4 C1QTNF5 shares homology with short chain collagens 
C1QTNF5 shares homology with other C1q-like proteins and the tumour necrosis 
factor (TNF) superfamily, which are both thought to share an evolutionary link 
(Shapiro et al., 1998).  These proteins form the C1q and TNF superfamily (Kishore 
et al., 2004).   C1q proteins contain a globular C1q (gC1q) domain, usually at the 
carboxyl terminus of a collagen stalk, with the gC1q domain involved in 
trimerisation and the collagen stalk enabling multimerisation of the trimers to form 
bouquets.  The TNF family also contains gC1q domains which trimerise, but they 
have stalks which, although rich in glycine and proline residues, are not collagenous 
(Shapiro et al., 1998).  Other members of C1q and TNF superfamily include C1q, 
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EMILIN-1, collagen types VIII and X and adiponectin (see Figure 1.9).  In 
homologous proteins containing the gC1q domain, an aromatic motif is responsible 
for initial trimer assembly (Brass et al., 1992, Chan et al., 1999), followed by the 
formation of a central solvent-filled channel stabilised by Ca2+ clusters providing 
strong ionic bonds (Kishore et al., 2004, Bogin et al., 2002).  C1q family members 
actually share only five conserved residues, each of which is contained within the 
hydrophobic core of the trimeric molecule.  Of the proteins whose gC1q domain 
structures have been determined, each contains a ten-strand -sandwich fold with a 
jelly-roll topography, consisting of two five-stranded -sheets, each made of 




Figure 1.9: The C1q and TNF superfamily. 
(source: Kishore et al., 2004) 
 
Members of the C1q and TNF superfamily: All members contain a 
C-terminal gC1q domain involved in trimerisation of the molecule, 
and trimers can be homotrimeric or heterotrimeric.  Most members 




1.7.5 C1QTNF5 protein properties 
C1QTNF5 is a 25kDa protein with three domains: a signal peptide, a collagen 
domain and a globular C1q domain.  The disease-causing mutation occurs in the 
gC1q domain and is predicted to alter the surface charge.  Functional studies have 
been carried out looking at E. coli-produced recombinant gC1q domain, with 
comparisons made between the wild type and mutant proteins.  The solubility of the 
purified wild-type and mutant gC1q was investigated at 37°C.  The wild type protein 
was found to be soluble up to 24 hours whilst the mutant protein had a tendency to 
form insoluble aggregates.  In addition, although both wild type and mutant gC1q 
showed predominantly monomeric protein when analysed by reducing sodium 
dodecyl sulphate polyacrylamide gel eletrophoresis (SDS-PAGE), under native 
conditions the wild type protein was found to be present mainly as trimeric with 
weak hexameric forms, whilst the mutant protein would not migrate through the gel.  
It was concluded that the Ser163Arg mutation causes misfolding and aggregation of 
the mutant protein (Hayward et al., 2003).  Further biochemical analysis was carried 
out on the gC1q domain looking at the multimeric state of the protein (Shu et al., 
2006b).  Both proteins were shown to oligomerise readily even under reducing 
conditions, with the wild-type forming monomers, dimers and trimers but the mutant 
showing only monomers and dimers.  It was suggested this was due to instability of 
the mutant protein, making it more susceptible to reducing conditions.  Further 
investigation into the effects of the Ser163Arg mutation and trimer assembly was 
carried out by Shu et al. (2006a).   Pull-down experiments using glutathione S-
transferase (GST)-tagged wild-type gC1q and His-tagged wild-type or mutant gC1q 
showed that it is the gC1q domain which is involved in self assembly and trimer 
formation, and that the wild type protein can interact with the mutant, with this result 
confirmed by yeast-two-hybrid experiments.  The gC1q domain contains a conserved 
aromatic motif homologous to aromatic motifs found in other C1q-like proteins, 
which are predicted to be important for self-assembly of multimeric species (Brass et 
al., 1992, Chan et al., 1999).  Using recombinant gC1q produced in E. coli and site-
directed mutagenesis to introduce point mutations, it was shown that the aromatic 
motif in the gC1q domain is important for such self-assembly.  Deletion of this 
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region resulted in a complete loss of self-assembly of the multimers, as did 
introducing missense mutations of the conserved residues. 
 
1.7.6 C1QTNF5 tissue expression 
Mandal et al. (2006c) investigated C1QTNF5 tissue expression in the mouse at 
different stages of development, with tissue expression studied in both embryonic 
and adult mice.  Embryonic expression was first observed at E11, continuing up to 
E17, the last stage investigated.  In the post-natal eye, expression was highest at P1 
and declined until P5, after which expression levels remained steady.  In 33 week old 
mice expression was highest in the posterior segment of the eye, followed by the iris-
ciliary body.  Low level expression was also observed in the brain, retina, lens, liver, 
lungs, heart, spleen, kidney, skeletal muscle, skin, testes and uterus.  Cellular 
expression was also investigated using in situ hybridisation with a C1QTNF5 
sequence-specific probe.  At E14.5 it was detected in the layer of neural crest and 
cranial paraxial mesoderm marking the anlage of the ciliary body and iris stoma, and 
at E18.5 it was detected in the presumptive iris and ciliary body.  In the adult mouse, 
C1QTNF5 was detected in the lateral plasma membrane of the RPE, the RPE apical 
processes, ganglion cells, ciliary body apical membranes and the plasma membrane 
of the lens epithelial cells.  In the RPE apical processes it co-localised with ezrin.  
However, no co-localisation was observed with TIMP-3, a marker for Bruch’s 
membrane.  Immunostaining of mouse RPE sections showed co-localisation with the 
tight junction protein 1, ZO-I, suggesting association with tight junctions, and 
immunostaining of Madin-Darby canine kidney (MDCK) cells also showed such 
ZO-I co-localisation in the lateral plasma membranes.  Immunoelectron microscopy 
confirmed the C1QTNF5 plasma membrane localisation, with levels being highest 
where the cells juxtapose, and along the lateral membrane and apical processes 
which interdigitate with the ROS. 
  
1.7.7 The effects of the Ser163Arg mutation on C1QTNF5 in a cellular 
system 
It has been shown that C1QTNF5 is expressed in the RPE, and that C1QTNF5 forms 
multimeric species.  It has also been shown that the Ser163Arg mutation affects 
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multimerisation of the gC1q domain, causing aggregation of the protein.  Several 
studies have investigated the mutation using full length C1QTNF5 and how this 
affects the protein in mammalian cellular systems. 
 
1.7.7.1 Wild-type C1QTNF5 is secreted but the mutant protein is not 
It was shown by Hayward et al. (2003) that C1QTNF5 is expressed by the RPE and 
is predicted to be secreted.  To investigate C1QTNF5 secretion and the effects of the 
Ser163Arg mutation in a mammalian cellular model, HEK293-EBNA cells were 
stably transfected with wild-type or mutant His-tagged C1QTNF5 (Shu et al., 
2006b).  In both cases, C1QTNF5 was detected in the cell lysate by Western blot, 
confirming its expression.  However, only wild-type C1QTNF5 was detected in the 
culture media.  Also, when cell lysates were analysed by native polyacrylamide gel 
electrophoresis (PAGE), the wild-type protein migrated through the gel whereas the 
mutant protein did not.  From these results it was concluded that the mutant protein is 
not secreted but is retained within the cells as a high molecular weight aggregate 
(Hayward et al., 2003).   
 
 A similar study was carried out using C-terminal V5-tagged C1QTNF5, transfected 
into COS-7 cells (Mandal et al., 2006a).  Cell lysate membrane and hydrophilic 
fractions, and culture media were analysed by Western blot under reducing and non-
reducing conditions.  Wild type C1QTNF5 was found to be present in all samples, 
whereas mutant C1QTNF5 was present only in the cell lysates and could not be 
detected in the culture media.  When analysed by reducing SDS-PAGE and Western 
blot both the wild type and mutant proteins were present as monomers.  However, 
under non-reducing conditions the wild type also formed dimers whereas again the 
mutant would not migrate through the gel.  From this it was also concluded that the 
Ser163Arg mutation in C1QTNF5 causes aggregation and lack of secretion of the 
mutant protein. 
 
1.7.7.2 Different cellular trafficking of the mutant protein 
ARPE-19, a spontaneously transformed human RPE-derived cell line, was transiently 
transfected with green fluorescent protein (GFP)-tagged wild-type or mutant 
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C1QTNF5 (Shu et al., 2006b).  Immunostaining analysis was carried out looking at 
the cellular localisation of the proteins.  Wild-type C1QTNF5 showed a diffuse 
cytoplasmic distribution, whereas the mutant appeared to show formation of 
intracellular aggregates.  Co-localisation immunostaining was carried out with the 
endoplasmic reticulum (ER) markers calreticulin and protein disulphide isomerase 
(PDI).  The mutant co-localised with both these markers whereas the wild-type did 
not.  From this it was concluded that the wild-type protein undergoes normal cellular 
trafficking for a secreted protein whereas the mutant is retained within the ER.  In 
addition, further immunostaining showed no co-localisation between mutant 
C1QTNF5 and the Golgi apparatus 58K protein, whereas it was observed for the 
wild-type, providing further evidence for the wild-type protein only travelling 
through the secretory pathway.  To test whether either protein was preferentially 
degraded by the proteosome, stably transfected ARPE-19 cells were incubated with 
the proteosome inhibitors MG132 and MG115.  Levels of both proteins, detected by 
Western blot in cell lysates, increased following treatment.  However, when the cells 
were treated with cycloheximide to block protein synthesis, the mutant protein had a 
reduced half life when compared with the wild-type.  This suggests it is 
preferentially degraded by the proteosome.  Disease mechanisms have been 
suggested in which the mutant protein is retained within the ER as a high molecular 
weight aggregate, resulting in either a loss of function due to haploinsuffuciency, or a 
gain of function due to protein aggregation.  As mutant C1QTNF5 has been shown to 
interact with the wild-type, then such interactions occurring intracellularly could 
significantly reduce the amount of wild-type protein secreted too, raising the 
possibility of a dominant negative effect.   
 
1.7.7.3 C1QTNF5 and RPE cell adhesion to Bruch’s membrane 
To investigate a possible function for C1QTNF5 as an extracellular matrix protein, 
stably transfected HEK293-EBNA cells expressing either wild-type or mutant 
proteins were plated on laminin- or fibronectin-coated microtitre plates.  Mutant 
C1QTNF5-expressing cells showed significantly reduced adhesion when compared 
with the wild-type to laminin-coated plates, but no difference in adhesion was 
observed to fibronectin.  It was postulated that one role of C1QTNF5 could be in 
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adhesion of the RPE to Bruch’s membrane, and that the Ser163Arg mutation resulted 
in reduced adhesion which facilitated the build up of the extracellular debris seen in 
the L-ORMD (Shu et al., 2006b).  It was suggested that in vivo wild-type C1QTNF5 
multimerises to form a hexagonal lattice, as some other short chain collagens have 
been shown to do, and that this ability is affected by the Ser163Arg mutation 
(Hayward et al., 2003). 
 
1.7.8 C1QTNF5 interacts with CFH 
Preliminary studies have shown there to be an interaction between CFH and 
C1QTNF5.  Due to the similarities in phenotype between L-ORMD and AMD, and 
the expression of both CFH and C1QTNF5 by the RPE, it was investigated in this lab 
whether an interaction between CFH and C1QTNF5 could be observed.  Initial 
results, carried out by Dr X. Shu, suggested this was the case (unpublished data).  
Surface plasmon resonance (SPR) was carried out between recombinant gC1q and 
plasma-purified CFH, with an interaction observed when gC1q was immobilised to 
the chip and CFH was added in the fluid phase.  125I-labelled proteins were used in 
plate binding assays which showed an interaction between gC1q and CFH domains 
SCR6-8Y and SCR6-8H and it was shown by gel mobility shift assays and heparin 
affinity columns that gC1q, like CFH, is capable of binding polyanions.   
 
1.7.9 C1QTNF5 and obesity 
C1QTNF5 has been identified as playing a role in obesity.  Microarray profiling was 
carried out looking at adipocytes from abdominal subcuteanceous adipose deposits in 
Pima Indians, which showed that most differentially expressed genes between obese 
and non-obese individuals are involved in inflammation, with a larger proportion 
showing up-regulation than down-regulation (Lee et al., 2005).  C1QTNF5 and 
CD90 were up-regulated, with both located in chromosomal region 11q22-q24.  This 
region showed peak linkage with obesity in the population studied.  It is suggested 
that up the regulation of genes involved in inflammation (it is assumed this is the 
case for C1QTNF5) is perhaps not surprising due to adipose tissue inflammation and 
macrophage infiltration being associated with obesity.  Another study was carried out 
to identify polymorphisms in a Japanese population that confer susceptibility to 
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metabolic syndrome which identified a T101A polymorphism in C1QTNF5 showing 
significant association (Yamada et al., 2008). 
 
1.7.10 Membrane-type Frizzled-Related Protein (MFRP) 
MFRP is a type II membrane protein consisting of 579 amino acids.  It contains a C-
terminal domain which is homologous to the Wnt-binding cysteine-rich domains 
(CRD) of the Frizzled family of transmembrane proteins, two Tolloid repeats 
(comprising globular domains related to cubulin and the low-density lipoprotein 
receptor) which are homologous to the Tolloid metalloprotease family, and a 
membrane-spanning domain (Katoh, 2001, Sundin et al., 2005) (Figure 1.10).  The 
Frizzled family of proteins consist of receptors for Wnt binding and signalling, with 
the first Frizzled gene identified as a polarity-determining gene in Drosophila (Adler, 
1992).     
 
1.7.10.1 MFRP mutation and expression in the mouse eye 
MFRP is mutated in the mouse retinal degeneration 6 (rd6), which is an autosomal 
recessive trait causing discrete spots across the retina, progressive photoreceptor 
degeneration and subsequent retinal dysfunction (Kemeya et al., 2002).  MFRP is 
expressed in the RPE, cillary body and testis of the adult mouse, and has been found 
expressed as a bicistronic transcript with C1QTNF5 (Kameya et al., 2002, Mandal et 
al., 2006b).  Looking at expression levels within the embryo, MFRP was detected by 
quantitative real time polymerase chain reaction (qRT-PCR) at E11 to E17, peaking 
at E15.  In adult mouse whole eyes, expression levels were highest at P1, declining 
by around 75% by P5.  Expression levels were slightly lower still at P7, and 
remained unchanged up to P30.  This data indicates that MFRP has roles not only in 
eye development but also in maintenance as the eye ages.  Within the adult retina, 
MFRP localises to the apical and basal membranes of the RPE, although not the 
apical processes, as no co-localisation with ezrin was detected.  Immunostaining of 
MDCK cells, which endogenously express low levels of MFRP and C1QTNF5, 
showed MFRP to be localised to the apical membranes, where it showed co-
localisation with C1QTNF5.  However, whereas C1QTNF5 was also found localised 
to the lateral membranes, this was not the case for MFRP (Mandal et al., 2006b).  In 
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the rd6 mouse, MFRP expression levels in the embryo were similar to those in 
control mice.  However, expression levels were markedly lower after birth and, 
although expression levels rose up to a peak at P28, this peak was much later than in 
the control mice where expression peaked at around P14 after which it declined 
slightly (Won et al., 2008).  This pattern of expression in the control mouse differs 
from that reported previously (Mandal et al., 2006b). 
 
Again comparing wild-type and mutant mice, immunohistology was carried out on 
the retina.  In the wild-type animals, MFRP was found to be localised to the cillary 
body and RPE apical but not basal membranes.  No protein was detected in the 
mutant mice, and after carrying out Western blot analysis this was found to be due to 
truncation of the mutant MFRP.  Photoreceptor development peaks at around P7, so 
histological analysis was carried out on retinas from P7 through to P28.  In the 
mutant mice ROS were shortened and disorganised, although they did not appear to 
be reduced in number.  By P28 the thickness of the ONL is reduced and there is 
thinning of the ROS. Electron microscopy of mutant retina revealed areas where 
there was disorganisation and a reduction in numbers of apical microvilli (Won et al., 
2008).  ERG analysis was carried out on wild-type and rd6 mice, with aberrant ERG 
responses in mutant mice revealing rod dysfunction.  One function of the RPE is the 
daily phagocytosis of ROS, initiated by the onset of light (LaVail, 1976).  To 
determine if this was affected in the rd6 mice, levels of rhodopsin in the RPE were 
measured 1 hour after the onset of light.  These were found to be reduced when 
compared to wild-type.  In addition, levels of phosphorylated MerTK were reduced, 
suggesting that these mice have deficiencies in ROS phagocytosis.  Due to the 
homology between MFRP and the Frizzled family of receptors, it was also 
investigated whether any evidence could be found for MFRP localisation with -
catenin.  None was found, suggesting MFRP is not involved in signal transduction 









Figure 1.10: C1QTNF5 and MFRP are expressed as a bicistronic transcript. 
(source: Sundin et al., 2005, Kameya et al., 2005) 
 
MFRP is expressed as a bicistronic transcript with C1QTNF5. 
A - C1QTNF5 is contained with in the last two exons (13 and 14) of 
the MFRP transcript.  Genomic DNA and mRNA: white represents 
coding regions, shaded represents untranslated regions (individual 
exons are numbered).  Polypeptide: different domains are 
indicated by labels and shading (TM - transmembrane domain, 
CUB1 / CUB2 - cubulin-related 1 and 2, LDLa - low-density 
lipoprotein receptor-related, CRD - cystein-rich domain). 
B – MFRP:  N, amino terminus; C, carboxyl terminus; P, proline-
rich interval; Mem, membrane spanning helix; STP, serine-
threonine-proline-rich interval; CUB, cubilin-related; L, low-density 




1.7.10.2 MFRP mutation in the human eye 
In humans, MFRP mutation (the result of a frameshift insertion in exon 10) has been 
reported associated with extreme hyperopia, and although some dark adaptation 
difficulties were observed, there was no retinal degeneration (Sundin et al., 2005).  
Other reports have found mutations in MFRP associated with a syndrome resulting in 
nanophthalmos, retinitis pigmentosa, foveoschisis and optic disc drusen, caused by 
frame shift mutations, the result of either a 1 base pair insertion or deletion in exon 5 
(Ayala-Ramirez et al., 2006, Crespi et al., 2008).  It is interesting to note that no 
reduction in eye size is observed in the rd6 mouse, suggesting that MFRP functions 
may differ between the two species.  Whilst the mouse is an excellent model for 
human disease, there are distinct differences with humans.  For instance the mouse 
eye is adapted for nocturnal vision and so has slightly fewer cone photoreceptors and 
does not have a macula containing increased numbers of rods (Sundin, 2005).   
 
1.7.10.3 MFRP interacts with C1QTNF5 
MFRP and C1QTNF5 are expressed as a bicistronic transcript, suggesting that they 
are functionally related.  MFRP contains two cubulin (CUB) domains, which can 
also be found on complement components C1s and C1r.  The CUB domains 
participate in the interaction of these proteins with C1q, which contains a gC1q 
domain homologous to that found in C1QTNF5.  Several studies have confirmed an 
interaction between MFRP and C1QTNF5.  Mandal et al. (2006b) co-
immunoprecipitated both proteins from human RPE-choriod and whole mouse eye 
extract.  In addition they co-transfected COS-7 cells with C-terminal V5-tagged 
C1QTNF5 and N-terminal Xpress-tagged MFRP, and were able to pull down the 
complexed proteins using immunoprecipitation.  Shu et al. (2006b) used full-length 
C1QTNF5 as bait to screen a human brain yeast two-hybrid cDNA library and 
identified MFRP-containing clones.  Further investigation was carried out looking at 
gC1q interactions with the CUB domain, with pull-down experiments confirming an 
interaction between the two recombinant proteins.  Yeast two-hybrid again 
confirmed that the domains interact, and co-transfection of HEK-293T cells showed 




1.8 Aims of this study 
Age-related macular degeneration is a complex disease.  It impacts upon many 
people's lives, not only those affected but their carers and society too, and its 
incidence is increasing.  Due to its complexity and many contributing factors it is 
difficult to gain insights into the underlying disease mechanisms.  Also, although 
individuals have donated eyes for research, these tend to be in the later stages of the 
disease and therefore ascertaining what observations are causative and what are the 
result of other initiating factors can be difficult.  Some mouse models have been 
found which replicate some of the symptoms of human disease, and some inherited 
diseases have been identified which result in retinal degenerations, both of which are 
useful for increasing our understanding.  L-ORMD is one such inherited disease, 
with patients presenting the extensive sub-retinal deposits, CNV and retinal 
degeneration observed in AMD.  The disease-causing mutation and resulting protein 
product have been identified, making this a good target to study.  It is hoped that 
understanding disease mechanisms in L-ORMD with help to unravel what is 
occurring in AMD. 
 
In order to understand these processes, this study aims to investigate the effects of 
the Ser163Arg mutation in both a mammalian cellular system and on recombinant 
protein properties.  Using a physiologically relevant cell line, the effects of stable 
C1QTNF5 over-expression will be investigated, using both the wild-type and mutant 
proteins.  The observation that C1QTNF5 may be involved in RPE cell adhesion will 
be studied, as will the effects of mutant C1QTNF5 over-expression on the cellular 
system.  The interaction between C1QTNF5 and CFH will be further investigated, 
aiming to identify which regions of CFH are involved.  Also, due to the reported 
interaction between MFRP and C1QTNF5, and the involvement of MFRP in ROS 
phagocyotsis, the stably transfected cell lines will also be used to determine if any 
role for C1QTNF5 can be found in ROS phagocytosis. 
2 CHAPTER 2  
:  




2.1 Cell culture procedures  
 
2.1.1 Mammalian cell culture 
Unless otherwise specified, all ARPE-19 and EBNA293 cells were cultured at 37°C, 
5% CO2, using the following tissue culture media.  For stock solution concentrations, 
see Section 2.8.3.  All cell cultures were checked and confirmed negative for 
mycoplasma infection (carried out by HGU Technical Services). 
 
 ARPE-19:  Reagent    Volume 
   DMEM F12    500ml 
   FCS     50ml 
   Penicillin/streptomycin  5ml 
 
 EBNA293: Reagent    Volume 
   DMEM (with L-glutamate)  500ml 
   FCS     50ml 
   Penicillin/streptomycin  5ml 
   MEM vitamins   5ml 
   Sodium pyruvate   5ml 
   Non-essential amino acids  5ml 
   L-glutamate    5ml 
 
For 25cm2 tissue culture flasks, cells were passaged once they had reached 80% 
confluence.  This involved washing the cells twice with PBS, adding 1 pastette 
volume of trypsin/EDTA (1:1 mixture of stock solutions provided by HGU technical 
services, see Section 2.8.3) and incubating at 37°C for 2-3 minutes or until the cells 
had detached.  Three pastette volumes of culture media were then added to neutralise 
the trypsin.  To a fresh 25cm2 tissue culture flask, 2 pastette volumes of media were 
added, followed by 1 pastette volume of cell suspension.  For other flask sizes, 
volumes were adjusted accordingly. 
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2.1.2 Bacterial cell culture 
Escherichia coli cultures were used to produce recombinant His-gC1q.  Unless 
otherwise specified, all E. coli cultures were incubated 37°C, rotated at 225rpm, with 
cultures maintained in Lauria Broth (LB), supplied by HGU technical services.  
Bacterial clones were supplied by and bacterial culture protocols had previously been 
optimised by Dr X. Shu (MRC Human Genetics Unit). 
 
Large-scale cultures were grown from glycerol stocks stored at -80°C.  These were 
streaked onto an LB-agar plate containing ampicillin (provided by HGU technical 
services) and incubated overnight at 37°C to obtain individual colonies.  One colony 
was then transferred to 5ml LB containing 0.1mg/ml ampicillin and incubated 
overnight as before.  These were then added to 1.2l LB and incubated until an OD595 
0.6-1.0 was reached.  IPTG was then added to a concentration of 1mM, the 
temperature reduced to 20°C and the culture incubated overnight to allow for 
expression of recombinant protein. 
 
2.1.3 Yeast cell culture 
Pichia pastoris cultures were used to produce recombinant SCR modules.  In all 
instances, basic minimal media plus glycerol (BMG) and basic minimal media plus 
methanol (BMM) were prepared as described below, with solutions sterile filtered 
prior to use. 
 
BMG: 100mM potassium phosphate pH6.0 
   1.34% yeast nitrogen base with ammonium sulphate 
   4 x 10-5% biotin 
   1% glycerol 
 
BMM: 100mM potassium phosphate pH6.0 
   1.34% yeast nitrogen base with ammonium sulphate 
   4 x 10-5% biotin 
   1% methanol 
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Stabs of each clone were provided by Dr A. Herbert (University of Edinburgh), 
which were streaked onto a yeast extract peptone dextrose medium plus sorbitol 
(YPDS) agar plates and incubated overnight at 37°C enabling individual colonies to 
be obtained.  YPDS plates were prepared using the following in 1l distilled water, 
which was autoclaved prior to pouring the plates: 
 
YPDS:   10g yeast extract 
    182.2g sorbitol 
     20g peptone 
     20g agar 
 
The individual colonies obtained were used to inoculate 5ml BMG, and incubated at 
37°C, 225 rpm for 48 hours, until the culture turned milky-white.  The cultures were 
then added to 100ml BMG, in a 500ml shaker flask, and incubated overnight at 
37°C, 225 rpm.  The 100ml cultures were then added to 1l BMG, divided into 2 x 2l 
flasks and incubated as before until an OD595 10.0 was reached.  The cell pellets were 
collected by centrifugation at 500g for 10 minutes, resuspended in 200ml BMM and 
transferred to a 1l shaker flask.  Cultures were incubated at 25°C, 225rpm for 4 days, 
with 1% methanol by volume (2ml) added every 24 hours to induce recombinant 
protein expression.   
 
 
2.2 Stably transfected cell line creation 
Stably transfected ARPE-19 or EBNA293 cell lines were created, over-expressing 
recombinant His-tagged C1QTNF5 (His-C1QTNF5).  ARPE-19 cell lines expressed 
either wild-type or mutant His-C1QTNF5, with the required plasmid vectors created 
in this study.  EBNA293 cell lines were created which expressed wild-type His-
C1QTNF5, with plasmid vectors created and supplied for use by Dr X. Shu (MRC 
Human Genetics Unit, Edinburgh). 
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2.2.1 Creating ARPE-19 cell lines stably expressing wild-type and 
mutant His-C1QTNF5 
Creation of the cell lines involved making plasmid constructs with His-C1QTNF5 
inserts, subsequent transfection of ARPE-19 with the vectors and then screening of 
the ARPE-19 clones for His-C1QTNF5 expression. 
 
2.2.1.1 Creating pEGFP-C1-C1QTNF5 (minus EGFP) constructs 
The vectors were created using the pEGFP-C1 plasmid, with pEGFP removed and 
replaced with His-C1QTNF5.   
 
2.2.1.1.1 DNA separation and purification by agarose gel 
electrophoresis 
Several stages in the creation of the pEGFP-C1-C1QTNF5 inserts required 
separation and/or purification of DNA by agarose gel electrophoresis.  Unless 
otherwise specified, this was carried out using the following method. 
 
1g agarose was dissolved in 100ml 0.5x TBE buffer (20x stock: 216g Tris base, 110g 
boric acid, 18.6g EDTA, to make 1l with dH2O) by heating in a microwave until 
boiling.  0.2mg/ml ethidium bromide was added once the liquid had cooled a little.  
DNA samples were diluted in 1x loading buffer (6x stock: 25µg bromophenol blue, 
25µg xylene cyanol, 3ml glycerol, 6.95ml dH2O) before loading on to the gel 
immersed in 0.5x TBE buffer.  Gels were run at 150V until suitable separation had 
occurred.  The DNA standard size marker used was bacteriophage lambda digested 
with HindIII (DNA marker X, Roche).  
 
DNA was purified from the agarose gel using the QIAquick PCR Purification Kit 
(Qiagen) as follows.  All centrifugation steps were carried out using a benchtop 
microcentrifuge.  Using the pre-prepared buffers supplied, 3 volumes of buffer PB 
was added to 1 volume of DNA-containing agarose gel (excised from the main gel) 
(100mg ~ 100l) in a microcentrifuge tube.  The mixture was incubated at 50°C for 
10 minutes to dissolve the gel, and then loaded to the QIAquick column via 
centrifugation for 1 minute with the flow-through discarded.  The column was 
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washed by addition of 0.5ml Buffer QG and centrifugation for 1 minute with the 
flow-through discarded, followed by addition of 0.75ml Buffer PE, centrifugation for 
1 minute and the flow-through again discarded.  An additional centrifugation ensured 
complete removal of wash buffers from the column.  DNA was eluted by placing the 
QIAquick column in a fresh microcentrifuge tube, adding 30l sterile H2O, leaving 
to stand for 1 minute and then centrifugation for 1 minute, with the elution retained 
and the column discarded. 
 
2.2.1.1.2  Plasmid amplification in Escherichia coli 
At several stages in the preparation of the pEGFP-C1-His-C1QTNF5 constructs, it 
was necessary to amplify plasmids in E. coli.  Each stage follows the standard 
method of transfection, culture and purification as described below. 
 
E. coli TOP-10 cells (Invitrogen) show no resistance to ampicillin, and both the 
pGEM-T-Easy and pEGFP-C1 vectors confer resistance to this antibiotic.  3µl of 
purified vector was added to 1 vial of competent cells as provided by the supplier and 
only just obtained from -80 ºC freezer.  These were incubated on ice for 30 minutes 
before heat shocking at 42ºC for 30 seconds and placing on ice for a further 2 
minutes.  250µl super optimal broth with catabolite repression (SOC) medium 
(provided with the cells) was added, and the mixture incubated at 37 ºC on rotation 
for 1 hour.  30µl cell suspension was then spread on LB-agar plates containing 
ampicillin (provided by HGU technical services), with 100µl per plate 100mM IPTG 
and 50µl per plate 50mg/ml 5bromo-4-chloro-3-indolylbeta-D-galactopyranoside (X-
gal).  The plates were incubated overnight at 37ºC to allow for individual colonies to 
grow.  Six white colonies were selected for each insert, as selection criteria meant 
these rather than blue colonies contained plasmids with inserts disrupting the lac Z 
gene.  The colonies were amplified overnight at 37 ºC in 5ml LB containing 
0.1mg/ml ampicillin, and cell pellets collected by centrifugation at 3000g for 5 
minutes.   
 
The plasmids were purified from the cell pellets using the QIAprep Spin Miniprep 
Kit (Qiagen), as follows.  All centrifugation steps were carried out using a benchtop 
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microcentrifuge.  Using the pre-prepared buffers supplied, the cell pellet was 
resuspended in 250µl Buffer P1 plus RNase A and transferred to a microcentrifuge 
tube.  To this was added 250µl Buffer P2 and the tube inverted 4 times to mix.  
350µl Buffer N3 was added and the tube was again inverted 4 times to mix, followed 
by centrifugation at 13,000 rpm for 10 minutes.  The supernatant was then added to a 
QIAprep spin column followed by centrifugation at 13,000 rpm for 60 seconds.  The 
flow through was discarded.  The column was then washed, firstly with 0.5ml Buffer 
PB followed by centrifugation at 13,000 rpm for 60 seconds, and then with 0.75ml 
Buffer PE again followed by centrifugation at 13,000 rpm for 60 seconds.  An 
additional centrifugation was carried out to remove any residual wash buffer.  The 
flow through was discarded after each centrifugation step.  The plasmid was then 
eluted from the column in 30µl dH2O, incubating for 1 minute, before placing the 
spin column in a fresh microcentrfuge tube and centrifuging at 13,000 rpm for 60 
seconds. 
 
2.2.1.1.3 PCR amplification of C1QTNF5 inserts 
C1QTNF5 inserts were created with restriction sites suitable for insertion into 
pEFGP-C1, minus EGFP (enhanced green fluorescent protein).  The N-terminal 
restriction site was for NheI and the C-terminal site was for BamHI.  The following 
primers were used for creation via polymerase chain reaction (PCR) of both the wild 
type and mutant C1QTNF5 inserts: 
 
N-terminal: GCT AGC ATG GCG ATG AGG CCA CTC CTC GTC 
C-terminal:   GGA TCC CTA ATG GTC ATG GTG ATG ATG AGC  
AAA GAC TGG GGA GCT  
 
The N-terminal primer includes a Kozak sequence (G/ANNATGG) and start codon, 
and the C-terminal primer contains a hexa-histidine (‘His’)-tag sequence for addition 
of this tag to the C-terminal of the recombinant C1QTNF5, and a stop codon.  Inserts 
were created via polymerase chain reaction (PCR) amplification of a human 
complementary DNA (cDNA) template, provided by Dr X. Shu (Human Genetics 
Unit, Edinburgh), using the Expand High Fidelity PCR System (Roche), and primers 
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were commercially produced (Sigma).  The following reaction criteria were 
followed:   
 
 Reagent  Volume Concentration 
N-terminal primer 2.0l   10M  
C-terminal primer 2.0l  10M 
cDNA template 0.5l   Provided by Dr X Shu 
dNTP   2.0l   20µM 
10x reaction buffer M 2.5l   N/A  
Polymerase  0.2l   N/A 
DMSO   1.25l   N/A 
dH2O   9.55l N/A 
 
  Temperature Time 
1. 95 °C  60 seconds 
2. 95 °C  30 seconds 
3. 58 °C  60 seconds 
4. 72 °C  90 seconds 
5. Go to step 2, 34 times 
6. 72 °C  600 seconds 
  
PCR products were purified using 1% agarose gel electrophoresis, with complete 
PCR reaction mixtures loaded.  The appropriate bands were excised from the gel and 
then purified using the QIAquick PCR Purification Kit (QIAGEN), eluting in 30l 
sterile H2O, to give purified inserts ready for ligation into the pGEM-T-Easy vector 
and amplification in E. coli TOP10.  Ligation was carried out using the Rapid DNA 
Ligation Kit (Roche) and by incubating 5µl 2x reaction buffer, 3µl C1QTNF5 insert, 
1µl vector and 1µl T4 ligase overnight at 16°C.  Plasmds were then amplified in E. 
coli TOP-10 as described in Section 2.2.1.1.2. 
 
2.2.1.1.4 Selection of C1QTNF5 inserts 
A sample of each purified plasmid was then analysed to check for the presence of a 
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C1QTNF5 insert with the correct sequence.  Plasmids were first digested with the 
restriction enzymes NheI and BamHI using the following reaction mixture and 
incubation for 3 hours at 37 ºC.   
 
 Reagent  Volume  
BamH1  0.5ul  
Nhe1   0.5ul  
Reaction buffer M 1ul    
Plasmid  3l  
dH2O   Up to 10ul  
 
Digestion reactions were then analysed by 1% agarose gel electrophoresis to check 
for the presence of bands of approximately 700bp, corresponding to inserts for His-
tagged C1QTNF5.  Plasmids showing inserts of this size were then sequenced to 
check this was correct.  Sequencing was carried out by HGU technical services. 
 
2.2.1.1.5 Preparation of the pEGFP-C1 vector and C1QTNF5 inserts 
The pEGFP-C1 vector was prepared for ligation with the C1QTNF5 inserts by 
digestion with NheI and BamHI to remove the region encoding EGFP, and the 
C1QTNF5 inserts were removed from the pGEM-T-Easy constructs by digestion 
with the same enzymes.  The following digestion reactions were incubated at 37 ºC 
for 3 hours: 
 
 Reagent  Volume  
 BamHI  0.5µl 
 NheI   0.5µl 
 Reaction buffer M 1µl   
 Plasmid  5.0l       
 dH20   Up to 10µl  
 
Following digestion, the plasmid and inserts were purified using 1% agarose gel 
electrophoresis and gel extraction as described previously. 
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2.2.1.1.6 Ligation, selection and screening of the pEGFP-C1-C1QTNF5 
(minus EGFP) constructs 
Ligations were set up between vector and either wild-type or mutant C1QTNF5 
insert using the Rapid DNA Ligation Kit (Roche).  Following the manufacturers’ 
instructions, 4µl C1QTNF5 insert and 1µl pEGFP-C1 vector were incubated with 2µl 
5x dilution buffer and 3µl H2O for 10 minutes at room temperature.  To this was then 
added 10µl 2x ligation buffer and 1µl T4 ligase, and the reaction incubated overnight 
at 16°C.  The resulting plasmid constructs were then used to transform E. coli TOP-
10, amplified and purified as described previously.  Following the same method as 
Section 2.2.1.1.4, a sample of each was taken to test for the presence of the correct 
sized insert via digestion with NheI and BamHI, and suitable constructs with inserts 
of the correct size were chosen to test for expression of His-C1QTNF5 in ARPE-19. 
 
2.2.1.2 Checking expression of His-C1QTNF5 in ARPE-19 
Transient transfection and immunostaining were carried out to check that His-
C1QTNF5 was expressed in ARPE-19 when using the pEGFP-C1-C1QTNF5 
constructs.  ARPE-19 cells were grown to <50% confluency on glass slides in 6-well 
tissue culture plates, and then transfected with either the wild-type or mutant 
C1QTNF5 constructs as follows.  4ul FuGene (Roche) were added to 100ul serum-
free media and incubated at room temperature for 5 minutes.  3l DNA was then 
added and the mixture incubated at room temperature for 15 minutes.  Fresh culture 
media was added to the cells, followed by the FuGENE mixture.  Cells were allowed 
to grow overnight, slides were then washed twice with PBS and cells fixed to the 
slides with ice-cold methanol for 5 minutes and again washed twice with PBS.  
Immunohistochemistry was carried out as described in Section 2.3, using the anti-His 
primary and anti-mouse Texas Red secondary antibodies. 
 
2.2.1.3 Determination of correct G418 concentration 
In order to select stably transfected ARPE-19 cells, it was necessary to determine the 
correct G418 concentration.  ARPE-19 cells were grown to confluence in 6 well 
tissue culture plates, after which time culture media was changed for that containing 
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0, 300, 400, 500, 600 or 700g/ml G418.  Cells were incubated for 2 weeks, 
changing the culture media for fresh G418-containing culture media every three 
days.  After this time the media was changed back to standard ARPE-19 culture 
media and the cells incubated for a further week.  It was then determined by light 
microscopy whether any live cells remained.  The minimum concentration required 
for no live cells to remain (500g/ml) was selected for future use. 
 
2.2.1.4 Transfection and screening of ARPE-19 colonies 
Following clarification by immunohistochemistry that His-C1QTNF5 was expressed 
in ARPE-19 following transient transfection with the pEGFP-C1QTNF5 constructs, 
stably transfected cell lines were created.  Transfection of ARPE-19 was carried out 
using the microporator and supplied buffers as this has an optimised protocol for 
high-efficiency tansfection of many cell lines, including ARPE-19. 
 
ARPE-19 cells were grown to 80% confluence and detached using 1 volume of 
trypsin.  Following trypsin neutralization with 3 volumes of culture media containing 
10% FCS, cell number was counted using a haemocytometer and a suspension 
volume containing 56 x 105 cells was aliquoted into a 15ml Falcon tube.  This was 
centrifuged at 3000g to obtain a cell pellet which was resuspended in 1ml Buffer R.  
5µg DNA (wild type or mutant pEGFP-C1-C1QTNF5 vector) was added to 100µl 
cell suspension and gently mixed.  Cells were tranfected using microporator with the 
following parameters: 1350 V/ 20 ms/ 2 pulses. 
 
Each transfection reaction was then divided between three 30cm2 tissue culture 
dishes containing ARPE-19 selection media (DMEM-F12, FCS, P/S, 500ug/ml 
G418) and incubated for 2 weeks or until cell death occurred of the untransfected 
cells, leaving only transfected cells.  Media was changed for fresh every 3 days.  The 
plates were incubated for a further week to allow the transfected cell colonies to 
become viable.  Individual colonies were then detached with trypsin/EDTA, 
transferred to 24 well plates and subsequently amplified into 25cm3 flasks.  Each cell 
line was maintained under selection with G418 to ensure continued plasmid 
presence, following the method described in Section 2.1.1.  After the first passage, 
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the remaining cells from each flask were screened via Western blot for the 
expression of His-C1QTNF5 using the mouse anti-His primary antibody (see Section 
2.6.5).   
 
2.2.2 Creating an EBNA293 cell line stably expressing wild-type His-
C1QTNF5 
EBNA293 were transfected with the pCEP-Pu vector containing a wild-type His-
C1QTNF5 insert, created by and supplied for use by Dr X. Shu (MRC Human 
Genetics Unit, Edinburgh).  pCEP-Pu contains a puromycin resistance gene for 
selection of transfected cell lines.  Culture media puromycin concentrations had 
previously been optimised by Dr X .Shu. 
 
2.2.2.1 Transfection and screening of EBNA293 colonies 
EBNA293 were grown to <50% confluence in 1 well of a 6 well tissue culture plate.  
The cells were then transfected with the pCEP-Pu construct using FuGENE as 
described in Section 2.2.1.2.  Following transfection, cells were incubated overnight 
and then detached with trypsin/EDTA and transferred to two 30cm2 tissue culture 
dishes containing EBNA293 culture media plus 500g/ml puromycin.  The plates 
were incubated for two weeks ensuring only transfected cells remained.  Individual 
colonies were detached with trypsin/EDTA and transferred to 24 well tissue culture 
plates.  Once they had reached confluence these were transferred to 25cm2 tissue 
culture flasks.  After the first passage the remaining cells from each flask were 
screened by Western blot for His-C1QTNF5 expression using the mouse anti-His 
primary antibody (see Section 2.6.5).   
 
2.2.3 Checking secretion of His-C1QTNF5 in the transfected cell lines 
Secretion of His-C1QTNF5 in the stably transfected ARPE-19 and EBNA293 cell 
lines was tested, with samples analysed by Western blot.  In all instances the primary 
antibody used was mouse anti-His and the secondary antibody was horse raddish 





2.2.3.1 Checking secretion in the ARPE-19 transfected cell lines 
Secretion of His-C1QTNF5 was first tested in 2 wild-type and 2 mutant His-
C1QTNF5 stably transfected ARPE-19 cell lines.  Each cell line was grown to 
confluence in 3 wells of a 6-well tissue culture plate.  Culture media was then 
changed to serum free and the cells incubated for a further 3 days.  Culture media for 
each cell line was then pooled and centrifuged at 3000g for 5 minutes, with the 
supernatant retained.  The culture media were diluted 1:2 with 20% trichloroacetic 
acid (TCA) and left on ice for 20 minutes to enable precipitation of any proteins, 
followed by centrifugation at 3,000 rpm with the supernatant discarded.  The protein 
pellets were then analysed by reducing SDS-PAGE and subsequent Western Blot as 
described in Section 2.6.4 and Section 2.6.5, with primary antibody mouse anti-His, 
secondary antibody HRP-labelled rabbit anti-mouse and the standard ECL detection 
reagents used. 
 
2.2.3.1.1 Comparing secretion levels in the ARPE-19 cell lines 
Levels of His-C1QTNF5 secretion were compared between the selected wild-type 
and mutant stably transfected ARPE-19 cell lines, GFWT19 and GFMT22.  Cell 
lines were each grown to confluence in 1 well of a 24 well tissue culture plate, after 
which the media was replaced with 1ml serum free media and the cells incubated for 
a further 5 days.  Culture media were collected and set aside.  Cells were then 
detached in 250l trypsin/EDTA, followed by the addition of 750l media containing 
serum to neutralise the trypsin.  Cell concentrations were then determined using a 
haemocytometer, with an aliquot from each cell solution taken up to the maximum 
volume possible so that each contained the same number of cells.  Aliquots of the 
culture media were then taken and placed in microcentrifuge tubes, with volumes 
also adjusted to reflect the same number of cells in each sample and centrifuged at 
13,000 rpm for 1 minute in a benchtop microcentrifuge, with the supernatant then 
transferred to fresh microcentrifuge tubes.  To the centrifuged aliquots, 10l Ni-NTA 
bead suspension (Qiagen) was added (having previously been washed twice with 1ml 
PBS and resuspended to the same volume prior to washing), and the samples 
incubated on rotation for 1 hour.  The beads were then allowed to settle, the liquid 
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aspirated from the tube and the beads washed twice with 1ml PBS allowing them to 
settle in between washes.  After the final wash had been removed from the tube, the 
beads were centrifuged at 13,000rpm for 1 minute to collect a compact pellet and the 
excess liquid removed.  Bead samples and cell samples were then resuspended in 
reducing SDS-PAGE loading buffer and analysed by reducing SDS-PAGE and 
subsequent Western Blot as described in Section 2.6.4 and Section 2.6.5, with 
primary antibody mouse anti-His, secondary antibody HRP-labelled rabbit anti-
mouse and the ECL+ detection reagents used. 
 
A secretion time line was also carried out, comparing levels of His-C1QTNF5 
secretion after 1, 2 or 3 days.  Three wells of cells for each cell line were cultured 
and samples prepared as described above, with 1 well samples taken after 1, 2 or 3 
days incubation.  Cell samples were not collected, but media samples were analysed 
as described above. 
 
2.2.3.2 Checking secretion in the EBNA293 transfected cell lines 
Secretion of His-C1QTNF5 in the stably-transfected EBNA293 cell line was tested 
by TCA precipitation of the culture media proteins, as described in Section 2.2.3.1.   
 
2.2.3.2.1 Secretion time line in the EBNA293 cell lines 
Secretion of wild-type and mutant His-C1QTNF5 was compared in the stably 
transfected EBNA293 cell lines.  Cell lines were each grown to confluence in 3 wells 
of a 24 well tissue culture plate, after which the media was replaced with 1ml serum 
free media and the cells incubated for a further 1, 2 or 3 days, with culture media 
then collected into microcentrifuge tubes and centrifuged at 13,000 rpm for 1 minute 
on a benchtop centrifuge.  Supernatants were then transferred to fresh tubes and 10l 
Ni-NTA bead suspension was added (having previously been washed twice with 1ml 
PBS and resuspended to the same volume prior to washing), and the samples 
incubated on rotation for 1 hour.  The beads were then allowed to settle, the liquid 
aspirated from the tube and the beads washed twice with 1ml PBS allowing them to 
settle in between washes.  After the final wash had been removed from the tube, the 
beads were centrifuged at 13,000 rpm for 1 minute to collect a compact pellet and the 
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excess liquid removed.  Bead samples and cell samples were then resuspended in 
reducing SDS-PAGE loading buffer and analysed by reducing SDS-PAGE and 
subsequent Western Blot as described in Section 2.6.4 and Section 2.6.5, with 
primary antibody mouse anti-His, secondary antibody HRP-labelled rabbit anti-




Unless otherwise specified, immunohistochemical analysis of adherent cells was 
carried out using the following method.  Tables 2.1 and 2.2 give the concentrations 
of all primary and secondary antibodies used. 
 
Table 2-1: Primary antibodies used in immunohistochemistry 






















Table 2-2: Secondary antibodies used in immunohostochemistry 
Antibody Species Supplier Dilution 
Anti-mouse Texas Red 
Anti-rabbit FITC 
















2.3.1 General immunostaining method 
Cells were grown to 60-80% confluency on glass slides in 6 well tissue culture plates 
using the appropriate culture media.  Media was then aspirated from the wells and 
the cells washed twice with PBS.  Cells were then fixed to the slides in ice-cold 
methanol for 5 minutes, followed by two further washes in PBS.  Slides were 
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blocked for 1 hour with 10mg/ml BSA in PBS at room temperature and again 
washed twice with PBS.  Cells were then incubated with the primary antibody, 
diluted in PBS to the specified concentration, for 1 hour at room temperature, and 
washed 3 times for 5 minutes with PBS.  Fluorescent-labelled secondary antibody 
was added, again diluted in PBS to the appropriate concentration, followed by 
incubation for 1 hour at room temperature and then 3 washes for 5 minutes with 
PBS.  Slides were mounted in mounting medium (Vectashield) containing 4',6-
diamidino-2-phenylindole (DAPI) and analysed by fluorescent microscopy. 
 
2.3.2 Transient transfection and immunostaining of ARPE-19 for 
cellular trafficking of C1QTNF5 
Using the pEGFP-C1-C1QTNF5 constructs, ARPE-19 cells were transfected as 
described in Section 2.2.1.4, using 10l cell suspension and 0.5g DNA per reaction.  
Following transfection, each reaction was transferred to separate wells of a 6 well 
tissue culture plate, each containing a glass slide and ARPE-19 culture media.  Cells 
were incubated for 48 hours at 37°C.  Media was then aspirated from the wells and 
cells washed twice with PBS.  Cells were fixed with ice-cold methanol for 5 minutes 
and again washed twice with PBS.  Immunohistochemistry was then carried out as 
described in Section 2.3.1, using primary antibodies of mouse anti-His and rabbit 




2.4 Cell culture assays 
The following cell culture assays were carried out on untransfected ARPE-19, the 
ARPE-19 stably transfected cell lines, untransfected EBNA293 and the EBNA293 
stably transfected cell lines.  The ARPE-19 stably transfected cell line over-
expressing His-C1QTNF5 were produced in this study, as was the EBNA293 stably 
transfected cell line over-expressing wild-type His-C1QTNF5.  However, the mutant 
His-C1QTNF5-expressing EBNA293 cell line was produced by Dr X. Shu (MRC 




2.4.1 Apoptosis (TUNEL) assays  
The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labelling 
(TUNEL) assay was carried out to detect levels of apoptosis in ARPE-19 cells, either 
of untransfected ARPE-19 where apoptosis had been induced with H2O2 or of the 
transfected cell lines.  Once cells had been prepared, the TUNEL assay was carried 
out following the same method in each instance.  
 
2.4.1.1 Inducing apoptosis in ARPE-19 
ARPE-19 cells were grown to confluence on glass slides in 3 wells of a 6-well tissue 
culture plates.  1 well of cells was then incubated for a further 12 hours in media 
containing 0.5M H2O2, with the remaining two wells incubated for a further 2 hours 
in normal culture media.  These provided the apoptosis-induced, positive and 
negative control samples respectively.  Following the further incubation, the cells 
were washed twice with PBS and fixed to the slides with 4% methanol-free PFA for 
25 minutes at 4°C, followed by two 5 minute washes with PBS at room temperature.  
The slides were then ready for analysis using the TUNEL assay. 
 
2.4.1.2 Culturing the APRE-19 transfected cell lines prior to apoptosis 
detection 
ARPE-19 and wild-type or mutant His-C1QTNF5-expressing APRE-19 cells were 
grown to confluence on glass slides in 6-well tissue culture plates in culture media 
containing 10% FCS.  This was then changed to serum-free media and the cells 
incubated for a further 1, 2 or 3 days.  The slides were then washed twice with PBS 
and the cells fixed to the slides with 4% methanol-free paraformaldehyde (PFA) for 
25 minutes at 4°C, followed by two 5 minute washes with PBS at room temperature.    
In addition, 2 extra untransfected ARPE-19 slides were prepared, incubating in 




2.4.1.3 The TUNEL assay 
TUNEL assay analysis was carried out using the DeadEnd Fluorimetric TUNEL 
System (Promega) and following the manufacturers’ instructions.  Unless otherwise 
specified, all steps were carried out at room temperature.  Cells were permeabilised 
with 0.2% Triton X-100 solution in PBS for 5 minutes, and then washed for 5 
minutes with PBS.  After removing excess liquid, cells were covered with 100µl 
equilibration buffer and incubated at room temperature for at least 10 minutes.  
Whilst the cells were equlibriating, the rTdT incubation buffer and positive control 
slides were prepared.  To prepare the positive control slides, following 
permeabilisation and washing, the cells were covered with 100µl DNase I buffer and 
incubated for 5 minutes.  The liquid was then tapped off and 100µl DNase buffer I 
containing 10 units/ml DNase I was added followed by incubation for 10 minutes.  
Slides were then washed by immersing 3-4 times in dH2O.  The rTdT buffer was 
prepared by mixing 45µl equilibration buffer, 5µl nucleotide mix and 1µl rTdT 
enzyme per sample and positive control slide.    For the negative control slides, rTdT 
buffer was prepared in the same manner but omitting the rTdT enzyme.  Following 
draining of excess liquid, 50µl of the appropriate rTdT buffer was then added to each 
slide and incubated in the dark at 37°C for 1 hour, ensuring that the slides do not dry 
out.  Meanwhile, 20x saline-sodium citrate (SSC) was diluted 1:10 to create a 2x 
SSC solution.  Following sufficient incubation, the slides were then immersed in the 
2x SSC for 15 minutes, and subsequently washed 3 times for 5 minutes in PBS.  
Slides were then mounted in Vectashield plus DAPI and analysed by fluorescence 
microscopy as before. 
 
2.4.2 Cell adhesion assay 
Cell adhesion assays were carried out following the optimised cell adhesion assay 
method (Section 2.4.2.2).  
 
2.4.2.1 Optimising the cell adhesion assay 
Optimisation was required to obtain a reproducible cell adhesion assay method.  
Optimised stages included blocking the plate, determining correct cell number, 
washing to remove non-adherent cells and fixing of adherant cells. 
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2.4.2.1.1 Blocking the plate 
It was investigated whether bovine serum albumin (BSA), heat-inactivated BSA 
(both using a high 98% purity or low 96% purity grade of BSA) or using 1% 
skimmed milk would be most suitable as a blocking solution.   
 
Heat-inactivated PBS-BSA (HI-PBS/BSA) was prepared by dissolving 10 mg/ml 
BSA in PBS and filtering through a 2 µm disposable filter (Schleicher) to remove 
any large undissolved particles.  Any concentration greater than 10 mg/ml would 
form a solid gel when heat-inactivated, which is unsuitable for blocking wells.  The 
solution was heated in a 90°C water bath until it went cloudy but not white indicating 
that the protein was denatured but had not formed large aggregates.  High grade and 
low grade BSA were used to prepare HI-PBS/BSA solutions.  Blocking solutions 
were also prepared using high and low grade BSA at 3 % solution in PBS without 
heat inactivation, 1 % skimmed milk  in dH2O or PBS alone. 
 
Two hundred microlitres of each blocking solution was added to the wells of a 96-
well microtitre plate and incubated at room temperature for 2 hours.  After washing 
two times with 200l per well PBS, 100µl ARPE-19 cell suspension at 5 x 105 
cells/ml in standard ARPE-19 culture media was added to each well and incubated at 
37°C for 1 hour.  Wells were washed three times with 200l per well PBS and the 
number of adherent cells determined by staining with crystal violet (see Section 
2.4.2.2). 
 
2.4.2.1.2 Determination of correct cell number and washes 
The concentration of cells added to the wells and the number of washes required 
were investigated.  Too vigorous washing could remove adherent cells from the 
wells, and too few washes or too high a cell concentration could mean non-adherent 
cells remain.   
 
Using 96-well microtitre plates, 100l 10.0mg/ml laminin, diluted in PBS, was added 
to each well and incubated overnight at 4°C.  The wells were washed once with 
200l PBS using a multichannel pipette, with all liquid aspirated from the wells.  
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Blocking was then carried out using 200l per well HI-PBS/BSA (low grade) for 2 
hours at room temperature, followed by three washes with 200l PBS as before.  
100l ARPE-19 cell suspension containing 2.5x105, 5.0x105, 7.5x105 or 1.0x106 
cells/ml diluted in culture media was added to the wells and the plate incubated for 1 
hour at 37°C.  The cell suspension was then aspirated from the wells using the 
multichannel pipette.  In this and all subsequent washing stages, care was taken not 
to dislodge loosely adhered cells.  Pipette tips were placed gently against the edge of 
the well base and liquid was applied or removed slowly.  Wells were either washed 
1, 2 or 3 times, with the number of adherant cells determined by staining with crystal 
violet (see Section 2.4.2.2).  The assay was carried out in triplicate to test which 
combination of cell concentration and number of washes gave the most reproducible 
results. 
 
2.4.2.1.3 Investigating different fixatives 
To investigate the effects of different fixatives, 96 well microtitre plates were coated 
with increasing concentrations of laminin in PBS.  These were then blocked for 2 
hours with low-grade HI-PBS/BSA (prepared as before) and washed with 200l per 
well PBS.  100l cell suspension at 5.0x105 cells/ml in culture media was added to 
each well and incubated for 1 hour at 37°C.  Wells were washed twice with 200l per 
well PBS and then fixed with 100l per well of either 5% aqueous glutaraldehyde, 
methanol or not fixed (PBS alone added) for 20 minutes at room temperature.  Wells 
were washed twice with 200l per well PBS and the degree of cell adhesion 
measured using crystal violet (see Section 2.4.2.2). 
 
2.4.2.2 Optimised cell adhesion assay 
A 96 well microtitre plate was coated overnight at 4°C with the desired extracellular 
matrix proteins (1g/well of laminin, fibronectin, His-C1QTNF5 or His-gC1q) 
diluted in PBS.  The solution was then aspirated from wells, 200µl per well HI-BSA 
added and the plate incubated at room temperature for 2 hours.  The wells were 
washed three times with 200l per well PBS, and 100l cell suspension at 5.0x105 
cells/ml in culture media was added per well.  The plate was then incubated for 1 
hour (unless otherwise specified) at 37°C.  Following this, undetached cells were 
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carefully removed from the wells by aspiration, ensuring pipette tips did not detach 
cells from the wells.  The wells were then washed twice with 200l per well PBS, 
again ensuring minimal detachment of the attached cells. One hundred microlitres of 
5% aqueous glutaraldehyde was added to each well to fix the adherent cells, and the 
plate was incubated at room temperature for 20 minutes.  To determine the level of 
adherant cells, wells were then washed three times with 200l per well PBS, 100µl 
0.1% crystal violet (in 0.2M MES, pH6.0) was added to each well and the plate 
incubated at room temperature for 10 minutes.  The wells were then washed three 
times with 200l per well PBS, 100 µl 10% acetic acid was added to each well and, 
after mixing, the OD595 measured. 
 
2.4.3 Cell spreading assay  
96 well microtitre plates were coated overnight with 100l per well of 10mg/ml 
laminin or fibronectin diluted in PBS.  Wells were then washed three times with PBS 
and 100l cell suspension at a concentration of 5.0x105 cells/ml in culture media was 
added to each well.  The plates were incubated at 37°C for 2 hours, after which time 
images were taken of the cells using a light microscope from which to determine the 
number of spread cells. 
 
2.4.4 Phagocytosis assays 
Phagocytosis assays were carried out to compare levels of FITC-labelled ROS 
phagocytosis in the different ARPE-19 cell lines.  Levels of phagocytosis were 
determined by flow cytometry. 
 
2.4.4.1 Preparing and FITC-labelling rod outer segments 
Bovine retinas were stored at -80°C until required.  Following defrosting on ice, each 
retina was resuspended in 1ml sucrose homogenizing medium (34% sucrose, 65mM 
NaCl, 2mM MgCl2, 5mM tris-acetate pH7.4, 1x protease inhibitor tablet) and shaken 
vigorously for 1 minute to detach the ROS.  Following centrifugation at 4,600 rpm 
for 4 minutes using a benchtop microcentrifuge, the supernatant was removed and 
diluted with 2 volumes 10mM tris-acetate pH7.4.  The pellet was resuspended in 1ml 
sucrose homogenizing medium, homogenized with a loose-fitting pestle (4-5 passes) 
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and centrifuged as before at 4,600 rpm for 4 minutes.  The supernatant was removed 
and diluted with 2 volumes tris-acetate pH7.4.  The supernatants were pooled and 
centrifuged at 2,600 x g for 4 minutes.  The supernatant was discarded and ROS 
pellet resuspended in 1ml 0.1M sodium bicarbonate pH9.0 
 
To fluorescently-label the ROS, 10l FITC (10mg/ml in 0.1M sodium bicarbonate 
pH9.0) was added to the ROS suspension and incubated overnight at 4°C in the dark.  
Prior to use, FITC-labeled ROS (FITC-ROS) were centrifuged at 2,600g for 4 
minutes, the supernatant removed and the ROS pellet resuspended in 2ml 0.1M 
sodium bicarbonate pH9.0. 
 
2.4.4.2 Measuring phagocytosis of FITC-ROS by ARPE-19 cells using 
flow cytometry 
The following general method was adapted for each phgoytosis assay.  When 
investigating the effects of an anti-gC1q antibody (supplied by Dr X. Shu), the 
antibody was added to the cells after 3 days incubation in serum-free media and the 
addition of fresh culture media, diluting to a concentration of 0.1mg/ml.  When 
investigating the effects of additional CFH this was added in the same manner at 
concentrations of 0, 1, 5, 10, 50 and 100g/ml.  In both instances, cells were then 
incubated at 37°C for 1 hour prior to the addition of FITC-ROS.   
 
Cells were grown to 80% confluence in 6 well plates in normal culture medium.  The 
medium was then changed to serum free for 3 days.  After 3 days, the serum was 
changed for fresh serum free medium and 120l FITC-ROS suspension was added to 
the appropriate wells, and the cells incubated for the allocated incubation time with 
FITC-ROS for up to 48 hours.  Cells were then washed twice with PBS and detached 
using 1ml trypsin/EDTA.  Three ml normal culture medium was added to neutralize 
the trypsin and cell pellets were collected by centrifugation at 3000g for 5 minutes.  
Cell pellets were then washed twice in PBS and resuspended in 2ml PBS.  Cell 




2.5 Human blood procedures and assays 
All methods were optimised by and carried out with the assistance of Aisleen McColl 
(MRC Centre for Inflammation Research, Edinburgh). 
 
2.5.1 Isolation and maturation of macrophages from whole blood 
Monocytes were isolated from whole blood and macrophages prepared for use by 
Aisleen McColl.  The monocytes were plated onto 6 well tissue culture plates and 
incubated at 37˚C for 1 week to allow their differentiation into macrophages.  Some 
of the cells were steroid-treated with dexamethasone, as this enhances their 
phagocytic activity. 
 
Mature macrophages were washed twice with PBS and detached from the wells 
using 5 mM EDTA, 0.1% BSA on ice for 30 minutes.  It was not possible to use 
trypsin as this blocks phagocytosis.  Vigorous pipetting was carried out to assist in 
detaching the cells, which were then collected, centrifuged and resuspended to a 
concentration of 0.7 x 106 cells/ml in Iscove’s modified Dulbecco’s medium 
(IMDM), with or without autologous serum. 
 
2.5.2 Neutrophil preparation 
Neutrophils (purified from whole blood by Aisleen McColl) were cultured in IMDM, 
with or without 10% autologous serum at 37˚C for 22 hours at a concentration of 4 x 
106 cells/ml.  Neutrophils undergo apoptosis when left in culture, although if left for 
longer periods of time they will become necrotic.  Neutrophils were then incubated 
with AnnexinV, with a 10 minute incubation at 37˚C to allow for labelling of the 
apoptotic neutrophils. 
 
2.5.3 Macrophage phagocytosis of apoptotic neutrophils with 
autologous serum 
24-well tissue culture plates were coated overnight at 4°C with 1g/well His-
C1QTNF5, His-gC1q or CFH diluted in 100l PBS.  The coated wells were washed 
with PBS and the liquid removed from the wells.  500l of macrophage suspension 
with autologous serum was added to each well and the plates incubated at 37 ˚C for 
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45 minutes.  After incubation, the media and non-adherant cells were removed from 
the wells, which were then washed once with IMDM.  400l per well of labelled 
neutrophil suspension was added and the plates incubated at 37 ˚C for 30 minutes.  
Following incubation, the liquid was removed from the wells and the cells detached 
by addition of trypsin/EDTA and incubated on ice for 10 minutes.  Cells were then 
analysed by flow cytometry to determine the degree of phagocytosis by the 
macrophages of the labelled neutrophils. 
 
2.5.4 Macrophage phagocytosis of apoptotic neutrophils without 
autologous serum 
500µl macrophage suspension without autologous serum and containing either CFH, 
wild-type or mutant His-C1QTNF5 or 10% autologous serum as a positive control 
was added to wells of a 24-well tissue culture plate.  The plates were incubted at 
37°C for 45 minutes to allow the macrophages to adhere to the wells.  Media was 
then aspirated from the wells, which were then washed once with IMDM.  400l per 
well of labelled neutrophil suspension was added, containing either CFH, wild-type 
or mutant His-C1QTNF5 or 10% autologous serum positive control, and the plates 
incubated at 37 ˚C for 30 minutes.  Following incubation, the liquid was removed 
from the wells and the cells detached by addition of trypsin/EDTA and incubation on 
ice for 10 minutes.  Cells were then analysed by flow cytometry to determine the 
degree of phagocytosis by the macrophages of the labelled neutrophils. 
 
 
2.6 Protein procedures 
 
2.6.1 Ni-NTA affinity purification of His-C1QTNF5 from mammalian cell 
culture media 
Unless otherwise specified, the following method was used for purification of His-
C1QTNF5 from the culture media of both the stably-transfected EBNA293 and 
ARPE-19 cell lines.  Cells were grown to 80% confluence in media containing 10% 
FCS.  This was then changed to serum-free media and the cells incubated for a 
further 5 days.  The culture media was then collected and clarified by centrifugation 
 81 
at 10,000g for 10 minutes.  To the culture media was then added 30mM NaH2PO4, 
150mM NaCl, 10mM imidazole and the pH adjusted to 8.0.  2ml per litre of culture 
media of Ni-NTA bead suspension was washed twice with an excess of PBS and 
then added to the culture media and incubated on rotation at 4°C for 2 hours.  This 
was then poured down a chromatography column, collecting the beads within the 
column.  These were washed with 20ml per 2ml bead suspension of 30mM 
NaH2PO4, 150mM NaCl, 20mM imidazole pH8.0, followed by 20ml per 2ml bead 
suspension of 30mM NaH2PO4, 150mM NaCl, 50mM imidazole pH8.0.  His-
C1QTNF5 was then eluted from the beads in 1ml fractions of 1M imidazole, pH10.0, 
with 10l from each elution analysed by reducing SDS-PAGE for the presence of 
pure His-C1QTNF5. Appropriate elution fractions were pooled and dialysed for 24 
hours against 1l PBS using dialysis tubing, with the buffer replaced for fresh after 12 
hours. 
 
2.6.2 Ni-NTA affinity purification of His-gC1q from E. coli 
Recombinant His-gC1q was purified from E. coli cell pellets, cultured as follows, 
unless otherwise specified.  Cell pellets were collected by centrifugation at 3000rpm 
for 10 minutes. 
 
Cell pellets were resuspended in 5ml per gram of 50mM NaH2PO4, 300mM NaCl, 
10mM imidazole, pH8.0 plus 1mg/ml lysozyme and incubated on rotation for 30 
minutes.  The cells were then lysed using 2 passes through a French press.  The lysed 
mixture was centrifuged at 10,000g for 30 minutes to remove cellular debris, with the 
supernatant retained.  Ni-NTA beads were washed twice in PBS with 1ml bead 
suspension per 100ml supernatant used.  The beads were then added to the 
supernatant and incubated on rotation for 2 hours at 4°C.  This was then poured 
down a chromatography column, collecting the beads within the column.  These 
were washed with 20ml per 2ml bead suspension of 30mM NaH2PO4, 150mM NaCl, 
20mM imidazole pH8.0, followed by 20ml per 2ml bead suspension of 30mM 
NaH2PO4, 150mM NaCl, 50mM imidazole pH8.0.  His-gC1q was then eluted from 
the beads in 1ml fractions of 1M imidazole pH10, with 10l from each elution 
analysed by reducing SDS-PAGE.  Appropriate elution fractions were pooled and 
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dialysed for 24 hours against 1l PBS using dialysis tubing, with the buffer replaced  
after 12 hours. 
 
2.6.3 Purification of SCR modules from Pichia pastoris culture media 
by SP-Sepharose ion exchange chromatography 
P. pastoris cultures were grown according to the standard method, with secreted 
SCR proteins purified from the culture supernatant.  All purification methods had 
been optimised previously by Dr A. Herbert (University of Edinburgh). 
 
2.6.3.1 Purification of SCR7-8Y and SCR7-8H 
Culture supernatants were collected via centrifugation at 2,500g for 15 minutes, with 
the cell pellets discarded.  5mM EDTA was added to each before diluting 1:6 with 
distilled water.  The diluted supernatants were loaded to 5ml SP-Sepharose columns 
and subsequently washed with 10ml, 20mM potassium phosphate pH6.0.  Protein 
was eluted in 2ml fractions of 1M NaCl, 20mM potassium phosphate pH6.0, which 
were then screened by SDS-PAGE for the presence of protein.  Fractions containing 
the appropriate protein were pooled and dialysed for 24 hours against 1l PBS using 
dialysis tubing, with the buffer replaced after 12 hours. 
 
2.6.3.2 Purification of SCR19-20 
The same purification method was followed as for SCR7-8Y/H, however protein was 
eluted from the column in 1M NaCl, 20mM potassium phosphate pH7.0 
 
2.6.4 Reducing and non-reducing SDS-PAGE 
Reducing and non-reducing sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) were carried out using pre-cast NuPAGE Novex Bis-
Tris Gels (Invitrogen), NuPAGE running and sample buffers (Invitrogen) and the 
XCell SureLock Mini-Cell system (Invitrogen).  Protein and cell samples were 
prepared by incubating with 4x NuPAGE LDS Sample Buffer, 10x NuPAGE 
Reducing Agent (omitted for non-reducing gels) and dH2O up to a volume of 20µl at 
70°C for 10 minutes.  Gels (4-12% or 10%) were immersed in either NuPAGE 
MOPS (3-(N-morpholino)propanesulfonic acid) or MES (2-(N-
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morpholino)ethanesulfonic acid) running buffer, samples and SeeBlue Plus 2 protein 
standard marker (Invitrogen) were loaded and the gels run for 60 minutes at 180V 
constant voltage.  If required, proteins were then visualised by immersing the gel in 
Coomassie stain for 1 hour followed by washing overnight in dH2O, changing for 
fresh as required. 
 
2.6.5 Western blot 
Following protein separation, transfer to Hybond-P membranes was carried out using 
the XCell SureLock Mini-Cell Blot Module system (Invitrogen).  1 piece of Hybond-
P membrane was cut to the size of the gel, with this and the gel being sandwiched 
between two pieces of Whatman filter paper, also cut to the size of the gel and 
soaked in transfer buffer (1.46g Tris base, 7.2g glycine, made up to 1l with dH2O).  
The blot module was then assembled, sufficient amounts of transfer buffer added and 
the transfer run for 60 minutes at 30V constant voltage.  The membrane was then 
blocked overnight at 4°C in 1% skimmed milk powder dissolved in PBS, 0.01% 
TWEEN20.  The blot was then incubated with primary antibody diluted to the 
appropriate concentration in PBS, 0.01% TWEEN20 (see Table 2.3) for 1 hour at 
room temperature, followed by 3x 5 minute washes in PBS, 0.01% TWEEN20.  
Secondary antibody was diluted to the appropriate concentration in the same buffer 
and incubated with the blot for 1 hour at room temperature followed by 3x 5 minute 
washes as before. 
Table 2-3: Primary and secondary antibodies used for Western blots. 




Dr X Shu 
1:3000 
1:1000 
Secondary antibodies Supplier Dilution 
HRP-labelled rabbit anti-mouse 






Secondary antibody detection was carried out using the Enhanced 
Chemiluminescence (ECL) or Enhanced Chemiluminescence Plus (ECL+) Western 
blotting detection reagents (Amersham Biosciences).  Following washing, excess 
liquid was drained from the membrane which was then covered in detection reagent 
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(diluted following the manufacturers’ instructions) and incubated for 1 minute (ECL) 
or 5 minutes (ECL+).  Following draining of the detection reagent from the 
membrane, detection was then carried out using an X-ray film exposure cassette and 
Kodak X-Omat AR imaging film.  Following exposure, the film was then developed 
using a phosphorimager X-ray machine (Konica Minolta). 
 
2.6.6 Isoelectric focusing gel electrophoresis 
Isoelectric focusing (IEF) gel electrophoresis was carried out using pre-cast Novex 
pH3-10 IEF Gels (Invitrogen), the Novex IEF pH3-10 Buffer Kit (Invitrogen) and 
the XCell SureLock Mini-Cell system (Invitrogen).  Protein samples were prepared 
by mixing with 2x Novex Sample Buffer pH3-10 and dH2O up to a volume of 20µl.   
The gel tank was assembled using 1x IEF anode buffer (20x stock, Invitrogen) and 
1x IEF cathode buffer pH3-10 (50x stock, Invitrogen).  Samples and IEF pH3-10 
markers (Invitrogen) were loaded to the gel, which was run at 100V constant voltage 
for 60 minutes, then at 200V constant voltage for 60 minutes and finally at 500V 
constant voltage for 30 minutes.  Proteins were then fixed to the gel by immersion in 
12% TCA for 30 minutes, followed by washing with adequate H2O.  Proteins were 
then visualised by immersing the gel in coomassie stain for 1 hour followed by 
washing overnight in dH2O, changing for fresh as required. 
 
2.6.7 Native PAGE 
Native PAGE was carried out using the Hoefer SE600 Vertical Slab Unit, following 
the standard Laemmli system.  Resolving gels of 8%, 10% or 12% were poured (see 
Table 2.4 for formulations), overlaid with 5% stacking gels (see Table 2.4).  Protein 
samples were diluted in running buffer (5x stock: 15.1g Tris base, 72g glycine, make 
up to 1l with dH2O), with protein standard samples of lactalbumin, carbonic 
anhydrase, ovalbumin and BSA obtained from the Molecular Weight Marker Kit for 
Non-denaturing PAGE, 14,000 – 500,000 range (Sigma).  Gels were run in 1x 
running buffer for 8 hours at 30V constant voltage, with proteins visualised by 
Coomassie staining followed by adequate washing overnight in dH2O, changing for 
fresh as required. 
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Table 2-4: Native PAGE resolving and stacking gel formulations. 
All volumes are in millilitres. 
 Resolving gel Stacking gel 
Gel percentage 8% 10% 12% 5% 
dH2O 
30% acrylamide mix 
1.5M Tris pH8.8 
1.0M Tris pH6.8 



























2.6.8 Bradford assay 
The Bradford assay was used to determine the concentration of protein solutions.  
Standard samples were prepared by diluting a stock solution of 10mg/ml BSA in 
PBS to 0, 0.078, 0.156, 0.313, 0.625, 1.25 and 2.5g/ml.  0.98ml Bradford reagent 
was added to disposable 1ml cuvettes and 20l of either standard sample or protein 
solution was added to this.  These were then mixed and left at room temperature for 
10 minutes.  The OD595 of each was then measured and the OD595 of the standard 
samples was used to create a standard curve from which the concentrations of the 
protein solutions could be determined. 
 
2.6.9 Protein solubility assay 
Wild-type and mutant His-C1QTNF5 were incubated at 37°C for 10 minutes, 
followed by centrifugation at 13,000 rpm using a benchtop centrifuge at 37°C to 
remove any insoluble protein, with the protein concentration then determined by 
Bradford assay.  Each was then diluted to 200g/ml in PBS at 37°C up to a volume 
of 2ml.  The protein solutions were then incubated at 37°C, with 200l samples taken 
after 0, 2, 4, 6, 10 and 36 hours and placed into separate microcentrifuge tubes.  Each 
sample tube was then immediately centrifuged at 13,000 rpm on a benchtop 
centrifuge for 10 minutes at 37°C, after which time the OD280 of each sample was 
taken and a 20l aliquot prepared for analysis by reducing SDS-PAGE. 
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2.6.10 MALDI-TOF M/S 
MALDI-TOF M/S analysis was carried out by Dr J. Creanor (University of 
Edinburgh), using the Voyager-DE STR Biospectrometry Workstation. 
 
 
2.7 Protein interaction assays 
Protein interaction assays were carried out investigating interactions between wild-
type and mutant His-C1QTNF5 or wild-type His-gC1q and either CFH, recombinant 
SCR modules or CRP.  All His-C1QTNF5 and His-gC1q was produced in this study, 
as were SCR7-8Y, SCR7-8H and SCR19-20.  CFH was purified from whole blood 
and supplied by Professor R. Sim (University of Oxford), SCR3-4 was 
recombinantly produced in P. pastoris and supplied by Dr H. Hocking (University of 
Edinburgh) and CRP was purchased commercially (Sigma).  
 
2.7.1 Plate binding assays 
An initial plate binding assay was carried out using the unoptimised method, as 
follows.  96-well microtitre plates were coated with 1g/well His-gC1q diluted in 
PBS overnight at 4°C.  Wells were then washed 3 times with 200l per well PBS, 
0.01% TWEEN20.  Wells were blocked with 100l per 10mg/ml BSA diluted in 
PBS for 2 hours at room temperature, followed again by washing with 200l per well 
PBS, 0.01% TWEEN20.  CFH was diluted to the desired concentrations in PBS and 
100l added per well.  The plates were incubated at room temperature for 1 hour, and 
the wells then washed 3 times with 200l per well PBS, 0.01% TWEEN20.  Primary 
antibody, OX23, stock solution (340g/ml) was diluted to 10g/ml in PBS and 100l 
added to each well.  The plates were incubated for 1 hour at room temperature, 
followed by washing with 200l per well PBS, 0.01% TWEEN20 as before.  
Secondary antibody, alkaline phosphatase-labelled rabbit anti-mouse (Sigma), was 
diluted 1:1000 in PBS and 100l added to each well.  The plates were again 
incubated at room temperature for 1 hour followed by 3 washes with 200l per well 
PBS, 0.01% TWEEN20.  Secondary antibody was then detected using the p-
nitrophenyl phosphate tablet kit (Sigma) with 100l reagent added per well and after 
20 minutes incubation at room temperature the OD450  measured was using the plate 
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reader.  Control assays were also carried out following the same method but rather 
than coating with His-gC1q, 200l PBS alone was added to the wells.  Measurements 
from wells with a His-gC1q coat gave readings for total binding, measurements form 
wells without a His-gC1q coat gave readings for background binding and specific 
binding was calculated by deduction of specific binding from total binding for each 
CFH concentration. 
 
2.7.1.1 Plate binding assay optimisation 
The plate binding assay was optimised with regards to primary antibody 
concentration, dilution buffer pH and His-gC1q coat concentration. 
 
2.7.1.1.1 Optimising primary antibody concentration 
96-well microtitre plates were coated and blocked as described in Section 2.7.1.  
CFH was diluted in PBS and added to the wells and the plate incubated at room 
temperature for 1 hour as before.  Wells were then washed 3 times with 200l per 
well PBS, 0.01% TWEEN20 and 100l per well OX23 solution was added, diluted 
from stock to 1:34, 1:340, 1:1000 or 1:3400 in PBS.  The plates were incubated at 
room temperature for 1 hour, and then washed, secondary antibody applied, washed 
again and detection solution applied as described previously.  The plates were 
incubated with detection reagent for 10, 20 or 30 minutes prior to OD450 
measurements being taken.   
 
2.7.1.1.2 Optimising pH 
The plate binding assay was carried out as described in Section 2.7.1.  However, a 
primary antibody dilution of 1:340 was used with a 20 minute detection time, and 
only one CFH concentration of 0.5g/ml was used, diluting in 10mM MES at pH6.0 
or pH6.5, or PBS.  Following the addition of CFH, all subsequent wash stages and 
antibody incubations were carried out in either 10mM MES at pH6.0 or pH6.5, or 
PBS, with or without 0.01% TWEEN20, as appropriate. 
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2.7.1.1.3 Optimising His-gC1q concentration 
The plate binding assay was carried out as described in Section 2.7.1.  However, 
plates were coated with His-gC1q diluted to 0, 0.001, 0.01, 0.1, 1.0 or 10.0g/ml in 
PBS.  Also, a primary antibody dilution of 1:340 was used with a 20 minute 
detection time and CFH was diluted in 10mM MES pH6.5 with all subsequent wash 
and antibody incubation stages carried out using this buffer with or without 
TWEEN20. 
 
2.7.1.1.4 The optimised plate binding assay method 
96-well microtitre plates were coated with 1g/well His-gC1q diluted in PBS 
overnight at 4°C.  Wells were washed 3 times with 200l per well PBS, 0.01% 
TWEEN20.  To each well was then added 200l 10mg/ml BSA diluted in PBS and 
the plates incubated at room temperature for 2 hours.  The wells were then washed 3 
times with 200l per well PBS, 0.01% TWEEN20.  CFH was diluted to the 
appropriate concentration in 10mM MES pH6.5, with 100l added per well and the 
plate incubated for 1 hour at room temperature.  Wells were washed 3 times with 
200l per well 10mM MES pH6.5, 0.01% TWEEN20.  Primary antibody was diluted 
1:340 in 10mM MES pH6.5 and 100l was added to each well followed by 
incubation at room temperature for 1 hour.  Wells were subsequently washed 3 times 
as before and secondary antibody added, diluted 1:1000 in 10mM MES pH6.5.  
Following incubation at room temperature for 1 hour, wells were washed 3 times as 
before.  To each well was added 100l detection reagent and the plates incubated at 
room temperature for 20 minutes prior to taking OD450  measurements using the plate 
reader. 
 
2.7.1.2 His-gC1q and CFH plate binding assay 
The optimised plate binding assay method was followed, coating the plates with His-
gC1q and adding CFH in the fluid phase. 
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2.7.1.3 His-C1QTNF5 and CFH plate binding assay 
The optimised plate binding assay was followed, except plates were coated with 
1g/well of either wild-type or mutant His-C1QTNF5.  CFH was again added in the 
fluid phase. 
 
2.7.1.4 CFH and CRP plate binding assay 
The optimised plate binding assay was followed, except plates were coated with 
1g/well CRP.  CFH was again added in the fluid phase. 
 
2.7.1.5 CRP and His-gC1q/His-C1QTNF5 plate binding assay 
The optimised plate binding assay was followed, except plates were coated with 
1g/well CRP.  Wild-type or mutant His-C1QTNF5 were added in the fluid phase, 
with a primary antibody of mouse anti-His (Sigma) used diluted in 1:1000 in PBS.   
 
2.7.2 Surface plasmon resonance 
All SPR experiments were carried out using the Biacore T100 machine and Biacore 
T100 Control software, with all analysis carried out using the Biacore T100 
Evaluation software.  In all instances, pH scouting, coating the chips and kinetic 
assays were carried out using the software wizards provided.  All buffers and protein 
samples used were at 37°C and at all stages the Biacore T100 sample compartment 
and operating temperature were maintained at 37°C, and in all instances running 
buffer was 10mM HEPES pH7.4, 150mM NaCl, 0.005% P20 (supplied by Biacore). 
 
2.7.2.1 pH scouting and coating of the CM5 chips 
pH scouting was carried out in order to determine the optimal buffer conditions for 
coating of wild-type and mutant His-C1QTNF5 to the CM5 chips.  Chips were 
prepared prior to use by 3x 1 minute injections with 50mM NaOH (Biacore) at a 
flow rate of 1µl per minute, to remove any unwanted ions or uncoupled dextran.  
Following this, the chip was washed with running buffer for 5 minutes at a flow rate 
of 10µl per minute.  pH scouting was then carried out to determine the optimal buffer 
pH for either wild-type or mutant His-C1QTNF5, giving the weakest conditions for a 
high level of attraction of protein to the chip surface which rapidly dissociates once 
 90 
conditions return to physiological (running buffer alone).  This was carried out 
following the immobilisation pH scouting wizard and using only the flow cells which 
were to be coated with protein.  His-C1QTNF5 was diluted to a concentration of 
25mM in 10mM acetate pH4.5, 5.0 or 5.5 (Biacore), or 10mM HEPES pH6.0, 6.5 or 
7.0.  120 second injections at a flow rate of 10µl per minute were used, washing 
between each stage with 50mM NaOH.  The optimal buffers were selected as 10mM 
HEPES pH6.5 for wild-type His-C1QTNF5 and 10mM HEPES pH6.0 for the mutant 
protein. 
 
Immobilisation of His-C1QTNF5 to the CM5 chips was carried out using 
the immobilisation wizard, following the protocol for amine coupling.  The 
appropriate chip type and blank or reference flow cells were selected, and the desired 
levels of bound response units set at either 200RU or 1000RU.  EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride) (Biacore) and NHS (N-
hydroxysuccinimide) (Biacore) were used to activate the chip surface and, once 
sufficient protein was bound, ethanolamine was used to quench any uncoupled sites.  
Ethanolamine alone was used for the blank flow cells.  The chip was then washed 
with running buffer at 50µl per minute to remove any loosely bound protein. 
 
2.7.2.2 SPR analysis of His-C1QTNF5 interactions with CFH, SCR7-
8Y/H, SCR19-20, SCR3-4 and CRP 
SPR analysis of His-C1QTNF5 interactions with CFH, SCR7-8Y/H, SCR19-20, 
SCR3-4 and CRP were all carried out using the kinetics/affinity wizard facility.  
Following the wizard protocol, the chips were normalised with glycerol prior to 
beginning each run, 3 start-up cycles were run, injection times were 30 seconds and 
dissociation times were either 2000 seconds for CFH or 300 seconds for the SCR 
modules and CRP.  An internal repeat was carried out for each run, taking a mid-
range dilution and, for each protein, experiments were run on at least one 200RU and 
one 1000RU chip for both wild-type and mutant His-C1QTNF5 chips.  Experimental 




2.7.3 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) was carried out using the AutoITC MicroCal 
and the DRV 2000 auto ITC software.  To set up the instrument, the reference cell 
was washed 3 times with 2ml H2O, and then filled to the indicated level with PBS.  
Samples were then added to the sample tray, allowing for reactions involving 
macromolecule (CFH) and ligand (His-gC1q), and macromolecule (CFH) and PBS 
only.  When investigating reactions with a predicted kD in the nM range, 2ml CFH 
was added at a concentration of 0.5M in PBS and 0.7ml His-gC1q was added at 
7.5M in PBS.  When investigating reactions with a predicted kD in the M range, 
2ml CFH was added at a concentration of 5M and 0.7ml His-gC1q was added at 
125M in PBS.  The instrument and sample drawer were then left to equilibriate to 
37°C.  Reaction parameters when investigating nM kD interactions were 25 
injections of 4.8l and a 9.8 second equilibration period.  Reaction parameters when 
investigating M interactions were 42 injections of 4.8l and a 9.8 second 
equilibriation period.   
 
2.7.4 His-C1QTNF5 co-factor assays 
It was investigated whether His-C1QTNF5 had any effect on CFH co-factor activity 
with FI, adapting a method supplied by Professor R. Sim (University of Oxford).  
His-C1QTNF5 was produced in this study, whilst C3b, CFH and FI were provided 
by Prof. R. Sim. 
 
2.7.4.1 Fluid-phase co-factor assay 
The following reagents were incubated together in PBS at 37°C up to a total volume 
of 20µl; C3b (5µg), CFH (0.5µg), FI (0.1µg) and wild-type or mutant His-C1QTNF5 
(0.5µg).  In addition, control reactions were also set up omitting CFH, FI, His-
C1QTNF5 or combinations thereof.  Following incubation, total reactions were 
analysed by reducing SDS-PAGE as described in Section 2.6.4.  Co-factor activity 
was confirmed by the presence of C3b degradation products, visible after Coomassie 
staining of the SDS-PAGE gel, at 43kDa and 46kDa. 
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2.7.4.1.1 Fluid-phase co-factor assay time course 
The following reagents were incubated together in PBS at 37°C up to a total volume 
of 100µl; C3b (25µg), CFH (2.5µg), FI (0.5µg) and wild-type or mutant His-
C1QTNF5 (2.5µg).  In addition, control reactions were also set up omitting His-
C1QTNF5.  20µl samples were taken after 0, 1, 5 and 15 minutes and immediately 
prepared for analysis by reducing SDS-PAGE by addition of LDS sample buffer and 
reducing agent (as described in Section 2.6.4).  This was to prevent any further co-
factor activity from occurring.  Samples were then analysed by reducing SDS-PAGE.  
Co-factor activity was confirmed by the presence of C3b degradation products, 
visible after Coomassie staining of the SDS-PAGE gel, at 43kDa and 46kDa. 
 
2.7.4.2 Solid phase co-factor assay 
A 96-well microtitre plate was coated overnight in 1µg/well wild-type or mutant His-
C1QTNF5 in 100µl PBS, or 100µl PBS alone, as illustrated in Figure 2.1.  The wells 
were then washed 3 times with 200µl per well PBS, 0.01% TWEEN20 and blocked 
at room temperature for 2 hours with 200µl per well 10mg/ml BSA in PBS, again 
followed by 3 washes with 200 µl per well PBS, 0.01% TWEEN20.  To the wells 
was then added CFH, diluted in PBS to concentrations of 0, 0.5 and 2.0µg/ml, as 
illustrated in Figure 2.1.  The plate was incubated for 2 hours at room temperature 
and washed 3 times as before with PBS, 0.01% TWEEN20.  To each well was then 
added C3b (20µg) and FI (0.4µg) up to a final volume of 80µl in PBS.  The plate was 
incubated at 37°C, with 20µl samples taken after 30, 60 and 90 minutes.  
Immediately after taking, each sample was prepared for analysis by reducing SDS-
PAGE by incubating with LDS sample buffer and reducing agent at 70°C, as 
described in Section 2.6.4.  Samples were then analysed by reducing SDS-PAGE, 










       Wild-type His-C1QTNF5
Protein coat          Mutant His-C1QTNF5
                     PBS
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2.8 Equipment, consumables and reagents 
 
2.8.1 Equipment 
Equipment Type/model Supplier 
Balance 
Benchtop microcentrifuge 
Heated benchtop microcentrifuge 

















Medical film processor 
Spectrophotometer 
Tissue culture hood 
Water bath 








French Pressure CellPress 
Origo H3-SET 





















































Microtitre plates (96 well) 
Pastette 
Plates (for agar) 
Shaker flask (500ml and 1l) 
Sterile filter 
Syringe 
Tissue culture dish 
Tissue culture flasks 
Tissue culture plate (24 and 6 well) 
Whatman filter paper 
X-ray film 










HGU technical services 















































































HGU technical services 
Sigma 














HGU technical services 
HGU technical services 














































Protease inhibitor tablets 
Potassium phosphate 
Puromycin 

























HGU technical services 


































































3 CHAPTER 3  
: 
 CREATING STABLY TRANSFECTED 





This chapter discusses the creation and analysis of stably transfected ARPE-19 cell 
lines expressing wild-type or mutant His-tagged C1QTNF5 (His-C1QTNF5).  
C1QTNF5 is expressed in the RPE, with immunostaining of mouse tissue sections 
showing C1QTNF5 to be located apically between the RPE and ROS, and basally 
between the RPE and Bruch’s membrane (Mandal et al., 2006b).  Studies into the 
effects of the Ser163Arg mutation in C1QTNF5 using stably transfected EBNA293 
showed that the wild type but not the mutant protein is secreted, whilst 
immunostaining of transiently transfected ARPE-19 cells suggested that the mutant 
protein aggregates and is retained within the endoplasmic reticulum (Shu et al., 
2006b).  ARPE-19 is a spontaneously transformed human RPE-derived cell line 
which retains many features of the RPE such as the ability to form morphologically 
polarised monolayers and to phagocytose rod outer segments (Dunn et al., 1998, 
Finnemann et al., 1997).  Mandal et al. (2006c) also found the wild type protein to be 
secreted but not the mutant when investigating V5-tagged C1QTNF5 expressed in 
COS-7 cells.  Stably transfected EBNA293 expressing mutant C1QTNF5 also 
showed reduced adhesion to laminin-coated plates compared with wild-type 
C1QTNF5 expressing cells (Shu et al. 2006b).  Such studies have used either the 
mouse, transiently transfected ARPE-19 or COS-7 (a transformed African green 
monkey kidney cell line) or stably transfected human EBNA293 cells (embryonic 
kidney in origin) to study C1QTNF5.  This study will use stably transfected ARPE-
19 cell lines to investigate the function of the Ser163Arg mutation.  C1QTNF5 is 
expressed by the RPE so ARPE-19 is therefore physiologically relevant for studying 
C1QTNF5 expression and the effects of the Ser163Arg disease-causing mutation in 
L-ORMD.  Creation of stably transfected ARPE-19 cell lines allows for functional 
assays to be carried out as stably transfected cells show constant expression levels.  
Comparisons can be made looking at the effects of over-expression of wild-type or 
mutant C1QTNF5 which could give insights into disease mechanisms in L-ORMD 




3.2 Creating stably transfected ARPE-19 cell lines 
In order to create stably transfected ARPE-19 cell lines, plasmid vector constructs 
were made containing either wild-type or mutant C1QTNF5 inserts, with expression 
confirmed via transient transfection in ARPE-19.  Stably transfected cells were then 
selected for with G418 and individual colonies screened for His-C1QTNF5 
expression.   
 
3.2.1 Creation of pEGFP-C1 constructs containing C1QTNF5 
The transfected ARPE-19 cell lines expressing wild type or mutant His-C1QTNF5 
were created using pEGFP-C1 plasmid vector constructs.  pEGFP-C1 can be used for 
expression of recombinant proteins in mammalian cell lines, and contains the 
neomycin/G418 selectable marker, allowing for selection of transfected cells.  Figure 
3.1 shows the vector map for pEGFP-C1, with the cytomegalovirus (CMV) promoter 
upstream of EGFP (encoding the enhanced green fluorescent protein, EGFP) and the 
multiple cloning site (MCS).  EGFP was removed by restriction enzyme digestion 
and replaced with the C1QTNF5 inserts containing an additional C-terminal His-tag. 
 
3.2.1.1 PCR amplification of C1QTNF5 inserts 
Wild-type or mutant C1QTNF5 inserts were created by PCR amplification of human 
cDNA templates (supplied by Dr X. Shu, MRC Human genetics Unit, Edinburgh), 
with N-terminal NheI and C-terminal BamHI restriction enzyme sites for ligation 
into pEGFP-C1.  PCR products were separated by agarose gel electrophoresis and 
bands corresponding to approximately 750bp were excised and purified from the gel 
(Figure 3.2, lanes 1 and 4).  The PCR would only work in the presence of dimethyl 










3.2.1.2 Selection of C1QTNF5 inserts 
Purified C1QTNF5 inserts were ligated into pGEM-T-Easy and amplified in E. coli 
TOP10 cells.  Individual colonies (5 for each construct) were selected and amplified.  
The plasmids were then extracted and samples digested with restriction enzymes to 
check for the presence of inserts of the correct size for C1QTNF5, with analysis by 
agarose gel electrophoresis (see Figure 3.3).  Constructs corresponding to lanes 2 – 6 
and 8 – 10 were selected for sequence analysis to check that the inserts matched the 
published C1QTNF5 sequence with or without the 163Arg mutation as appropriate. 
 
3.2.1.3 Preparation of the pEGFP-C1 vector and C1QTNF5 inserts 
pEGFP-C1 was restriction enzyme digested with NheI and BamHI and separated by 
agarose gel electrophoresis to obtain the pEGFP-C1 vector minus its EGFP insert, 
which was then purified from the gel (Figure 3.4A).  C1QTNF5 inserts showing the 
correct sequence were restriction enzyme digested to remove them from pGEM-T-
Easy, then separated and purified by agarose gel electrophoresis (Figure 3.4B).   
 
3.2.1.4 Construction, amplification and screening of C1QTNF5-
containing pEGFP-C1 (minus EGFP) constructs 
C1QTNF5 inserts were ligated into pEGFP-C1 minus EGFP and the constructs 
amplified in pGEM-T-Easy.  Six colonies from each were selected, amplified by 
overnight culture and the plasmids purified, with the presence of C1QTNF5 inserts of  
the correct size checked by agarose electrophoresis (Figure 3.5).  One construct for 
mutant C1QTNF5 and one for wild-type C1QTNF5 was selected for use in creating 
the stably transfected ARPE-19 cell lines, with the inserts checked by sequencing 




Figure 3.2: Agarose gel electrophoresis showing wild-type and mutant 
C1QTNF5 inserts created by PCR 
 
Lanes: 1 – Wild-type C1QTNF5 plus DMSO, 2 – Wild-type 
C1QTNF5 minus DMSO, 3 – Wild-type C1QTNF5 no template, 4 – 
Mutant C1QTNF5 plus DMSO, 5 – Mutant C1QTNF5 no DMSO, 6 
– Mutant C1QTNF5 no template. 
Bands of approximately 700bp (base pairs) were excised and 
purified from lanes 1 and 4.  The relative molecular mass markers 
and corresponding size in base pairs are shown. 
 
 
Figure 3.3: Agarose gel electrophoresis showing restriction enzyme 
digestion of pGEM-T-Easy constructs to check for the presence of wild-
type or mutant C1QTNF5 inserts. 
 
C1QTNF5 are seen as bands of approximately 750bp (base pairs).  
The relative molecular mass markers and corresponding size in 





 A       B  
Figure 3.4: A – Restriction enzyme digestion of wild type and mutant 
constructs, separated by agarose gel electrophoresis. 
 
Bands at approximately 750bp corresponding to wild-type (WT) 
and mutant (MT) C1QTNF5 were purified for ligation into pEGFP-
C1 minus EGFP. 
B – Restriction enzyme digestion of pEGFP-C1 to remove the GFP 
insert.  Band corresponding to digested pEGFP-C1 was purified 
from the gel for ligation with C1QTNF5 inserts.  The relative 
molecular mass markers and corresponding size in base pairs are 









 A     B 
Figure 3.5: Agarose gel electrophoresis showing restriction enzyme 
digested pEGFP-C1 constructs (minus EGFP) checking for the presence 
of wild-type (WT) C1QTNF5 (A) or mutant (MT) C1QTNF5 (B) inserts 
  
C1QTNF5 are seen as bands of approximately 750bp.   
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3.2.2 Checking expression of His-C1QTNF5 in ARPE-1 cells using 
pEGFP-C1-C1QTNF5 
Before commencing with creation of the stably transfected ARPE-19 cell lines, it 
was necessary to ascertain that His-C1QTNF5 was expressed when the selected 
constructs were transiently transfected into ARPE-19.  Transfection was carried out 
using FuGENE, and His-C1QTNF5 expression confirmed by immunostaining.  
Figure 3.6 shows ARPE-19 cells expressing either wild-type or mutant His-
C1QTNF5, as well as untransfected ARPE-19 cells.   
 
3.2.3 Stable cell line creation and screening 
As His-C1QTNF5 was expressed when ARPE-19 were transiently transfected with 
the pEGFP-C1-C1QTNF5 constructs, these were deemed suitable for use in creation 
of the stably transfected ARPE-19 cell lines.   
 
3.2.3.1 Determination of correct G418 concentration 
G418 is an aminoglycoside antibiotic which blocks peptide elongation during 
translation and so polypeptide synthesis in prokaryotic and eukaryotic cells.  pEGFP-
C1 contains the G418/neomycin selectable marker, conferring G418 resistance to 
transfected cells.  In order to select for transfected cells, it was necessary to 
determine the minimum concentration of G418 required for toxicity to ARPE-19 
cells.   
 
ARPE-19 cells were cultured for 2 weeks in 0 – 700µg/ml G418, after which time 
the G418 was removed and, following a further week’s incubation, it was determined 
if any live cells remained.  Table 3.1 shows the results obtained.  500µg/ml was the 
minimum concentration required to kill ARPE-19 cells. Toxicity was determined by 
the absence of live cells following culture. 
 
Table 3-1: G418 concentration requirement in media to kill cultured ARPE-19 cells.  
 
G418 µg/ml 0 300 400 500 600 700 
Live cells Yes Yes Yes No No No 
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Figure 3.6: Immunostaining of ARPE-19 cells transiently transfected with 
the wild-type (WT) (A) and mutant (MT) (B) pEGFP-C1-C1QTNF5 
constructs showing expression of His-tagged protein. 
 
His-tagged protein is shown in red.  Primary antibody: mouse anti-
His, secondary antibody: rabbit anti-mouse TxRed.  DAPI-stained 
nuclei are shown in blue. 
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3.2.3.2 Transfecting and screening of ARPE-19 colonies 
Transfections were carried out using the microporator rather than FuGENE as this 
has been optimised for ARPE-19 transfection and shown previously in this lab to 
have greater transfection efficiency than FuGENE.  Even so, it should be noted that 
in this instance transfection levels were not high and screening did not reveal many 
suitable cell lines.  Individual clones were amplified and samples of cell lysate 
screened for His-C1QTNF5 expression by Western blot.   
 
Individual clones were amplified into 25cm2 flasks in culture media containing 10% 
serum, with the entire cell pellet used to screen for His-C1QTNF5.  This was due to 
low His-C1QTNF5 expression levels requiring a greater cell mass for detection.  
Figure 3.7 shows a Western blot for 8 screened cell pellets corresponding to 8 
separate clones.  The band at approximately 28kDa in lane 2 is His-C1QTNF5, 
indicating that this particular cell line is expressing the recombinant protein. 
In total, 18 wild-type and 15 mutant cell lines were screened.  Only 2 wild-type 
(GFWT19 and GFWT29) and 2 mutant (GFMT4 and GFMT22) cell lines were 
found to be expressing His-C1QTNF5. 
 
3.2.3.3 Checking for His-C1QTNF5 secretion in selected cell lines 
Previous studies had indicated that wild-type but not mutant C1QTNF5 was secreted, 
and that the mutant protein was retained within the cell.  TCA precipitated proteins 
from the culture media of the 2 wild-type and 2 mutant His-C1QTNF5 expressing 
cell lines were analysed by Western blot for the presence of His-C1QTNF5.  As can 
be seen from Figure 3.8, His-C1QTNF5 was found to be present in the culture media 




Figure 3.7: Western blot of cell lysates from selected ARPE-19 
transfections, screening for His-C1QTNF5. 
 
In the above figure, lanes 1-8 represent individual cell lines.  The 
band at approximately 28kDa in lane 2 is His- C1QTNF5.  This cell 
line was selected as showing His-C1QTNF5 expression.  Primary 
antibody: mouse anti-His; secondary antibody: HRP labelled rabbit 





Figure 3.8: Western blot of TCA precipitated media proteins from culture 
media of stably transfected ARPE-19 cell lines expressing wild-type His- 
C1QTNF5 (GFWT19 and GFWT29) or mutant His-C1QTNF5 (GFMT4 
andGFMT22). 
 
Bands correspond to His-C1QTNF5.  Primary antibody: mouse 
anti-His; secondary antibody: HRP-labelled rabbit anti-mouse.  
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3.3 Checking secretion levels 
Figure 3.8 indicates that wild type and mutant His-C1QTNF5 are secreted in the 
stably transfected ARPE-19 cell lines.  It had previously been observed (Shu et al. 
2006b; Mandal et al. 2006c) that wild-type C1QTNF5 but not the mutant is secreted 
in EBNA293 cells.  However, these studies were either carried out in less 
physiologically relevant cell lines (Mandal et al. 2006c) and/or the C1QTNF5 
recombinant protein had a large GFP tag (Shu et al. 2006b)  
 
Before investigating this observation further, it was necessary to determine that the 
wild type (GFWT19) and mutant (GFMT22) cell lines to be used in future 
experiments are secreting His-C1QTNF5 at similar levels.  Post-confluent cells were 
cultured for 5 days in serum-free media, with cell pellets and culture media collected 
for analysis.  After adjusting lysate and culture media volumes for cell number, His-
tagged protein was affinity purified using Ni-NTA beads.  Due to the low levels of 
His-C1QTNF5 produced this was considered to be a highly sensitive method of 
protein detection suitable for accurate comparisons.  Figure 3.9 shows a Western blot 
of the culture media eluates, with similar intensities observed for the His-C1QTNF5 
bands at approximately 28kDa, corresponding to GFWT19 and GFMT22 
respectively.  This indicates that these cell lines are secreting His-C1QTNF5 to 
similar levels.  However, His-C1QTNF5 was not observed in the cell lysate sample 
eluates for either GFWT19 or GFMT22, even when using ECL+ for detection, 
indicating that not enough protein was retained within the cells of either cell line to 
allow detection by Western blot, under these conditions. 
 
3.3.1 His-C1QTNF5 secretion time course  
As the previous experiment was carried out over 5 days, a secretion time course was 
carried out to determine if any differences in levels of secretion between the cell 
lines could be observed over shorter time periods.  Media samples were taken at 
specified time intervals and, after normalising for cell number as before, analysed by 
Western blot for His-C1QTNF5 (see Figure 3.10).  Both cell lines showed His-
C1QTNF5 secretion after 1, 2 and 3 days.  Expression levels were similar, although 
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slightly higher in GFWT19.  This was not considered great enough to prevent future 
comparisons being made between the two cell lines. 
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Figure 3.9: Western blot of Ni-NTA affinity purified culture media proteins 
from cell lines GFWT19 and GFMT22. 
 
Culture media volumes were adjusted for cell number prior to 
purification.  Both cell lines show similar expression levels of His-
C1QTNF5, indicated by bands at approximately 28kDa.  Primary 
antibody: mouse anti-His, secondary antibody: HRP-labelled rabbit 
anti-mouse.  kDa: relative molecular mass 
 
 
Figure 3.10: Western blot of Ni-NTA affinity purified culture media proteins 
from cell lines GFWT19 and GFMT22. 
 
Samples were taken 1, 2 and 3 days post-confluence in serum free 
media.  Culture media volumes were adjusted for cell number prior 
to purification.  GFWT19 shows slightly higher expression levels of 
His-C1QTNF5, indicated by bands at approximately 28kDa.  
Primary antibody: mouse anti-His, secondary antibody: HRP-




3.4 Cellular trafficking of His-C1QTNF5 
Previous studies investigating GFP-tagged recombinant C1QTNF5 using transiently 
transfected ARPE-19 cells had shown the wild-type protein to have a diffuse cellular 
localisation, as would be expected for a secreted protein, whereas mutant C1QTNF5 
aggregated and was retained within the endoplasmic reticulum.  It had also been 
shown that mutant GFP-tagged C1QTNF5 was not secreted when stably expressed in 
EBNA293 although the wild-type protein was (Shu et al., 2006b).  V5-tagged mutant 
C1QTNF5 was also not secreted when transiently over-expressed in COS7 cells 
(Mandal et al., 2006c).  However, results from Section 3.2 show that mutant and 
wild-type His-C1QTNF5 are secreted when stably over-expressed in ARPE-19 cells.  
Expression levels can differ between transiently and stably transfected cells, and the 
protein expressed in this instance had a His rather than the larger GFP or V5 epitope 
tag.  Therefore it was necessary to determine whether the cellular trafficking of wild-
type and mutant His-C1QTNF5 differed between cell lines GFWT19 and GFMT22. 
 
3.4.1 Immunostaining of stably transfected ARPE-19 cell lines 
Immunostaining was carried out on cell lines GFWT19 and GFMT22, which showed 
similar secretion levels of C1QTNF5, and untransfected ARPE-19 cells.  Primary 
antibodies used were against the endoplasmic reticulum markers calreticulin and 
protein disulphide isomerase (PDI), beta-catenin and either the C-terminal His-tag or 
C1QTNF5.   Calreticulin and PDI have both been used previously when investigating 
C1QTNF5 cellular trafficking (Shu et al. 2006b).  Calreticulin binds misfolded 
proteins within the ER preventing their translocation to the Golgi apparatus.  PDI is a 
chaperone which is located in the ER and catalyses the formation and breakage of 
disulphide bonds, facilitating the correct folding of proteins.  Beta-catenin is a 
subunit of the cadherin protein complex and is involved in Wnt signalling.  It is 
commonly observed to be associated with the plasma membrane. 
 
3.4.1.1 Immunostaining for beta-catenin and His-C1QTNF5 
Beta-catenin is located at the plasma membrane and so enables detection of cellular 
boundaries.  Figure 3.11 shows stably transfected cell lines GFWT19 and GFMT22, 
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with beta-catenin immunostaining seen in green and anti-His immunostaining in red.  
His- C1QTNF5 shows a diffuse cytoplasmic localisation in both cell lines.  No 
differences were observed between GFWT19 or GFMT22 cell lines. 
 
3.4.1.2 Immunostaining for calreticulin and His-C1QTNF5 
Calreticulin is localised in the ER.  If a protein is aggregated and retained within the 
ER, it would be expected to co-localise with calreticulin.  As can be seen from Figure 
3.12, in both GFWT19 and GFMT22, diffuse cytoplasmic association was observed 
between calreticulin (green) and His-tagged C1QTNF5 (red), with no apparent 
aggregated protein retained within the ER.  No differences were observed between 
GFWT19 or GFMT22 cell lines, with the same calreticulin distribution observed in 
untransfected ARPE-19. 
 
3.4.1.3 Immunostaining for PDI and C1QTNF5 
PDI is located within the ER.  If a protein were aggregated and retained within the 
ER, it would be expected that this would co-localise with PDI.  As can be seen from 
Figure 3.13, in both GFWT19 and GFMT22, a diffuse cytoplasmic localisation was 
observed for C1QTNF5 (green), with no apparent aggregated protein retained within 
the ER and limited co-localisation of C1QTNF5 and PDI (red).  No differences were 
observed between GFWT19 or GFMT22 cell lines, with the same PDI distribution 
observed in untransfected ARPE-19.  It should be noted that the same distribution is 
seen when anti-C1QTNF5 and anti-His primary antibodies are used (Figures 3.12 
and 3.13). 
 
3.4.2 Immunostaining of transiently transfected ARPE-19 
Immunostaining of the stably transfected cell lines did not highlight any differences 
between GFWT19 and GFMT22 cell lines with respect to His-C1QTNF5 cellular 
trafficking, suggesting that mutant His-C1QTNF5 is not aggregated or retained 
within the ER.  It is possible that expression levels are lower in stably transfected 
cells compared to transiently transfected.  At higher expression levels, it is possible 
that an increased tendency to aggregate for either the wild-type or mutant protein 
may be detected.  At higher expression levels, the cellular machinery and protein-
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folding pathways are under greater stress, meaning that the cell may be less able to 
cope with misfolded proteins, which then accumulate within the ER.  ARPE-19 cells 
were therefore transiently transfected with either the wild type or mutant C1QTNF5 
pEGFP-C1 (minus EGFP) constructs.  Immunostaining for beta-catenin and His-
C1QTNF5 was carried out.  Twelve images were analysed for wild-type and mutant 
His-C1QTNF5 expressing cells and the distributions of His-C1QTNF5 compared 
(Figures 3.14 and 3.15).  No differences were observed between cells expressing 
wild-type or mutant C1QTNF5. 
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Figure 3.11: Immunostaining of cell lines GFWT19 (expressing wild-type 
His-C1QTNF5), GFMT22 (expressing mutant His-C1QTNF5) and 
untransfected ARPE-19 cells. 
 
Anti-beta-catenin staining is seen in green.  Anti-His staining, 
corresponding to His-C1QTNF5, is seen in red.  In both GFWT19 




Figure 3.12: Immunostaining of cell lines GFWT19 (expressing wild-type 
His-C1QTNF5), GFMT22 (expressing mutant His-C1QTNF5) and 
untransfected ARPE-19. 
 
Anti-calreticulin staining is seen in green.  Anti-His staining, 
corresponding to His-C1QTNF5, is seen in red.  In both GFWT19 
and GFMT22 His-C1QTNF5 shows a diffuse cytoplasmic 
localisation.  No co-localisation was observed between His-
C1QTNF5 and calreticulin in either cell line. 
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Figure 3.13: Immunostaining of cell lines GFWT19 (expressing wild-type 
His-C1QTNF5), GFMT22 (expressing mutant His-C1QTNF5) and 
untransfected ARPE-19. 
 
Anti-PDI staining is seen in red, anti-C1QTNF5 staining is seen in 
green.  In both GFWT19 and GFMT22 C1QTNF5 shows diffuse 
cytoplasmic localisation.  No co-localisation was observed between 










Figure 3.14: Immunostaining of transiently transfected ARPE-19 cells 
expressing wild-type His-C1QTNF5 (images 1-12) and untransfected 
ARPE-19. 
 
Images were taken of different transfected ARPE-19 cells, with 
untransfected cells shown in box 1. 
A: Nuclear staining (blue) with DAPI, anti-His immunostaining (red) 
showing cytoplasmic distribution of His-C1QTNF5, B: Anti-beta-
catenin (green) showing cellular boundaries, C: Merged anti-His 
and anti-beta-catenin showing showing cellular boundaries and 









Figure 3.15: Immunostaining of transiently transfected ARPE-19 cells 
expressing mutant His-C1QTNF5 (images 1-12) and untransfected ARPE-
19. 
 
Images were taken of different transfected ARPE-19 cells, with 
untransfected cells shown in box 1. 
A: Nuclear staining (blue) with DAPI, anti-His immunostaining (red) 
showing cytoplasmic distribution of His-C1QTNF5, B: Anti-beta-
catenin (green) showing cellular boundaries, C: Merged anti-His 
and anti-beta catenin showing cellular boundaries and cytoplasmic 
distribution of His-C1QTNF5. 
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3.5 Checking apoptosis levels 
It is possible that over-expression of mutant His-C1QTNF5 may reduce cell viability 
and so increase levels of apoptosis, and this could release His-C1QTNF5 into the 
medium, perhaps accounting for at least part of the His-C1QTNF5 detected in the 
culture media of GFMT22 cells.  After confirming that apoptotic ARPE-19 cells 
could be detected using the TUNEL assay, levels of apoptosis were compared 
between untransfected ARPE-19, GFWT19 and GFMT22.  
 
3.5.1 The TUNEL assay 
The TdT-mediated dUTP nick-end labelling (TUNEL) assay allows for the detection 
of single apoptotic cells within a larger cell population.  Cells undergoing apoptosis 
generate fragments of DNA 180-200 base pairs in length (Bortner et al., 1995).  The 
TUNEL assay fluorescently labels the 3’ OH ends of such DNA strands.   The 
DeadEnd™ Fluorometric TUNEL System (Promega) used in this study labels these 
3’ OH ends with fluorescein-12-dUTP using recombinant terminal deoxynucleotide 
transferase, (rTDT), allowing for their detection by fluorescence microscopy or flow 
cytometry. 
 
3.5.2 Inducing and detecting apoptosis in ARPE-19 cells 
Hydrogen peroxide has been shown to induce apoptosis in cultured human retinal 
pigment epithelial cells (Jin, 2001).  Cultured ARPE-19 cells were treated with 
hydrogen peroxide, and then apoptotic cells detected using the TUNEL assay 
described above.  Figure 3.16 shows hydrogen peroxide treated ARPE-19 cells, 
positive and negative control cells.  Apoptotic cells are shown in green.  The results 
indicate that it is possible to detect apoptotic cells in confluent ARPE-19 using this 
method. 
 
3.5.3 Detecting apoptosis levels in the ARPE-19 transfected cell lines 
Apoptosis levels of confluent cells were measured after 1, 2 or 3 days post-
confluence in serum-free media using the TUNEL assay.  Five images were taken at 
each time point for ARPE-19, GFWT19 or GFMT22 cultures at 10X magnification 
and the number of apoptotic cells in each image scored.  As can be seen from Table 
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3.2, there were no differences in the levels of apoptosis between the cell lines, and 
apoptosis levels were negligible in all cases. 
 
   
 Number of apoptotic cells
Day ARPE-19 GFWT19 GFMUT22
1 0 0 0
2 0 1 1
3 2 1 2  
Table 3-2: Total number of apoptotic cells in 5 images of confluent cell lines ARPE-19, 
GFWT19 and GFMT22 after 1, 2 or 3 days post-confluence in serum-free media.  
Levels of apoptosis were negligible in all cases. 
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Figure 3.16: TUNEL assay staining of ARPE-19 cells. 
 
Nuclei (DAPI staining) are shown in blue.  Apoptotic nuclei are 
shown in green.  Images are for negative control cells (negative), 
positive control cells (positive) and cells where apoptosis has been 
induced with hydrogen peroxide (treated).  The images show that it 




3.6 Cell adhesion assays 
A previous study suggested that C1QTNF5 might be involved in RPE cell adhesion, 
in particular to Bruch’s membrane (Shu et al., 2006b).  The study had been carried 
out using stably transfected EBNA293 cell lines expressing GFP-tagged wild type or 
mutant C1QTNF5, with the mutant cell line showing reduced adhesion to laminin-
but not fibronectin-coated microtitre plates.   
 
Laminin and fibronectin are extracellular matrix proteins.  Laminin consists of ,  
and  chains which create a framework that interacts with collagens, other ECM 
components and cell surface receptors such as integrins and some proteoglycans.  
Laminin provides a structural extracellular framework and, through its interactions  
with cell surface receptors, can influence signal transduction, migration and focal 
adhesion (Alberts et al., 2002, Miner, 2008).  Fibronectin is a dimer consisting of 
two polypeptide chains, and can be found in various isoforms as a result of 
alternative splicing.  Each polypeptide chain contains several domains involved in 
collagen-binding, cell attachment (via the RGD motif and cell surface integrins), 
heparin binding and interactions with cell surface receptors.  Fibronectin provides a 
structural framework for cell attachment and spreading, and also has roles in signal 
transduction (Alberts et al., 2002). 
 
C1QTNF5 shares homology with other collagens such as collagen IV, which has a 
globular head group and has been shown to form a polygonal lattice, providing a 
basement membrane framework (Yurchenco, 1987), and collagen X, which forms a 
hexagonal lattice and has been shown to be involved in cell adhesion via the 21 
integrin, amongst others (Kwan et al., 1991, Luckman et al., 2003).  Laminin and 
fibronectin have also been shown to interact with collagens.  It was therefore 
investigated whether ARPE-19 shows adhesion to C1QTNF5 or its gC1q domain, or 
whether ARPE-19 cells stably expressing either wild type or mutant His-C1QTNF5 
would show any differences in adhesion to laminin- or fibronectin-coated plates, 
which might suggest that C1QTNF5 is involved in cell-extracellular matrix 
interactions and adhesion. 
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3.6.1 Optimising the assay 
It was necessary to optimise the cell adhesion assay since initial results obtained 
following the described assay of Shu et al. (2006b) were variable.  Several studies 
have been carried out using cell adhesion assays to test cell adhesion to extracellular 
matrices (Qi et al., 2002, Luckman et al., 2003, Humphries et al., 2001, Bax et al., 
2003). Stages from these assays were investigated and combined to obtain a 
repeatable method for determination of cell adhesion to use with the stably 
transfected ARPE-19 cell lines.  The stages involved in the cell adhesion assay 
included coating the plate, blocking non-specific binding sites, addition and 
incubation of cells, washing, fixing and detection of adherant cells.  The stages 
optimised in the method were blocking the plate, determination of correct cell 
number, washing and fixing. 
 
3.6.1.1 Blocking the plate 
Following coating of the microtitre plate with the desired extracellular matrix, it was 
necessary to block the plate to prevent non-specific cell adhesion.  Blocking 
solutions used previously include 3% BSA in PBS (Qi et al., 2002) and 10mg/ml 
heat denatured BSA in PBS (Bax et al., 2003, Luckman et al., 2003, Humphries, 
2001).  These two blocking solutions were investigated, using high (98%) and low 
(96%) grade BSA, as well as 5% skimmed milk in PBS. 
 
As can be seen from Figure 3.17, heat-inactivated 10mg/ml low grade BSA in PBS 
was effective in preventing ARPE-19 adhering to the plate.  This blocking solution 
was used in all future assays. 
 
3.6.1.2 Determination of correct cell number and washes 
Whilst it is necessary to use a high enough cell concentration in the assay to enable 
comparisons to be made between levels of cell adhesion, too high a cell 
concentration may affect the reliability of results.  In addition, whilst it is necessary 
to remove non-adherant cells from the wells following incubation, care has to be 
taken so that loosely adherant cells are not removed as well.  Comparisons were 
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made between different cell concentrations and the number of washes to determine 
which combination produced the most reliable results. 
 
Previous studies have used cell concentrations of 5x104 cells/ml (Luckman et al., 
2003),1x105 cells/ml (Qi 2002) and 5x105 cells/ml (Humphries, 2001, Bax et al., 
2003).  This study chose to investigate concentrations of 2.5x105, 5.0x105, 7.5x105 
and 1.0x106 cells/ml, and 1, 2 or 3 washes of 200l per well PBS.  Figure 3.18 shows 
the results obtained.  A cell concentration of 5x105 cells/ml and 2 washes was chosen 
for use in all future assays. 
 
3.6.1.3 Investigating different fixatives 
It is possible that the variable results obtained when following the previously 
described assay were caused by removal of adherant cells during the detection phase 
of the assay, where cells are stained with crystal violet and wells are washed 
repeatedly to remove excess stain.  In order to prevent this from happening, adherant 
cells can be fixed to the wells.  5% (w/v) glutaraldehyde has been described as a 
suitable fixative for use in cell adhesion assays (Bax et al., 2003, Humphries, 2001), 
and ice-cold methanol has been used as a fixative when carrying out immunostaining 
(section 3.1.2).  These two fixatives were compared and the most reproducible were 
results obtained when 5% (w/v) glutaraldehyde was used (Figure 3.19).  This fixative 





Figure 3.17: Bar chart showing the effectiveness of different blocking 
solutions to prevent ARPE-19 cells from adhering to 96 well microtitre 
plates. 
 
OD595 corresponds to the degree of cell adhesion.  10mg/ml heat-
inactivated low grade BSA in PBS (HI-Low Grade BSA) was most 





























Figure 3.18:  ARPE-19 cells adhesion to increasing concentrations of 
laminin. 
 
Different cell concentrations and number of washes were 
investigated to obtain the most reproducible results.  The optimal 
conditions were 5.0x10
5
 cell/ml and 2 washes, indicated by an 
arrow.  Blue: 2.5x10
5
 cell/ml; pink: 5.0x10
5




















































3.6.2 Cell adhesion assays 
The optimised cell adhesion assay was used to investigate ARPE-19 adhesion to 
C1QTNF5 and its gC1q domain.  Adhesion of the stably transfected cell lines 
GFWT19 and GFMT22 to either laminin- or fibronectin-coated plates was also 
investigated.   
 
3.6.2.1 ARPE-19 adhesion to C1QTNF5 and gC1q 
It was investigated whether ARPE-19 would adhere to C1QTNF5- or gC1q-coated 
microtitre plates.  Laminin was used as a positive control.  As can be seen from 
Figure 3.20, ARPE-19 cells adhered to laminin in a dose-dependant manner.  
However, no adhesion of ARPE-19 cells was observed to C1QTNF5, gC1q or BSA. 
 
3.6.2.2 Adhesion to laminin-coated plates 
Using the optimised cell adhesion assay, adhesion of ARPE-19, GFWT19 and 
GFMT22 cells to laminin-coated plates was investigated over increasing time 
periods.  This was to determine if there was any difference in both total adhesion and 
rate of adhesion between the cell lines.  Figure 3.21 shows the results obtained.  No 
differences were observed between the cell lines for each of the incubation times. 
 
3.6.2.3 Adhesion to fibronectin-coated plates 
Using the optimised cell adhesion assay, adhesion of ARPE-19, GFWT19 and 
GFMT22 to fibronectin-coated plates was investigated over increasing time periods.  
Figure 3.22 shows the results obtained, with OD595 being indicative of the total cell 




Figure 3.19: The effects of different fixatives on the total number of 
adherant cells. 
 
5% (w/v) glutaraldehyde gave the least reduction in adherant cells. 




Figure 3.20: Adhesion of ARPE-19 cells to increasing concentrations of 
different extracellular matrices. 
 
No adhesion was observed to C1QTNF5 (pink), gC1q (green) or 
BSA (red).  A dose-dependant adhesion to laminin was observed 






























Figure 3.21: Adhesion of ARPE-19, GFWT19 and GFMT22 to laminin-
coated microtitre plates using varying incubation times. 
 
No differences were observed in levels of adhesion between the 
cell lines at any of the incubation times. 
 
 
Figure 3.22: Adhesion of ARPE-19, GFWT19 and GFMT22 to fibronectin-
coated microtitre plates using varying incubation times. 
 
No differences were observed in levels of adhesion between the 


















































3.7 Cell spreading  
It was also investigated whether there are differences in cell spreading between the 
ARPE-19 cell lines.  Cell-ECM contacts are not only required for adhesion but also 
affect cell morphology, polarity and viability.  Cell spreading involves cytoskeletal 
re-organisation and the formation of focal contacts, so that differences in ability to 
spread can be indicative of a cell’s ability to change its morphology, to become 
polarised and to interact with its environment (Hynes, 1999).  It was therefore 
investigated whether any differences in cell spreading could be observed between the 
cell lines. 
 
3.7.1 Cell spreading assays 
Cell spreading of ARPE-19 has previously been investigated, using fibronectin-
coated plates (Elib et al., 2005).  The method was adapted for use in this study using 
laminin-coated plates.  Figure 3.23 shows spread and non-spread cells.  Non-spread 
cells retain a rounded morphology (indicated by the black arrow) whereas spread 
cells show a cytoplasmic halo and can have cellular projections (white arrow). 
 
3.7.1.1 Cell spreading on laminin 
Cell lines ARPE-19, GFWT19 and GFMT22 were allowed to spread on laminin-
coated 96-well microtitre plates for 2 hours, after which time the number of spread 
cells was determined.  Figure 3.24 shows images of the three cell lines after two 
hours incubation and spreading on laminin.  Spread cells can be seen for both ARPE-
19 and GFWT19, which in some cases have produced cellular projections, whereas 
GFMT22 remain spherical and shows little spreading. Two hundred cells were 
counted for each and scored as either spread or non-spread and with or without 
cellular projections.  The assay was repeated three times and the results pooled.  As 
can be seen from Figure 3.25, GFMT22 showed a significant reduction in cell 
spreading on laminin coated plates, χ2 (2-sided, N = 200) = 21.7, p < 0.001, and 
GFWT19 showed a significant increase in cellular projections, χ2 (2, N = 200) = 
43.8, p < 0.001. 
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Figure 3.23: ARPE-19 cells spread on laminin. 
 
White arrow indicates a spread cell with cellular projections. 
Black arrow indicates a non-spread cell. 
 
 
Figure 3.24: 20x magnification of cell lines ARPE-19, GFWT19 and 
GFMT22 spread on laminin. 
 
ARPE-19 and GFWT19 can be seen as spread cells, whereas 
GFMT22 remains spherical and shows minimal spreading.  







Figure 3.25: Number of spread cells for cell lines ARPE-19, GFWT19 and 
GFMT22 on laminin-coated plates. 
 
The total number of spread cells was counted out of 200, as were 
the number showing cellular projections.  The assay was repeated 
3 times, and standard errors are shown. 
 
 
Figure 3.26: Number of spread cells for cell lines ARPE-19, GFWT19 and 
GFMT22 on fibronectin-coated plates. 
 
The total number of spread cells was counted out of 200.  The 
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3.7.1.2 Cell spreading on fibronectin 
The cell spreading assay was repeated using fibronectin-coated microtitre plates and 
the number of spread cells scored for each cell line out of a total of 200.  As can be  
seen from Figure 3.26, ARPE-19 and GFWT19 show similar levels of spreading 
whereas this is significantly reduced in GFMT22, χ2 (2-sided, N = 200) = 11.3, p < 




Stably transfected ARPE-19 cell lines expressing wild type or mutant His-C1QTNF5 
have been created.  ARPE-19 cells are physiologically relevant for use in 
investigating the effects of C1QTNF5 over-expression and the Ser163Arg mutation.  
An advantage of using the stably transfected cell lines over transient ones is that 
expression levels can be determined and remain constant.  Few cell lines were 
created due to the low transfection efficiency of ARPE-19, as previously observed in 
this lab.  It is likely that this is simply a feature of ARPE-19 rather than due to over-
expression of C1QTNF5.  However, C1QTNF5 expression in the stably transfected 
cell lines was difficult to detect due to the low expression levels.  This could be 
coincidence, or might indicate that high levels of C1QTNF5 are detrimental to the 
cells.   
 
Whereas previously it had been shown that wild-type but not mutant C1QTNF5 is 
secreted (Shu et al., 2006b, Mandal et al., 2006c), this study has shown that both 
forms of the protein are secreted.  In addition there does not appear to be high levels 
of retention of either protein within the cells, since His-C1QTNF5 was difficult to 
detect in both GFWT19 and GFMT22 cell lysates by Western blot.  Shu et al. 
(2006b) were using stably transfected EBNA293 cells expressing His-C1QTNF5 to 
investigate secretion, rather than ARPE-19, so it is possible that His-C1QTNF5 is 
simply not secreted in that cell line.  It is also possible that an insufficient volume of 
culture medium was analysed, or that the cells were not incubated for long enough to 
allow for sufficient secretion.  Mandal et al. (2006c) were investigating V5-tagged 
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C1QTNF5 expression in transiently transfected COS-7 cells and analysed culture 
media after 48 hours’ incubation.  It is possible again that insufficient culture 
medium was analysed, or that either the V5 tag or expression in COS-7 does not 
allow for secretion of mutant C1QTNF5.   
 
Levels of apoptosis were compared between GFWT19, GFMT22 and ARPE-19 
cells, and found to be negligible in each cell line after 5 days post-confluence in 
serum free media.  This would support any His-C1QTNF5 detected in the culture 
media being present as a result of secretion rather than via release from dying cells. 
 
Secreted proteins are synthesised in the ER before they travel to the Golgi apparatus 
to be packaged for secretion.   However, misfolded proteins are retained within the 
ER and subsequently subject to ER-associated degradation via translocation to the 
cytosol, ubiquitination and degradation by proteosomes (Ellgaard et al., 2003). 
Therefore, the observation that mutant but not wild type C1QTNF5 co-localised with 
calreticulin and PDI, and that wild type but not mutant C1QTNF5 co-localised with 
the Golgi apparatus (Shu et al., 2006b) would appear to support wild type C1QTNF5 
travelling through the secretory pathway whilst the mutant was retained within the 
ER.  However, in the present study immunostaining was carried out in stably 
transfected cell lines looking at the sub-cellular distributions of His-C1QTNF5 and 
the presence or absence of co-localisation with the ER markers calreticulin and PDI.  
No differences were observed between the two cell lines, and no retention of protein 
within the ER was observed.  The previous study was carried out using transiently 
transfected ARPE-19 expressing GFP-tagged protein whereas this study used stably 
transfected cells expressing His-tagged protein.  It is possible that expression levels 
differed between transiently and stably transfected cells and that this could have an 
effect on the tendency to aggregate or the inability to secrete.  ARPE-19 cells were 
therefore transiently transfected with the pEGFP-C1 (minus EGFP)-C1QTNF5 
constructs and the sub-cellular distribututions of His-C1QTNF5 analysed by 
immunostaining.  However, no differences were observed between wild-type- or 
mutant-His-C1QTNF5 expressing cells.  Therefore, it is likely that the difference 
observed between this and the previous study was not due to differences in 
 138 
C1QTNF5 expression levels resulting from transient expression of C1QTNF5.  It is 
possible that having a GFP tag promotes aggregation or impairs secretion of mutant 
but not wild-type C1QTNF5, and this may explain the differences observed.    
 
It has been suggested that C1QTNF5 may be involved in RPE-extracellular matrix 
adhesion, possibly to Bruch’s membrane, and that the C1QTNF5 mutation could 
cause a reduction in adhesion, possibly due to haploinsufficiency (Hayward et al., 
2003).  Secretion experiments have shown that wild type and mutant protein are both 
secreted and undergo similar cellular trafficking in ARPE-19 cells, so 
haploinsufficiency is unlikely to be an issue.  However, it was investigated whether 
differences between the wild-type and mutant proteins could affect cell adhesion, 
either of ARPE-19 cells directly to C1QTNF5 or of C1QTNF5-expressing cell lines 
to extracellular matrix proteins.  C1QTNF5 shares homology with other collagens 
such as collagens VI and X, which form extracellular lattices and bind to cells via 
integrin interactions with their helical collagen domains and globular head groups 
(Yurchenco et al., 1987, Kwan et al., 1991, Luckman et al., 2003).  However ARPE-
19 cells did not show adhesion to either C1QTNF5 or gC1q, suggesting that 
C1QTNF5 is unlikely to be directly involved in RPE-extracellular matrix adhesion.  
It was also investigated whether ARPE-19 cells stably over-expressing wild type or 
mutant C1QTNF5 shows any differences in adhesion to laminin or fibronectin when 
compared with untransfected cells.  Again, no differences in levels of adhesion were 
observed.  This suggests that C1QTNF5 is unlikely to have an indirect effect on 
RPE-extracellular matrix adhesion.  It is possible that C1QTNF5 may still be 
involved but that another downstream factor is limiting and therefore cancels out any 
effects of wild-type C1QTNF5 over-expression.  However, over-expression of 
mutant C1QTNF5 did not reduce cell adhesion, as might be expected if it was 
involved, as the wild-type and mutant proteins have been shown to interact (Shu et 
al., 2006b) and over-expression of mutant could therefore alter the effects of 
endogenous wild type protein. 
 
Cell-extracellular matrix interactions are not only involved in cell adhesion, but can 
also have effects on cellular morphology, polarisation and cytoskeletal organisation.  
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Cell spreading involves cytoskeletal re-organisation and the formation of focal 
contacts, so differences in ability to spread can be indicative of a cell’s ability to 
change morphology, become polarised and interact with its environment (Hynes, 
1999).  Cell spreading was investigated by looking at the transfected cell lines on 
laminin-coated plates, and a reduction in spreading was seen in the mutant cell line 
GFMT22.  In addition, an increase in the percentage of spread cells showing cellular 
projections was seen in the wild type cell line GFWT19.  This would suggest that 
C1QTNF5 is involved (either directly or indirectly) in interactions with the ECM and 
ECM-mediated alterations in cell morphology.  The RPE is a polarised epithelium, 
and forms apical microvilli which interdigitate with ROS, facilitating their 
phagocytosis upon shedding.  C1QTNF5 has been shown to be localised to this 
boundary, and to co-localise with ezrin (Mandal et al., 2006c).  Ezrin has been 
shown to be involved in the formation of these apical microvilli, along with basal 
infoldings (where C1QTNF5 is also localised) (Bonhilha et al., 1999, Mandal et al., 
2006c).  CFH knockout mice show a disrupted RPE-ROS boundary (Coffey et al., 
2007), and MFRP, with which C1QTNF5 has been shown to interact (Shu et al., 
2006b, Mandal et al., 2006c), has recently been shown to be involved in RPE 
microvilli formation, maintenance of the ROS-RPE boundary and ROS phagocytosis 
(Won et al., 2008).  It is tempting to suggest that C1QTNF5 could be involved in the 
formation or maintenance of the RPE-ROS boundary in vivo.  Mutation in C1QTNF5 
has been shown to reduce the morphological changes in ARPE-19 cells when plated 
on laminin and fibronectin in vitro.  In vivo it is possible that affected individuals 
could have a disrupted RPE-ROS boundary.  It is not possible to confirm this in 
donated eyes as only aged eyes have been donated, which show many other features 
of L-ORMD, so cause and effect cannot be established.  Further investigation into 
the nature of the morphological changes observed is required, for instance to 
establish what receptors are involved and if there are any effects of C1QTNF5 over-
expression or mutation on the phagocytic capabilities of the transfected cell lines. 
4 CHAPTER 4  
: 





Several studies have already been carried out looking at C1QTNF5 properties and 
the effects of the Ser163Arg mutation.  To summarise, C1QTNF5 is a 25kDa 
secreted protein which shares homology with short chain collagens (Hayward et al., 
2003).  It consists of 3 domains: a secretory domain, a collagen domain and a 
globular C1q (gC1q) region.  The gC1q region has been shown to be involved in 
self-assembly of the protein to form trimers and hexamers under native conditions, 
with an aromatic motif conserved within the C1q superfamily essential for intiating 
the assembly.  The Ser163Arg disease-causing mutation in L-ORMD is located in the 
gC1q region and is predicted to alter the surface charge of this head group.  Wild 
type and mutant proteins have been shown to interact and form multimeric species, 
indicating that the Ser163Arg mutation does not affect this property (Shu et al., 
2006b).  Using E. coli expressed protein, it has been shown that mutant gC1q forms 
an insoluble, high molecular weight aggregate whereas wild-type gC1q is soluble 
(Hayward et al., 2005).  Mandal et al. (2006c) found that recombinant full length 
V5-tagged mutant C1QTNF5 produced using a mammalian expression system (COS-
7) had an increased tendency to form aggregates which would not migrate through an 
SDS-PAGE gel under reducing or non-reducing conditions.  When His-tagged 
C1QTNF5 was stably expressed in EBNA293 cells it was reported that the wild type 
protein was secreted and formed trimers and hexamers under native conditions, 
whereas the mutant protein was not secreted and formed a high molecular weight 
aggregate (Shu et al., 2006b).  Therefore, the published data so far would suggest a 
disease mechanism in L-ORMD caused by aggregation and/or lack of secreted 
C1QTNF5. 
 
It has been shown in Chapter 3 that wild-type and mutant His-C1QTNF5 are both 
secreted when stably expressed in ARPE-19, and that neither protein appears to form 
an aggregate or to be retained within the cell.  Due to the contradiction between this 
result and the published data, further investigation is required into the effects of the 
Ser163Arg mutation on C1QTNF5.  In particular, it needs to be determined whether 
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the mutant protein does indeed form insoluble aggregates and whether the 163Arg 
mutation affects multimerisation. 
 
 
4.2 Producing recombinant C1QTNF5 
In order for comparisons to be made between wild-type and mutant C1QTNF5, it 
was necessary to produce reasonable quantities of the recombinant proteins.  When 
recombinant wild type and mutant His-C1QTNF5 were stably produced in ARPE-19 
with small C-terminal His tags, the secreted proteins were found to be present in the 
culture medium.  However, recombinant His-C1QTNF5 is produced at very low 
levels in ARPE-19, meaning that these cell lines would not be practical for large 
scale protein production.  EBNA293 is a human embryonic kidney derived cell line 
which has been used previously as a mammalian expression system to produce 
recombinant proteins, for instance EMILIN-1, which is an extracellular matrix 
protein containing a self-interacting gC1q domain homologous to C1QTNF5 
(Spessotto et al., 2003).  Therefore, a stably transfected EBNA293 cell line 
producing wild-type His-tagged C1QTNF5 was produced from which to purify 
recombinant protein.  A stably transfected EBNA293 cell line producing mutant His-
tagged C1QTNF5 had previously been created and was supplied for use by Dr X. 
Shu. 
 
4.2.1 Creating an EBNA293 cell line stably expressing wild type 
C1QTNF5 
EBNA293 cells were transfected with a pCEP-Pu vector construct containing His-
C1QTNF5 insert, supplied by Dr X. Shu.  This vector has been used previously for 
expression of recombinant proteins in EBNA293 (Hopf et al., 2001) and contains a 
selectable marker for selection of transfected cells with puromycin. 
 
4.2.1.1 Transfection, selection and screening of EBNA293 for stable 
transfection and expression of His-C1QTNF5 
Following transfection, EBNA293 were maintained in culture media containing 
2µg/ml puromycin.  Individual colonies were amplified and cell lysates screened by 
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Western blot for His-C1QTNF5 expression.  Figure 4.1 is an example of a screening 
Western blot.  Lanes A to H contain cell lysate samples from individual colonies.  
The band at approximately 28kDa seen in lanes A, C, D, E, G and H is His-
C1QTNF5.  The additional band at approximately 14kDa is most likely to be 
degraded His-C1QTNF5, possibly the gC1q domain which is 15kDa in size.  Cell 
line A was selected for use in future assays. 
 
4.2.1.2 Checking secretion of His-C1QTNF5  
TCA precipitated culture medium proteins from the selected cell line were analysed 
by Western blot to check whether His-C1QTNF5 was secreted.  As can be seen from 
Figure 4.2, His-C1QTNF5 (approximately 28kDa) was present in both the cell lysate 
and precipitated culture medium protein samples, indicating that it is secreted. 
 
4.2.1.3 Immunostaining of wild-type and mutant His-C1QTNF5 
expressing cell lines 
Immunostaining was carried out on the above cell line and also on the mutant His-
C1QTNF5 expressing EBNA293 cell line supplied by Dr X. Shu (Figure 4.3).  Anti-
His antibodies confirmed the expression of His-C1QTNF5 in both cell lines.  A 
diffuse cytoplasmic distribution of His-C1QTNF5 was observed in both, suggesting 
similar cellular trafficking between the cell lines and no aggregation or retention of 
His-C1QTNF5 within the ER.  Beta-catenin staining indicates cellular boundaries. 
 
4.2.2 Secretion of mutant His-C1QTNF5 
When carrying out the above immunostaining, the C1QTNF5 aggregation and 
retention within the ER described previously (Shu et al., 2006b) was not observed.  It 
was therefore investigated whether mutant His-C1QTNF5 was actually secreted from 
this cell line.  Culture media from the wild type and mutant His-C1QTNF5-
expressing EBNA293 cell lines were analysed by Western blot at 1, 2 and 3 days 
post-confluence, after replacing the media with serum free medium to allow 
accumulation of secreted protein in the culture medium.  His-C1QTNF5 was purified 
using Ni-NTA affinity chromatography beads allowing for detection of low levels of 
protein.  His-C1QTNF5 was found to be present in the culture media of both cell 
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lines, increasing from 1 to 3 days (see Figure 4.4).  Samples were not normalised for 
cell number and cell lines were not selected for similar expression levels, so the 
apparent differences in levels of His-C1QTNF5 expression between the cell lines 





Figure 4.1: Western blot showing cell lysate samples from screened 
transfected EBNA293 cell lines checked for expression of His-C1QTNF5. 
 
His-C1QTNF5 can be seen at approximately 28kDa.  The band in 
lane C at approximately 14kDa is most likely partially degraded 
protein.  Primary antibody – mouse anti-His; secondary antibody – 
rabbit anti-mouse HRP.  kDa: relative molecular mass 
 
Figure 4.2: Western blot of cell lysate (C) and TCA precipitated culture 
media protein (M) samples from the wild type His-C1QTNF5 expressing 
EBNA293 cell line. 
 
The band at approximately 28kDa is His-C1QTNF5.  The figure 
shows that His-C1QTNF5 is present in the cell lysates and  is 
secreted into the culture medium.  Primary anitbody – mouse anti-




Figure 4.3: Immunostaining of stably transfected EBNA293 expressing 
wild type (WT) or mutant (MT) His-C1QTNF5 and untransfected EBNA293. 
Anti-beta catenin staining seen in green.  Anti-His staining, 
corresponding to His-C1QTNF5, is seen in red.  In both WT His-
C1QTNF5 and MT His-C1QTNF5, His-C1QTNF5 shows diffuse 
cytoplasmic localisation. 
 
Figure 4.4: Western blot of Ni-NTA purified culture media proteins from 
transfected EBNA293 stably expressing wild-type or mutant His-C1QTNF5. 
Samples were taken at 1, 2 or 3 days post confluence in serum 
free media.  Bands at approximately 28kDa are His-C1QTNF5 
monomer, and bands at approximately 50kDa are His-C1QTNF5 
dimer.  Primary anitbody – mouse anti-His; secondary antibody – 
rabbit anti-mouse HRP.  kDa: relative molecular mass 
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4.2.3 Purifying recombinant His-C1QTNF5 from transfected EBNA293 
Wild-type and mutant His-C1QTNF5 are both secreted from the stably transfected 
EBNA293 cell lines.  Larger quantities of the protein are secreted from these cell 
lines than the transfected ARPE-19 cell lines GFWT19 and GFMT22, making 
feasible large-scale production and purification of His-C1QTNF5 for use in future 
assays. 
 
Cells were grown to confluence in media containing 10% serum, and then incubated 
in serum-free media for 5 days to allow accumulation of secreted protein in the 
culture media.  His-C1QTNF5 was affinity purified from culture medium 
supernatants using Ni-NTA affinity chromatography, with His-C1QTNF5 eluted in 1 
ml fractions using 1M imidazole, pH10.  Figure 4.5 shows reducing SDS-PAGE of 
elution fractions for wild type His-C1QTNF5 (A) and mutant His-C1QTNF5 (B).  
Bands corresponding to His-C1QTNF5 monomers, dimers and trimers can be 
observed.  Additional bands were also observed in the mutant fractions, highlighted 
by the black arrow.   
 
Elution fractions were pooled and dialysed into PBS.  Figure 4.6 shows reducing 
SDS-PAGE and Western blot analysis of the pooled proteins.  It can be seen that 
even under reducing conditions both wild type and mutant His-C1QTNF5 are present 
as monomeric, dimeric and trimeric species.  In addition, the extra bands observed 
only for the mutant protein in Figure 4.5 are observed here too, although it was 
necessary to load excess protein onto the gel to enable detection.  
 
4.3 Producing His-gC1q in E. coli 
As well as producing full length His-C1QTNF5 using a mammalian expression 
system, His-tagged globular C1q domain (His-gC1q) was produced using a bacterial 
expression system. The clones had been created and supplied by Dr X. Shu.  Such 
recombinant E. coli-produced gC1q domains have been used in previous studies 
looking at C1QTNF5 (Shu et al., 2006a). 
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                          A           B 
Figure 4.5: Reducing SDS-PAGE of successive elution fractions for wild-
type (A) and mutant (B) His-C1QTNF5 purified from the culture media of 
the stably transfected EBNA293 cell lines. 
 
Protein was eluted in 1M imidazole, pH10, with 10l eluant loaded 
per well. 
The arrow indicates additional bands present in the mutant.  kDa: 
relative molecular mass 
 
 A        B 
Figure 4.6: Reducing SDS-PAGE (A) and Western blot (B) of pooled and 
dialysed wild type (WT) and mutant (MUT) His-C1QTNF5 
 
Additional bands are observed for the mutant when excess protein 
is loaded to the gel (WT’ MUT’).  Primary antibody – mouse anti-





4.3.1 Purifying wild-type His-gC1q from E. coli 
Wild-type His-gC1q-expressing E. coli was cultured at 37°C until sufficient biomass 
had been reached, whereupon the temperature was reduced to 20°C and expression 
was induced by addition of IPTG.  Reducing the temperature slowed the rate of 
protein production, which is high in E. coli, to help facilitate correct protein folding 
and prevent the formation of inclusion bodies.  This was especially important as the 
construct does not contain a secretion signal peptide and so the protein remains 
intracellular. Figure 4.7 (A and B) shows sample cell lysates analysed by SDS-PAGE 
and Western blot of induced (I) and non-induced (NI) cultures.  His-gC1q can be 
seen at between 15 and 20kDa in induced samples. 
 
Following large-scale culture and cell lysis, intracellular His-gC1q was purified from 
clarified lysates by Ni-NTA affinity chromatography, with the protein eluted in 1M 
imidazole, pH10.  Figure 4.7 (C) shows a reducing SDS-PAGE of the eluted 
fractions, with monomeric, dimeric and trimeric species present.  All the fractions 
were then pooled and dialysed into PBS.  Figure 4.7 (D and E) shows a reducing 
SDS-PAGE and Western blot for the pooled and dialysed protein.  Multimeric 
species can again be observed. 
 
4.3.2 Purifying mutant His-gC1q from E. coli 
E. coli clones expressing mutant His-gC1q were also supplied by Dr X. Shu.  
However, it was not possible to purify protein from the cell lysates due to the 
formation of insoluble inclusion bodies.  Figure 4.8 shows the elution fractions 
obtained, analysed by reducing SDS-PAGE.  In addition to possible multimeric His-
gC1q, many contaminating bands are present.  Therefore it was decided not to pursue 




 A   B     C 
 
   D      E 
 
Figure 4.7: A – Reducing SDS-PAGE of non-induced (NI) and induced (I) E. 
coli cultures showing expression of wild-type His-gC1q in the induced 
culture. 
 
B – Western blot of A, showing His-gC1q expressing in the induced 
culture. 
C –  Reducing SDS-PAGE of elution fractions purified from a large 
scale culture.  Monomeric, dimeric and trimeric His-gC1q can be 
seen. 
D – Reducing SDS-PAGE of pooled His-gC1q elution fractions, 
showing monomeric, dimeric and trimeric protein. 
E – Western blot of D with low (His-gC1q A) and high (His- gC1q 
B) concentrations of protein loaded to the gel.  Monomeric, dimeric 
and trimeric species are present with higher order multimers in His-
gC1q B. 
For Western blots: Primary anitbody – mouse anti-His; secondary 




Figure 4.8: Reducing SDS-PAGE of successive mutant His-gC1q eluted 
fractions purified from transfected E. coli cell lysates by Ni-NTA affinity 
chromatography. 
 
It was not possible to obtain pure protein, indicating that mutant 




4.4 Comparing wild-type and mutant His-C1QTNF5 
Previous studies indicated that differences existed relating to the solubility and 
aggregation of wild-type and mutant C1QTNF5.  However, the results from the 
previous chapter indicated that this was not necessarily the case, so further 
investigations were carried out, looking at solubility and multimerisation of the 
recombinant proteins, to determine what differences could be observed between the 
wild-type and mutant. 
 
4.4.1 Bradford assay 
All protein concentrations were determined by Bradford assay.  Bovine serum 
albumin sample solutions of known concentration were analysed to give a standard 
curve, from which the recombinant protein concentrations were determined.  The 
standard curve process was repeated each time the assay was carried out.  Figure 4.9 
gives an example of such a standard curve and subsequent calculation of protein 
concentration.   
 
4.4.2 Investigating C1QTNF5 solubility  
Previous studies had indicated that mutant but not wild-type C1QTNF5 formed 
insoluble aggregates.  Soluble protein concentrations of wild-type and mutant gC1q 
had been determined after incubation at 37°C for up to 24 hours, and it was found 
that the mutant protein showed a total decrease in soluble protein concentration of 
approximately 85% compared with a roughly 15% decrease in the wild type 
(Hayward et al., 2003).  However, this result was obtained using E. coli expressed 
wild-type and mutant gC1q domains and it has been shown in section 4.3.2 that, 
when expressed in E. coli, the mutant protein forms insoluble inclusion bodies.  
Therefore, the result obtained may have been due to an impure, misfolded mutant 
gC1q rather than the Ser163Arg mutation.  The assay was repeated using wild-type 
and mutant His-C1QTNF5 purified from the stably transfected EBNA293 cell lines.  
Both proteins were shown to be soluble in PBS up to 36 hours, with no observable 
reduction over this time period when samples were analysed by reducing SDS-PAGE 
(Figure 4.10).  OD280 measurements were also taken and although both proteins 
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showed a slight reduction in soluble protein over this time course, there was no 
difference between the wild-type and mutant samples (Figure 4.11).  It should 
however be noted that mutant His-C1QTNF5 precipitates at room temperature in  



























            Sample calculation: 
 
y = sample OD595 
    = 1.35 
  x = sample concentration 
    
y = 0.2481x + 0.7959 
So, x = (y – 0.7959) / 0.2481 
  
  Therefore, x = (1.35 – 0.7959) / 0.2481 
     = 2.23 mg/ml 
 
Figure 4.9: Sample Bradford assay standard curve and calculation of 
protein sample concentration. 
 
The standard curve OD595 values were obtained using PBS/BSA 





 A        B 
Figure 4.10: Reducing SDS-PAGE of wild type (A) and mutant (B) His-
C1QTNF5. 
 
Proteins were incubated at 37°C with samples taken for analysis 
for up to 36 hours.  Samples were centrifuged at 13,000 rpm for 10 





Figure 4.11: OD280 readings for wild type and mutant His-C1QTNF5 at 37°C 
in PBS for up to 36 hours. 
 
Samples were centrifuged at 13,000 rpm for 10 minutes prior to 



















4.4.3 Polyacrylamide gel electrophoretic analysis of C1QTNF5 and 
gC1q 
When analysing purified His-C1QTNF5 by reducing SDS-PAGE it was observed 
that both the wild-type and mutant proteins formed monomeric, dimeric and trimeric 
species, and these did not appear to differ between the proteins.  Other gC1q-
containing proteins such as C1q and collagens X and VIII have been shown to form 
trimeric species which are highly resistant to reducing conditions, and it has been 
suggested this is due to buried Ca2+ clusters providing stability to the trimers 
(Kishore et al., 2004a, Kishore et al., 2004b, Bogin et al., 2002, Stephan et al., 
2004).  It has been proposed that in homologous proteins containing the gC1q 
domain, an aromatic motif is responsible for initial trimer assembly (Brass et al., 
1992, Chan et al., 1999), followed by the formation of a central solvent-filled 
channel stabilised by Ca2+ clusters providing strong ionic bonds (Kishore et al., 
2004b).  Supramolecular assembly differs between gC1q-containing proteins.  
Exposed aromatic strips at the surface of the trimers promote hydrophobic 
interactions for supramolecular assembly of collagen X and VIII (Stephan et al., 
2004, Kishore et al., 2004b).  However, interactions between the collagen domains of 
C1q and MBL (which contains a gC1q-like domain) cause these proteins to form 
tulip-like clusters (Kishore et al., 2004a). 
 
Polyacrylamide gel electrophoresis separates proteins according to their 
electrophoretic mobility, which can be dependant upon protein molecular weight, 
higher order structure and post-translation modifications.  Analysis by reducing  
SDS-, non-reducing SDS- or native PAGE was carried out to give insight into the 
nature of the bonds and molecular interactions involved in C1QTNF5 
multimerisation. 
 
4.4.3.1 Reducing and non-reducing SDS-PAGE 
Protein samples for reducing SDS-PAGE were prepared by heating in the presence 
of SDS and dithiothreitol (DTT).  SDS is an anionic detergent which denatures 
secondary and non-disulphide-linked tertiary structures and gives proteins a uniform 
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negative charge in proportion to their mass.  DTT reduces disulphide bridges found 
in protein tertiary structure.  Prior treatment with both of these chemicals should 
allow for protein separation due to mass alone.  Proteins undergoing non-reducing 
SDS-PAGE were prepared by heating in the presence of SDS alone.  Gel migration is 
therefore dependant upon mass and disulphide-linked tertiary structure. 
 
Figure 4.12 shows reducing and non-reducing SDS-PAGE gels for wild-type and 
mutant His-C1QTNF5 and wild-type His-gC1q.  Under reducing conditions, both 
wild-type and mutant His-C1QTNF5 and wild type His-gC1q show monomeric, 
dimeric and trimeric species, the latter two of which show resistance to reducing 
conditions.  Faint additional bands can be observed in the mutant, as noted 
previously (Figure  4.5/Section 4.2.3).  Faint bands for higher order multimers can 
also be seen in His-gC1q and were observed previously by Western blot (Figure 4.7, 
E).  Under non-reducing conditions, wild-type and mutant His-C1QTNF5 form 
monomeric, dimeric, trimeric and higher order multimeric species, indicating the 
presence of disulphide-linked tertiary structures.   
 
4.4.3.2 Native PAGE 
During native PAGE analysis, protein migration is dependant upon charge, protein 
size and oligomeric state.  No SDS or DTT is present therefore the protein has only 
its native charge, which will affect the rate at which it migrates through the gel.  
Samples are not heated or denatured so native protein size and oligomeric state will 
also affect migration rate.  The distance migrated is dependant upon these factors in 
combination with the gel pore size.  Therefore, native PAGE analysis can show the 
native oligmeric state of the protein under the conditions investigated.   
 
In this study, native discontinuous electrophoresis and subsequent generation of a 
molecular weight standard curve (Ferguson plot) was carried out following the 
method described by Gallagher (2000).  This requires standard proteins of known 
molecular weight to be separated on gels of varying acrylamide plus bisacrylamide 
concentration (%T).  The distance migrated, or relative mobility (Rf) for each protein 
and each %T is calculated.  Plotting the log Rf against %T for each protein gives a 
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 A   B     C 
Figure 4.12: Reducing versus non-reducing SDS-PAGE of His-C1QTNF5 
and His-gC1q protein. 
 
A - Reducing SDS-PAGE of wild-type (WT and mutant (MUT) His-
C1QTNF5, showing monomeric, dimeric and trimeric protein 
B – Reducing SDS-PAGE of wild type His-gC1q, showing 
monomeric, dimeric and trimeric protein. 
C – Non-reducing SDS-PAGE of wild type His-gC1q (gC1q) and 
wild type (WT) and mutant (MT) His-C1QTNF5.  His-gC1q can be 
see as monomeric, dimeric and trimeric protein.  His-C1QTNF5 
can be seen as monomeric, dimeric, trimeric and higher order 
multimeric protein, and is the same for both wild type and mutant.  
kDa: relative molecular mass 
 
Figure 4.13: Isoelectric focusing gel for wild type (WT) and mutant (MUT) 
His-C1QTNF5. 
 
Wild type protein is present as two species with pI’s aproximately 
7.5 and 6.8, and the mutant protein is present as a single species 
with a pI of aproximately 6.5.  pI - relative protein pI. 
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slope with a gradient, Kr. This is the retardation coefficent for that protein, and is a 
measure of how effectively the protein is slowed by an increase in %T.  Plotting log 
Kr against log MW for the standard proteins gives a standard curve from which 
unknown molecular weights can be determined.  This method does however assume 
that protein shape does not significantly alter protein migration between either the 
standard or sample proteins.  C1QTNF5 is a relatively small protein with a known 
globular domain, so it was assumed that protein shape would not be an issue in this 
instance.  Also, ideally, standard proteins should be used which have a similar pI to 
the sample protein. 
 
4.4.3.2.1 pI determination 
As migration through a native PAGE gel relies partially upon the native charge of a 
protein, it is necessary to determine the pI of the proteins to be investigated.  These 
were determined by isoelectric focusing PAGE (Figure 4.13), with wild-type His-
C1QTNF5 existing as two species of pI 7.5 and 6.8 and the mutant existing as a 
single species of pI 6.5.  Native gel conditions used were appropriate for proteins of 
pI 8.0 or below.   
 
4.4.3.2.2 Native PAGE standard gels 
Before running the His-C1QTNF5 samples, calibration was required against proteins 
for which the molecular weight and oligomeric state are already known, using gels 
ranging in pore size.  Ferguson plots could then be obtained against which His-
C1QTNF5 migration could be compared.  All gels were run at 37°C because at this 
temperature both wild-type and mutant His-C1QTNF5 were found to be soluble. 
 
Figure 4.14 shows standard proteins lactalbumin (A), carbonic anhydrase (B), 
ovalbumin (C) and BSA (D) run on 8%, 10% and 12% polyacrylamide gels.  
Distance migrated was plotted against gel concentration for each of the proteins and 
the gradients calculated (Figure 4.15).  Protein molecular weight was then plotted 
against the log of the gradients to give the native PAGE standard curve (Ferguson 
plot) (Figure 4.16). 
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Figure 4.14: Native PAGE analysis of standard proteins lactalbumin (A), 
carbonic anhydrase (B), ovalbumin (C) and BSA (D), run  8%, 10% and 
12% polyacrylamide gels. 
 
Distances migrated by each protein, including multimeric forms, 
were used to calculate relative mobilities and to plot a native PAGE 
standard curve (see Figures 4.15 and  4.16). 
Figure 4.15: Native protein relative mobilities (mm) were plotted against 
gel concentration, and the gradients (Kr) calculated for each of the 
standard proteins. 
 
These were used to plot the native PAGE standard curve (Figure 
4.16). 
 




y = -0.0845x + 2.611
R2 = 0.9962

















































Figure 4.16: Log of the gradients from Figure 4.15 (log Kr). 
 
This was plotted against molecular weight for each of the native 
protein standards to give the native PAGE standard curve, from 
which native molecular weights for His-C1QTNF5 were calculated. 
 
Figure 4.17: Native PAGE analysis of wild-type (W) and mutant (M) His-
C1QTNF5 on 8%, 10% and 12% polyacrylamide gels. 
 
Wild-type protein is present predominantly as two species.  
Distance migrated for each species through each of the gels was 
used to calculate the relative mobility (Figure 4.18).  Mutant His-
C1QTNF5 would not migrate through the gel.  SG - stacking gel. 
 






















Figure 4.18: Native protein relative mobilities (mm) plotted against gel 
concentration for both of the two wild-type His-C1QTNF5 species, 
showing calculated gradients (Kr) for each. 
 
Kr values were then used to calculate molecular weight using the 
native PAGE standard curve (Figure 4.16). 



































4.4.3.2.3 Native PAGE analysis of His-C1QTNF5 
Wild-type and mutant His-C1QTNF5 were analysed on 8%, 10% and 12% 
polyacrylamide gels under native conditions (Figure 4.17).  Wild-type His- 
C1QTNF5 migrated as two species.  The distance migrated for each species was 
plotted against the gel concentration (Figure 4.18).  The gradients for each were then 
compared to the native PAGE standard curve to give predicted molecular weights of 
77.88kDa and 145.53kDa, indicating the protein is present as a major trimeric and 
weak hexameric species (assuming a monomeric molecular weight of approximately 
25kDa).  Mutant His-C1QTNF5 would not migrate through the gel. 
 
4.4.4 Post-translational modification of C1QTNF5 
C1QTNF5 is a secreted protein and therefore unlikely to undergo post-translational 
modifications such as phosphorylation or ubiquitination.  Secreted proteins can 
undergo N- or O-glycosylation and alterations in this could account for the additional 
bands seen in the mutant.  Prediction of N-glycosylation sites was carried out on 
C1QTNF5 (http://www.cbs.dtu.dk/services/NetNGlyc/) and no predicted sites were 
identified.  However, prediction sites for O-glycosylation were identified 
(http://www.cbs.dtu.dk/services/NetOGlyc/), as shown in Figure 4.19, with these 
occurring in the collagen and N-terminal of the gC1q domains. 
 
4.4.5 Matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry comparison of wild type and mutant C1QTNF5  
Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) is a technique used for the accurate mass analysis of 
biomolecules (Karas and Hillenkamp, 1988).  Applications include predicting protein 
identity, de novo peptide sequencing, investigating post-translational modifications 
and comparing recombinant and endogenous proteins, and the technique can be used 
for both purified proteins and complex mixtures (Zaluzec et al., 1995, Hortin, 2006).  
In this study, MALDI-TOF MS was used to determine the identity of the additional 
bands seen on reduced SDS-PAGE of mutant His-C1QTNF5 (see Figure 4.5) and to 












    Name                         S/T   Pos  G-score I-score Y/N   
    Sequence                      S     16   0.205   0.097   .    
    Sequence                      S     26   0.456   0.064   .    
    Sequence                      T     37   0.511   0.127   T    
    Sequence                      S     43   0.401   0.066   .    
    Sequence                      T     92   0.694   0.687   T    
    Sequence                      S     99   0.549   0.042   S    
    Sequence                      S    104   0.616   0.026   S    
    Sequence                      S    107   0.611   0.053   S    
    Sequence                      S    111   0.565   0.027   S    
    Sequence                      S    113   0.561   0.036   S    
    Sequence                      S    119   0.449   0.451   .   
    Sequence                      T    144   0.273   0.053   .  
    Sequence                      T    158   0.203   0.022   .   
    Sequence                      S    163   0.164   0.032   .    
    Sequence                      S    174   0.157   0.021   .   
    Sequence                      S    177   0.198   0.026   .    
    Sequence                      S    190   0.255   0.066   .    
    Sequence                      S    192   0.277   0.089   .    
    Sequence                      S    220   0.170   0.253   .    
    Sequence                      T    223   0.243   0.056   .    
    Sequence                      S    225   0.209   0.026   .    
    Sequence                      T    226   0.312   0.054   .    
    Sequence                      S    228   0.229   0.057   .    
    Sequence                      S    234   0.352   0.050   .    
    Sequence                      S    238   0.396   0.070   .   
    Sequence                      S    239   0.386   0.032   . 
 
       Figure 4.19: Predicted O-glycosylation sites for C1QTNF5. 
(http://www.cbs.dtu.dk/services/NetOGlyc/) 
The G-score is the score from the best general predictor; the I-
score is the score from the best isolated site predictor. If the G-
score is >0.5 the residue is predicted as glycosylated; the higher 
the score the more confident the prediction. For threonines an 
additional score is used: if the G-score is <0.5 but the I-score >0.5 
and there are no predicted neighbouring sites (distance <10 
residues) the residue is also predicted as glycosylated. There are 
2 predicted glycosylation sites within the collagen domain (red) and 
5 predicted sites within the gC1q domain (green). 
The secretory domain is shown in blue. 
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4.4.5.1 MALTI-TOF MS 
When undergoing MALDI-TOF MS analysis, crystallised samples are ionised using 
lasers, changing from the solid phase into gaseous, charged molecules.  Because non-  
volatile organic molecules do not readily absorb energy at the wavelength required 
for ionisation to occur, they are co-crystallised with an energy absorbing matrix.  
This enables desorption/ionisation to take place.  Once ionised, molecules are  
accelerated along a flight tube until they reach a detector.  The time taken between 
ionisation and detection is dependant upon the ion’s molecular mass and charge 
(Karas and Hillenkamp, 1988).  Due to the relationship between flight time and 
mass-to-charge ratio (m/z), identification of proteins by MALDI-TOF MS can be 
carried out using peptide mass mapping.  Proteins are digested with a known enzyme 
such as trypsin to produce peptide fragments.  These are then analysed by MALDI-
TOF MS and the spectra obtained is compared to protein databases with predicted 
proteolytic peptide masses.  This technique allows for identification of proteins 
within complex mixtures as well as for analysis of purified proteins (Zaluzec et al., 
1995, Hortin, 2006).  Post-translational modifications such as glycosylation can also 
be predicted by MALDI-TOF MS due to alterations in peptide mass from that 
predicted by the amino acid sequence, although accurate predictions cannot always 
be made as oligosaccharide structures can be removed from glycopeptides during 
analysis (Zaluzec et al., 1995).  
 
4.4.5.2 Analysis of trypsin-digested wild-type and mutant His-C1QTNF5  
In order to confirm the recombinant proteins produced were His-C1QTNF5, and to 
identify any possible differences between the wild-type and mutant proteins, 
MALDI-TOF MS analysis was carried out on the trypsin digested proteins.  Firstly, 
the proteins underwent reducing SDS-PAGE, with bands corresponding to 
monomers and dimers excised from the gel (Figure 4.20).  The additional bands 
observed in the mutant were also excised.  Proteins were then purified, digested with 
trypsin and subsequently analysed.  Each band was identified as C1QTNF5 by 
peptide mass mapping. 
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Table 4.1 shows the predicted peptide fragment masses for trypsin digested wild-type 
His-C1QTNF5, and Table 4.2 shows the same for the mutant.  Figure 4.21 shows the 
spectra obtained for band 1 (dimeric, wild-type protein) and band 3 (dimeric mutant 
protein) seen in Figure 4.20.  Peaks in the spectra were compared with the predicted 
peptide mass fragments to enable their identification.  Table 4.3 and Table 4.4 show 
whether the predicted fragments could be identified in their corresponding spectra.  
Some fragments were identified as single peaks with a m/z ratio of 1, such as 
fragment 18 which was has a predicted mass of 1866.934Da and was identified as 
m/z peaks of 1866.8875 and 1866.8854 in the wild-type and mutant spectra 
respectively.  Such fragments can be identified with a high degree of confidence.  
The identification of other fragments can be predicted if they are assumed to be  
joined, and if these conjoined fragments are doubly charged.  For instance the peak at 
m/z of 1772.8695 in the wild-type spectra could be fragment 29 joined to fragment 
16 with a charge of 2+.  However, such peaks must be identified with caution as this 
peak could also correspond to fragment 14 attached to fragment 9 with a double 
charge. 
 
The Ser163Arg mutation has created an extra trypsin cleavage site in the mutant, as 
can be seen from tables 4.3 and 4.4.  Fragments which differ between the two 
proteins are highlighted in yellow.  It is possible to identify m/z peaks which differ 
between the wild-type and mutant spectra, and which could be the result of different 
cleavages between the two proteins.  For instance, the m/z peak at 815.4352 in the 
wild-type could contain one such fragment (fragment 25), with this peak not present 
in the mutant spectra.  The m/z peak at 2016.8932 present in the mutant is of the 
correct size to contain fragments 25 or 26, which contain the 163Arg mutation and 





Figure 4.19: Reducing SDS-PAGE of wild type (WT) and mutant (MT) His-
C1QTNF5. 
 
Bands corresponding to momoner and dimer were excised from 
the gel for analysis by MALDI-TOF MS.  The additional bands seen 
in the mutant at approximately 40kDa were also excised and 










Table 4-1: Predicted peptide fragments for trypsin digested wild type His-C1QTNF5. 
 
Fragment masses are calculated assuming no post-translational 
modifications.  Fragment sizes were calculated assuming cleavage 










Mass Position Missed cleavages Peptide sequence
1 885.4312 1-8 0 SPPLDDNK
2 3392.692 1-34 1 SPPLDDNKIPSLCPGHPGLP 
3 2526.278 9-34 0 IPSLCPGHPGLPGTPGHHGS QGLPGR
4 2854.428 9-37 1 IPSLCPGHPGLPGTPGHHGS 
5 675.3168 35-40 1 DGRDGR
6 1226.576 38-50 1 DGRDGAPGAPGEK
7 898.4264 41-50 0 DGAPGAPGEK
8 2029.021 41-62 1 DGAPGAPGEKGEGGRPGLPG PR
9 1149.612 51-62 0 GEGGRPGLPGPR
10 1728.889 51-68 1 GEGGRPGLPGPRGDPGPR
11 598.2943 63-68 0 GDPGPR
12 2386.12 63-88 1 GDPGPRGEAGPAGPTGPAGE CSVPPR
13 1806.844 69-88 0 GEAGPAGPTGPAGECSVPPR 
14 2398.146 69-94 1 GEAGPAGPTGPAGECSVPPR SAFSAK
15 610.3195 89-94 0 SAFSAK
16 766.4206 89-95 1 SAFSAKR
17 634.3267 95-99 1 RSESR
18 1866.934 96-112 1 SESRVPPPSDAPLPFDR
19 1407.727 100-112 0 VPPPSDAPLPFDR
20 3018.532 100-127 1 VPPPSDAPLPFDRVLVNEQG HYDAVTGK
21 1629.823 113-127 0 VLVNEQGHYDAVTGK
22 3831.895 113-146 1 VLVNEQGHYDAVTGKFTCQV 
23 2221.09 128-146 0 FTCQVPGVYYFAVHATVYR
24 3222.644 128-155 1 FTCQVPGVYYFAVHATVYRA SLQFDLVK
25 1020.572 147-155 0 ASLQFDLVK
26 3946.995 147-183 1 ASLQFDLVKNGESIASFFQF 
27 2945.44 156-183 0 NGESIASFFQFFGGWPKPAS LSGGAMVR
28 5604.794 156-207 1
NGESIASFFQFFGGWPKPAS 
LSGGAMVRLEPEDQVWVQV                           
29 2678.371 184-207 0 LEPEDQVWVQVGVGDYIGIY ASIK
30 5009.42 184-228 1 LEPEDQVWVQVGVGDYIGIY 
31 3173.37 208-228 0 TDSTFSGFLVYSDWHSSPVF AHHHHHH
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Table 4-2: Predicted peptide fragments for trypsin digested mutant His-C1QTNF5. 
 
Fragment masses are calculated assuming no post-translational 
modifications.  Fragment sizes were calculated assuming cleavage 














mass position #MC peptide sequence
1 885.4312 1-8 0 SPPLDDNK
2 3392.692 1-34 1 SPPLDDNKIPSLCPGHPGLP GTPGHHGSQGLPGR
3 2526.278 9-34 0 IPSLCPGHPGLPGTPGHHGS QGLPGR
4 2854.428 9-37 1 IPSLCPGHPGLPGTPGHHGS QGLPGRDGR
5 675.3168 35-40 1 DGRDGR
6 1226.576 38-50 1 DGRDGAPGAPGEK
7 898.4264 41-50 0 DGAPGAPGEK
8 2029.021 41-62 1 DGAPGAPGEKGEGGRPGLPG PR
9 1149.612 51-62 0 GEGGRPGLPGPR
10 1728.889 51-68 1 GEGGRPGLPGPRGDPGPR
11 598.2943 63-68 0 GDPGPR
12 2386.12 63-88 1 GDPGPRGEAGPAGPTGPAGE CSVPPR
13 1806.844 69-88 0 GEAGPAGPTGPAGECSVPPR 
14 2398.146 69-94 1 GEAGPAGPTGPAGECSVPPR SAFSAK
15 610.3195 89-94 0 SAFSAK
16 766.4206 89-95 1 SAFSAKR
17 634.3267 95-99 1 RSESR
18 1866.934 96-112 1 SESRVPPPSDAPLPFDR
19 1407.727 100-112 0 VPPPSDAPLPFDR
20 3018.532 100-127 1 VPPPSDAPLPFDRVLVNEQG HYDAVTGK
21 1629.823 113-127 0 VLVNEQGHYDAVTGK
22 3831.895 113-146 1 VLVNEQGHYDAVTGKFTCQV PGVYYFAVHATVYR
23 2221.09 128-146 0 FTCQVPGVYYFAVHATVYR
24 2448.228 128-148 1 FTCQVPGVYYFAVHATVYRA R
25 1089.642 147-155 1 ARLQFDLVK
26 862.5032 149-155 0 LQFDLVK
27 3788.926 149-183 1 LQFDLVKNGESIASFFQFFG GWPKPASLSGGAMVR
28 2945.44 156-183 0 NGESIASFFQFFGGWPKPAS LSGGAMVR
29 5604.794 156-207 1 NGESIASFFQFFGGWPKPAS LSGGAMVRLEPEDQVWVQVG 
30 2678.371 184-207 0 LEPEDQVWVQVGVGDYIGIY ASIK
31 5009.42 184-228 1 LEPEDQVWVQVGVGDYIGIY ASIKTDSTFSGFLVYSDWHS 
32 3173.37 208-228 0 TDSTFSGFLVYSDWHSSPVF AHHHHHH
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    (A) 
 
     (B) 
 
Figure 4.21: MALDI-TOF MS spectra for dimeric wild type (A) and dimeric 
mutant (B) His-C1QTNF5. 
 
Proteins were excised from a reducing SDS-PAGE gel (Figure 


































2208.08371806.85531165.6035 1429.6963 2428.1324815.4352 2648.3299 3173.44112874.43572097.05811118.5390 1339.6989


































Table 4-3:  Comparative analysis of predicted fragments of trypsin digested wild type 
His-C1QTNF5 against peaks obtained by MALDI-TOF MS analysis of trypsin digested 
dimeric wild type His-C1QTNF5. 
 
In the above table, some fragments were predicted to be present 
as single charged species (highlighted in red), whilst some were 
predicted to be joined to other fragments and to be present as 
doubly charged species.  * indicates where one peak could be 
identified by more than one set of conjoined fragments.  Fragments 
in grey are contained within the gC1q domain.  Fragments in 
yellow differ between the wild type and mutant proteins due to an 
extra trypsin cleavage site in the mutant. 
Mass Identified Peak Additional
1 885.4312 No
2 3392.692 No




7 898.4264 Possibly 832.3208 Attached to fragment 16, charge 2+
8
2029.021 Possibly 2208.037   
1878.8709
Attached to fragment 12, charge 2+                                                         
Attached to fragment 11, charge 2+
9
1149.612 Yes 1149.6155 
1772.8695*
Single peak, charge 1+                                                                            
Attached to fragment 14, charge +
10 1728.889 No
11
598.2943 Possibly 1878.8709  
1808.8553
Attached to fragment 8, charge 2+                                                              
Attached to fragment 20, charge 2+
12
2386.12 Yes 2386.1419  
2208.0837  
2097.0581
Single peak, charge 1+                                                                                  
Attached to fragment 8, charge 2+                                                                
Attached to fragment 13, charge 2+
13 1806.844 Possibly 2097.0581 Attached to fragment 12, charge 2+
14 2398.146 Possibly 1772.8695* Attached to fragment 9, charge 2+
15
610.3195 Possibly 2278.1252   
815.4352
Attached to fragment 26, charge 2+                                                            
Attached to fragment 2, charge 2+
16
766.4206 Possibly 832.3208  
1772.8695*
Attached to fragment 7, charge 2+                                                             
Attached to fragment 29, charge 2+
17 634.3267 No
18 1866.934 Yes 1866.8875 Single peak, charge 1+
19
1407.727 Yes 1407.7733  
1878.8709
Single peak, charge 1+                                                                         
Attached to fragment 31, charge 2+
20 3018.532 Possibly 1808.8553 Attached to fragment 11, charge 2+
21 1629.823 Yes 1629.8308 Single peak, charge 1+
22 3831.895 No
23 2221.09 No
24 3222.644 Possibly 2874.4357 Attached to fragment 3, charge 2+
25 1020.572 Possibly 815.4352 Attached to fragment 15, charge 2+
26 3946.995 Possibly 2279.1252 Attached to fragment 15, charge 2+
27 2945.44 Possibly 2648.3299 Attached to fragment 31
28 5604.794 No
29 2678.371 Possibly 1772.8695* Attached to fragment 16, charge 2+
30 5009.42 No
31
3173.37 Yes 3173.4411 
1878.8709  
2648.3299
Single fragment, charge 1+                                                                     
Attached to fragment 19, charge 2+                                                          
Attached to fragment 27, charge 2+
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Table 4-4:  Comparative analysis of predicted fragments of trypsin digested mutant 
His-C1QTNF5 against peaks obtained by MALDI-TOF MS analysis of trypsin digested 
dimeric mutant His-C1QTNF5. 
 
In the table above, some fragments were predicted to be present 
as single charged species (highlighted in red), whilst some were 
predicted to be joined to other fragments and to be present as 
doubly charged species.  * indicates where one peak could be 
identified by more than one set of conjoined fragments.  Fragments 
in grey are contained within the gC1q domain.  Fragments in 
yellow differ between the wild type and mutant proteins due to an 
extra trypsin cleavage site in the mutant. 







7 898.4264 Yes 1226.6013  
832.319
Single fragment, charge 1+                             
Attached to fragment 17, charge 2+
8 2029.021 No
9 1149.612 Yes 1149.6257  
2046.0364  
1773.8769
Single fragment, charge 1+                             
Attached to fragment 28, charge 2+               






15 610.3195 Possibly 1773.8767 Attached to fragment 9, charge 2+                                    
16 766.4206 No
17 634.3267 Possibly 832.319 Attached to fragment 7, charge 2+
18 1866.934 Yes 1866.8854 Single fragment, charge 1+
19 1407.727 Yes 1407.7599 Single fragment, charge 1+
20 3018.532 No
21 1629.823 Yes 1629.8222 Single fragment, charge 1+
22 3831.895 No
23 2221.09 Possibly 2584.3227 Attached to fragment 28, charge 2+
24 2448.228 No
25 1089.642 Possibly 2016.8932* Attached to fragment 28, charge 2+
26 862.5032 Possibly 2016.8932* Attached to fragment 32, charge 2+
27 3788.926 No
28 2945.44 Possibly 2046.0364  
2584.3227  
2016.8932*
Attached to fragment 9, charge 2+                                    
Attached to fragement 23, charge 2+                                 




32 3173.37 Possibly 2016.8932* Attached to fragment 26, chage 2+
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4.4.5.3 MALDI-TOF MS analysis of native His-C1QTNF5 
MALDI-TOF MS analysis was also carried out on undigested His-C1QTNF5 to 
ascertain if any differences could be observed between the native multimeric states 
of the wild-type and mutant proteins.  Figure 4.22 shows the spectra obtained, with 
similar peaks observed for both proteins.  Due to the measurements being taken close 
to the maximum possible m/z for the machine, background noise levels are high.  
Peaks at approximately 25000, 50000, 75000, 100000 and 125000 m/z correspond to 
multimeric His-C1QTNF5.  It is not possible to say whether these correspond to 
monomeric, dimeric, trimeric etc species because, for instance, the peak at 25000 
m/z could be monomeric protein with a charge of 1+ or trimeric protein with a 
charge of 3+.  However, there were no obvious differences in the pattern of peaks 
obtained for the wild-type and mutant proteins. 
 
A m/z shift was observed between the proteins, with the wild-type protein being 
slightly larger than the mutant protein (Figure 4.23).  Table 4.5 shows the differences 
in m/z, before and after adjusting for the Ser163Arg mutation.  It is possible these are  
caused by differences in post-translational modifications although it has not been 
possible to predict, based upon the m/z difference, what these could be. 
 174 
 
    (A) 
 
     (B) 
 
Figure 4.22: MALDI-TOF MS spectra of native wild type (A) and mutant (B) 
His-C1QTNF5. 
 
Both proteins show similar multimeric species. 
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Figure 4.23: MALDI-TOF MS spectra for native wild type (black) and 
mutant (red) His-C1QTNF5. 
 
A shift is observed in the m/z ration between the proteins, with the 
wild type protein being slightly larger. 
 
                    
m/z m/z m/z m/z
Wild type 24976.86 49982.27 75055.93 100313.9
Mutant 24772.36 49629.59 74482.59 99305.27
Difference 204.5 352.68 573.34 1008.64
Ser163Arg adjusted 272.8 489.28 778.24 1281.84  
 
Table 4-5: Shows the difference in m/z for the main peaks in the wild type and mutant 





4.5 Purifying His-C1QTNF5 from ARPE-19 
His-C1QTNF5 has been successfully purified from stably transfected EBNA293 
cells which express the protein at high levels.  ARPE-19 is a physiologically relevant 
cell line, with stably transfected ARPE-19 cell lines created previously which 
express the protein at much lower levels (see Chapter 3).  A small amount of wild-
type and mutant His-C1QTNF5 was purified from the culture media of these cell 
lines and compared with the EBNA293-produced protein to see if there were any 
obvious differences, which may prevent the EBNA293-produced protein being 
suitable for use in future studies. 
 
4.5.1 Expressing and purifying His-C1QTNF5 
Stably transfected cell lines GFWT19 and GFMT22 were used to produce the 
protein.  In both cell lines, His-C1QTNF5 has been shown to be secreted, so the 
protein was Ni-NTA affinity purified from culture medium following the same 
method as for EBNA293 produced protein.  Eluted fractions were analysed by SDS-
PAGE, as can be seen in Figures 4.24.  Wild-type fractions were pooled and dialysed 
into PBS.  Mutant fractions were also pooled and dialysed into PBS. 
 
4.5.2 Reducing and non-reducing analysis of His-C1QTNF5 
Reducing and non-reducing Western blots were carried out for both wild-type and 
mutant pooled proteins (Figure 4.25).  The same banding pattern, corresponding to 
protein multimers, was observed for wild-type and mutant, with multimeric species 
observed under both reducing and non-reducing conditions.  Higher order multimers 
(greater than trimeric) were observed under non-reducing conditions which were not 




Figure 4.24: Reducing SDS-PAGE of successive eluted fractions for wild-
type and mutant His-C1QTNF5 purified from stably transfected ARPE-19 
cell lines. 
  
In both instances, fractions 1 – 5 were pooled and dialysed into 
PBS.  kDa: relative molecular mass 
 
 
Figure 4.25: Reducing and non-reducing SDS-PAGE of pooled His-
C1QTNF5 fractions for  wild-type (WT) and mutant (MUT) His-C1QTNF5, 
purified from stably transfected ARPE-19 cell lines. 
 





4.5.3 MALDI-TOF MS analysis of ARPE-19-produced His-C1QTNF5 
MALDI-TOF MS analysis was carried out on native wild-type and mutant His-
C1QTNF5 purified from ARPE-19.  Figure 4.26 shows the spectrum obtained for the 
wild-type protein.  The protein was very dilute and there was an insufficient amount 
to concentrate without losing it, so the spectra obtained is not very clear.  Peaks can 
be observed at m/z of 24971.57, 37147.75 and 49932.44, which are almost identical 
to those obtained for the wild-type EBNA-produced protein.  This would indicate 
that the EBNA protein is very similar, if not identical to the ARPE-19 protein and so 
suitable for use in future assays.  There was insufficient mutant His-C1QTNF5 for 






Figure 4.26: MALDI-TOF MS spectra of native wild type His-C1QTNF5 
purified from the culture media of stably transfected ARPE-19. 
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Recombinant, secreted wild-type and mutant His-C1QTNF5 has been purified from a 
mammalian expression system for use in future assays.  Recombinant His-gC1q has 
also been purified from a bacterial expression system.  Confirming the observation 
from Chapter 3, both wild-type and mutant His-C1QTNF5 were secreted when 
expressed in EBNA293.  It was also shown that, when stably expressed in 
EBNA293, the mutant protein appears to undergo the same cellular trafficking as the 
wild-type and is not retained within the ER.  Both these results are different from 
those reported previously when His-C1QTNF5 was stably expressed in EBNA293 
(Shu et al., 2006b).   It is possilbe that secreted mutant His-C1QTNF5 was not 
detected in the previous study due to differences in detection methods.  For instance, 
Shu et al. analysed acid-precipitated culture media proteins, whereas in this study 
His-tagged proteins were affinity purified using Ni-NTA beads.  It is also possible 
that only a small amount of culture media was analysed so a low level of secreted 
mutant His-C1QTNF5 could not be detected.  Mandal et al. (2006c) also reported a 
lack of secretion for mutant C1QTNF5.  However, it is not stated how the culture 
medium was analysed so again it is possible that their detection method was not 
sensitive enough to detect a low level of protein.  In the present study, mutant His-
C1QTNF5 has been detected in the culture media of both stably transfected 
EBNA293 and ARPE-19 cells so it can be concluded that the mutant protein, like the 
wild type, is indeed secreted.  Immunostaining of wild-type and mutant His-
C1QTNF5-expressing EBNA293 was also contradictory to that reported previously 
(Shu et al., 2006b), however it is not possible to explain how the previous result was 
obtained, and retention within the ER is not observed in this study.  Combining these 
results with those from Chapter 3 makes it unlikely that the disease mechanisms in 
L-ORMD are due to a lack of secretion or retention of the mutant C1QTNF5 within 
the ER.  It is more likely that altered function of the mutant protein contributes to the 
disease mechanisms.   
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Recombinant His-C1QTNF5 has been produced in order to investigate an altered 
function of the 163Arg mutant.  Characterisation studies were carried out comparing 
the wild-type and mutant proteins and are summarised as follows.  Both proteins 
were found to be soluble in PBS at 37°C, although the mutant precipitated at room 
temperature.  SDS-PAGE analysis showed that both wild-type and mutant formed 
monomers, dimers and trimers under reducing conditions, with additional bands seen 
in the mutant, but both forms also formed higher order multimers under non-reducing 
conditions.  His-gC1q formed monomers, dimers and trimers under reducing and 
non-reducing conditions, and again formed higher order multimers.  Native PAGE 
analysis showed wild-type His-C1QTNF5 to be present as predominantly trimers but 
also some hexamers.  The mutant protein would not migrate through the gel.  
However, both proteins migrated through an isoelectric focusing gel, with the wild-
type protein present as two species with pI’s of 7.5 and 6.8 (possibly trimers and 
hexamers) and the mutant as a single species with pI of 6.5.  MALDI-TOF MS 
analysis of trypsin digested His-C1QTNF5 confirmed that both the purified 
recombinant proteins were C1QTNF5 and that the additional bands in the mutant 
were also C1QTNF5.  Differences in spectra were observed between the two 
proteins, and possible sites of disulphide or covalent bonds were identified.  Native 
MALDI-TOF MS showed that both forms of the protein have similar multimeric 
species and, although a shift was observed between them, the pattern of peaks 
otherwise appeared to be the same. 
 
These protein characterisation studies highlighted several similarities and differences 
between the wild-type and mutant proteins.  Similarities were observed when 
reducing SDS-PAGE analysis was carried out.  The same multimeric species were 
observed for wild-type and mutant His-C1QTNF5 and His-gC1q, and these species 
also showed resistance to reducing conditions.  This confirms previous studies which 
have identified the gC1q domain as being involved in C1QTNF5 trimerisation (Shu 
et al., 2006a, Hayward et al., 2003).  The resistance of the trimers to reduction has 
been observed in other gC1q-containing proteins such as C1q and collagens X and 
VIII, and is proposed to be due to buried Ca2+ clusters providing ionic bonds and 
stability to the trimers (Kishore et al., 2004a, Kishore et al., 2004b, Bogin et al., 
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2002, Stephan et al., 2004).  Due to the homology between C1QTNF5 and these 
gC1q-containing proteins, it is highly likely that the same Ca2+ clusters are present in 
this instance too.     
 
Non-reducing SDS-PAGE showed the presence of higher order multimers for wild-
type and mutant His-C1QTNF5, suggesting the presence of disulphide-linked or 
other tertiary structures resistant to SDS.  Some higher order multimers were also 
present in His-gC1q, although to a much lesser degree.  This suggests that the 
collagen domain (missing in His-gC1q) is at least partially involved in C1QTNF5 
higher order multimerisation.  It has been suggested that C1QTNF5 may form a 
hexagonal lattice similar to collagen X or VIII via interactions between the gC1q 
domains (Hayward et al., 2003, Mandal et al., 2006c).  However, for these collagens, 
higher order multimer formation is predicted to occur via interactions between N- 
and C-terminal globular regions, with C-terminal C1q-like domains involved in 
trimerisation and the N-terminal non-collagenous domains interacting with this 
trimeric head group to form 3D tetrahedral structures (Bogin et al., 2002, Stephan et 
al., 2004).  C1QTNF5 only has a C-terminal gC1q domain, so it is possible that 
C1QTNF5 forms the tulip-like clusters predicted for C1q and MBL, where the 
collagen tails of the trimers interact to form bunch-like structures (Kishore et al., 
2004b).    
 
Native PAGE analysis of His-C1QTNF5 at 37°C showed that the wild-type protein 
was present as predominantly trimeric with weaker hexameric species.  Such 
hexamers may account for the higher order multimers seen by non-reducing SDS-
PAGE analysis of full length His-C1QTNF5.  The mutant protein would not migrate 
through the gel.  Both proteins however migrated through an isoelectric focusing gel, 
which showed them to have altered pI’s.  The wild-type protein was present as two 
species of pI 7.5 and pI 6.8, which could correspond to trimeric and hexameric 
protein.  The mutant protein had a pI of 6.5.  This implies the conditions used when 
carrying out native PAGE were suitable for migration of both proteins based upon 
their pI and another factor must be responsible for the lack of migration of the 
mutant.  Mutant His-C1QTNF5 does have a greater tendency to precipitate than the 
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wild-type protein in PBS, possibly the result of an altered surface charge.  Both 
proteins were shown to be soluble in PBS at 37°C, but only the mutant precipitated at 
room temperature.  It is possible that the mutant protein precipitated during the 
running of the native PAGE, preventing it from entering the gel.  It should be noted 
that the mutant protein migrated through the stacking gel but then halted as it reached 
the main gel.  It is possible that the alteration in gel pH may have caused 
precipitation which the wild-type protein was resistant to.  It has previously been 
suggested that the failure of the mutant protein to migrate through the native PAGE 
is due to its aggregation (Hayward et al., 2003, Shu et al., 2006b), however no 
evidence for aggregation has been found so far, so that this suggestion is not 
supported by this study.  In a previous study (Hayward et al., 2003), aggregation due 
to the Ser163Arg mutation was also shown by looking at the solubility of E. coli-
produced gC1q domains.  However, it has been shown here that the mutant gC1q 
forms inclusion bodies when expressed in E. coli.  Proteins which form such 
inclusion bodies are inherently mis-folded and insoluble, so no conclusions can be 
drawn about the native state of such a protein.  In fact, it has been shown in this 
study that mutant full length His-C1QTNF5, as well as the wild-type, is indeed 
soluble. 
 
MALDI-TOF MS analysis of both proteins highlighted similarities and differences 
between them.  When analysing trypsin digested protein, differences in the peaks 
were observed which could be the result of an extra trypsin cleavage site introduced 
in the mutant by the 163Arg mutation.  Peaks were also observed which could be 
trypsin digested fragments joined to each other.  Proteins undergoing MALDI-TOF 
MS analysis are subject to conditions similar to those when analysed by non-
reducing SDS-PAGE (Hortin, 2006), so any covalent or disulphide linked tertiary 
structures should remain.  Such interactions had been predicted in this study by non-
reducing SDS-PAGE analysis of His-C1QNF5 and His-gC1q.  In particular, covalent 
bonding is predicted to occur in the gC1q head region and peaks which could be 
identified as two fragments from this region have been found, supporting this 
prediction.  Native MALDI-TOF MS analysis showed both proteins formed similar 
multimeric species, again making it unlikely that the mutant protein is aggregated.  A 
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shift was observed between the two proteins, with the mutant being slightly smaller.  
It is possible this is due to differences in post translational modifications between the 
proteins, for instance in O-glycosylation as this has been predicted to occur. 
 
There is plenty of scope for further work into the differences between wild-type and 
mutant proteins.  For instance, it has not been possible to determine the native 
multimeric state of the mutant protein in solution in PBS.  Native PAGE analysis of 
the wild-type protein revealed it to consist of predominantly trimeric and weaker 
hexameric species, however the mutant would not migrate through the gel.  Dynamic 
light scattering may be able to solve this question as both proteins were found to be 
soluble in PBS at 37°C.  It is possible that the change in pH prevented the mutant 
protein from migrating through the native PAGE gel, so further investigation could 
be carried out to determine whether pH affects the solubility or multimeric state of 
both of the proteins.  It is interesting to note that both proteins were soluble in 1M 
imidazole which is at pH10.0.  Two species were present when the wild-type protein 
was analysed on an IEF gel.  These could correspond to trimeric and hexameric 
protein.  2D gel analysis could help to confirm or deny this.  MALDI-TOF MS 
analysis of trypsin digested protein fragments revealed possible sites for covalent and 
disulphide bonding.  Further analysis of regions which were predicted to be joined 
could give insight into either the tertiary structure of C1QTNF5 or the nature of the 
interactions between the subunits involved in multimerisation.  Any effects of the 
163Arg could then be investigated which would have possible implications for 
disease mechanisms. 
 
5 CHAPTER 5  
: 
 INVESTIGATING AN INTERACTION 






Several haplotypes and polymorphisms in CFH have been implicated in increased 
risk of developing AMD (Edwards et al., 2005, Haines et al., 2005, Klein et al., 
2005, Hageman et al., 2005, Li et al., 2006).  CFH is a regulatory protein in the 
alternative pathway of the innate immune system and consists of 20 modules, or 
SCRs.  One such disease-associated polymorphism (Y402H) occurs in SCR7.  This 
module has been shown to have involvement in binding polyanions and CRP 
(Blackmore et al., 1996, Jarva et al., 1999, Giannakis et al., 2003), although CFH 
binding to native CRP has been disputed (Hakobyan et al., 2008).  Studies into the 
effects of this polymorphism have shown that the two alleles differ in their ability to 
bind such polyanions (Clark et al., 2006, Prosser et al., 2007, Herbert et al., 2007) 
and CRP (Skerka et al., 2007, Laine et al., 2007, Yu et al., 2007), and this has 
implications for disease mechanisms.  CFH is expressed by the RPE (Chen et al., 
2006, Mandal et al., 2006), with aged CFH-deficient mice showing severe retinal 
abnormalities, accumulation of autofluorescent sub-retinal deposits and visual 
dysfunction (Coffey et al., 2007).  Due to the similarities in phenotype between L-
ORMD and AMD, and the expression of both CFH and C1QTNF5 by the RPE, it 
was investigated in this lab whether an interaction between CFH and C1QTNF5 
could be observed.  Initial results, carried out by Dr X. Shu, suggested this was the 
case (unpublished data).  Surface plasmon resonance (SPR) was carried out between 
recombinant gC1q and plasma-purified CFH, with an interaction observed (Figure 
5.1).  I125 plate binding assays showed an interaction between gC1q and CFH 
domains SCR6-8Y and SCR6-8H (Figure 5.2).  It was also shown by gel mobility 
shift assays and heparin affinity columns that gC1q, like CFH, is capable of binding 
polyanions (Figure 5.3).  This study further investigated the interaction, in particular 
interactions between CFH, SCR7-8, SCR3-4, SCR19-20 or CRP and His-gC1q or 
His-C1QTNF5 (wild-type and mutant). 
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Figure 5.1: Surface plasmon resonance showing an interaction between 
gC1q and CFH. 
 
gC1q was immobilized to the chip and increasing concentrations of 





Figure 5.2: C1QTNF5 and gC1q interact with CFH, SCR6-8H and SCR6-8Y, 
but not C1q or transferrin. 
 
Plates were coated with C1QTNF5, gC1q or C1q and I
125
-labelled 
CFH, SCR6-8H, SCR6-8Y, C1q or transferrin were added in the 
fluid phase and levels of bound protein detected. Binding rates are 









































Figure 5.3: gC1q binds heparin with a higher affinity than SCR7. 
 
The interactions were investigated using a heparin affinity column 
with proteins eluted in a NaCl gradient.  SCR2-3 showed no 
interaction with the column, eluting in minimal NaCl.  SCR7 
showed an interaction with heparin and eluted from the column in 
approximately 0.5M NaCl.  gC1q also showed an interaction with 
heparin and eluted in aproximately 0.75M NaCl, indicating it has a 
greater affinity for heparin than SCR7. Green - OD280, Yellow - 




Figure 5.4: Gel mobility shift assay showing an interaction between gC1q 
and heparin DP12 
 
GAG migration is retarded when it interacts with gC1q.  (GAG - 





5.2 Producing CFH and related proteins for use in assays 
As discussed in Chapter 4, recombinant His-C1QTNF5 and His-gC1q have already 
been produced for use in assays.  It was necessary however to produce CFH and the 
recombinant SCR modules to further investigate the CFH-C1QTNF5 interaction.  
CFH was purified from human plasma, as described previously (Sim et al., 1993) 
and supplied by Professor R. Sim (Oxford University).  Pichia pastoris clones 
expressing recombinant SCR 7-8 (tyrosine and histidine alleles) and SCR19-20 were 
supplied by Dr A. Herbert (Edinburgh University) and were used to express and 
purify these proteins.  SCR3-4 had previously been produced and was supplied by Dr 
H. Hocking (Edinburgh University), and CRP was commercially produced (Sigma). 
 
5.2.1 Expressing and purifying SCR7-8Y and SCR7-8H  
Following large scale culture of the expressing P. pastoris clones and following the 
method optimised by Dr A. Herbert, SCR7-8Y and SCR7-8H were purified from the 
culture supernatants by SP sepharose ion exchange chromatography.  Proteins were 
eluted with 1M NaCl, 20mM potassium phosphate pH6.0 and analysed by reducing 
SDS-PAGE.  Figure 5.5 (A and B) shows elution fractions for SCR7-8Y and SCR7-
8H, with the protein-containing fractions for each protein pooled.  Pooled eluates 
were then dialysed into PBS, analysed by reducing SDS-PAGE (Figure 5.7) and 
protein concentration determined by Bradford assay (see section 4.4.1). 
 
5.2.2 Expressing and purifying SCR19-20  
Again following large scale culture of the expressing P. pastoris clone, SCR19-20 
was purified from the culture supernatant by SP sepharose ion exchange 
chromatography.  Proteins were eluted with 1M NaCl, 20mM potassium phosphate 
pH7.0 and analysed by reducing SDS-PAGE.  Figure 5.6 shows the elution fractions.  
All eluates were pooled and dialysed into PBS, analysed by reducing SDS-PAGE 
(Figure 5.7) and protein concentration again determined by Bradford assay. 
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  (A)       (B) 
Figure 5.5: Reducing SDS-PAGE of successive elution fractions for SCR7-
8Y (A) and SCR7-8H (B), purified from the culture media of transfected P. 
pastoris by SP-sepharose ion exchange chromatography. 
 
Proteins were eluted in 2ml fractions of 1M NaCl, 20mM potassium 
phosphate pH6.0.  Elution fractions containing protein were pooled 





Figure 5.6: Reducing SDS-PAGE of successive elution fractions for 
SCR19-20 purified from the culture media of transfected P. pastoris by SP-
sepharose ion exchange chromatography. 
 
Proteins were eluted in 2ml fractions of 1M NaCl, 20mM potassium 
phosphate pH7.0.  Elution fractions containing protein were pooled 





Figure 5.7: Reducing SDS-PAGE of pooled and dialysed elution fractions 
for SCR7-8Y (A), SCR7-8H (B) and SCR19-20 (C). 
 
kDa: relative molecular mass 
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5.3 Plate binding assays 
Previous I125 plate binding assays carried out by Dr X. Shu had shown there was an 
interaction between SCR6-8 and gC1q.  This interaction was investigated further 
using full length His-C1QTNF5 (wild-type and mutant) or His-gC1q.  Plates were 
coated overnight with a fixed concentration of His-gC1q at 4°C, or His-C1QTNF5 at 
37°C (due to mutant His-C1QTNF5 being soluble at this temperature but not at 4°C).  
Following blocking, varying concentrations of CFH were added in the fluid phase.  
Bound CFH was then detected with a mouse anti-CFH primary antibody, OX23.  
OX23 was supplied by Prof R. Sim, and recognises both CFH and FHL-1, implying 
the antibody epitope is located in SCR1-7.  Bound OX23 was then detected with a 
secondary rabbit anti-mouse alkaline phosphatase-labelled antibody and p-
nitrophenyl phosphate, unless otherwise specified. 
 
5.3.1 Plate binding assay optimisation 
Following an initial, unoptimised method, it was investigated whether an interaction 
could be observed between His-gC1q and CFH.  However, as can be seen from 
Figure 5.8, following 10 minutes incubation both total binding and background 
binding to the plate are reaching saturation.  Specific binding was calculated by 
deducting background binding from the total binding.  It was not possible to 
accurately detect an interaction between His-gC1q and CFH without optimising the 
method.  Optimisation was carried out in order to reduce background binding, 
determine an appropriate primary (OX23) antibody concentration and optimise 
detection incubation time. 
 
5.3.1.1 Optimising primary antibody concentration 
Using the same amount of His-gC1q coat and CFH and secondary antibody 
concentrations as previously, different primary antibody (OX23) concentrations were 
investigated, in combination with increasing detection incubation times (Figure 5.9).  
Primary antibody concentrations were 1/34, 1/340, 1/1000 and 1/3400 dilutions of 
the stock solution (340g/ml), and incubation times were 10, 20 and 30 minutes.  A 
primary antibody concentration of 1:340, diluted in PBS, and an incubation time of 
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20 minutes were found to be suitable to give a sufficiently high signal without 
reaching saturation.  It should be noted that the total binding appears to peak at 







Figure 5.8: An un-optimised plate binding assay investigating an 
interaction between His-gC1q and CFH. 
 
His-gC1q was immobilised to the plate and increasing 
concentrations of CFH were added in the fluid phase.  Bound CFH 
was detected with OX23, which in turn was detected with alkaline 
phosphatase-labelled rabbit anti-mouse antibody.  This was 
detected using p-nitrophenyl phosphate.  Due to high background 
binding of CFH to uncoated wells and detection saturation it was 
not possible to accurately determine any interaction with His-gC1q.  


























Figure 5.9: Plate binding assays optimising OX23 concentration and 
detection incubation time. 
 
Increasing concentrations of CFH were added to His-gC1q-coated 
plates, and this was then detected with OX23 at varying dilutions of 
a stock solution (1/34, 1/340, 1/1000, 1/3400).  Bound OX23 was 
detected using an alkaline phosphtase-labelled rabbit anti-mouse 
antibody and detected with p-nitrophenyl phosphate. Detection 






























































An OX23 dilution of 1/340 and a detection time of 20 minutes were 
considered optimai, with the OD450 remaining below 2.0. As before, 
CFH binding appears to increase up to a concentration of 
approximately 0.5g/ml, after which it decreases.  Total binding 
only is shown. 
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5.3.1.2 Optimising pH 
As can be seen from Figure 5.8, background binding of CFH to the blocked wells is 
high.  CFH was added to the wells after diluting in PBS pH7.2.  It was investigated 
whether adding CFH diluted in 10mM MES at pH6.0 or pH6.5 would reduce the 
background binding whilst still allowing for the interaction with His-gC1q to occur.  
At pH6.5 specific binding of CFH to the His-gC1q-coated wells was the same as at 
pH7.2, however background binding was considerably less.  At pH6.0 the 
background binding was reduced further still, however there was also a reduction in 
specific binding (Figure 5.10).  All future assays were carried out diluting CFH in 
10mM MES pH6.5. 
 
5.3.1.3 Optimising His-gC1q coat concentration 
The microtitre plates were coated with His-gC1q diluted in PBS at varying 
concentrations to determine which concentration enabled maximum CFH binding 
without applying an excess of His-gC1q.  As can be seem from Figure 5.11, 1g/well 
His-gC1q appeared to give nearly the maximum bound CFH per well.  Increasing 
His-gC1q concentration to 10g/ml did not greatly increase the maximum bound 
CFH.  It should be noted again that CFH binding appears to peak and then decline.  
In this instance specific binding was reported, having deducted any background 
binding from the total.  1g/well His-gC1q was used to coat the wells in all future 
assays. 
 
5.3.2 Plate binding assay 
Following the optimised conditions from Section 5.3.1, plate binding assays were 
carried out investigating CFH interactions with His-gC1q and His-C1QTNF5 (wild-
type and mutant).  Interactions were also investigated between CFH and CRP or His-





Figure 5.10: Diluting CFH in 10mM MES pH6.5 reduced background 
binding without reducing specific binding, when compared with PBS 
pH7.2. 
 
Diluting CFH in 10mM MES pH6.0 reduced background binding 
further still but there was also a reduction in specific binding.  
Plates were coated with 1g/well His-gC1q.  Primary antibody: 





Figure 5.11: Coating the wells with 1g/well His-gC1q is optimal for 
carrying out the plate binding assay. 
 
Concentrations below this are limiting for the amount of CFH 










































5.3.2.1 Plate binding assay investigating an interaction between His-
gC1q and CFH 
CFH (fluid phase) was found to bind to His-gC1q (solid phase) at pH6.5 (Figure 
5.12).  CFH specific binding appeared to increase up to a CFH concentration of 
nearly 0.5g/ml, after which an apparent reduction in binding was observed.  
Specific binding is calculated by deducting the background binding from the total 
binding, so when background binding is greater than total binding the specific 
binding appears to be negative.  It should be noted that no interaction could be found 
when CFH was in the solid phase and His-gC1q was in the fluid phase (primary 
antibody: mouse anti-His). 
 
5.3.2.2 Plate binding assay investigating an interaction between CFH 
and His-C1QTNF5 
CFH (fluid phase) was found to interact with His-C1QTNF5 (solid phase) at pH6.5 
(Figure 5.13).  Interactions were observed with both wild-type and mutant His-
C1QTNF5 and, as observed in Figure 5.12, CFH specific binding appeared to 
increase up to a maximum CFH concentration (in this instance approximately 
0.15g/ml) after which an apparent reduction in binding was observed.  Again, 
specific binding was calculated by deducting the background binding from the total 
binding, so when background binding is greater than total binding the specific 
binding appears to be negative.  CFH appeared to have a greater affinity for mutant 
His-C1QTNF5 compared with the wild type, and the reduction in binding observed 
at increasing CFH concentrations was greater for the mutant too.  As observed in 
Section 5.3.2.1, no interaction could be found when the plates were coated with CFH 
and His-C1QTNF5 was added in the fluid phase (primary antibody: mouse anti-His). 
 
5.3.2.3 Plate binding assay investigating an interaction between CFH 
and CRP 
Previous studies have reported an interaction between CFH and CRP, detected by 
plate binding assay (Sjoberg et al., 2007).  It was investigated whether this result 
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could be repeated, as this would provide a positive control for the plate binding 
assays.  Such an interaction was observed (Figure 5.14), as reported previously. 
The apparent reduction in binding with increased CFH concentration observed when 
using His- gC1q/His-C1QTNF5 coated plates was not observed here, suggesting this 
is a phenomenon specific to that interaction. 
 
5.3.2.4 Plate binding assay investigating an interaction between CRP 
and His-C1QTNF5/His-gC1q 
It was also investigated whether His-C1QTNF5 or His-gC1q could interact with 
CRP.  In this instance, plates were coated with CRP and His-gC1q or His-C1QTNF5 
(wild-type) was added in the fluid phase.  This is because no anti-CRP antibody was 
available.   The primary antibody used was mouse anti-His.  No interactions were 
























Figure 5.12: CFH binds His-gC1q.   
 
Plates were coated with His-gC1q and increasing concentrations of 
CFH were added in the fluid phase. Specific binding is shown.  
This increases up to a CFH concentration of approximately 
0.5g/ml, after which it appears to decrease.  Bound CFH was 
detected with primary antibody OX23 and secondary antibody 
alkaline phosphatase labelled rabbit anti-mouse, and this was 
detected with p-nitrophenyl phosphate. 
 
 
Figure 5.13: CFH binds wild-type and mutant His-C1QTNF5. 
 
Plates were coated with His-C1QTNF5 and increasing 
concentrations of CFH were added in the fluid phase.  Specific 
binding is shown.  This increases up to a CFH concentration of 
approximately 0.15g/ml, after which it appears to decrease.  CFH 
shows a higher affinity for mutant His-C1QTNF5.  Bound CFH was 
detected with primary antibody OX23 and secondary antibody 
alkaline phosphatase labelled rabbit anti-mouse, and this was 


























Figure 5.14: CFH binds to CRP.  Plates were coated with CRP and 
increasing concentrations of CFH were added in the fluid phase. 
 
Bound CFH was detected with primary antibody OX23 and 
secondary antibody alkaline phosphatase labelled rabbit anti-




Figure 5.15: His-gC1q and His-C1QTNF5 (wild-type) do not bind CRP.  
Plates were coated with CRP and increasing concentrations of His-gC1q 
or His-C1QTNF5 were added in the fluid phase. 
 
Bound protein was detected with primary antibody mouse anti-His 
and secondary antibody alkaline phosphatase labelled rabbit anti-



































5.4 Surface plasmon resonance 
The Biacore T100 utilises surface plasmon resonance (SPR) as a technique for 
detecting and analysing molecular interactions.  It can be used for confirmation of 
protein-protein interactions and can give accurate information about reaction kinetics 
(McDonnell et al., 2001, Wear et al., 2006).  The technique has been used previously 
to investigate interactions between complement pathway proteins (Hellwage et al., 
1999), and was used to investigate further the interaction between CFH and His-
C1QTNF5.  Analysis was carried out using His-C1QTNF5 (wild-type and mutant) 
and CFH, SCR7-8 Y, SCR7-8H, SCR19-20, SCR3-4 or CRP. 
 
5.4.1 Biacore T100 and SPR theory  
When using the Biacore T100 to analyse molecular interactions, alterations are 
measured in the parameters required for SPR to occur at the surface of a gold chip, 
comprising of a layer of gold film on a glass surface.  Surface plasmons are a surface 
electromagnetic wave found on the interface between a metal surface and an external 
medium.  When a light beam hits the metal surface at an angle it is usually totally 
reflected.  However, at a particular wavelength and incident angle, resonance of the 
surface plasmons can occur .  This results in a reduction in the intensity of the 
reflected light.  The wavelength/incident angle at which SPR will occur is dependant 
upon the conditions at the metal surface, and any molecules on or very near the 
surface will affect this. 
 
When detecting SPR, the Bicaore T100 uses monochromatic light in a wedge shape 
giving a broad distribution of incident angles.  The incident angle giving a reduction 
in reflected light is detected.  This will alter dependant upon what molecules are 
attached to the surface of the chip (Figure 5.16).  In a typical experiment, the gold 
surface of the chip is coated with a particular molecular ligand and this surface is 
exposed to the flow cell.  Running experimental buffer through the flow cell will 
give a baseline refractive index at which SPR will occur for that particular surface.  
When the experimental buffer subsequently contains analyte, this will attach to the 
surface of the chip and alter the angle at which SPR occurs.  Analyte binding to 
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ligand will increase the refractive index, so the machine records the new position of 
reduced reflected light.  Changes in refractive index are given as response units 
(RU), where a change of 1000RU corresponds to an approximately 0.1° angle 
change. 
 
5.4.2 Coating CM5 chips with His-C1QTNF5 
All chips used in the study were CM5 chips.  These have a carboxymethyl-dextran 
matrix coating on the exposed gold surface, creating a hydrophilic environment upon 
which to attach the experimental ligand.  Dextran is flexible and allows for molecular 
movement and so increased accessibility of the immobilised ligand.  The ligand is 
covalently bound to the dextran matrix via amine coupling.  Treatment of the chip 
surface with NHS and EDS prior to coating modifies around 30% of the carboxylates 
to succinamide esters, which are highly reactive with primary amines, forming 
covalent bonds.  Primary amines are found on lysine residues and at the N-terminus 
of proteins and peptides.  It should be noted that coupling of ligand to the matrix 
occurs at random orientations and can be via residues important for ligand binding, 





Figure 5.16: Biacore T100 measures changes in the parameters required 
for SPR to occur at the surface of a gold chip. 
(Source: www.rci.rutgers.edu ) 
Monochromatic light is beamed through a prism at the sensor chip 
surface in a wedge shape, covering a broad distribution of incident 
angles.  At a particular incident angle SPR will occur, resulting in a 
reduction in reflected light (see graph AI).  With ligand attached to 
the chip and experimental buffer alone running through the flow 
cell, a baseline sensorgram reading is obtained (see graph BI).  
When running buffer contains analyte, this binds to the ligand 
altering the incident angle at which SPR will occur (AII).  As 
increasing amounts of analyte bind to the immobilised ligand, so 
the incident angle increases to deviate from baseline and the 
sensorgram resonance signal increases (BII).  Dissociation of 







5.4.2.1 pH scouting 
In order for the ligand to become covalently bound to the dextran matrix, sufficient 
amounts need to be electrostatically concentrated at the chip surface.  At a pH above 
3.5 the dextran matrix is negatively charged.  The ligand is diluted in buffer at a pH 
above 3.5 but below its pI, giving it a net positive charge.  This means it will be 
attracted to the matrix when it is flowed over in solution.  To determine the optimal 
conditions required for concentration of sufficient ligand at the chip surface, pH 
scouting was carried out, with the ligand diluted in buffers covering a range of pHs.  
Following equilibriation of the chip in running buffer, the ligand solution was 
applied for 60 seconds.  After this time the buffer was then changed back to running 
buffer.  The optimal pH is that which is closest to the protein's pI and gives a high 
concentration of protein at the chip surface whilst still giving rapid dissociation when 
the buffer is changed back to running buffer.  Figure 5.17 and 5.18 show the pH 
scouting for wild-type and mutant His-C1QTNF5.  The optimal buffer for wild-type 
His-C1QTNF5 was 10mM acetate pH5.0, and 10mM acetate pH6.0 for the mutant. 
 
5.4.2.2 Coating the chips 
When coating chips, a theoretical maximum level of RU is aimed for (RUmax), from 
which the desired amount of bound ligand (RUligand) can be determined: 
 RUligand = RUmax / (MWanalyte / MWligand) 
 
For protein:protein interaction, RUmax = 100.  However, a reduction in specific 
activity is always observed when coating chips, so an RUmax of at least 2-3 times this 
should be aimed for.  Under native conditions His-C1QTNF5 is predominantly 
trimeric (see section 4.4.3.2).  Trimeric His-C1QTNF5 has a molecular weight of 
approximately 75kDa.  Therefore the desired amount of bound ligand is 48RU.  
However, due to the expected reduction in specific activity, 200RU of bound ligand 
was aimed for when coating the chips.  In addition to this, chips were also coated 




Figure 5.17: Wild-type His-C1QTNF5 pH scouting using a CM5 chip. 
 
10mM acetate pH5.0 was selected for coating the chips. 
 
Figure 5.18: Mutant His-C1QTNF5 pH scouting using a CM5 chip. 
 
10mM HEPES pH 6.0 was selected for coating the chips. 
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5.4.3 Investigating an interaction between His-C1QTNF5 and CFH by 
SPR 
Once the chips were prepared, it was investigated whether any interactions could be 
observed between His-C1QTNF5 and fluid-phase CFH, SCR7-8Y, SCR7-8H, 
SCR19-20, SCR3-4 and CRP.  Experiments and affinity calculations involving His-
C1QTNF5 and CFH were carried out using the low density 200RU chips.  
Experiments and affinity calculations involving His-C1QTNF5 and the SCR modules 
were carried out using low density 200RU and high density 1000RU chips, with at 
least one analysis carried out using each chip. 
 
5.4.3.1 Analysing His-C1QTNF5 interactions with CFH  
Using the CM5 chips coated with 200RU wild-type or mutant His-C1QTNF5, 
interactions with six sequential injections containing increasing concentrations of 
CFH diluted in running buffer (10mM HEPES pH7.4, 150mM NaCl, 0.01% P20) 
were investigated.  Each sample injection was for 30 seconds, followed by 2000 
seconds' dissociation time where running buffer alone was flowed over the chip.  A 
final 7th injection was carried out containing the same concentration of CFH as 
injection 3, providing an internal control.  The experimental data was then analysed 
using the “kinetic/affinity” software facility.  Figure 5.19 shows the sensorgrams and 
data analysis for three repeat experiments using the wild-type His-C1QTNF5 chips.  
Figure 5.20 shows the sensorgrams and data analysis for two repeat experiments 
using the mutant His-C1QTNF5 chips.  CFH shows an approximately 17.5-fold 
greater average affinity (kD) for mutant His-C1QTNF5 (1.1x10-9 M) compared with 
the wild-type (1.9x10-8 M).  Although not significant (one-tailed t-test (3) = 0.883, p 
= 0.221), this result is suggestive that there may be differences in CFH binding 
between the two proteins.  Further repeats would help to confirm any significance.  







Figure 5.19: SPR sensorgrams showing that CFH (fluid phase) interacts 
with wild-type His-C1QTNF5-coated CM5 chips. 
Chips were coated with 200RU wild-type His-C1QTNF5, with three 
separate experiments carried out.  Individual affinities (kD), 
association rates (ka1 – 1/ms, ka2 – 1/s) and dissociation rates 
(kd1 and kd2 – 1/s) for each experiment are shown.  The average 
affinity (kD) of CFH for wild-type His-C1QTNF5 is 1.9x10
-8 
M.  The 
predicted model which best fits the data is ‘two-state binding with 
conformational change’.  CFH was added in the fluid phase, with 








































Figure 5.20: SPR sensorgrams showing that CFH (fluid phase) interacts 
with mutant His-C1QTNF5-coated CM5 chips. 
 
Chips were coated with 200RU mutant His-C1QTNF5, with two 
separate experiments carried out.  Individual affinities (kD), 
association rates (ka1 – 1/ms, ka2 – 1/s) and dissociation rates 
(kd1 and kd2 – 1/s) for each experiment are shown.  The average 
affinity (kD) of CFH for mutant His-C1QTNF5 is 1.1x10
-9 
M.  The 
predicted model which best fits the data is ‘two-state binding with 
conformational change’. CFH was added in the fluid phase, with 




























5.4.3.2 Analysing His-C1QTNF5 interactions with SCR7-8Y 
Using the CM5 chips coated with 200RU and 1000RU of wild-type or mutant His-
C1QTNF5, interactions with six sequential injections containing increasing 
concentrations of SCR7-8Y diluted in running buffer were investigated.  Each 
sample injection was for 30 seconds, followed by 300 seconds dissociation time      
where running buffer alone was flowed over the chip.  As before, a 7th repeat 
injection was carried out providing an internal control.  The experimental data was  
then analysed using the “kinetic/affinity” software facility.  Figure 5.21 shows the 
sensorgrams and data analysis for three repeat experiments investigating interactions 
with wild-type His-C1QTNF5.  Two experiments were carried out using the 200RU 
chips and one experiment was carried out using the 1000RU chip.  Figure 5.22 shows 
the sensorgrams and data analysis for three repeat experiments investigating 
interactions with mutant His-C1QTNF5.  Again, two experiments were carried out 
using the 200RU chips and one experiment was carried out using the 1000RU chip.  
SCR7-8Y showed similar affinities (kD) for wild-type (9.7x10-6 M) and mutant 
(2.8x10-6 M) His-C1QTNF5.  The predicted model which best fitted the data for each 
was ‘1:1 binding’.   
 
5.4.3.3 Analysing His-C1QTNF5 interactions with SCR7-8H 
Using the CM5 chips coated with 200RU and 1000RU of wild-type or mutant His-
C1QTNF5, interactions with six sequential injections containing increasing 
concentrations of SCR7-8H were investigated.  Each sample injection was for 30 
seconds, followed by 300 seconds dissociation time where running buffer alone was 
flowed over the chip.  As before, a 7th repeat injection was carried out providing an 
internal control.  The experimental data was then analysed using the 
“kinetic/affinity” software facility.  Figure 5.23 shows the sensorgrams and data 
analysis for two repeat experiments investigating an interaction with wild-type His-
C1QTNF5.  One experiment was carried out using a 200RU chip and one experiment 
was carried out using a 1000RU chip.  Figure 5.24 shows the sensorgrams and data 
analysis for three repeat experiments investigating an interaction with mutant His-
C1QTNF5.  Two experiments were carried out using 200RU chips and one 
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experiment carried out using a 1000RU chip.  SCR7-8H showed similar affinities 
(kD) for wild-type (4.2x10-6 M) and mutant (1.8x10-6 M) His-C1QTNF5, and both 
affinites were similar to those obtained with SCR7-8Y.  The predicted model which 










































































Figure 5.21: SPR sensorgrams showing that SCR7-8Y (fluid 
phase) interacts with wild-type His-C1QTNF5-coated CM5 
chips.  Chips were coated with either 200RU (sensorgrams A and 
B) or 1000RU (sensorgram C) wild-type His-C1QTNF5.  Individual 
affinities (kD), association rates (ka – 1/ms) and dissociation rates 
(kd – 1/s) for each experiment are shown.  The average affinity 
(kD) of SCR7-8Y for wild-type His-C1QTNF5 is 9.7x10
-6 
M.  The 
predicted model which best fits the data is ‘1:1 binding’. CFH was 
added in the fluid phase, with increased binding responses 























































































Figure 5.22: SPR sensorgrams showing that SCR7-8Y (fluid phase) 
interacts with mutant His-C1QTNF5-coated CM5 chips.  Chips were coated 
with either 200RU (sensorgrams A and B) or 1000RU (sensorgram C) mutant 
His-C1QTNF5.  Individual affinities (kD), association rates (ka – 1/ms) and 
dissociation rates (kd – 1/s) for each experiment are shown.  The average 
affinity (kD) of SCR7-8Y for mutant His-C1QTNF5 is 2.8x10
-6 
M.  The predicted 
model which best fits the data is ‘1:1 binding’. CFH was added in the fluid 





















































































Figure 5.23: SPR sensorgrams showing that SCR7-8H (fluid phase) 
interacts with wild-type His-C1QTNF5-coated CM5 chips. 
Chips were coated with either 200RU (sensorgram A) or 1000RU      
(sensorgram B) wild-type His-C1QTNF5.  Individual affinities (kD), 
association rates (ka – 1/ms) and dissociation rates (kd – 1/s) for 
each experiment are shown.  The average affinity (kD) of SCR7-8H 
for wild-type His-C1QTNF5 is 4.2x10
-6 
M.  The predicted model 
which best fits the data is ‘1:1 binding’. CFH was added in the fluid 



























































































Figure 5.24: SPR sensorgrams showing that SCR7-8H (fluid phase) 
interacts with mutant His-C1QTNF5-coated CM5 chips. 
 
Chips were coated with either 200RU (sensorgrams A and B) or 
1000RU (sensorgram B) mutant His-C1QTNF5.  Individual 
affinities (kD), association rates (ka – 1/ms) and dissociation rates 
(kd – 1/s) for each experiment are shown.  The average affinity 
(kD) of SCR7-8H for mutant His-C1QTNF5 is 1.8x10
-6 
M.  The 
predicted model which best fits the data is ‘1:1 binding’. CFH was 
added in the fluid phase, with increased binding responses 






































5.4.3.4 Analysing His-C1QTNF5 interactions with SCR19-20 
Following the same experimental parameters as for SCR7-8Y and SCR7-8H, His- 
C1QTNF5 interactions with SCR19-20 were investigated.  Figure 5.25 shows the 
sensorgrams and data analysis for three repeat experiments investigating an 
interaction with wild-type His-C1QTNF5.  One experiment was carried out using a 
200RU chip and two experiments were carried out using the 1000RU chip.  Figure 
5.26 shows the sensorgrams and data analysis for three repeat experiments 
investigating an interaction with mutant His-C1QTNF5.  Two experiments were 
carried out using the 200RU chips and one experiment was carried out using the 
1000RU chip.  SCR19-20 showed a greater affinity (kD) for mutant His-C1QTNF5 
(2.0x10-7 M) compared with wild-type (1.9x10-5 M).  The predicted model which best 
fitted the data for each was ‘1:1 binding’.   
 
5.4.3.5 Analysing His-C1QTNF5 interactions with SCR3-4 
Following the same parameters as for SCR7-8 and using the 200RU-coated chips, 
His-C1QTNF5 interactions with SCR3-4 were investigated.  No interactions were 
observed between wild-type or mutant His-C1QTNF5 and SCR3-4. 
 
5.4.3.6 Analysing His-C1QTNF5 interactions with CRP 
It was investigated whether an interaction between CRP and wild-type His-
C1QTNF5 could be observed.  Sequential injections containing increasing 
concentrations of CRP diluted in running buffer were investigated.  It was not 
possible to detect an interaction. 
 
5.4.3.7 Summary of SPR kinetic data 
Tables 5.1 and 5.2 summarise the kinetic data obtained for interactions with wild-
type and mutant His-C1QTNF5.  In all instances, analytes showed a greater affinity 
(kD) for mutant His-C1QTNF5 compared to the wild-type, with the exception of  
SCR7-8Y where the association rate was marginally slower.  For full length CFH 
this was a 17.5-fold increase.  Modules SCR7-8Y and SCR7-8H showed only slight 
increases (3.4-fold and 2.3-fold respectively), whereas SCR19-20 showed a 95-fold 
increase.  When looking at the rates of association for each analyte, these were again 
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greater for the mutant, and dissociation rates were slower.  Two association and two 
dissociation rates are given for full length CFH as these were calculated  
based upon a two-state binding model.  For the ligands CFH, SCR7-8Y and SCR7-
8H association rates and dissociation rates differ only slightly between wild-type and 
mutant His-C1QTNF5.  For SCR19-20, however, association rates show only a 2-





































































Figure 5.25: SPR sensorgrams showing that SCR19-20 (fluid phase) 
interacts with wild-type His-C1QTNF5-coated CM5 chips. 
 
Chips were coated with either 200RU (sensorgram A) or 1000RU 
(sensorgrams B and C) wild-type His-C1QTNF5.  Individual 
affinities (kD), association rates (ka – 1/ms) and dissociation rates 
(kd – 1/s) for each experiment are shown.  The average affinity 
(kD) of SCR19-20 for wild-type His-C1QTNF5 is 1.9x10
-5 
M.  The 
predicted model which best fits the data is ‘1:1 binding’. CFH was 
added in the fluid phase, with increased binding responses 
































































































Figure 5.26: SPR sensorgrams showing that SCR19-20 (fluid phase) 
interacts with mutant His-C1QTNF5-coated CM5 chips. 
Chips were coated with either 200RU (sensorgrams A and B) or 
1000RU (sensorgram B) mutant His-C1QTNF5.  Individual 
affinities (kD), association rates (ka – 1/ms) and dissociation rates 
(kd – 1/s) for each experiment are shown.  The average affinity 
(kD) of SCR19-20 for mutant His-C1QTNF5 is 2.0x10
-7 
M.  The 
predicted model which best fits the data is ‘1:1 binding’. CFH was 
added in the fluid phase, with increased binding responses 






































            
Wild-type His-C1QTNF5
kD (M) CFH SCR7-8Y SCR7-8H SCR19-20
1.0E-09 7.8E-06 7.6E-06 3.5E-05
4.9E-08 1.2E-05 7.4E-07 1.7E-05
5.6E-09 9.3E-06 5.6E-06
Ave 1.9E-08 9.7E-06 4.2E-06 1.9E-05
ka (1/ms) CFH1 CFH2 (1/s) SCR7-8Y SCR7-8H SCR19-20
6.0E+06 9.0E-03 2.4E+05 1.4E+05 3.4E+04
8.1E+04 2.0E-02 1.0E+05 1.9E+06 9.6E+04
4.1E+06 2.0E-02 2.1E+05 3.6E+05
Ave 3.4E+06 1.0E-02 1.8E+05 1.0E+06 1.6E+05
kd (1/s) CFH1 CFH2 SCR7-8Y SCR7-8H SCR19-20
2.9E-02 2.6E-03 1.9E+00 1.1E+00 1.2E+00
7.1E-03 2.5E-03 1.3E+00 1.4E+00 1.6E+00
7.1E-02 8.1E-03 1.9E+00 2.0E+00
Ave 3.6E-02 4.4E-03 1.7E+00 1.2E+00 1.6E+00  
            
Mutant His-C1QTNF5
kD (M) CFH SCR7-8Y SCR7-8H SCR19-20
2.1E-09 1.7E-06 1.3E-07 2.6E-08
8.3E-11 3.9E-06 3.3E-06 1.3E-07
2.9E-06 2.1E-06 4.4E-07
Ave 1.1E-09 2.8E-06 1.8E-06 2.0E-07
ka (1/ms) CFH1 CFH2 (1/s) SCR7-8Y SCR7-8H SCR19-20
6.8E+05 1.1E-02 2.6E+03 2.8E+05 1.3E+05
1.3E+06 3.6E-03 3.3E+05 2.6E+05 1.0E+05
5.4E+05 6.1E+05 2.4E+04
Ave 1.0E+06 7.4E-03 2.9E+05 3.8E+05 8.5E+04
kd (1/s) CFH1 CFH2 SCR7-8Y SCR7-8H SCR19-20
1.2E-02 1.4E-03 4.6E-03 3.7E-02 3.2E-03
6.8E-03 5.9E-05 1.3E+00 8.5E-01 1.4E-02
1.5E+00 1.3E+00 1.0E-02
Ave 9.6E-03 7.3E-04 9.4E-01 7.2E-01 9.1E-03  
 
Table 5-1: The dissociation constant (kD), association rate (ka) and dissociation rate 
(kd) constants of the analytes CFH, SCR7-8Y, SCR7-8H and SCR19-20 for wild-type 
and mutant His-C1QTNF5 as determined by SPR.  The difference in mean dissociation 
constant for SCR19-20 between wild-type and mutant His-C1QTNF5 is significant 
(one-tailed t-test (4) = 2.231, p = 0.045).  The difference in mean dissociation constant 
for CFH between wild-type and mutant His-C1QTNF5 is suggestive, and may be 




             
kD (M) CFH SCR7-8Y SCR7-8H SCR19-20
17.5 3.4 2.3 95.3
ka (1/ms) CFH 1 CFH 2(1/s) SCR7-8Y SCR7-8H SCR19-20
3.4 1.9 0.6 2.7 1.9
kd (1/s) CFH 1 CFH 2(1/s) SCR7-8Y SCR7-8H SCR19-20
3.7 6 1.8 1.8 173.2  
Table 5-2: The fold differences in dissociation constant (kD), association rate (ka) and 
dissociation rate (kd) of the analytes CFH, SCR7-8Y, SCR7-8H and SCR19-20 for 
mutant His-C1QTNF5 compared with wild-type as determined by SPR. 
 
In all instances, affinities and association rates were greater and 
dissociation rates slower for mutant His-C1QTNF5 compared with 
wild-type, with the exception of SCR7-8Y where the association 




5.5 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) quantifies the heat absortion/evolution 
accompanying molecular associations in solution, from which reaction kinetics and 
stoichiometry can be determined (Pierce et al., 1999, Okhrimenko et al., 2007).  
Experiments were carried out investigating the interaction between His-gC1q and 
CFH, with calculations of experimental protein concentrations based upon affinities 
obtained by SPR for either full length CFH or SCR19-20 (section 5.4). 
 
5.5.1 ITC theory 
During an ITC experiment, the time-dependant power input necessary to maintain a 
sample and reference cell at the same temperature is measured.  This is dependant 
upon the reaction stoichiometry, association constant, free energy, enthalpy, entropy 
and heat capacity of binding.  ITC can therefore provide a detailed insight into the 
parameters of molecular interactions in solution.  Both the sample and reference cells 
are made from highly efficient thermal conductors (e.g. hasteloy or gold) surrounded 
by an adiabatic jacket, with the temperature of each accurately measured.  The ITC 
machine aims to maintain both cells at the same temperature.  The sample cell 
contains the macromolecule in buffer solution, whereas the reference cell contains 
buffer alone.  With constant stirring, the ligand is titrated into the sample cell and the 
power input required to maintain both sample and reference cell at the same 
temperature is recorded.  This will be dependant upon whether the reaction is 
endothermic or exothermic.  In addition, a control experiment is carried out where 
the ligand is titrated into buffer alone.  Deducting this from the experimental data 
cancels out any effects of stirring or heat of dilution of the ligand (Pierce et al., 
1999). 
 
5.5.2 Investigating an interaction by ITC between CFH and His-gC1q 
It was investigated whether an interaction could be observed between His-gC1q and 
CFH by ITC.  In all experiments His-gC1q was titrated into CFH.  Determination of 
the concentration requirements for an ITC experiment can be calculated based upon 
the equation s = kD x [cell], where s is in the range 20-1000, and initial titrant 
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concentrations should be approximately 10-20 times the protein concentration in the 
cell, [cell].  Values for kD were obtained by SPR, as described in Section 5.4.  
Experimental concentrations were calculated based upon affinities of either full 
length CFH or SCR19-20 for wild-type His-C1QTNF5.  SCR19-20 was chosen 
because whilst the full length protein has been shown to interact with His-C1QTNF5, 
it is thought that CFH initially attaches to ligands such as C3b and polyanions via its 
C-terminal SCR20 domain (Jokiranta et al., 2005, Ferreira et al., 2006), before 
undergoing a conformational change to make other domains accessible. 
 
It was determined by SPR that the affinity (kD) of CFH for wild-type His-C1QTNF5 
ranges from 1.0x10-9 M to 5.0x10-8 M (Section 5.4.3.1).  Taking the lowest of these, 
1nM, and a mid-range s value of 500 gives a CFH concentration of 0.5M and a His-
gC1q concentration 15 times that of 7.5M.  ITC was carried out using these 
concentrations of proteins at 25°C with 25 injections of 4.81l.  No interaction was 
observed (Figure 5.27). 
 
It was also determined by SPR that the affinity (kD) of SCR19-20 for wild-type His-
C1QTNF5 ranges from 1.7x10-5 M to 5.6x10-6 M (Section 5.4.3.4), with the lower of 
these being 5M.  It was not possible to concentrate His-gC1q beyond 125M 
without precipitation.  However, as the His-gC1q concentration should be 10-20 
times the cell concentration, a CFH concentration of 12.5M would give an s value 
of 62.5.  This is low but within the acceptable range of 20-1000.  ITC was carried out 
using these protein concentrations at 25°C and 42 injections of 4.81l.  Again, no 





Figure 5.27: ITC was carried out investigating an interaction between CFH 
and His-gC1q. 
 
Experimental concentrations of both proteins were calculated 
based upon a nM affinity (kD) of CFH for His-gC1q.  The 
experiment was carried out at 25°C with 25 injections of 4.81l.  
No interaction was observed. 
 































































Figure 5.28: ITC was carried out investigating an interaction between CFH 
and His-gC1q. 
 
Experimental concentrations of both proteins were calculated 
based upon a M affinity (kD) of CFH for His-gC1q.  The 
experiment was carried out at 25°C with 42 injections of 4.81l.  




5.6 Investigating the effects of His-C1QTNF5 on CFH co-
factor activity 
One of the functions of CFH is to act as a co-factor for Factor I-mediated cleavage of 
C3b.  This activity has been mapped to CFH SCRs 1-4, 12-14 and 20 (Kuhn et al., 
1995, Jokiranta et al., 2000, Sharma et al., 2003, Oppermann et al., 2006).  It has 
been shown in Sections 5.3 and 5.4 that His-C1QTNF5 interacts with CFH and that 
this interaction involves at least SCR7-8 and SCR19-20.  It was therefore 
investigated whether His-C1QTNF5 (wild-type or mutant) had any effect on CFH 
co-factor activity, either in solution or when CFH was in complex with surface-
bound His-C1QTNF5. 
 
5.6.1 The effects of His-C1QTNF5 on CFH co-factor activity in solution 
It has previously been shown that when CFH acts as a co-factor for Factor I-
mediated C3b cleavage in solution, and the reaction mixture is analysed by SDS-
PAGE, C3b degradation products at 68, 46 and 43kDa can be observed (Sim et al., 
1981, Alsenz et al., 1984).  This method was adapted to investigate any effects of 
His-C1QTNF5 on CFH co-factor activity, with wild-type His-C1QTNF5 either 
added to the reaction or replacing Factor I (FI).  Following incubation at 37°C for 1  
hour, the reaction mixture was analysed by reducing SDS-PAGE.  As can be seen 
from Figure 5.29, CFH showed co-factor activity with FI resulting in C3b cleavage 
(lane A: note 68, 46 and 43kDa cleavage products).  This was not affected by the 
addition of wild-type His-C1QTNF5 (lane B).  When CFH was replaced with wild-
type His-C1QTNF5 no degradation occurred (lane C), indicating C1QTNF5 is not 




Figure 5.29: Wild-type His-C1QTNF5 has no effect on CFH co-factor 
activity in solution. 
 
Different combinations of reactants were incubated at 37°C for 1 
hour and then analysed by reducing SDS-PAGE. 
C3b degradation is indicated by the presence of degradation 






Figure 5.30: Wild-type and mutant His-C1QTNF5 have no effect on the rate 
of CFH co-factor activity in solution. 
 
Reaction mixtures containing either C3b, CFH and FI or C3b, CFH, 
FI and His-C1QTNF5 were incubated at 37°C, with samples taken 
for analysis by reducing SDS-PAGE after 0, 1, 5 and 15 minutes. 
C3b degradation is indicated by the presence of degradation 
products at 68kDa, 43kDa and 46kDa. 
No differences were observed either with or without His-C1QTNF5, 




The previous assay investigated the effects of His-C1QTNF5 on co-factor activity 
after incubation for 1 hour at 37°C, with no effects observed.  However, it is possible 
that His-C1QTNF5 could affect the rate of C3b degradation, and the effects of this 
may not be observable after times as long as 1 hour.  Therefore, the assay was 
repeated with samples taken for analysis by reducing SDS-PAGE after incubating at 
37°C for 0, 1, 5 and 15 minutes.  The assay was carried out with or without 
additional His-C1QTNF5 and both wild-type and mutant proteins were used.  As can 
be seen from Figure 5.30, no effects were observed on the rate of C3b degradation 
for either wild-type or mutant His-C1QTNF5. 
 
5.6.2 The effects on CFH co-factor activity when bound to C1QTNF5 
The previous section investigated the effects of His-C1QTNF5 on CFH co-factor 
activity in solution.  However, it was not possible to show any interaction between 
His-C1QTNF5 and CFH in solution when carrying out ITC (see Section 5.5).  Whilst 
an interaction may occur and this may not affect CFH co-factor activity, it is also 
possible no effect was observed in Section 5.6.1 due to a lack of interaction between 
CFH and His-C1QTNF5.  It has been shown by plate binding assay that CFH will 
bind to immobilised His-C1QTNF5.  Therefore it was investigated whether CFH 
bound to immobilised His-C1QTNF5 still maintained co-factor activity.  Following 
the plate binding assay method, wild-type or mutant His-C1QTNF5 was immobilised 
to microtitre plates and CFH was added at 0, 0.5 and 2.0µg/ml.  Following 
incubation and adequate washing, the C3b co-factor assay reagents were added to the 
wells and the plates incubated at 37°C.  Samples were taken after 30, 60 and 120 
minutes and analysed by reducing SDS-PAGE for the presence of C3b cleavage 
products at 68, 46 and 43kDa.  As can be seen from Figure 5.31, faint bands 
corresponding to cleavage products at 68kDa were observed for both wild-type and 
mutant His-C1QTNF5-coated plates after 120 minutes incubation, and this was 
greatest when 2.0µg/ml CFH was used.  No cleavage products were observed when 







Figure 5.31: CFH which has interacted with immobilised His-C1QTNF5 
(wild-type and mutant) retains co-factor activity. 
 
Following the plate binding assay method, wild-type or mutant His-
C1QTNF5 was immobilised to microtitre plates and CFH was 
added at 0, 0.5 and 2.0µg/ml.  C3b co-factor assay reagents were 
added to the wells and the plates incubated at 37°C.  Samples 
were taken after 30, 60 and 120 minutes and analysed by reducing 
SDS-PAGE for the presence of C3b cleavage products at 68, 46 
and 43kDa.  Faint bands corresponding to cleavage products at 
68kDa were observed for both wild-type and mutant His-
C1QTNF5-coated plates after 120 minutes incubation, and this 
was greatest when 2.0µg/ml CFH was used.  No cleavage 
products were observed when plates were not coated with His-
C1QTNF5.  68kDa cleavage products can be seen as faint bands 
above the darker C3bα bands present at 64kDa (see within boxes). 
 
 





It has been shown that CFH interacts with His-C1QTNF5, supporting the 
observations reported previously by Dr X. Shu.  The interaction was confirmed by 
plate binding assays and SPR, and shown to occur between His-C1QTNF5 (wild-
type and mutant) and full-length CFH, as well as SCRs 7-8 and 19-20.  Interactions 
with full-length CFH have been shown to involve at least the gC1q domain of His-
C1QTNF5.  No interactions could be observed between His-C1QTNF5 and either 
SCR3-4 or CRP. 
 
As well as confirming an interaction, both SPR and plate binding assays suggested 
that CFH has a greater affinity for mutant His-C1QTNF5 compared with wild-type.  
Average affinities (kD) obtained by SPR showed this to be in the nM range and an 
approximately 17.5-fold increase in affinity was observed for the mutant protein. 
When the data was analysed using the kinetics/affinity software facility, the 
predicted model which best fitted the data was ‘two-state binding with 
conformational change.’  Whilst this model did indeed provide the best fit for the 
data obtained, it cannot be concluded that this actually describes what occurs when 
CFH interacts with His-C1QTNF5.  This is in part due to the limited number of 
available models with which to fit the data when carrying out kinetic analysis.  It is 
also due to the limited amount of information SPR analysis provides.  Very little is 
known about how the ligand is attached to the dextran matrix, for instance via which 
residues this occurs.  Also, in the case of mutant His-C1QTNF5, the multimeric state 
of the protein has yet to be determined (see Chapter 4).  Therefore, the predicted 
binding model should instead be taken as an indication that the reaction kinetics do 
not fit a simple 1:1 binding model and it is likely that some sort of conformational 
rearrangement is occurring, possibly involving multiple binding domains.  
Comparisons can be made between analyte affinities for wild-type and mutant 
proteins within each experiment, however further analysis would need to be carried 
out to determine if the scale of the affinites bears relation to the in vivo situation. 
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SCR7-8Y and SCR7-8H showed similar affinities (kD) for both wild-type and 
mutant His-C1QTNF5, although these were slightly higher for the mutant. SCR19-
20, however, showed a 95-fold greater affinity for mutant His-C1QTNF5 compared 
with the wild-type.  This can be explained by the 173-fold decrease in dissociation 
rate seen when SCR19-20 interacts with the mutant.  When analysing the data for 
both SCR7-8 and SCR19-20 using the kinetics/affinity software facility, the 
predicted model offering the best fit in all cases was the ‘1:1 binding model’, 
although, as discussed above, this prediction comes with limitations. 
 
It has been proposed that when CFH interacts with polyanions it undergoes a 
conformational change allowing multiple subunits to bind.  CFH is predicted to form 
a coiled omega structure when in solution (Oppermann et al., 2006).  It is proposed 
that initial polyanion binding occurs via the C-terminal SCR20 domain, which is 
exposed when the protein is in the coiled structure.  The protein then undergoes a 
conformational change exposing other residues, such as SCR7, which are then able 
to interact with their appropriate ligands (Jokiranta et al., 2005, Oppermann et al., 
2006, Prosser et al., 2007).  The data obtained by SPR also supports such a 
conformational change occurring when CFH interacts with C1QTNF5.  It has been 
shown in this study that SCR19-20 interacts with His-C1QTNF5, as does SCR7-8.  
However the data obtained by SPR for these interactions conforms to a simple 1:1 
binding model, unlike that for full length CFH.  The dissociation rates for the SCR 
domains are much more rapid than for full length CFH, with this averaging to an 
approximately 75-fold difference for wild-type His-C1QTNF5.  This would imply 
that, after initial association, multiple domains bind and ‘solidify’ the interaction.  If 
CFH in solution is indeed in an omega structure, then the most accessible domains 
would be the C-terminal ones such as SCR19-20, which could undergo initial 
binding.  SCR19-20 shows a 95-fold greater affinity for mutant His-C1QTNF5 
compared with the wild-type, which could account for at least some of the increased 
affinity observed with full length CFH.  It is also possible other domains are 
involved, providing scope for further investigation.   
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Further support for a conformational change comes from the plate binding assays.  
For both His-C1QTNF5- and His-gC1q-coated plates, CFH specific binding appears 
to increase up to a maximum CFH concentration (0.5g/ml CFH for His-gC1q and 
0.15g/ml for His-C1QTNF5), after which a decrease in specific binding is observed.  
This observation could be explained if CFH undergoes a conformational change 
when it interacts with His-gC1q or His-C1QTNF5, so reducing the accessibility of 
the OX23 epitope.  As increasing amounts of CFH bind, so the accessibility is 
reduced further still and the apparent specific binding decreases.  OX23 is a 
monoclonal antibody whose epitope lies in SCR1-7.  As discussed above, this region 
is predicted to be involved in a conformational change when CFH binds other ligands 
such as polyanions, so it is possible this is also the case when interacting with 
C1QTNF5.  It was not possible to detect by plate binding assay any interaction 
between CFH and His-C1QTNF5 when CFH is in the solid phase.  This observation 
could be a result of CFH attaching to the plate, preventing it from changing 
conformation upon His-C1QTNF5 binding, possibly via SCR19-20.  Due to the rapid 
dissociation rate shown by SPR for interactions with this domain, and the lengthy 
stages involved in the plate binding assay, any bound His-C1QTNF5 would 
dissociate before it could be detected.   
 
When carrying out the plate binding assays, CFH was diluted in 10mM MES pH6.5.  
This was shown to reduce background binding of CFH to the microtitre plate, when 
compared with PBS pH7.2, but not to reduce specific binding of CFH to His-
C1QTNF5 or His-gC1q.  Whilst physiological pH is usually around 7.4, at sites of 
inflammation this can be reduced slightly to around 6.5 (Lardner, 2001).  The 
observation that this reduction in pH does not adversely affect the CFH-C1QTNF5 
interaction is interesting, particularly with reference to the diseased eye.  
Inflammation plays a major role in AMD (Donoso et al., 2006), and most likely in L-
ORMD, which would imply the in vivo pH of a diseased retina may be nearer to 6.5 
than 7.2.  The evidence in this study would suggest that if this were the case, a slight 
reduction in pH would not adversely affect the interaction between CFH and His-
C1QTNF5.  SPR interactions were carried out at pH7.4, and for both SPR and plate 
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binding assays CFH showed a greater affinity for mutant His-C1QTNF5, which 
means that, within the range pH6.5 to pH7.4, this preference is not affected. 
 
No interactions were observed between His-C1QTNF5 or His-gC1q and CRP by 
either SPR or plate binding assay.  CFH has been shown to interact with CRP and 
this interaction is affected by the Y402H polymorphism in SCR7 (Blackmore et al., 
1996, Jarva et al., 1999, Giannakis et al., 2003).  His-C1QTNF5 has been shown to 
bind CFH via this domain too.  It is therefore possible, although no direct interaction 
with CRP was observed, that C1QTNF5 could affect its binding to CFH.  This could 
be via steric hinderance, when C1QTNF5 is bound to CFH, or by competing with 
CRP for CFH binding.  Instead of alterations in CRP binding to CFH due to the 
Y402H polymorphism contributing to the AMD phenotype, it is possible the altered 
affinity of CFH for C1QTNF5 due to the Ser163Arg mutation affects the CFH-CRP 
interaction and this could contribute to the disease mechanisms in L-ORMD.   
 
The previously reported interaction between C1QTNF5 and polyanions was not 
investigated further in this study.  However, CFH binding to polyanions also occurs 
via SCR7, so again it is possible that C1QTNF5 could cause steric hinderance or 
compete with polyanions for CFH binding, or vice versa.  Mutation in C1QTNF5 
affects its interaction with CFH, so it is possible that this could disrupt an 
equilibrium between C1QTNF5, CFH, CRP and/or polyanions, and this too could 
have possible implications for CFH function and disease mechanisms in retinal 
degeneration.   
 
One of the functions of CFH is to act as a co-factor for Factor I-mediated cleavage of 
C3b (Whaley et al., 1976, Pangburn et al., 1977).  It was investigated whether CFH 
interacting with His-C1QTNF5 could affect this function.  Firstly, it was investigated 
whether any effects of His-C1QTNF5 could be observed on CFH co-factor activity 
whilst in solution.  Adapting a previously described method (Sim et al., 1981, Alsenz 
et al., 1984), no effects were observed by either adding His-C1QTNF5 (wild-type 
and mutant) to the reaction mixture, or by replacing CFH with His-C1QTNF5.  
Therefore, fluid phase His-C1QTNF5 does not appear to have any effect on CFH co-
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factor activity.  However, in vivo C1QTNF5 has been shown to be associated with 
the RPE plasma membrane (Mandal et al., 2006c), and also to interact with the 
membrane protein MFRP (Shu et al. 2006b, Mandal et al. 2006b).  It is therefore 
unlikely that fluid-phase C1QTNF5 is in abundance in the retina, but rather that it is 
membrane associated, possibly in complex with other proteins.  The plate binding 
assay was adapted to investigate whether any effects on co-factor activity could be 
observed when CFH was bound to immobilised His-C1QTNF5.  It was shown that, 
for both wild-type and mutant His-C1QTNF5-coated plates, C3b degradation 
products were produced.  Unfortunately, it is not possible to say whether these were 
the result of CFH which was interacting with His-C1QTNF5 or CFH which had 
dissociated from the complex.  However, the assay did lend support to the theory that 
CFH undergoes a conformational change when it attaches to C1QTNF5.  CFH was 
added to the wells at concentrations of 0, 0.5 and 2.0g/ml.  The greatest amount of 
C3b degradation products were observed when 2.0g/ml CFH was used, implying 
that more CFH was present when added to the wells at the higher concentration.  No 
degradation products were observed in the control wells without a His-C1QTNF5 
coat.  The plate binding assays appeared to show maximum CFH binding at 
0.15g/ml, and at 2.0g/ml it appeared that there was no CFH bound.  The C3b solid 
phase assay shows this was not the case, indicating that, when carrying out the plate 
binding assay, the OX23 antibody was unable to detect bound CFH above a 
maximum amount of bound protein. 
 
As discussed above, it is possible there may not be abundant fluid-phase C1QTNF5 
in vivo.  No effects of fluid-phase His-C1QTNF5 were observed on CFH co-factor 
activity.  This may be because CFH does not interact with fluid-phase C1QTNF5 
and, as discussed above, it is likely that in vivo C1QTNF5 is membrane-associated 
and/or in complex with other proteins.  This could affect its ability to interact with 
CFH, either due to accessibility of C1QTNF5 domains or because CFH may require 
a matrix to assist in undergoing a conformational change and forming a strong 
association with C1QTNF5.  Indeed, this situation would be supported by the 
previous observation that C1QTNF5 interacts with GAGs.  To test these hypotheses, 
ITC was carried out looking for an interaction between His-gC1q and CFH in 
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solution, both in the nM and the M range of affinities.  No interaction could be 
observed in either case.  This may well be because the two proteins do not interact in 
solution.  However, it cannot be ruled out that the lack of observed interaction was 
due to flaws in the experimental protocol.  CFH is predicted to form a coiled omega 
structure in solution, with only the C-terminal domains accessible.  His-C1QTNF5 
has been shown by SPR to interact with SCR19-20, so it would still be predicted that 
an interaction could be observed between the C-terminal domains and His-gC1q, 
with rapid association and dissociation rates, even if the tertiary structure of CFH 
prevented a strong association involving multiple subunits.  This was not the case.  
The proteins used in ITC were at near-maximum concentrations, just below those at 
which precipitation occurred, and the ITC process also involves continuous stirring 
of the reaction solution in the sample cell.  It is possible that at such high 
concentrations and when undergoing vigorous stirring the proteins became misfolded 
and/or aggregated and were unable to interact.  Analysis of the solutions by gel 
filtration before and after carrying out the experiment could confirm if any 
misfolding and/or aggregation had occurred. 
 
Further analysis by gel filtration would also help answer some other questions 
regarding the CFH-C1QTNF5 interaction.  It could provide clarification of whether 
full length CFH interacts with C1QTNF5 in solution.  Incubating the two proteins 
together and then carrying out gel filtration analysis would result in a different 
pattern of elution if the two proteins were in complex compared with the elution 
patterns obtained for the individual proteins.  This would, however, require the nM 
affinities obtained by SPR of CFH for His-C1QTNF5 to be correct.  With affinities 
in this range it could be expected that the proteins would remain in complex whilst 
running through the column.  If the affinities are actually in the M range then it is 
likely dissociation would occur before the proteins were eluted from the column.  For 
this reason, again assuming the SPR affinities are correct, it would not be possible to 
detect any interaction between C1QTNF5 and the recombinant SCR domains.   
 
In addition to gel filtration, other experiments could also provide insight into the 
CFH-C1QTNF5 interaction.  Using SPR, more in depth analysis of which particular 
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SCR domains are involved in the interaction could be carried out.  This would 
involve using a wider range and combination of individual domains to determine 
those that are essential for the interaction.  Focusing on a function for the interaction, 
it could be investigated whether His-C1QTNF5 has any effect on CFH decay 
accelerating activity.  It could also be investigated whether there is any competition 
between CFH and His-C1QTNF5 for binding to polyanions, and whether this is 
affected by the His-C1QTNF5 mutation.  Whilst it is possible that C1QTNF5 may 
have a role in regulating CFH activity, it is also possible this is not the case.  It may 
be found that there is no effect, but rather that C1QTNF5 helps to localise CFH 
within the retina.  Either way, it needs to be determined which is the case as this 
could have important implications for disease mechanisms. 
 
 
6 CHAPTER 6  
: 
 INVESTIGATING A ROLE FOR 





One of the major roles of the RPE is the daily phagocytosis of shed ROS (Young & 
Bok, 1969).  This follows a circadian rhythm, with disc shedding promoted by the 
onset of light (La Vail, 1976).  Phagocytosis of ROS involves two stages; binding 
and internalisation.  Binding occurs via the integrin receptor, v5.  This is the only 
integrin receptor expressed by the RPE, which plays a role in retinal adhesion and 
maintenance of the ROS-RPE microvilli interdigitation, as well as in phagocytosis 
(Nandrot et al., 2006).  ROS binding to v5 occurs through the ligand MFG-E8, 
which recognises exposed PS residues on the shed outer segments (Nandrot et al., 
2007).  The tetraspanin, CD81, facilitates v5 attachment to the ROS, probably by 
regulating the processing and/or turnover of the integrin receptor (Chang et al., 
2007).  Internalisation of ROS has been shown to occur by two pathways.  Firstly, 
the v5 receptor stimulates phagocytosis by the FAK/MerTK signalling pathways, 
which was shown to occur independently of CD81 (Finnemann et al., 2003, 
Finnemann et al., 2006b, Chang et al., 2007).  Secondly, in a completely separate 
process, CD36 recognises oxidised phospholipids on the ROS membrane, promoting 
their phagocytosis.  It is suggested that these phospholipids arise due to light-induced 
oxidative damage, which is predicted to occur frequently in the highly exposed 
retinal region (Sun et al., 2006).   
 
C1QTNF5 has been shown to localise to the RPE apical processes (Mandal et al., 
2005), with individuals having L-ORMD showing abnormalities in rod adaptation 
kinetics, sub-retinal deposits and retinal degeneration (Jacobson et al., 2001, Kuntz et 
al., 1996, Miliam et al., 2000).  Analysis of a diseased eye revealed shortened ROS 
with disorganised disc membranes (Duval et al., 1986).  The rd6 mouse, which has a 
mutation in MFRP, has a reduced number of apical microvilli, decreased 
photoreceptor function, deficiencies in ROS phagocytosis and also undergoes retinal 
degeneration (Won et al., 2008).  C1QTNF5 is expressed as a bicistronic transcript 
with MFRP (Hayward et al. 2003), and C1QTNF5 has been shown to interact with 
MFRP CUB domains (Shu et al., 2006b).  This would suggest common functional 
pathways between the two proteins.  Since both proteins have been shown to localise 
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to the ROS-RPE apical boundary (Mandal et al., 2006b, Mandal et al., 2006c), where 
ROS phagocytosis occurs, it was investigated whether a role could be found for 
C1QTNF5 in RPE phagocytosis of ROS. 
 
 
6.2 Investigating a role for C1QTNF5 in RPE phagocytosis of 
rod outer segments 
Comparisons were made between the different transfected ARPE-19 cell lines to see 
if any effects of wild-type or mutant His-C1QTNF5 over-expression could be 
observed on phagocytosis of bovine ROS.  The same transfected cell lines as used in 
Chapter 3 were used here, and have already been shown to have similar His-
C1QTNF5 secretion levels, with no differences observed in levels of apoptosis, cell 
adhesion or cellular trafficking of His-C1QTNF5. 
 
6.2.1 Preparing and labelling ROS 
ROS were isolated from bovine retinas and labelled with FITC following previously 
described methods (Papermaster et al., 1974, McLaren et al., 1993).  Briefly, 
following removal from the eye and separation from the RPE, retinas were stored at -
80°C prior to use.  After thawing on ice and resuspending in homogenising medium, 
ROS were removed by gentle shaking-induced shearing and collected by 
centrifugation.  Washed ROS were then labelled over night with 10g/ml FITC in 
0.1mM sodium bicarbonate and washed twice with PBS prior to use.   
 
6.2.2 Investigating phagocytosis by flow cytometry 
Flow cytometry identifies cells based upon size, granularity and fluorescence.  Using 
these parameters is it possible to distinguish between different types of cells within a 
heterogeneous population.  Analysis by flow cytometry has been used previously to  
measure levels of FITC-ROS phagocytosis by cultured RPE cells (Miceli et al., 
1994, Kennedy et al., 1996), and these methods were adapted for use in this study.  
Briefly, cells were grown to confluence in 10% serum, after which they were 
cultured in serum-free media for 3 days.  This was to promote differentiation (Karl et 
al., 2007).   
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Following any specified treatments (e.g. addition of CFH or anti-gC1q), FITC-ROS 
were added to the culture media and the cells incubated for the specified time 
periods.  Cells were detached from the culture flasks by digestion with trypsin and 
analysed by flow cytometry.  Trypsin digestion removes externally bound ROS 
(Miceli et al., 1994), so analysis by flow cytometry measures levels of internalisation 
only.  It has been shown previously that labelling of cultured RPE with FITC is 
negligible (Kennedy et al., 1996), so this was not considered to be an issue here. 
 
Following incubation with FITC-ROS, it was possible firstly to identify the ARPE-
19 cell lines based upon size and granularity and then secondly to determine the 
degree of phagocytosis based upon the mean fluorescence of the cell population.  
Figure 6.1 shows the plots obtained when a) measuring cell size and granularity, 
allowing for identification of the ARPE-19 population, and b) size and fluorescence 
within the identified ARPE-19 population.  These different parameters allow for 
identification of ARPE-19 or ARPE-19 plus FITC-ROS, with specified levels of 
phagocytosis based upon the mean fluorescence of the identified population.   
 
6.2.2.1 Investigating levels of phagocytosis in the ARPE-19 transfected 
cell lines 
It was investigated whether any differences in levels of phagocytosis could be 
observed when comparing the transfected cell lines over-expressing wild-type or 
mutant His-C1QTNF5, or untransfected ARPE-19.  The assay was carried out as 
described above, with levels of phagocytosis determined after 0, 1.5, 3, 7, 24 and 48 
hours.  Levels of phagocytosis were calculated by deducting the mean fluorescence 
of the cell population from the mean fluorescence of the cell population plus FITC-
ROS, as described previously (Kennedy et al., 1996).  This was calculated separately 
for each cell line, with final levels of phagocytosis expressed as the fold-difference 
compared with untransfected ARPE-19 after 48 hours incubation.  The assay was 
repeated three times and the data pooled.  Cells over-expressing wild-type His-
C1QTNF5 showed increased levels of phagocytosis up to 48 hours compared with 
the other cell lines.  Cells expressing mutant His-C1QTNF5 showed approximately 
the same levels of phagocytosis as untransfected ARPE-19 (see Figure 6.2). 
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     (A) 
 
     (B) 
Figure 6.1:  Flow cytometry plots showing ARPE-19 (A) and ARPE-19 
incubated with FITC-ROS (B). 
ARPE-19 are identified by size (FSC-H) and granularity (SSC-H) 
and highlighted by the gate, R1.  The fluorescence (FHL-1) of the 
gated cells is then determined.  Cells incubated with FITC-ROS 
show a greater geometric mean fluorescence (12.98) than ARPE-
19 alone (2.50) indicating they have pahgocytosed the FITC-ROS. 
Histogram Statistics
Events % Gated % Total Mean Geo Mean
9892 100.00 98.92 2.94 2.50
Gate: G1 Gated Events: 9892
Total Events: 10000 X Parameter: FL1-H (Log)
R1
Histogram Statistics
Events % Gated % Total Mean Geo Mean
9896 100.00 98.96 14.99 12.88
Gate: G1 Gated Events: 9896






Figure 6.2: ARPE-19 over-expressing wild-type His-C1QTNF5 show greater 
levels of FITC-ROS phagocytosis compared with cells over-expressing 
mutant His-C1QTNF5 and untransfected ARPE-19, which show similar 
phagocytosis levels. 
 
Cells were incubated with FITC-ROS for increasing time periods up 
to 48 hours and analysed by flow cytometry.  Levels of 
phagocytosis were calculated as the fold difference in fluorescence 
compared with untransfected ARPE-19 after 48 hours.  The assay 




























6.2.2.2 Investigating the effects of additional His-C1QTNF5 
Using untransfected ARPE-19, wild-type or mutant His-C1QTNF5 was added to the 
culture medium at concentrations of 0, 0.25 and 10g/ml.  Following incubation for 
1 hour, the FITC-ROS were also added and the cells incubated for 30 hours.  Levels  
of phagocytosis were measured as before.  No effects of additional His-C1QTNF5 
were observed (see Figure 6.3).  The assay was not repeated. 
 
6.2.2.3 Investigating the effects of an anti-gC1q antibody 
The results from Section 6.2.2.1 show that over-expression of wild-type His-
C1QTNF5 in ARPE-19 results in increased levels of FITC-ROS phagocytosis.  It 
was investigated whether adding an antibody raised against C1QTNF5 could affect 
this observation.  It has been shown in previous studies that adding antibodies raised 
against the mannose receptor or CD36 can alter levels of ROS phagocytosis by 
cultured RPE cells (Boyle et al., 1991, Finnemann et al., 2001).  In the case of the 
mannose receptor, the antibody inhibited phagocytosis suggesting that it had a 
blocking effect.  However, in the case of CD36, addition of the antibody actually 
increased the level of phagoytosis.  It was suggested that the antibody caused 
dimerisation of the CD36 which had knock-on signalling effects, altering the rate of 
ROS internalisation.   
 
6.2.2.3.1 Confirming the antibody interacts with His-C1QTNF5 
A monoclonal antibody raised against an E. coli-produced recombinant gC1q domain 
had been produced previously by Dr X. Shu.  The gC1q domain is at the C-terminal 
of C1QTNF5, and His-C1QTNF5 contains a C-terminal poly-His tag.  It was 
therefore investigated whether the antibody would also recognise His-C1QTNF5.  
Recombinant wild-type and mutant His-C1QTNF5 (see Chapter 4) were analysed by 
Western blot, probing with the anti-gC1q antibody.  As can be seen from Figure 5.5, 




Figure 6.3: Adding wild-type or mutant His-C1QTNF5 to the culture media 
of untransfected ARPE-19 had no effect on levels of FITC-ROS 
phagocytosis. 
 
The protein was added at concentrations of 0, 0.25 or 10g/ml for 
1 hour prior to addition of the FITC-ROS, and levels of 
phagocytosis determined by flow cytometry. 
 
 
Figure 6.4: Western blot showing the anti-gC1q antibody recognises wild-
type and mutant His-C1QTNF5. 
 
A – Wild-type His-C1QTNF5, and B – Mutant His-C1QTNF5, 
detected with anti-gC1q. 
C – Wild-type His-C1QTNF5, detected with anti-His. 
D – His-gC1q, detected with anti-gC1q 



























6.2.2.3.2 The effects of adding anti-gC1q antibody 
Following culture for 3 days post-confluence in serum-free media, cells were 
incubated with antibody diluted 1:60 from stock in serum-free media for 1 hour.  
FITC-ROS were then added to the wells and the cells incubated for 30 hours.  This 
incubation time was shown in Figure 6.2 to be adequate to easily observe differences 
in levels of FITC-ROS phagocytosis between the cell lines.  As can be seen from 
Figure 6.5, when no antibody was added wild-type His-C1QTNF5-expressing cells 
showed an approximately 1.5-fold significant increase (two-sample t (4) = -2.735, p 
= 0.05) in levels of phagocytosis compared with untransfected cells.  No difference 
was observed between untransfected and mutant His-C1QTNF5-expressing cells.  
Upon addition of the antibody, levels of phagocytosis increased to 2.5-fold greater 
than untransfected ARPE-19 in the wild-type His-C1QTNF5-expressing cells (two-
sample t (4) = -5.311, p = 0.006), but no differences were observed for the other two 
cell lines.  The assay was repeated three times. 
 
6.2.2.4 Investigating the effects of CFH treatment 
It was shown in Chapter 5 that His-C1QTNF5 interacts with CFH, and this 
interaction involves the gC1q domain.  To determine whether CFH interacting with 
His-C1QTNF5 had any effects on levels of phagocytosis, CFH was added to the 
assay at concentrations of 0, 1, 5, 10 and 50g/ml and the cells incubated for 1 hour 
prior to the addition of FITC-ROS.  The cells were then incubated for 30 hours and 
levels of phagocytosis determined by flow cytometry as the fold-increase when 
compared to ARPE-19 with no additional CFH, with the assay repeated two times.  




Figure 6.5: ARPE-19 stably over-expressing wild-type His-C1QTNF5 show 
increased levels of phagoytosis of FITC-ROS compared with ARPE-19 
stably over-expressing mutant His-C1QTNF5 or untransfected ARPE-19. 
Adding anti-gC1q antibody (Ab) increases levels of phagocytosis in 
the wild-type His-C1QTNF5 cells further still, but has no effect on 
the other two cell lines.  The assay was repeated 3 times, with the 
error bars indicating standard errors. 
Figure 6.6: Adding CFH to the culture media of ARPE-19 or 
APRE-19 stably over-expressing wild-type or mutant His-
C1QTNF5 has no effect on levels of FITC-ROS phagocytosis. 
Cells were incubated with CFH for 1 hour prior to the addition of 
FITC-ROS.  The assay was repeated 3 times, with the error bars 
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6.3 The effects of C1QTNF5 on macrophage phagocytosis 
Macrophages have also been suggested to play a role in AMD, possibly in the 
clearance of sub-RPE deposits (Forrester, 2003).  Macrophages are present in the 
human diseased retina and CCL-2 knockout mice exhibit a phenotype very similar to 
AMD (Ambati et al., 2003).  It was therefore investigated whether His-C1QTNF5 
had any effect on macrophage phagocytosis of apoptotic neutrophils, working with 
and adapting methods optimised by Aisleen McColl (MRC Centre for Inflamation 
Research).  Monocytes were purified from whole blood and matured into 
macrophages by incubation at 37°C for 5 days.  The mature macrophages were then 
added to 6-well plates, either coated with the various proteins under investigation or 
with the protein added to the media.  Annexin-V-labelled apoptotic neutrophils were 
then added and, following incubation, levels of phagocytosis determined by flow 
cytometry.  Some macrophages were stimulated with dexamethasone prior to 
carrying out the assay as it has been shown that dexamethasone enhances 
nonphlogistic phagocytosis of apoptotic leukocytes by macrophages (Liu et al., 
1999).  The assay was carried out with or without autologous serum as it had 
previously been shown by A. McColl that autologous serum contained a substance 
which promoted phagocytosis of apoptotic cells. 
 
6.3.1 Detecting macrophages by flow cytometry 
Figure 6.7 shows the dot plots obtained when analysing the phagocytic macrophages 
by flow cytometry.  It is possible to distinguish between macrophages, neutrophils 
and lymphocytes (as it is impossible to remove all of these), as can be seen from 
graph 1.  It is also possible to distinguish which macrophages have phagocytosed 
annexin V-labelled neutrophils, as can be seen from graph 2. 
 
6.3.2 Macrophage phagocytosis with autologous serum 
To investigate whether wild-type His-gC1q, wild-type His-C1QTNF5 or CFH had 
any effect on macrophage phagocytosis of apoptotic neutrophils, the macrophages 
were plated onto 6-well plates coated with these proteins.  The phagocytosis assay 
was then carried out with autologous serum present, and macrophages were either 
pre-treated or not pre-treated with dexamethasone.  As can be seen from Figure 6.8, 
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there were no differences in levels of phagocytosis between the treatments, either 
with or without dexamethasone.  As has been shown previously (Liu et al., 1999), 
dexamethasone did increase levels of phagocytosis. 
 
6.3.3 Macrophage phagocytosis without autologous serum 
Following on from the observation by A. McColl that autologous serum contains a 
substance which promotes macrophage phagocytosis of apoptotic cells, the  
phagocytosis assay was carried out without autologous serum.  Each of the 
treatments (wild-type His-C1QTNF5, mutant His-C1QTNF5 and CFH) was added to 
the culture media in replace of the serum to see if they could restore this property.  
As can be seen from Figure 6.9, there were no differences in levels of phagocytosis 
between the treatments, either with or without dexamethasone.  Adding autologous 
serum did however increase levels of phagocytosis in both dexamethasone treated 




   (Graph 1)    (Graph 2) 
 
 
Figure 6.7: Dot plots obtained when analysing phagocytic macrophages 
by flow cytometry. 
 
Graph 1: The red circle indicates macrophages, the blue rectangle 
indicates neutrophils and the green rectangle indicates 
lymphocytes. 
Graph 2: The blue rectangles indicate Annexin V-labelled 
neutrophils, the green circle indicates non-phagocytic 
macrophages and the red circle indicates phagocytic macrophages 
which have taken up labelled neutrophils.  
The histogram shows macrophages contained within the black 
gate in graph 2.  M1 indicates phagocytic macrophages. 




Marker Left, Right Events % Gated % Total
All     1,  9910 9722 100.00 18.75
M1    63,  9910 824 8.48 1.59
File: Control BSA.002 Acquisition Date: 08-Nov-06





Figure 6.8: C1QTNF5, CFH and gC1q have no effect on levels of 
macrophage phagocytosis of apoptotic neutrophils in the presence of 
autologous serum. 
Pre-treating cells with dexamethasone increased levels of 
phagocytosis in all cases, but no effect of C1QTNF5, CFH or gC1q 
was observed.  THe assay was repeated twice with error bars 
showing standard errors. 
 
Figure 6.9: Wild-type His-C1QTNF5, mutant His-C1QTNF5 and have no 
effect on levels of macrophage phagocytosis of apoptotic neutrophils in 
the absence of autologous serum. 
Pre-treating cells with dexamethasone increased levels of 
phagocytosis in all cases, but no effect of C1QTNF5, CFH or gC1q 
was observed.  The assay was repeated twice with error bars 




















































An assay has been developed for determining levels of FITC-labelled ROS 
phagocytosis by cultured ARPE-19 cells.  Levels of internalisation only and not 
binding are measured, as the technique involves trypsinising the adherent cells prior 
to analysis by flow cytometry.  It was shown using this assay that the levels of 
internalised FITC-ROS increase for up to 48 hours in all cell lines.  The levels were 
compared between untransfected ARPE-19 and ARPE-19 over-expressing wild-type 
or mutant His-C1QTNF5, and were greater in the cells over-expressing the wild-type 
protein compared with the other two cell lines.  Levels of phagocytosis were 
measured after 30 hours and found to be approximately 1.5-fold greater in this cell 
line, but again there was no difference in levels of phagocytosis between the 
untransfected or mutant His-C1QTNF5-expressing cell lines.  It was shown in 
Chapter 3 that the transfected ARPE-19 cell lines used showed similar levels of His- 
C1QTNF5 secretion, so the differences observed between the two cell lines are 
unlikely to be due to differences in extracellular His-C1QTNF5.  These results would 
suggest that C1QTNF5 plays a role in RPE phagocytosis of ROS and that the 163Arg 
mutant protein is unable to function fully in this role.  Some levels of phagocytosis 
were observed in the mutant cell line, and these levels were the same as the 
untransfected cells.  Endogenous C1QTNF5 expression was not knocked out in the 
transfected cell lines so it is possible that this enabled some phagocytosis to occur at 
endogenous levels. 
 
However, it has been shown by Shu et al. (2006a) that wild-type and mutant 
C1QTNF5 interact.  This could mean that over-expression of mutant protein would 
result in sequestering of the endogenous wild-type protein, and imply that the 
phagocytosis observed in the mutant cell line is occurring independently of 
C1QTNF5.  It is not currently possible to say which situation is occurring. 
 
Previous studies into receptors and ligands involved in ROS phagocytosis have 
shown some molecules to be involved in ROS binding to the RPE and some 
molecules to be involved in internalisation.  For instance, the v5 integrin receptor 
is involved in ROS binding but not internalisation (Finnemann et al., 1997).  
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However, ROS attachment to this receptor stimulates proteins and signalling 
pathways which are responsible for internalising the ROS, such as FAK and MerTK 
(Finnemann et al., 2003, Finnemann et al., 2006b).  CD81, for instance, is not 
involved directly involved in ROS attachment to the RPE.  Rather, it is thought to 
regulate the processing and/or turnover of the intergrin receptor which indirectly 
affects both rate of binding and internalisation.  The assays used in this study only 
measured levels of internalisation, not binding.  However, although levels of 
internalisation were greater in the wild-type His-C1QTNF5-expressing cells, this 
could be due to increased binding and subsequent up-regulating of internalisation 
pathways.  Previous assays have used antibodies to investigate whether particular 
molecules are directly involved in ROS binding, for instance, when investigating the 
mannose receptor, anti-mannose receptor antibodies blocked ROS binding (Boyle et 
al., 1991), or whether the molecules are involved in signalling pathways, for instance 
anti-CD36 antibodies upregulated levels of internalisation, probably via dimerisation 
of the molecule (Finnemann et al., 2001).  When an antibody to the gC1q domain of 
C1QTNF5 was added to the phagocytosis assay, levels of FITC-ROS phagocyotsis 
increased in the wild-type His-C1QTNF5-expressing cell.  No differences were 
observed for the other two cell lines.  This not provides evidence that it is C1QTNF5 
which is responsible for the increased levels of phagocytosis seen when no antibody 
was present, but it would also suggest that the molecule is not directly involved in 
ROS binding otherwise this would have been blocked by the antibody.  Repeating 
the assay with a non-specific IgG antibody would confirm whether that this was the 
result of a specific interaction of the anti-gC1q antibody with gC1q.  C1QTNF5 is 
known to multimerise via its gC1q domain, so it is possible that addition of the 
antibody caused clustering of the molecules.  C1QTNF5, although secreted, has been 
shown to be membrane associated (Mandal et al., 2006c), and to interact with the 
membrane protein MFRP (Shu et al., 2006b, Mandal et al., 2006b).  It could 
therefore be predicted that C1QTNF5 plays a signalling role in phagocytosis, 




Whilst the assay results would certainly suggest a role for C1QTNF5 in ROS 
phagocytosis, there are several further experiments which could help to confirm this.  
Perhaps the most obvious is to add recombinant C1QTNF5 to untransfected ARPE-
19 and see if this has any effect.  This was carried out using the recombinant His-
C1QTNF5 (wild-type and mutant) produced previously, however no effects were 
observed.  This observation may have arisen for several reasons.  It is possible that 
the recombinant protein was not added at sufficiently high levels.  It is also possible 
that the cells were not incubated with the protein for long enough prior to addition of 
the FITC-ROS.  C1QTNF5 over-expression may regulate the expression or 
localisation of other proteins necessary for ROS phagocytosis and this did not occur 
after only 1 hour incubation.  It is also possible that the recombinant protein did not 
interact with whichever proteins endogenous C1QTNF5 interacts with, and that for 
interactions to occur the protein needs to be expressed within the cell and 
subsequently secreted.  Therefore, although the result was negative for this assay, 
this does not categorically rule out any involvement of C1QTNF5.  Another way of 
confirming the involvement of C1QTNF5 would be by using small interfering 
ribonucleic acid (siRNA) to knockout C1QTNF5 expression.  If this reduced levels 
of phagocytosis in any of the cell lines it would confirm an involvement of 
C1QTNF5.  In order to ascertain whether C1QTNF5 is involved in binding or 
internalisation of the ROS, fluorescence microscopy could be carried out.  Several 
studies have looked at levels of ROS binding to cultured RPE cells (Nandrot et al., 
2005, Sun et al., 2006), using fluorescently-labelled ROS and determining the 
number of bound ROS per cell.  These methods could be adapted for the ARPE-19 
cell lines used in this study. 
 
Further evidence for an involvement of C1QTNF5 in RPE phagocytosis comes from 
studies into the rd6 mouse.  This mouse has a mutation in MFRP affecting its ability 
to phagocytose ROS (Won et al., 2008).  C1QTNF5 interacts with MFRP in vitro 
(Shu et al., 2006b, Mandal et al., 2006b), and the two proteins are expressed as a 
bicistronic transcript, which would imply they are functionally related (Hayward et 
al., 2003).  They have also been shown to co-localise in cultured MDCK cells 
(Mandal et al., 2006).   With the exception of CFH, this study has not shown what 
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other proteins C1QTNF5 interacts with.  Adding anti-gC1q antibody to the 
phagocytosis assay has indicated that C1QTNF5 likely plays a signalling role, maybe 
involving clustering of the molecule.  C1QTNF5 is a secreted protein, so is required 
to interact with membrane proteins in order for this signal transduction to occur.  It is 
therefore highly likely that one such protein is MFRP.  Further analysis is needed to 
confirm this, again, for instance, using siRNA or anti-MFRP antibodies.  Other 
proteins shown to be involved in ROS phagocytosis include CD81, CD36 and the 
v5 integrin.  It would be interesting to investigate whether C1QTNF5 interacts 
with any of these proteins and so is involved in these known pathways, or if it is 
involved in a totally separate, novel pathway.   
 
It was shown in Chapter 5 that C1QTNF5 interacts with CFH.  Therefore, CFH was 
added to the phagocytosis assay to see if it had any effects on levels of phagocytosis.  
None was observed.  It is possible that this is because CFH interactions with 
C1QTNF5 are not involved in the phagocytosis process.  For instance, the purpose of 
the interaction with C1QTNF5 may be to localise CFH to a specific area, preventing 
complement activation.  However, it is also possible that CFH may be involved in 
phagocytosis but this was not detected by the assay.  As with adding C1QTNF5 to 
the assay, it is possible that a longer incubation time may be required.  It is also 
possible that the added CFH was not interacting with C1QTNF5 at the cell surface.  
This may be because CFH will only interact with C1QTNF5 under certain 
conditions, as was found in Chapter 5.  Maybe CFH interacts with ligands on the 
ROS surface, and so pre-incubating the ROS with CFH may have an effect on 
phagocytosis levels instead.  There are other ways in which the assay could be 
adapted to determine if CFH is involved.  Anti-CFH antibodies could be added, as 
was carried out for gC1q, or siRNA against CFH and so prevention of CFH 
production may also affect the levels of ROS phagocytosis.  Therefore, it is not at 
present possible to rule out any effect of CFH on ROS phagocytosis by the RPE. 
 
It is suggested that AMD disease mechanisms involve ineffective clearance of sub-
retinal debris, with some of this clearance being carried out by macrophages, and that 
defective macrophage recruitment leads to an accumulation of debris.  C1QTNF5 has 
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been shown to be involved in RPE apical phagocytosis, so it was hypothesised it may 
be able to promote phagocytosis by macrophages too.  C1q is a collagen homologous 
to C1QTNF5 which has been shown to do just that (Ogden et al., 2001).  No 
evidence was found in this study that C1QTNF5 has an effect on macrophage 
phagocytosis of apoptotic neutrophils.  This was not investigated in depth, with only 
preliminary experiments carried out.  Whilst it is possible that C1QTNF5 has no 
effect on macrophages, it is equally likely that the assay needs to be developed 
further before any effects can be seen.  Such developments could include pre-
incubating the apoptotic cells with C1QTNF5 or maturing the macrophages on plates 
coated with C1QTNF5.  These experiments however go beyond what it was possible 
to achieve within this study. 
 
It has been shown that C1QTNF5 is involved in the RPE phagocytosis of ROS.  As 
C1QTNF5 is mutated in L-ORMD, it is likely that deficits in this function are a 
major contributing factor towards disease progression, particularly as the mutant 
protein appears unable to carry out this role.  One of the major symptoms of L-
ORMD is extensive sub-RPE deposits.  It is possible these arise as a result of 
aberrant ROS phagocytosis.  For instance, Amin et al. (2004) showed that the 
composition of basal deposits secreted by RPE cells is dependant upon what they are 
phagocytosing apically.  L-ORMD patients are heterozygous for the Ser163Arg 
mutation, meaning that they also have wild-type protein present.  Therefore it would 
be expected that their phagocytosis mechanisms, although functioning to some 
degree, are compromised.  Over time this could lead to accumulation of sub-RPE 
deposits.  Lipofuscin, for instance, is thought to be the result of incomplete digestion 
of phagocytosed material (Reinboth et al., 1997).  The sub-RPE deposits seen in L-
ORMD resemble the BlamD seen in AMD.  These have been suggested to arise due 
to excess basal secretions by stressed RPE cells (van der Schaft et al., 1994).  If the 
RPE cells are not effectively phagocytosing shed ROS then this may in turn lead to 
RPE stress and subsequent BlamD deposition by the same mechanisms proposed to 
occur in AMD. 
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Dark adaptation difficulties are an early phenotypic marker for L-ORMD.  This 
would suggest that rod photoreceptor function is compromised.  It is possible that 
slight deficiencies in the ability to phagocytose shed ROS over several years would 
lead to photoreceptor dysfunction.  As part of the visual cycle, all-trans-retinal is 
trafficked between the ROS and RPE, where it is recycled back into 11-cis-retinal to 
be used again in the visual cycle (Strauss, 2005).  Although dark adaptation 
difficulties would therefore suggest problems with retinoid recycling rather than 
phagocytosis, accumulated phagocytosis deficiencies could have knock-on effects on 
other pathways occurring in the same tissue vicinity, or cause low levels of ROS 
debris to accumulate between the RPE and ROS, providing a physical barrier to 
retinoid trafficking between the two cell layers.  One of the major problems with 
slow, progressive late-onset diseases is determining which symptoms are cause and 
effect, particularly when in depth examination of the affected tissue can only occur 
after the individual has died.  Therefore, it remains unanswered whether sub-RPE 
debris leads to apical RPE and photoreceptor dysfunction, or vice versa. 







Age-related macular degeneration is a disease with serious implications, not only for 
the affected individual but also for society as a whole.  The population is ageing and 
prevalence of AMD increasing, which will inevitably increase the burden on 
healthcare systems (Evans et al., 1996).  Understanding the processes involved in 
AMD is therefore very important.  However, AMD is a complex disease with many 
contributing factors, both genetic and environmental (Hawkins et al., 1999, Mares-
Perlman et al., 1995, Smith et al., 2001, Hammond et al., 2002, Vojnikovic et al., 
2007).  This makes understanding disease mechanisms difficult.  Inherited diseases 
which show symptoms related to those in AMD can be very helpful in determining 
molecular pathways that may be involved.  One such disease is L-ORMD.  L-ORMD 
patients initially present with dark adaptation abnormalities, indicating photoreceptor 
dysfunction, and in later stages extensive sub-RPE deposits similar to those seen in 
AMD, leading to retinal degeneration (Duval et al., 1986, Brosnahan et al., 1994, 
Kuntz et al., 1996, Milam et al., 2000, Jacobson et al., 2001).  L-ORMD is an 
autosomal dominant disease caused by a Ser163Arg mutation in C1QTNF5 
(Hayward et al., 2003).  C1QTNF5 is a short-chain collagen, homologous to the C1q 
and TNF superfamily of proteins.  It is secreted and known to form multimeric 
species, and although studies have shown that it is secreted by the RPE and interacts 
with the membrane protein MFRP (with which it is thought to be co-expressed as a 
bicistronic transcript) (Shu et al., 2006b, Mandal et al., 2006c), no conclusive 
evidence has yet been published in relation to its function.  This study aimed to 
investigate a role for C1QTNF5 and the effects of the Ser163Arg mutation, both by 
creating and studying a stably transfected, physiologically relevant, mammalian 
cellular model, and by producing recombinant protein for use in assays.  Specifically, 
the study aimed to investigate in greater detail reports that the protein may be 
involved in adhesion of the RPE to Bruch’s membrane (Shu et al., 2006b), that the 
mutant protein aggregates and is not secreted (Shu et al., 2006b, Mandal et al., 
2006c), that the protein appears to interact with CFH (implicated in increased risk of 
developing AMD) and to determine if C1QTNF5 plays a role in RPE phagocytosis of 




7.2 The main findings of the study 
Stably transfected cell lines were created and used to investigate further previous 
reports that C1QTNF5 may have a role in cell adhesion, with mutation in C1QTNF5 
causing it to aggregate and be retained within the cell.  Recombinant proteins were 
produced and assays developed to gain further insights into the interaction between 
C1QTNF5 and CFH.  Also, the stably transfected cell lines were used to show that 
C1QTNF5 has a role in RPE phagocytosis of shed ROS. 
 
7.2.1 C1QTNF5 and extracellular matrix interactions 
Contrary to previous reports (Shu et al., 2006b), no evidence was found to support a 
role for C1QTNF5 in RPE cell adhesion to ECM surfaces such as Bruch’s 
membrane.  It was investigated whether ARPE-19 cells were able to adhere to 
C1QTNF5-coated plates, or whether any differences in levels of adhesion to laminin- 
or fibronectin-coated plates could be found between ARPE-19 over-expressing either 
wild-type or mutant C1QTNF5.  However in each case no differences were observed.  
As discussed in Chapter 3, the previously reported results regarding cell adhesion 
may have been the result of using a non-physiologically relevant cell line.  Cells are 
known to interact with laminin via integrin receptors, of which the RPE expresses 
only one – the v5 integrin receptor (Nandrot et al., 2006).  Over-expression of 
C1QTNF5 in EBNA293 cells may have promoted cell-extracellular matrix 
interactions involving proteins not expressed by ARPE-19.  Stably transfected 
ARPE-19 over-expressing wild-type His-C1QTNF5 did however show increased 
spreading on laminin- and fibronectin-coated plates.  This would suggest that 
C1QTNF5 may be involved in cell-ECM interactions and cytoskeletal 
rearrangements, possibly involving the v5 integrin. 
 
This study has shown that C1QTNF5 plays a role in RPE phagocytosis of shed ROS.  
Apically, the RPE-ROS boundary consists of RPE microvilli interdigitating with the 
ROS, and basally the RPE has infoldings.  C1QTNF5 has been shown to localise to 
both of these locations (Mandal et al., 2006a, Mandal et al., 2006b).  It was shown in 
 261 
Chapter 6 that C1QTNF5 over-expression results in increased levels of ROS 
phagocytosis, and that this result probably involves clustering of C1QTNF5 and 
perhaps interacting proteins.  The results also suggested that C1QTNF5 was not 
directly involved in ROS binding, as anti-gC1q antibodies did not inhibit but rather 
up-regulated phagocytosis.  Combining this result with the observation of increased 
spreading would point towards a C1QTNF5 function involving cytoskeletal 
rearrangements, possible facilitating phagocytosis.  Obviously the current results 
only allow speculation that this is the case.  However, it is conceivable that 
C1QTNF5 may be involved in maintenance of the RPE-ROS interdigitation by co-
ordinating cytoskeletal rearrangements.  Mutations in MFRP, with which C1QTNF5 
interacts, result in reduced apical microvilli and reduced phagoytosis, again raising 
the possibility that the two proteins share a functional pathway.   
 
7.2.2 The effects of mutation in C1QTNF5 on secretion and protein 
function 
Again contrary to previous reports (Shu et al., 2006b, Mandal et al., 2006c), mutant 
His-C1QTNF5 was not found to aggregate or to be retained within the ER.  Both the 
wild-type and mutant proteins were secreted, in both stably transfected ARPE-19 and 
EBNA293 cell lines.  This result implies that disease mechanisms in L-ORMD are 
probably not due to ER stress as a result of retained and aggregated protein, or 
haploinsufficiency due to lack of secreted protein.  It has, however, previously been 
shown that the wild-type and mutant proteins interact (Shu et al., 2006a), so it is 
possible that this may result in a reduction in the effective amount of secreted wild-
type protein.  Indeed, as results have shown that cells over-expressing mutant His-
C1QTNF5 do not show an increase in cell spreading or phagocytosis of ROS, this 
would imply that the mutant protein is unable to function correctly.  Therefore 
secreted mutant protein interacting with secreted wild-type protein may well prevent 
the wild-type protein from performing properly. 
 
7.2.3 C1QTNF5 interactions with CFH 
It has been shown that C1QTNF5 interacts with CFH, with this interaction involving 
at least SCR19-20 and SCR7-8.  CFH is known to undergo a conformational change 
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when it interacts with other ligands (Opperman et al., 2006, Prosser et al., 2007), and 
evidence in this study suggested that this was also the case when interacting with 
C1QTNF5.  When in solution, CFH is predicted to be in a folded back (omega) 
structure with an exposed C-terminus.  It binds ligands initially via its C-terminal 
domains and then undergoes a conformational change, facilitating interactions 
involving other domains.  The evidence obtained in this study indicates that this may 
also be the case in binding to C1QTNF5. 
 
The purpose of CFH interacting with C1QTNF5 has not yet been determined.  It is 
possible that C1QTNF5 is acting to localise CFH to a particular site within the retina, 
possibly acting in combination with GAGs.  Due to the high levels of ROS shedding 
and phagocytosis, it may be necessary to have a higher local concentration of CFH at 
this site to ensure there is no complement activation.  This would imply that 
C1QTNF5 is a multifunctional protein, acting to localise CFH as well as being 
involved in phagocytosis.  It is also possible that the CFH-C1QTNF5 interaction 
provides a novel function for CFH.  It may be involved in regulating C1QTNF5 
activity.  Adding anti-gC1q antibody to the phagocytosis assay suggested that 
clustering of C1QTNF5 may be involved in up-regulating ROS phagocytosis, so it is 
possible that this occurs when CFH binds.  Although no evidence was found for an 
effect of CFH on the phagocytosis assay, as discussed in Chapter 6, this does not rule 
out such an involvement.   
 
CFH showed a 17.5-fold higher affinity for mutant compared with wild-type His-
C1QTNF5, with SCR19-20 showing a 95-fold increase for the mutant.  It is possible 
that this altered affinity contributes to disease mechanisms in L-ORMD.  Whether 
C1QTNF5 is involved in localising CFH or as part of a signalling pathway, too high 
an affinity could have adverse effects.  It could prevent CFH interacting with other 
proteins, for instance in regulation of complement, or it could decrease dissociation 
or increase association rates which may alter a fine-tuned signalling pathway.  This 
might lead to a gain of function leading to the dominant inheritance pattern. 
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7.2.4 C1QTNF5 and RPE phagocytosis of ROS 
C1QTNF5 has been shown in this study to be involved in RPE phagocytosis of shed 
ROS.  Over-expression of the wild-type protein in ARPE-19 cells results in increased 
levels of phagocytosis, whilst cells over-expressing the mutant protein showed the 
same levels as in untransfected cells.  Further analysis using anti-gC1q antibody 
suggests that clustering of the protein may be involved, for instance in a signalling 
pathway, as this up-regulates phagocytosis, as observed for CD36 (Finnemann et al., 
2001).  In the mutant no effect on phagocytosis was observed.  It is perhaps 
unsurprising that C1QTNF5 is involved in phagocytosis.  It interacts with MFRP, 




7.3 A role for C1QTNF5 
In order to understand how C1QTNF5 mutation contributes towards retinal 
degeneration, it is necessary to understand its role in the healthy retina.  This study 
has shed light on certain aspects of this role, for instance its interaction with CFH 
and role in phagocytosis.  However, specific details of these functions have not yet 
been determined.  For instance, what proteins interact with C1QTNF5, what is the 
relevance of the CFH interaction and how does the interaction with MFRP affect its 
function?  By combining the data from this study with published results from other 
studies it is possible to speculate as to what may be occurring.  These models can 
explain the various pieces of evidence regarding a role for C1QTNF5, and can 
provide hypotheses for future studies to investigate.  C1QTNF5 is expressed in both 
the adult and developing eye.  It is likely that its roles differ at these different stages 
of the life cycle, not least because embryonic eyes do not undergo ROS shedding and 
subsequent phagocytosis.  The results from this study will be discussed with 
reference to a role in the adult eye, although it is also possible that developmental 
abnormalities may also contribute towards L-ORMD disease mechanisms. 
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7.3.1 C1QTNF5 in the healthy retina 
Previous studies have shown that C1QTNF5 is localised to the apical and basal 
plasma membranes of the RPE, as well as ganglion cells, ciliary body apical 
membranes and the plasma membrane of the lens epithelial cells (Mandal et al., 
2006c).  This study has investigated a role for C1QTNF5 in the RPE, so discussion 
will focus on this tissue only.  The results from this study showed that C1QTNF5 
was involved in cell spreading, which involves cell-ECM interactions and changes in 
cytoskeletal structure (Hynes, 1999).  With C1QTNF5 secreted and localised to the 
RPE plasma membrane it is likely to be involved in regulating in vivo cytoskeletal 
structure too, either directly or indirectly.  One of the most obvious structural 
features of the RPE is the apical microvilli, which increase RPE surface area and so 
facilitate phagocytosis of ROS.  It was shown in this study that C1QTNF5 is 
involved in ROS phagocyotsis, probably via a signalling pathway rather than direct 
ROS binding.  Previous studies have shown C1QTNF5 to interact with MFRP, 
although this protein was found to be located only at the base of the microvilli 
(Mandal et al., 2006b).  It was shown here that another C1QTNF5 interacting protein 
is CFH, which is localised throughout the entire length of the microvilli (Mandal et 
al., 2006c), and Dr X. Shu showed that C1QTNF5 interacts with heparin-like GAGs.  
Figure 7.1 shows a hypothetical model of the RPE-ROS boundary, and how these 
various molecules and their interactions may be arranged.  Concentrating on the 
apical microvillar base, MFRP is localised here where it probably interacts with 
C1QTNF5.  This interaction may involve clustering of both the C1QTNF5 and 
attached MFRP, possibly via additional interacting proteins.  Clustering of 
C1QTNF5 is predicted to upregulate phagocytosis, a process MFRP is known to be 
involved in, so if this were to occur in this region it could promote signalling 
pathways and subsequent phagocytosis of the shed ROS tips.  Alternatively, if 
C1QTNF5 is involved in forming and maintaining the microvilli by interactions with 
the ECM, then local MFRP interactions could prevent certain cytoskeletal 
rearrangements and thus define the basal boundaries of each microvillus.  Adding 





Figure 7.1: C1QTNF5 clustering may help to promote RPE phagocyotsis of 
shed ROS tips. 
 
C1QTNF5 interacts with CFH and MFRP.  CFH is located 
throughout the length of the microvilli, whilst MFRP is only located 
at the base.  It is possible that CFH, possibly in conjunction with a 
GAG framework, helps to prevent C1QTNF5 clustering.  This may 
also have effects on the cytoskeleton, helping to maintain the 
microvilli structure.  However, at the microvilli base C1QTNF5 
interacts with MFRP, causing clustering of the two molecules and 
possibly cytosketal rearrangements, resulting in phagocytosis of 

















As well as being attached to cell surfaces, GAGs can form part of the ECM.  CFH is 
localised to the RPE microvilli and so plausibly could interact with these ECM-
associated GAGs throughout the whole of this boundary.  One possibility is that by 
interacting with CFH and a framework of GAGs, C1QTNF5 is prevented from 
clustering.  Alternatively, interacting with GAGs alone may provide the framework 
whilst C1QTNF5 interacts with CFH merely to localise additional CFH protein to the 
area.  CFH may also have a new function, interacting with C1QTNF5 to help 
maintain the microvillar structure, as a counter balance to the MRFP interactions 
basally or with a signalling role in phagocytosis.  Unfortunately, it is not possible to 
predict what may or may not be the case until further analyses are carried out. 
 
7.3.1.1 Potential C1QTNF5 interacting proteins 
It is highly likely that MFRP and CFH are not the only proteins that C1QTNF5 
interacts with, although this has yet to be determined.  Figure 1.4 (Section 1.1.6.1) 
highlighted the main proteins and pathways involved in ROS phagocytosis, so it is 
possible that C1QTNF5 interacts with one or more of these, as well as yet-
unidentified proteins.  The v5 integrin is known to be involved in phagocytosis as 
well as cell-ECM interactions and, as discussed in section 7.1.1, it would not be 
implausible for C1QTNF5 to have an effect on interactions involving this protein, 
possibly through the membrane protein MFRP, as both proteins share overlapping 
functions (as summarised in Figure 7.2).   
 
Another plausible interacting protein would be CD81.  CD81 is a tetraspanin, and 
tetraspanins form membrane-associated webs involving many proteins 
(Berditchevski et al., 2001, Hemler et al., 2005, Levy et al., 2005).  CD81 is not 
involved directly in ROS phagocytosis, but has an indirect role in the processing of 
the v5 integrin (Chang et al., 2007).  CD81 requires regulation, and it has been 
shown in this study that C1QTNF5 has a regulatory or signalling role in ROS 
phagocytosis, rather than direct ROS binding.  C1QTNF5 may therefore interact with 
CD81, either directly or via MFRP.  CD81 is also known to interact with EBP50, 
which in turn interacts with ezrin and CRALBP.  Interestingly, C1QTNF5 and ezrin 
have been shown to localise to the RPE apical processes (Mandal et al., 2006c, 
 267 
Bonilha et al., 1999) and ezrin knockout mice present with a retinal phenotype very 
similar to that of the MFRP knockout mouse with reductions in apical microvilli and 
retarded photoreceptor development (Bonilha et al., 2005).  Also, if the mutation in 
C1QTNF5 were to affect how it interacts with other proteins, this could have knock-
on effects on downstream molecular pathways.  CRALBP, for instance, is involved 
in retinoid processing and indirectly interacts with CD81 (Strauss et al., 2005) so it is 
plausible that if C1QTNF5 interacts with CD81 this could indirectly disrupt finely-
tuned pathways such as retinoid processing in the visual cycle.  This would certainly 
explain the dark adaptation abnormalities seen in L-ORMD patients (discussed in 
more detail in Section 7.3.2).  Figure 7.3 summarises CD81 interactions and how 





Figure 7.2: C1QTNF5 and MFRP share overlapping functions with the v5 
integrin, namey in phagocytosis of shed ROS and in organising cell 
structure. 
 
It is possible, due to these overlapping functions that C1QTNF5 
and MFRP interact or share interacting proteins and functional 
pathways.  C1QTNF5 interacts with CFH, although a function for 















Figure 7.3: CD81 may interact with both MFRP and the v5 integrin. 
 
CD81 is a tetraspanin and is known to interact with EBP50 as well 
as the v5 integrin.  EBP50 interacts with ezrin, which is required 
for formation of the RPE apical microvilli, as well as CRALBP, 
which is involved in retinoid processing in the visual cycle.  
C1QTNF5 co-localises with ezrin, and patients with L-ORMD 
initially present with dark adaptation abnormalities, which could 
potentially be the result of mutant C1QTNF5 affecting CRALBP 
indirectly via interacting proteins such as MFRP, CD81 and 
EBP50.  If MFRP were to interact with CD81 then this would 

























7.3.2 C1QTNF5 in L-ORMD 
Disease progression in L-ORMD starts with initial dark adaptation abnormalities, 
leading to sub-RPE deposits, photoreceptor degeneration, retinal atrophy and CNV 
(Duval et al., 1986, Brosnahan et al., 1994, Kuntz et al., 1996, Milam et al., 2000, 
Jacobson et al., 2001).  As with AMD, it is not easy to determine which symptoms 
are cause and which are effect, i.e. what processes does the Ser163Arg mutation 
actually affect, what are the results of this and what symptoms are secondary to 
them?  Unlike AMD, L-ORMD is caused by a single point mutation in an identified  
protein and the disease has an early phenotypic marker – dark adaptation (Jacobson 
et al., 2001).  Dark adaptation in itself may be the result of sub-RPE deposits 
compromising the RPE and overlying photoreceptors.  However, when patients were 
given vitamin A supplements this improved their dark adaptation slightly, implying 
that it could be caused by photoreceptor dysfunction at this initial stage of the 
disease.  Duval et al. (1986) noted ROS were disorganised and shortened in a 
donated L-ORMD eye.  This may indicate that photoreceptor dysfunction is a major 
factor in L-ORMD disease progression, or, as discussed above, because it is not easy 
to determine primary and secondary symptoms, this may not be the case.  
 
The observation that over-expression of wild-type His-C1QTNF5 increases levels of 
phagocytosis of ROS in ARPE-19 cell cultures, whereas the mutant does not, 
supports the initial defects leading to L-ORMD occurring at the RPE apical 
boundary, rather than basally as has been suggested previously (Shu et al., 2006b).  
Any additional basal disease mechanisms cannot be ruled out at this stage, especially 
as C1QTNF5 is expressed basally too, although results from this study support an 
apical abnormality.  It is possible that dark adaptation difficulties are the result of an 
abnormality in the RPE-ROS boundary, possibly due to reduced apical microvilli, as 
seen in the rd6 mouse (Won et al., 2008).  This could lead to photoreceptor 
dysfunction and a stressed RPE.  Although in the rd6 mouse it is MFRP which is 
mutated, and in L-ORMD patients it is C1QTNF5, these proteins probably interact in 
vivo (Shu et al., 2006b, Mandal et al., 2006b).  Also, whilst the homozygous rd6 
mouse has a severe phenotype with fairly early onset and L-ORMD manifests later in 
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life, L-ORMD patients are heterozygous for the disease-causing mutation (Hayward 
et al., 2003) so it can be assumed that some residual C1QTNF5 function remains. 
 
It is also possible that the dark adaptation abnormalities observed in L-ORMD may 
be a result of ineffective ROS phagocytosis.  The young retina may be able to cope 
with a system that is not functioning at 100% efficiency, however as the tissue ages it 
becomes less able to do so and symptoms appear.  Dark adaptation abnormalities 
would perhaps suggest a deficit in retinoid recycling, rather than ROS phagocytosis.  
However, retinoid is required to be transported from the ROS to the RPE and back 
again, so it would not be implausible to suggest that stressing the photoreceptors or 
RPE by ineffective phagocytosis could have knock-on effects on other functions of 
these cells, particularly those involving molecular pathways occurring in the same 
vicinity.  There is also the possibility that C1QTNF5 or one of its interacting proteins 
is involved in retinoid recycling, and mutation in C1QTNF5 has an effect by altering 
the homeostasis of carefully balanced molecular pathways.  Determining C1QTNF5 
interacting proteins (as discussed in Section 7.2.1) would help ascertain which, if 
any, of these possibilities is occurring. 
 
Extensive sub-RPE deposits are another feature of L-ORMD.  These deposits 
resemble the BlamD seen in AMD, which are thought to be secreted by a stressed 
RPE (van der Schaft et al., 1994).  Assuming the sub-RPE deposits seen in L-ORMD 
do not cause the dark adaptation difficulties, then it would be plausible to suggest 
that the deposits may be the result of a compromised RPE which is secreting extra 
basement membrane material.  In addition, it has been shown by Amin et al., (2004) 
that when cultured RPE are fed ROS it is possible to modulate the amount and type 
of basal deposits formed, further supporting the involvement of ROS phagocytosis in 
sub-RPE deposit formation.  Cultured ARPE-19 cells were fed retinal homogenate, 
with the structure of sub-RPE deposits analysed by electron microscopy and 
compared to cells which had not received such treatment.  Deposits were classified 
as fibrillar, condensed and banded, and thought to be similar to BlamD, or 
membranous, thought to be similar to BlinD.  After feeding with retinal homogenate, 
the proportion of condensed and banded deposits formed was signifcantly increased 
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when compared with the control cultures.  A recent study by Hollyfield et al. (2008) 
showed that immunising mice against CEP could provoke inflammatory responses 
resulting in a pathology similar to that seen in AMD.  In addition, treated mice 
showed an increase in sub-RPE BlamD deposits.  CEP forms when oxidised DHA 
fragments interact with tissue proteins.  It is conceivable that reduced levels of ROS 
phagocytosis could cause accumulation of oxidised DHA either within the RPE or 
between the photoreceptors and RPE, resulting in increased CEP production.  This 
could then contribute towards the accumulation of basal laminar deposits and 
inflammatory response observed in L-ORMD (Milam et al., 2000).   
 
7.3.3 C1QTNF5 in AMD 
AMD is characterised by drusen, sub-RPE deposits, CNV and loss of central vision 
(Tezel, 2004).  Determining the underlying causes of these symptoms is difficult, 
although several genomic loci have been identified and molecular pathways 
suggested which may play a role in disease progression.  Drusen are thought to arise 
from initial nucleation events, possibly due to basal blebs from compromised RPE 
cells, which are not effectively removed and subsequently increase in size due to 
deposition of additional material and autoimmune responses.  Polymorphisms in 
CFH have been associated with increased risk of developing AMD (Edwards et al., 
2005, Haines et al., 2005, Klein et al., 2005), with extensive studies focusing on how 
the Y402H polymorphism affects the protein's ability to interact with known ligands 
such as GAGs and CRP (Clark et al., 2006, Herbert et al., 2007, Prosser et al., 2007).  
Variations in CFH interacting proteins such as C3 have also been implicated (Yates 
et al., 2007, Spencer et al., 2008).  Also, it has been suggested that deficiencies in 
extracellular deposit clearance by phagocytes such as macrophages contribute to 
their build-up in the sub-RPE space (Ambati et al., 2003).  The current theory with 
regards to AMD disease progression would therefore appear to be that the ageing 
RPE becomes compromised, as do the mechanisms which are in place to deal with 
this, initially leading to localised sub-RPE deposits.  These are not effectively cleared 
and an inflammatory response ensues.  This progresses, like a chain reaction, and 
leads to increased deposit formation, further compromising of the RPE and 
subsequent photoreceptor dysfunction and CNV.  Variations in proteins such as CFH 
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can affect how the eye is able to cope with these processes, increasing or decreasing 
the risk of developing symptoms.   
 
So how does C1QTNF5 fit into this picture?  It has been shown in this study that 
mutation in C1QTNF5 compromised the ability of the RPE to phagocytose ROS and 
possibly to organise its cytoskeleton.  This probably stresses the RPE causing fine-
tuned systems to be compromised and extracellular deposits to form.  With this 
model of RPE cell dysfunction in L-ORMD, it is assumed that apical C1QTNF5 
interactions are the primary site initiating the disease.  It has also been shown in this 
study that C1QTNF5 interacts with CFH.  However, the suggested model for how 
CFH polymorphism affects AMD disease progression assumes that its effects are 
primarily basal.  It is possible that there are two CFH-related events going on within 
the retina.  Apically, CFH (secreted by the RPE) may interact with C1QTNF5,  
affecting phagocytosis.  Slight differences in binding specificity between the two 
Y402H polymorphisms and C1QTNF5 may be enough to disrupt fine-tuned balances 
in molecular interactions.  This could have slow but significant effects on C1QTNF5 
and associated proteins functions, resulting in a slightly elevated level of sub-RPE 
deosits.  As the retina ages, these are enough to cause the initiation events predicted 
to result in drusen formation.  Once drusen have formed then CFH could play a part 
in regulating complement activation and so disease progression at this new basal 
location.  Therefore it is possible there are two different functions for CFH in AMD 
– one initiating the disease and one contributing towards its progression. 
 
 
7.4      Future work 
This study has highlighted several possible avenues for future investigation.  It has 
been shown that C1QTNF5 has involvement in ROS phagocytosis, contributing 
towards disease mechanisms in L-ORMD.  Further investigation of how C1QTNF5 
integrates into pathways involved in phagocytosis needs to be carried out.  As 
discussed in Section 7.3.1.1, it is possible C1QTNF5 is acting through CD81.  This 
possibility could be investigated by siRNA, targeting CD81 or its known interacting 
proteins and comparing subsequent levels of phagocytosis in the stably transfected 
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ARPE-19 cell lines.  To identify further molecular pathways involving C1QTNF5 
during phagocytosis, microarray analysis could be carried out.  This could be done 
using the stably transfected cell lines, before and after exposure to ROS.  It could 
also be investigated, using the protocol described by Amin et al. (2004), whether any 
differences in deposit formation are observed between cells over-expressing either 
wild-type or mutant C1QTNF5, with or without exposure to ROS.  It could be 
predicted that increased deposits would be observed in cells over-expressing wild-
type C1QTNF5 due to increased levels of phagocytosis.  However, if it is predicted 
that cellular stress contributes towards increased basal secretions in L-ORMD, it is 
possible that this method may not result in sufficient cellular stress to cause increased 
deposit formation in cells over-expressing mutant C1QTNF5.  Investigating levels of 
deposit formation when the cells are exposed to oxidised ROS could help to test this. 
 
In addition to using a cellular system, transgenic mice would help answer questions 
raised in this study.  For instance, it would be possible to look at the retinal structure 
and determine if loss or mutation of C1QTNF5 results in any abnormalities of the 
apical microvilli.  It would also be possible, assuming the same disease phenotype is 
observed as occurs in humans, to determine the composition of the sub-RPE 
deposits.  This is an important question which it has not yet been possible to answer.  
Determining deposit composition shed light on their origin, and so on the initiating 
factors in disease progression. 
 
The ultimate aim of this study is to understand how C1QTNF5 contributes towards 
disease mechanisms in L-ORMD.  This knowledge can then be applied to developing 
therapies for affected individuals.  One of the most important questions regarding 
such potential therapies is whether mutation in C1QTNF5 results in a loss or gain of 
function.  Disease mechanisms involving a loss of function have the potential to be 
targeted by gene therapy.  Wild-type and mutant C1QTNF5 interact, so it is likely 
formation of heterotrimers can have a dominant negative effect.  Localised over-
expression of wild-type C1QTNF5 may help to overcome this issue.  Prior to 
carrying out this study, it appeared that there was a gain of function in L-ORMD 
pathogenesis, caused by aggregation of mutant C1QTNF5 and retention within the 
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cell.  This study has not been able to support these findings.  If the Ser163Arg 
mutation results in loss of function alone, particularly in relation to ROS 
phagocytosis, then this greatly increase the likelyhood of gene therapy becoming a 




Abecasis, G. R., B. M. Yashar, et al. (2004). "Age-related macular degeneration: a 
high-resolution genome scan for susceptibility loci in a population enriched 
for late-stage disease." Am J Hum Genet 74(3): 482-94. 
Abrera-Abeleda, M. A., C. Nishimura, et al. (2006). "Variations in the complement 
regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are 
associated with membranoproliferative glomerulonephritis type II (dense 
deposit disease)." J Med Genet 43(7): 582-9. 
Adler, P. N. (1992). "The genetic control of tissue polarity in Drosophila." Bioessays 
14(11): 735-41. 
Alberts, J., Lewis, Raff, Roberts, Walter (2002). Molecular Biology of the Cell. New 
York, Garland Science. pp1463 
Alexander, J. P., J. M. Bradley, et al. (1990). "Expression of matrix 
metalloproteinases and inhibitor by human retinal pigment epithelium." 
Invest Ophthalmol Vis Sci 31(12): 2520-8. 
Algvere, P. V., J. Marshall, et al. (2006). "Age-related maculopathy and the impact 
of blue light hazard." Acta Ophthalmol Scand 84(1): 4-15. 
Allikmets, R. (2000). "Further evidence for an association of ABCR alleles with age-
related macular degeneration. The International ABCR Screening 
Consortium." Am J Hum Genet 67(2): 487-91. 
Allikmets, R. and M. Dean (2008). "Bringing age-related macular degeneration into 
focus." Nat Genet 40(7): 820-1. 
Allikmets, R., N. F. Shroyer, et al. (1997). "Mutation of the Stargardt disease gene 
(ABCR) in age-related macular degeneration." Science 277(5333): 1805-7. 
Alm, A. and A. Bill (1973). "Ocular and optic nerve blood flow at normal and 
increased intraocular pressures in monkeys (Macaca irus): a study with 
radioactively labelled microspheres including flow determinations in brain 
and some other tissues." Exp Eye Res 15(1): 15-29. 
Alsenz, J., J. D. Lambris, et al. (1984). "Localization of the complement-component-
C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic 
fragment of factor H." Biochem J 224(2): 389-98. 
 276 
Ambati, J., A. Anand, et al. (2003). "An animal model of age-related macular 
degeneration in senescent Ccl-2- or Ccr-2-deficient mice." Nat Med 9(11): 
1390-7. 
Amin, S., N. H. Chong, et al. (2004). "Modulation of Sub-RPE deposits in vitro: a 
potential model for age-related macular degeneration." Invest Ophthalmol Vis 
Sci 45(5): 1281-8. 
Anderson, D. H., R. F. Mullins, et al. (2002). "A role for local inflammation in the 
formation of drusen in the aging eye." Am J Ophthalmol 134(3): 411-31. 
Anderson, R. E. and M. B. Maude (1970). "Phospholipids of bovine outer segments." 
Biochemistry 9(18): 3624-8. 
Arris, C. E., D. J. Bevitt, et al. (2003). "Expression of mutant and wild-type TIMP3 
in primary gingival fibroblasts from Sorsby's fundus dystrophy patients." 
Biochim Biophys Acta 1638(1): 20-8. 
Ayala-Ramirez, R., F. Graue-Wiechers, et al. (2006). "A new autosomal recessive 
syndrome consisting of posterior microphthalmos, retinitis pigmentosa, 
foveoschisis, and optic disc drusen is caused by a MFRP gene mutation." Mol 
Vis 12: 1483-9. 
Ayyagari, R., M. N. Mandal, et al. (2005). "Late-onset macular degeneration and 
long anterior lens zonules result from a CTRP5 gene mutation." Invest 
Ophthalmol Vis Sci 46(9): 3363-71. 
Baumann, H. and J. Gauldie (1994). "The acute phase response." Immunol Today 
15(2): 74-80. 
Bax, D. V., S. E. Bernard, et al. (2003). "Cell adhesion to fibrillin-1 molecules and 
microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins." J Biol 
Chem 278(36): 34605-16. 
Baylor, D. (1996). "How photons start vision." Proc Natl Acad Sci U S A 93(2): 560-
5. 
Baylor, D. A. and M. E. Burns (1998). "Control of rhodopsin activity in vision." Eye 
12 ( Pt 3b): 521-5. 
Beatty, S., H. Koh, et al. (2000). "The role of oxidative stress in the pathogenesis of 
age-related macular degeneration." Surv Ophthalmol 45(2): 115-34. 
 277 
Berditchevski, F. (2001). "Complexes of tetraspanins with integrins: more than meets 
the eye." J Cell Sci 114(Pt 23): 4143-51. 
Bird, A. C. (2003). "The Bowman lecture. Towards an understanding of age-related 
macular disease." Eye 17(4): 457-66. 
Biro, A., Z. Rovo, et al. (2007). "Studies on the interactions between C-reactive 
protein and complement proteins." Immunology 121(1): 40-50. 
Blackmore, T. K., J. Hellwage, et al. (1998). "Identification of the second heparin-
binding domain in human complement factor H." J Immunol 160(7): 3342-8. 
Blackmore, T. K., T. A. Sadlon, et al. (1996). "Identification of a heparin binding 
domain in the seventh short consensus repeat of complement factor H." J 
Immunol 157(12): 5422-7. 
Bogin, O., M. Kvansakul, et al. (2002). "Insight into Schmid metaphyseal 
chondrodysplasia from the crystal structure of the collagen X NC1 domain 
trimer." Structure 10(2): 165-73. 
Bok, D. (2005). "Evidence for an inflammatory process in age-related macular 
degeneration gains new support." Proc Natl Acad Sci U S A 102(20): 7053-4. 
Bok, D. and M. O. Hall (1971). "The role of the pigment epithelium in the etiology 
of inherited retinal dystrophy in the rat." J Cell Biol 49(3): 664-82. 
Bonilha, V. L., S. C. Finnemann, et al. (1999). "Ezrin promotes morphogenesis of 
apical microvilli and basal infoldings in retinal pigment epithelium." J Cell 
Biol 147(7): 1533-48. 
Bonilha, V. L., M. E. Rayborn, et al. (2006). "Microvilli defects in retinas of ezrin 
knockout mice." Exp Eye Res 82(4): 720-9. 
Bortner, C. D., N. B. Oldenburg, et al. (1995). "The role of DNA fragmentation in 
apoptosis." Trends Cell Biol 5(1): 21-6. 
Boyle, D., L. F. Tien, et al. (1991). "A mannose receptor is involved in retinal 
phagocytosis." Invest Ophthalmol Vis Sci 32(5): 1464-70. 
Brass, A., K. E. Kadler, et al. (1992). "The fibrillar collagens, collagen VIII, collagen 
X and the C1q complement proteins share a similar domain in their C-
terminal non-collagenous regions." FEBS Lett 303(2-3): 126-8. 
 278 
Brosnahan, D. M., S. M. Kennedy, et al. (1994). "Pathology of hereditary retinal 
degeneration associated with hypobetalipoproteinemia." Ophthalmology 
101(1): 38-45. 
Caicedo, A., D. G. Espinosa-Heidmann, et al. (2005). "Blood-derived macrophages 
infiltrate the retina and activate Muller glial cells under experimental 
choroidal neovascularization." Exp Eye Res 81(1): 38-47. 
Chan, D., S. Freddi, et al. (1999). "Interaction of collagen alpha1(X) containing 
engineered NC1 mutations with normal alpha1(X) in vitro. Implications for 
the molecular basis of schmid metaphyseal chondrodysplasia." J Biol Chem 
274(19): 13091-7. 
Chang, Y. and S. C. Finnemann (2007). "Tetraspanin CD81 is required for the alpha 
v beta5-integrin-dependent particle-binding step of RPE phagocytosis." J Cell 
Sci 120(Pt 17): 3053-63. 
Chen, L., P. Yang, et al. (2002). "Distribution, markers, and functions of retinal 
microglia." Ocul Immunol Inflamm 10(1): 27-39. 
Chen, M., J. V. Forrester, et al. (2007). "Synthesis of complement factor H by retinal 
pigment epithelial cells is down-regulated by oxidized photoreceptor outer 
segments." Exp Eye Res 84(4): 635-45. 
Clark, S. J., V. A. Higman, et al. (2006). "His-384 allotypic variant of factor H 
associated with age-related macular degeneration has different heparin 
binding properties from the non-disease-associated form." J Biol Chem 
281(34): 24713-20. 
Coffey, P. J., C. Gias, et al. (2007). "Complement factor H deficiency in aged mice 
causes retinal abnormalities and visual dysfunction." Proc Natl Acad Sci U S 
A 104(42): 16651-6. 
Conrad, D. H., J. R. Carlo, et al. (1978). "Interaction of beta1H globulin with cell-
bound C3b: quantitative analysis of binding and influence of alternative 
pathway components on binding." J Exp Med 147(6): 1792-1805. 
Crabb, J. W., M. Miyagi, et al. (2002). "Drusen proteome analysis: an approach to 
the etiology of age-related macular degeneration." Proc Natl Acad Sci U S A 
99(23): 14682-7. 
 279 
Crespi, J., J. A. Buil, et al. (2008). "A novel mutation confirms MFRP as the gene 
causing the syndrome of nanophthalmos-renititis pigmentosa-foveoschisis-
optic disk drusen." Am J Ophthalmol 146(2): 323-328. 
Curcio, C. A. and C. L. Millican (1999). "Basal linear deposit and large drusen are 
specific for early age-related maculopathy." Arch Ophthalmol 117(3): 329-
39. 
D'Cruz, P. M., D. Yasumura, et al. (2000). "Mutation of the receptor tyrosine kinase 
gene Mertk in the retinal dystrophic RCS rat." Hum Mol Genet 9(4): 645-51. 
Despriet, D. D., A. A. Bergen, et al. (2008). "Comprehensive analysis of the 
candidate genes CCL2, CCR2, and TLR4 in age-related macular 
degeneration." Invest Ophthalmol Vis Sci 49(1): 364-71. 
Dewan, A., M. Liu, et al. (2006). "HTRA1 promoter polymorphism in wet age-
related macular degeneration." Science 314(5801): 989-92. 
Donoso, L. A., D. Kim, et al. (2006). "The role of inflammation in the pathogenesis 
of age-related macular degeneration." Surv Ophthalmol 51(2): 137-52. 
Dowling, J. E. and R. L. Sidman (1962). "Inherited retinal dystrophy in the rat." J 
Cell Biol 14: 73-109. 
Dunn, K. C., A. D. Marmorstein, et al. (1998). "Use of the ARPE-19 cell line as a 
model of RPE polarity: basolateral secretion of FGF5." Invest Ophthalmol 
Vis Sci 39(13): 2744-9. 
Duvall, J., N. M. McKechnie, et al. (1986). "Extensive subretinal pigment epithelial 
deposit in two brothers suffering from dominant retinitis pigmentosa. A 
histopathological study." Graefes Arch Clin Exp Ophthalmol 224(3): 299-
309. 
Edwards, A. O., R. Ritter, 3rd, et al. (2005). "Complement factor H polymorphism 
and age-related macular degeneration." Science 308(5720): 421-4. 
Eibl, K. H., D. Kook, et al. (2006). "Inhibition of human retinal pigment epithelial 
cell attachment, spreading, and migration by alkylphosphocholines." Invest 
Ophthalmol Vis Sci 47(1): 364-70. 
Ellgaard, L. and A. Helenius (2003). "Quality control in the endoplasmic reticulum." 
Nat Rev Mol Cell Biol 4(3): 181-91. 
 280 
Evans, J. and R. Wormald (1996). "Is the incidence of registrable age-related 
macular degeneration increasing?" Br J Ophthalmol 80(1): 9-14. 
Evans, J. R., A. E. Fletcher, et al. (2004). "Age-related macular degeneration causing 
visual impairment in people 75 years or older in Britain: an add-on study to 
the Medical Research Council Trial of Assessment and Management of Older 
People in the Community." Ophthalmology 111(3): 513-7. 
Fearon, D. T. and K. F. Austen (1977). "Activation of the alternative complement 
pathway with rabbit erythrocytes by circumvention of the regulatory action of 
endogenous control proteins." J Exp Med 146(1): 22-33. 
Feeney-Burns, L., E. S. Hilderbrand, et al. (1984). "Aging human RPE: 
morphometric analysis of macular, equatorial, and peripheral cells." Invest 
Ophthalmol Vis Sci 25(2): 195-200. 
Fernando, A. N., P. B. Furtado, et al. (2007). "Associative and structural properties 
of the region of complement factor H encompassing the Tyr402His disease-
related polymorphism and its interactions with heparin." J Mol Biol 368(2): 
564-81. 
Ferreira, V. P., A. P. Herbert, et al. (2006). "Critical role of the C-terminal domains 
of factor H in regulating complement activation at cell surfaces." J Immunol 
177(9): 6308-16. 
Fine, S. L., J. W. Berger, et al. (2000). "Age-related macular degeneration." N Engl J 
Med 342(7): 483-92. 
Finnemann, S. C. (2003). "Focal adhesion kinase signaling promotes phagocytosis of 
integrin-bound photoreceptors." Embo J 22(16): 4143-54. 
Finnemann, S. C., V. L. Bonilha, et al. (1997). "Phagocytosis of rod outer segments 
by retinal pigment epithelial cells requires alpha(v)beta5 integrin for binding 
but not for internalization." Proc Natl Acad Sci U S A 94(24): 12932-7. 
Finnemann, S. C. and E. F. Nandrot (2006). "MerTK activation during RPE 
phagocytosis in vivo requires alphaVbeta5 integrin." Adv Exp Med Biol 572: 
499-503. 
Finnemann, S. C. and R. L. Silverstein (2001). "Differential roles of CD36 and 
alphavbeta5 integrin in photoreceptor phagocytosis by the retinal pigment 
epithelium." J Exp Med 194(9): 1289-98. 
 281 
Fisher, S. A., G. R. Abecasis, et al. (2005). "Meta-analysis of genome scans of age-
related macular degeneration." Hum Mol Genet 14(15): 2257-64. 
Forrester, J. V. (2003). "Macrophages eyed in macular degeneration." Nat Med 
9(11): 1350-1. 
Frank, R. N., R. H. Amin, et al. (1999). "Antioxidant enzymes in the macular retinal 
pigment epithelium of eyes with neovascular age-related macular 
degeneration." Am J Ophthalmol 127(6): 694-709. 
Fritsche, L. G., T. Loenhardt, et al. (2008). "Age-related macular degeneration is 
associated with an unstable ARMS2 (LOC387715) mRNA." Nat Genet 40(7): 
892-6. 
Gal, A., Y. Li, et al. (2000). "Mutations in MERTK, the human orthologue of the 
RCS rat retinal dystrophy gene, cause retinitis pigmentosa." Nat Genet 26(3): 
270-1. 
Gallagher, S. R. (2000). "One-dimensional electrophoresis using non-denaturing 
conditions." Curr. Protoc. cell Biol. (5): 6.5.1-6.5.11 
Gershov, D., S. Kim, et al. (2000). "C-Reactive protein binds to apoptotic cells, 
protects the cells from assembly of the terminal complement components, and 
sustains an antiinflammatory innate immune response: implications for 
systemic autoimmunity." J Exp Med 192(9): 1353-64. 
Giannakis, E., T. S. Jokiranta, et al. (2003). "A common site within factor H SCR 7 
responsible for binding heparin, C-reactive protein and streptococcal M 
protein." Eur J Immunol 33(4): 962-9. 
Gregory, C. Y. and M. O. Hall (1992). "The phagocytosis of ROS by RPE cells is 
inhibited by an antiserum to rat RPE cell plasma membranes." Exp Eye Res 
54(6): 843-51. 
Gros, P., F. J. Milder, et al. (2008). "Complement driven by conformational 
changes." Nat Rev Immunol 8(1): 48-58. 
Hageman, G. S., D. H. Anderson, et al. (2005). "A common haplotype in the 
complement regulatory gene factor H (HF1/CFH) predisposes individuals to 
age-related macular degeneration." Proc Natl Acad Sci U S A 102(20): 7227-
32. 
 282 
Hageman, G. S., L. S. Hancox, et al. (2006). "Extended haplotypes in the 
complement factor H (CFH) and CFH-related (CFHR) family of genes 
protect against age-related macular degeneration: characterization, ethnic 
distribution and evolutionary implications." Ann Med 38(8): 592-604. 
Hageman, G. S., P. J. Luthert, et al. (2001). "An integrated hypothesis that considers 
drusen as biomarkers of immune-mediated processes at the RPE-Bruch's 
membrane interface in aging and age-related macular degeneration." Prog 
Retin Eye Res 20(6): 705-32. 
Hageman, G. S. and R. F. Mullins (1999). "Molecular composition of drusen as 
related to substructural phenotype." Mol Vis 5: 28. 
Haines, J. L., M. A. Hauser, et al. (2005). "Complement factor H variant increases 
the risk of age-related macular degeneration." Science 308(5720): 419-21. 
Hakobyan, S., C. L. Harris, et al. (2008). "Complement factor H binds to denatured 
rather than to native pentameric C-reactive protein." J Biol Chem 283(45): 
30451-60. 
Hall, M. O., B. L. Burgess, et al. (1990). "The effect of inhibitors of glycoprotein 
synthesis and processing on the phagocytosis of rod outer segments by 
cultured retinal pigment epithelial cells." Glycobiology 1(1): 51-61. 
Hammond, C. J., A. R. Webster, et al. (2002). "Genetic influence on early age-
related maculopathy: a twin study." Ophthalmology 109(4): 730-6. 
Hargrave, P. A. (2001). "Rhodopsin structure, function, and topography the 
Friedenwald lecture." Invest Ophthalmol Vis Sci 42(1): 3-9. 
Hart, S. P., K. M. Alexander, et al. (2005). "C-reactive protein does not opsonize 
early apoptotic human neutrophils, but binds only membrane-permeable late 
apoptotic cells and has no effect on their phagocytosis by macrophages." J 
Inflamm (Lond) 2: 5. 
Hawkins, B. S., A. Bird, et al. (1999). "Epidemiology of age-related macular 
degeneration." Mol Vis 5: 26. 
Hayward, C., X. Shu, et al. (2003). "Mutation in a short-chain collagen gene, 
CTRP5, results in extracellular deposit formation in late-onset retinal 
degeneration: a genetic model for age-related macular degeneration." Hum 
Mol Genet 12(20): 2657-67. 
 283 
Hellwage, J., T. S. Jokiranta, et al. (1999). "Functional properties of complement 
factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of 
C3b and differential regulation by heparin." FEBS Lett 462(3): 345-52. 
Hellwage, J., S. Kuhn, et al. (1997). "The human complement regulatory factor-H-
like protein 1, which represents a truncated form of factor H, displays cell-
attachment activity." Biochem J 326 ( Pt 2): 321-7. 
Hemler, M. E. (2005). "Tetraspanin functions and associated microdomains." Nat 
Rev Mol Cell Biol 6(10): 801-11. 
Herbert, A. P., J. A. Deakin, et al. (2007). "Structure shows that a glycosaminoglycan 
and protein recognition site in factor H is perturbed by age-related macular 
degeneration-linked single nucleotide polymorphism." J Biol Chem 282(26): 
18960-8. 
Herbert, A. P., D. C. Soares, et al. (2006). "Disease-associated sequence variations in 
factor H: a structural biology approach." Adv Exp Med Biol 586: 313-27. 
Hildebrand M, G. G. (2001). Analysis of Vertebrate Structure. New York, John 
Wiley & Sons Inc. pp635 
Holers, V. M., T. Kinoshita, et al. (1992). "The evolution of mouse and human 
complement C3-binding proteins: divergence of form but conservation of 
function." Immunol Today 13(6): 231-6. 
Hollyfield J. G., V. L. Bonilha, et al. (2008). "Oxidative damage-induced 
inflammation initiates age-related macular degeneration." Nat. Med. 
14(2):194-8. 
Hopf, M., W. Gohring, et al. (2001). "Crystal structure and mutational analysis of a 
perlecan-binding fragment of nidogen-1." Nat Struct Biol 8(7): 634-40. 
Hortin, G. L. (2006). "The MALDI-TOF mass spectrometric view of the plasma 
proteome and peptidome." Clin Chem 52(7): 1223-37. 
Hughes, A. E., N. Orr, et al. (2006). "A common CFH haplotype, with deletion of 
CFHR1 and CFHR3, is associated with lower risk of age-related macular 
degeneration." Nat Genet 38(10): 1173-7. 
Humphries, M. J. (2001). "Cell adhesion assays." Mol Biotechnol 18(1): 57-61. 
Hynes, R. O. (1999). "Cell adhesion: old and new questions." Trends Cell Biol 9(12): 
M33-7. 
 284 
Iyengar, S. K., D. Song, et al. (2004). "Dissection of genomewide-scan data in 
extended families reveals a major locus and oligogenic susceptibility for age-
related macular degeneration." Am J Hum Genet 74(1): 20-39. 
Jacobson, S. G., A. V. Cideciyan, et al. (2001). "Phenotypic marker for early disease 
detection in dominant late-onset retinal degeneration." Invest Ophthalmol Vis 
Sci 42(8): 1882-90. 
Jarva, H., T. S. Jokiranta, et al. (1999). "Regulation of complement activation by C-
reactive protein: targeting the complement inhibitory activity of factor H by 
an interaction with short consensus repeat domains 7 and 8-11." J Immunol 
163(7): 3957-62. 
Jin, G. F., J. S. Hurst, et al. (2001). "Rod outer segments mediate mitochondrial 
DNA damage and apoptosis in human retinal pigment epithelium." Curr Eye 
Res 23(1): 11-9. 
Johnson, L. V., S. Ozaki, et al. (2000). "A potential role for immune complex 
pathogenesis in drusen formation." Exp Eye Res 70(4): 441-9. 
Johnson, P. T., K. E. Betts, et al. (2006). "Individuals homozygous for the age-
related macular degeneration risk-conferring variant of complement factor H 
have elevated levels of CRP in the choroid." Proc Natl Acad Sci U S A 
103(46): 17456-61. 
Jokiranta, T. S., Z. Z. Cheng, et al. (2005). "Binding of complement factor H to 
endothelial cells is mediated by the carboxy-terminal glycosaminoglycan 
binding site." Am J Pathol 167(4): 1173-81. 
Jokiranta, T. S., J. Hellwage, et al. (2000). "Each of the three binding sites on 
complement factor H interacts with a distinct site on C3b." J Biol Chem 
275(36): 27657-62. 
Jozsi, M. and P. F. Zipfel (2008). "Factor H family proteins and human diseases." 
Trends Immunol 29(8): 380-7. 
Kameya, S., N. L. Hawes, et al. (2002). "Mfrp, a gene encoding a frizzled related 
protein, is mutated in the mouse retinal degeneration 6." Hum Mol Genet 
11(16): 1879-86. 
 285 
Kanda, A., W. Chen, et al. (2007). "A variant of mitochondrial protein 
LOC387715/ARMS2, not HTRA1, is strongly associated with age-related 
macular degeneration." Proc Natl Acad Sci U S A 104(41): 16227-32. 
Karas, M. and F. Hillenkamp (1988). "Laser desorption ionization of proteins with 
molecular masses exceeding 10,000 daltons." Anal Chem 60(20): 2299-301. 
Kennedy, C. J., P. E. Rakoczy, et al. (1996). "A simple flow cytometric technique to 
quantify rod outer segment phagocytosis in cultured retinal pigment epithelial 
cells." Curr Eye Res 15(9): 998-1003. 
Killingsworth, M. C., J. P. Sarks, et al. (1990). "Macrophages related to Bruch's 
membrane in age-related macular degeneration." Eye 4 ( Pt 4): 613-21. 
Kim, D. D. and W. C. Song (2006). "Membrane complement regulatory proteins." 
Clin Immunol 118(2-3): 127-36. 
Kishore, U., C. Gaboriaud, et al. (2004). "C1q and tumor necrosis factor superfamily: 
modularity and versatility." Trends Immunol 25(10): 551-61. 
Kishore, U., R. Ghai, et al. (2004). "Structural and functional anatomy of the 
globular domain of complement protein C1q." Immunol Lett 95(2): 113-28. 
Klein, M. L., D. W. Schultz, et al. (1998). "Age-related macular degeneration. 
Clinical features in a large family and linkage to chromosome 1q." Arch 
Ophthalmol 116(8): 1082-8. 
Klein, R. J., C. Zeiss, et al. (2005). "Complement factor H polymorphism in age-
related macular degeneration." Science 308(5720): 385-9. 
Kuhn, S., C. Skerka, et al. (1995). "Mapping of the complement regulatory domains 
in the human factor H-like protein 1 and in factor H1." J Immunol 155(12): 
5663-70. 
Kuhn, S. and P. F. Zipfel (1996). "Mapping of the domains required for decay 
acceleration activity of the human factor H-like protein 1 and factor H." Eur J 
Immunol 26(10): 2383-7. 
Kuntz, C. A., S. G. Jacobson, et al. (1996). "Sub-retinal pigment epithelial deposits 
in a dominant late-onset retinal degeneration." Invest Ophthalmol Vis Sci 
37(9): 1772-82. 
Kwan, A. P., C. E. Cummings, et al. (1991). "Macromolecular organization of 
chicken type X collagen in vitro." J Cell Biol 114(3): 597-604. 
 286 
Laine, M., H. Jarva, et al. (2007). "Y402H polymorphism of complement factor H 
affects binding affinity to C-reactive protein." J Immunol 178(6): 3831-6. 
Lardner, A. (2001). "The effects of extracellular pH on immune function." J Leukoc 
Biol 69(4): 522-30. 
LaVail, M. M. (1976). "Rod outer segment disc shedding in relation to cyclic 
lighting." Exp Eye Res 23(2): 277-80. 
Lee, Y. H., S. Nair, et al. (2005). "Microarray profiling of isolated abdominal 
subcutaneous adipocytes from obese vs non-obese Pima Indians: increased 
expression of inflammation-related genes." Diabetologia 48(9): 1776-83. 
Lengyel, I., J. M. Flinn, et al. (2007). "High concentration of zinc in sub-retinal 
pigment epithelial deposits." Exp Eye Res 84(4): 772-80. 
Levy, S. and T. Shoham (2005). "Protein-protein interactions in the tetraspanin web." 
Physiology (Bethesda) 20: 218-24. 
Li, M., P. Atmaca-Sonmez, et al. (2006). "CFH haplotypes without the Y402H 
coding variant show strong association with susceptibility to age-related 
macular degeneration." Nat Genet 38(9): 1049-54. 
Lin, R. J., M. S. Blumenkranz, et al. (2006). "A novel His158Arg mutation in TIMP3 
causes a late-onset form of Sorsby fundus dystrophy." Am J Ophthalmol 
142(5): 839-48. 
Luckman, S. P., E. Rees, et al. (2003). "Partial characterization of cell-type X 
collagen interactions." Biochem J 372(Pt 2): 485-93. 
Lutz, D. A., Y. Guo, et al. (1995). "Natural, high-mannose glycoproteins inhibit ROS 
binding and ingestion by RPE cell cultures." Exp Eye Res 61(4): 487-93. 
Majewski, J., D. W. Schultz, et al. (2003). "Age-related macular degeneration--a 
genome scan in extended families." Am J Hum Genet 73(3): 540-50. 
Maller, J., S. George, et al. (2006). "Common variation in three genes, including a 
noncoding variant in CFH, strongly influences risk of age-related macular 
degeneration." Nat Genet 38(9): 1055-9. 
Mandal, M. N. and R. Ayyagari (2006). "Complement factor H: spatial and temporal 
expression and localization in the eye." Invest Ophthalmol Vis Sci 47(9): 
4091-7. 
 287 
Mandal, M. N., V. Vasireddy, et al. (2006). "Spatial and temporal expression of 
MFRP and its interaction with CTRP5." Invest Ophthalmol Vis Sci 47(12): 
5514-21. 
Mandal, M. N., V. Vasireddy, et al. (2006). "CTRP5 is a membrane-associated and 
secretory protein in the RPE and ciliary body and the S163R mutation of 
CTRP5 impairs its secretion." Invest Ophthalmol Vis Sci 47(12): 5505-13. 
Mares-Perlman, J. A., W. E. Brady, et al. (1995). "Dietary fat and age-related 
maculopathy." Arch Ophthalmol 113(6): 743-8. 
Marmor M, W. T. (1998). The Retinal Pigment Epithelium. New York, Oxford 
University Press. pp745 
Marshall, G. E., A. G. Konstas, et al. (1993). "Collagens in ocular tissues." Br J 
Ophthalmol 77(8): 515-24. 
Marshall, G. E., A. G. Konstas, et al. (1992). "Type IV collagen and laminin in 
Bruch's membrane and basal linear deposit in the human macula." Br J 
Ophthalmol 76(10): 607-14. 
Mayerson, P. L. and M. O. Hall (1986). "Rat retinal pigment epithelial cells show 
specificity of phagocytosis in vitro." J Cell Biol 103(1): 299-308. 
McDonnell, J. M. (2001). "Surface plasmon resonance: towards an understanding of 
the mechanisms of biological molecular recognition." Curr Opin Chem Biol 
5(5): 572-7. 
McRae, J. L., T. G. Duthy, et al. (2005). "Human factor H-related protein 5 has 
cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive 
protein, and associates with lipoprotein." J Immunol 174(10): 6250-6. 
Meri, S. and M. K. Pangburn (1990). "Discrimination between activators and 
nonactivators of the alternative pathway of complement: regulation via a 
sialic acid/polyanion binding site on factor H." Proc Natl Acad Sci U S A 
87(10): 3982-6. 
Miceli, M. V. and D. A. Newsome (1994). "Insulin stimulation of retinal outer 
segment uptake by cultured human retinal pigment epithelial cells determined 
by a flow cytometric method." Exp Eye Res 59(3): 271-80. 
 288 
Milam, A. H., C. A. Curcio, et al. (2000). "Dominant late-onset retinal degeneration 
with regional variation of sub-retinal pigment epithelium deposits, retinal 
function, and photoreceptor degeneration." Ophthalmology 107(12): 2256-66. 
Miner, J. H. (2008). "Laminins and their roles in mammals." Microsc Res Tech 
71(5): 349-56. 
Montes, T., E. Goicoechea de Jorge, et al. (2008). "Genetic deficiency of 
complement factor H in a patient with age-related macular degeneration and 
membranoproliferative glomerulonephritis." Mol Immunol 45(10): 2897-904. 
Moore, D. J. and G. M. Clover (2001). "The effect of age on the macromolecular 
permeability of human Bruch's membrane." Invest Ophthalmol Vis Sci 
42(12): 2970-5. 
Mullins, R. F., N. Aptsiauri, et al. (2001). "Structure and composition of drusen 
associated with glomerulonephritis: implications for the role of complement 
activation in drusen biogenesis." Eye 15(Pt 3): 390-5. 
Nagaki, K., K. Iida, et al. (1978). "Reaction mechanisms of beta1H globulin." Int 
Arch Allergy Appl Immunol 57(3): 221-32. 
Nandrot, E. F., M. Anand, et al. (2007). "Essential role for MFG-E8 as ligand for 
alphavbeta5 integrin in diurnal retinal phagocytosis." Proc Natl Acad Sci U S 
A 104(29): 12005-10. 
Nandrot, E. F., M. Anand, et al. (2006). "Novel role for alphavbeta5-integrin in 
retinal adhesion and its diurnal peak." Am J Physiol Cell Physiol 290(4): 
C1256-62. 
Nandrot, E. F., Y. Kim, et al. (2004). "Loss of synchronized retinal phagocytosis and 
age-related blindness in mice lacking alphavbeta5 integrin." J Exp Med 
200(12): 1539-45. 
Ogden, C. A., A. deCathelineau, et al. (2001). "C1q and mannose binding lectin 
engagement of cell surface calreticulin and CD91 initiates macropinocytosis 
and uptake of apoptotic cells." J Exp Med 194(6): 781-95. 
Okada, T., O. P. Ernst, et al. (2001). "Activation of rhodopsin: new insights from 
structural and biochemical studies." Trends Biochem Sci 26(5): 318-24. 
Okhrimenko, O. and I. Jelesarov (2008). "A survey of the year 2006 literature on 
applications of isothermal titration calorimetry." J Mol Recognit 21(1): 1-19. 
 289 
Oppermann, M., T. Manuelian, et al. (2006). "The C-terminus of complement 
regulator Factor H mediates target recognition: evidence for a compact 
conformation of the native protein." Clin Exp Immunol 144(2): 342-52. 
Pangburn, M. K., D. C. Morrison, et al. (1980). "Activation of the alternative 
complement pathway: recognition of surface structures on activators by 
bound C3b." J Immunol 124(2): 977-82. 
Pangburn, M. K. and H. J. Muller-Eberhard (1978). "Complement C3 convertase: 
cell surface restriction of beta1H control and generation of restriction on 
neuraminidase-treated cells." Proc Natl Acad Sci U S A 75(5): 2416-20. 
Pangburn, M. K., R. D. Schreiber, et al. (1977). "Human complement C3b 
inactivator: isolation, characterization, and demonstration of an absolute 
requirement for the serum protein beta1H for cleavage of C3b and C4b in 
solution." J Exp Med 146(1): 257-70. 
Pierce, M. M., C. S. Raman, et al. (1999). "Isothermal titration calorimetry of 
protein-protein interactions." Methods 19(2): 213-21. 
Pino, R. M. and E. Essner (1981). "Permeability of rat choriocapillaris to 
hemeproteins. Restriction of tracers by a fenestrated endothelium." J 
Histochem Cytochem 29(2): 281-90. 
Prosser, B. E., S. Johnson, et al. (2007). "Structural basis for complement factor H 
linked age-related macular degeneration." J Exp Med 204(10): 2277-83. 
Qi, J. H., Q. Ebrahem, et al. (2002). "Expression of Sorsby's fundus dystrophy 
mutations in human retinal pigment epithelial cells reduces matrix 
metalloproteinase inhibition and may promote angiogenesis." J Biol Chem 
277(16): 13394-400. 
Reinboth, J. J., K. Gautschi, et al. (1997). "Lipofuscin in the retina: quantitative 
assay for an unprecedented autofluorescent compound (pyridinium bis-
retinoid, A2-E) of ocular age pigment." Exp Eye Res 65(5): 639-43. 
Riley-Vargas, R. C., D. B. Gill, et al. (2004). "CD46: expanding beyond complement 
regulation." Trends Immunol 25(9): 496-503. 
Ripoche, J., A. J. Day, et al. (1988). "The complete amino acid sequence of human 
complement factor H." Biochem J 249(2): 593-602. 
 290 
Ryeom, S. W., R. L. Silverstein, et al. (1996). "Binding of anionic phospholipids to 
retinal pigment epithelium may be mediated by the scavenger receptor 
CD36." J Biol Chem 271(34): 20536-9. 
Ryeom, S. W., J. R. Sparrow, et al. (1996). "CD36 participates in the phagocytosis of 
rod outer segments by retinal pigment epithelium." J Cell Sci 109 ( Pt 2): 
387-95. 
Sarks, S., S. Cherepanoff, et al. (2007). "Relationship of Basal laminar deposit and 
membranous debris to the clinical presentation of early age-related macular 
degeneration." Invest Ophthalmol Vis Sci 48(3): 968-77. 
Schick, J. H., S. K. Iyengar, et al. (2003). "A whole-genome screen of a quantitative 
trait of age-related maculopathy in sibships from the Beaver Dam Eye 
Study." Am J Hum Genet 72(6): 1412-24. 
Schmidt S, E. A. Postel E. A et al. (2003). "Detailed analysis of allelic variation in 
the ABCA4 gene in age-related maculopathy." Invest Ophthalmol Vis Sci 
44(7): 2868-75. 
Scholl, H. P., M. Fleckenstein, et al. (2007). "An update on the genetics of age-
related macular degeneration." Mol Vis 13: 196-205. 
Seddon, J. M., S. L. Santangelo, et al. (2003). "A genomewide scan for age-related 
macular degeneration provides evidence for linkage to several chromosomal 
regions." Am J Hum Genet 73(4): 780-90. 
Shapiro, L. and P. E. Scherer (1998). "The crystal structure of a complement-1q 
family protein suggests an evolutionary link to tumor necrosis factor." Curr 
Biol 8(6): 335-8. 
Sharma, A. K. and M. K. Pangburn (1996). "Identification of three physically and 
functionally distinct binding sites for C3b in human complement factor H by 
deletion mutagenesis." Proc Natl Acad Sci U S A 93(20): 10996-1001. 
Sheraidah, G., R. Steinmetz, et al. (1993). "Correlation between lipids extracted from 
Bruch's membrane and age." Ophthalmology 100(1): 47-51. 
Shu, X., B. Tulloch, et al. (2006). "Biochemical characterisation of the C1QTNF5 
gene associated with late-onset retinal degeneration. A genetic model of age-
related macular degeneration." Adv Exp Med Biol 572: 41-8. 
 291 
Shu, X., B. Tulloch, et al. (2006). "Disease mechanisms in late-onset retinal macular 
degeneration associated with mutation in C1QTNF5." Hum Mol Genet 
15(10): 1680-9. 
Silverstein, R. L. and M. Febbraio (2000). "CD36 and atherosclerosis." Curr Opin 
Lipidol 11(5): 483-91. 
Sim, E., A. B. Wood, et al. (1981). "Pattern of degradation of human complement 
fragment, C3b." FEBS Lett 132(1): 55-60. 
Sim, R. B., A. J. Day, et al. (1993). "Complement factor I and cofactors in control of 
complement system convertase enzymes." Methods Enzymol 223: 13-35. 
Sjoberg, A. P., L. A. Trouw, et al. (2007). "The factor H variant associated with age-
related macular degeneration (His-384) and the non-disease-associated form 
bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic 
cells." J Biol Chem 282(15): 10894-900. 
Skerka, C., N. Lauer, et al. (2007). "Defective complement control of factor H 
(Y402H) and FHL-1 in age-related macular degeneration." Mol Immunol 
44(13): 3398-406. 
Smith, W., J. Assink, et al. (2001). "Risk factors for age-related macular 
degeneration: Pooled findings from three continents." Ophthalmology 108(4): 
697-704. 
Soames, C. J. and R. B. Sim (1997). "Interactions between human complement 
components factor H, factor I and C3b." Biochem J 326 ( Pt 2): 553-61. 
Spencer, K. L., M. A. Hauser, et al. (2007). "Haplotypes spanning the complement 
factor H gene are protective against age-related macular degeneration." Invest 
Ophthalmol Vis Sci 48(9): 4277-83. 
Spencer, K. L., L. M. Olson, et al. (2008). "C3 R102G polymorphism increases risk 
of age-related macular degeneration." Hum Mol Genet 17(12): 1821-4. 
Spessotto, P., M. Cervi, et al. (2003). "beta 1 Integrin-dependent cell adhesion to 
EMILIN-1 is mediated by the gC1q domain." J Biol Chem 278(8): 6160-7. 
Starita, C., A. A. Hussain, et al. (1995). "Decreasing hydraulic conductivity of 
Bruch's membrane: relevance to photoreceptor survival and lipofuscinoses." 
Am J Med Genet 57(2): 235-7. 
 292 
Stephan, S., M. J. Sherratt, et al. (2004). "Expression and supramolecular assembly 
of recombinant alpha1(viii) and alpha2(viii) collagen homotrimers." J Biol 
Chem 279(20): 21469-77. 
Stone, E. M., T. A. Braun, et al. (2004). "Missense variations in the fibulin 5 gene 
and age-related macular degeneration." N Engl J Med 351(4): 346-53. 
Stone, E. M., A. J. Lotery, et al. (1999). "A single EFEMP1 mutation associated with 
both Malattia Leventinese and Doyne honeycomb retinal dystrophy." Nat 
Genet 22(2): 199-202. 
Strauss, O. (2005). "The retinal pigment epithelium in visual function." Physiol Rev 
85(3): 845-81. 
Sun, M., S. C. Finnemann, et al. (2006). "Light-induced oxidation of photoreceptor 
outer segment phospholipids generates ligands for CD36-mediated 
phagocytosis by retinal pigment epithelium: a potential mechanism for 
modulating outer segment phagocytosis under oxidant stress conditions." J 
Biol Chem 281(7): 4222-30. 
Sundin, O. H., G. S. Leppert, et al. (2005). "Extreme hyperopia is the result of null 
mutations in MFRP, which encodes a Frizzled-related protein." Proc Natl 
Acad Sci U S A 102(27): 9553-8. 
Tate, D. J., Jr., M. V. Miceli, et al. (1995). "Phagocytosis and H2O2 induce catalase 
and metallothionein gene expression in human retinal pigment epithelial 
cells." Invest Ophthalmol Vis Sci 36(7): 1271-9. 
Tezel, T. H., N. S. Bora, et al. (2004). "Pathogenesis of age-related macular 
degeneration." Trends Mol Med 10(9): 417-20. 
Tong, J. P. and Y. F. Yao (2006). "Contribution of VEGF and PEDF to choroidal 
angiogenesis: a need for balanced expressions." Clin Biochem 39(3): 267-76. 
van der Schaft, T. L., W. C. de Bruijn, et al. (1993). "Basal laminar deposit in the 
aging peripheral human retina." Graefes Arch Clin Exp Ophthalmol 231(8): 
470-5. 
van der Schaft, T. L., W. C. de Bruijn, et al. (1992). "Element analysis of the early 
stages of age-related macular degeneration." Arch Ophthalmol 110(3): 389-
94. 
 293 
van Lookeren Campagne, M., C. Wiesmann, et al. (2007). "Macrophage complement 
receptors and pathogen clearance." Cell Microbiol 9(9): 2095-102. 
Venables, J. P., L. Strain, et al. (2006). "Atypical haemolytic uraemic syndrome 
associated with a hybrid complement gene." PLoS Med 3(10): e431. 
Vojnikovic, B., S. Njiric, et al. (2007). "Ultraviolet sun radiation and incidence of 
age-related macular degeneration on Croatian Island Rab." Coll Antropol 31 
Suppl 1: 43-4. 
Volanakis, J. E. and M. H. Kaplan (1974). "Interaction of C-reactive protein 
complexes with the complement system. II. Consumption of guinea pig 
complement by CRP complexes: requirement for human C1q." J Immunol 
113(1): 9-17. 
Walport, M. J. (2001). "Complement. First of two parts." N Engl J Med 344(14): 
1058-66. 
Walport, M. J. (2001). "Complement. Second of two parts." N Engl J Med 344(15): 
1140-4. 
Wear, M. A. and M. D. Walkinshaw (2006). "Thermodynamics of the cyclophilin-
A/cyclosporin-A interaction: a direct comparison of parameters determined 
by surface plasmon resonance using Biacore T100 and isothermal titration 
calorimetry." Anal Biochem 359(2): 285-7. 
Weeks, D. E., Y. P. Conley, et al. (2004). "Age-related maculopathy: a genomewide 
scan with continued evidence of susceptibility loci within the 1q31, 10q26, 
and 17q25 regions." Am J Hum Genet 75(2): 174-89. 
Weiter, J. J., F. C. Delori, et al. (1986). "Retinal pigment epithelial lipofuscin and 
melanin and choroidal melanin in human eyes." Invest Ophthalmol Vis Sci 
27(2): 145-52. 
Whaley, K. and S. Ruddy (1976). "Modulation of the alternative complement 
pathways by beta 1 H globulin." J Exp Med 144(5): 1147-63. 
Wiesmann, C., K. J. Katschke, et al. (2006). "Structure of C3b in complex with CRIg 
gives insights into regulation of complement activation." Nature 444(7116): 
217-20. 
 294 
Won, J., R. S. Smith, et al. (2008). "Membrane frizzled-related protein is necessary 
for the normal development and maintenance of photoreceptor outer 
segments." Vis Neurosci 25(4): 563-74. 
Wu, Z., T. W. Lauer, et al. (2007). "Oxidative stress modulates complement factor H 
expression in retinal pigmented epithelial cells by acetylation of FOXO3." J 
Biol Chem 282(31): 22414-25. 
Yamada, Y., S. Ichihara, et al. (2008). "Genetic risk for metabolic syndrome: 
examination of candidate gene polymorphisms related to lipid metabolism in 
Japanese people." J Med Genet 45(1): 22-8. 
Yang, Z., N. J. Camp, et al. (2006). "A variant of the HTRA1 gene increases 
susceptibility to age-related macular degeneration." Science 314(5801): 992-
3. 
Yates, J. R., T. Sepp, et al. (2007). "Complement C3 variant and the risk of age-
related macular degeneration." N Engl J Med 357(6): 553-61. 
Young, R. W. and D. Bok (1969). "Participation of the retinal pigment epithelium in 
the rod outer segment renewal process." J Cell Biol 42(2): 392-403. 
Yurchenco, P. D. and G. C. Ruben (1987). "Basement membrane structure in situ: 
evidence for lateral associations in the type IV collagen network." J Cell Biol 
105(6 Pt 1): 2559-68. 
Zaluzec, E. J., D. A. Gage, et al. (1995). "Matrix-assisted laser desorption ionization 
mass spectrometry: applications in peptide and protein characterization." 
Protein Expr Purif 6(2): 109-23. 
Zipfel, P. F., M. Edey, et al. (2007). "Deletion of complement factor H-related genes 
CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome." 
PLoS Genet 3(3): e41. 
Zipfel, P. F., S. Heinen, et al. (2006). "Complement and diseases: defective 
alternative pathway control results in kidney and eye diseases." Mol Immunol 
43(1-2): 97-106. 
Zipfel, P. F. and C. Skerka (1994). "Complement factor H and related proteins: an 
expanding family of complement-regulatory proteins?" Immunol Today 
15(3): 121-6. 
 295 
Zipfel, P. F. and C. Skerka (1999). "FHL-1/reconectin: a human complement and 
immune regulator with cell-adhesive function." Immunol Today 20(3): 135-
40. 
 
 
